{"ctNumber":"2024-519654-37-00","ctStatus":"Authorised","startDateEU":"2025-11-07","decisionDate":"2025-10-06T16:40:02.969","publishDate":"2026-10-06T03:35:51.23782364","ctPublicStatusCode":4,"authorizedApplication":{"authorizedPartI":{"id":135393,"rowSubjectCount":460,"rowCountriesInfo":[{"eutctId":100000000439,"name":"Korea, Republic of","isoNumber":410,"isoAlpha2Code":"KR","isoAlpha3Code":"KOR","current":true},{"eutctId":100000000346,"name":"Brazil","isoNumber":76,"isoAlpha2Code":"BR","isoAlpha3Code":"BRA","current":true},{"eutctId":100000000456,"name":"Malaysia","isoNumber":458,"isoAlpha2Code":"MY","isoAlpha3Code":"MYS","current":true},{"eutctId":100000000549,"name":"Turkey","isoNumber":792,"isoAlpha2Code":"TR","isoAlpha3Code":"TUR","current":true},{"eutctId":100000000329,"name":"Australia","isoNumber":36,"isoAlpha2Code":"AU","isoAlpha3Code":"AUS","current":true},{"eutctId":100000000557,"name":"United States","isoNumber":840,"isoAlpha2Code":"US","isoAlpha3Code":"USA","current":true},{"eutctId":100000000354,"name":"Canada","isoNumber":124,"isoAlpha2Code":"CA","isoAlpha3Code":"CAN","current":true},{"eutctId":100000000482,"name":"New Zealand","isoNumber":554,"isoAlpha2Code":"NZ","isoAlpha3Code":"NZL","current":true},{"eutctId":100000000522,"name":"Singapore","isoNumber":702,"isoAlpha2Code":"SG","isoAlpha3Code":"SGP","current":true},{"eutctId":100000000536,"name":"Switzerland","isoNumber":756,"isoAlpha2Code":"CH","isoAlpha3Code":"CHE","current":true},{"eutctId":100000000541,"name":"Thailand","isoNumber":764,"isoAlpha2Code":"TH","isoAlpha3Code":"THA","current":true},{"eutctId":100000000423,"name":"India","isoNumber":356,"isoAlpha2Code":"IN","isoAlpha3Code":"IND","current":true},{"eutctId":100000000429,"name":"Israel","isoNumber":376,"isoAlpha2Code":"IL","isoAlpha3Code":"ISR","current":true},{"eutctId":100000000556,"name":"United Kingdom","isoNumber":826,"isoAlpha2Code":"GB","isoAlpha3Code":"GBR","current":true},{"eutctId":100000000325,"name":"Argentina","isoNumber":32,"isoAlpha2Code":"AR","isoAlpha3Code":"ARG","current":true},{"eutctId":100000000538,"name":"Taiwan","isoNumber":158,"isoAlpha2Code":"TW","isoAlpha3Code":"TWN","current":true}],"products":[{"id":562843,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"12408372","productPharmForm":"VIAL FOR INTRAVENOUS USE","euMpNumber":"PRD12408372","prodAuthStatus":1,"prodName":"Ficerafusp Alfa","pharmForm":"VIAL FOR INTRAVENOUS USE","sponsorProductCode":"BCA101","activeSubstanceName":"FICERAFUSP ALFA","euSubstNumber":"SUB301432","nameOrg":"BICARA","productSubstances":[{"productPk":"12408372","substancePk":"404854","nameOrg":"BICARA","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"FICERAFUSP ALFA","substanceEvCode":"SUB301432","synonyms":["Bifunctional monoclonal antibody against epidermal growth factor receptor and transforming growth factor beta","BCA101","Ficerafusp alpha"]}],"activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"1500","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"156","maxTreatmentPeriod":24,"timeUnitCode":"3","evCode":"PRD12408372","sponsorProductCodeEdit":"BCA101","miaNumber":"DE_BW_01_MIA_2023_0054","devices":[],"characteristics":["7"],"routes":["SOLUTION FOR INFUSION"],"allSubstancesChemicals":false,"productName":"Ficerafusp Alfa","jsonActiveSubstanceNames":"ficerafusp alfa","pharmaceuticalFormDisplay":"VIAL FOR INTRAVENOUS USE"},{"id":562851,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"12352441","productPharmForm":"CONCENTRATE FOR SOLUTION FOR INFUSION","euMpNumber":"PRD12081133","marketingAuthNumber":"EU/1/15/1024/003","prodAuthStatus":2,"prodName":"KEYTRUDA 25 mg/mL concentrate for solution for infusion","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"PEMBROLIZUMAB","euSubstNumber":"SUB167136","authorisationCountryCode":"IS","mrpNumber":"EMEA/H/C/003820","nameOrg":"MERCK SHARP & DOHME B.V.","productSubstances":[{"productPk":"12352441","substancePk":"387061","nameOrg":"MERCK SHARP & DOHME B.V.","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"PEMBROLIZUMAB","substanceEvCode":"SUB167136"}],"atcCode":"L01FF02","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"200","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"6.9","productChangedRelationMA":true,"productChangeDescription":"Relabeled for the clinical trial and administered with ficerasup alfa","maxTreatmentPeriod":24,"timeUnitCode":"3","evCode":"PRD12081133","miaNumber":"DE_BW_01_MIA_2023_0054","devices":[],"characteristics":["4","7"],"routes":["INTRAVENOUS USE"],"allSubstancesChemicals":false,"productName":"KEYTRUDA 25 mg/mL concentrate for solution for infusion","jsonActiveSubstanceNames":"pembrolizumab","pharmaceuticalFormDisplay":"SOLUTION FOR INFUSION"},{"id":562847,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"12352442","productPharmForm":"CONCENTRATE FOR SOLUTION FOR INFUSION","euMpNumber":"PRD12081134","marketingAuthNumber":"EU/1/15/1024/003","prodAuthStatus":2,"prodName":"KEYTRUDA 25 mg/mL concentrate for solution for infusion","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"PEMBROLIZUMAB","euSubstNumber":"SUB167136","authorisationCountryCode":"LI","mrpNumber":"EMEA/H/C/003820","nameOrg":"MERCK SHARP & DOHME B.V.","productSubstances":[{"productPk":"12352442","substancePk":"387061","nameOrg":"MERCK SHARP & DOHME B.V.","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"PEMBROLIZUMAB","substanceEvCode":"SUB167136"}],"atcCode":"L01FF02","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"200","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"6.9","productChangedRelationMA":true,"productChangeDescription":"Relabeled for the clinical trial and administered with ficerasup alfa","maxTreatmentPeriod":24,"timeUnitCode":"3","evCode":"PRD12081134","miaNumber":"DE_BW_01_MIA_2023_0054","devices":[],"characteristics":["7","4"],"routes":["INTRAVENOUS USE"],"allSubstancesChemicals":false,"productName":"KEYTRUDA 25 mg/mL concentrate for solution for infusion","jsonActiveSubstanceNames":"pembrolizumab","pharmaceuticalFormDisplay":"SOLUTION FOR INFUSION"},{"id":562845,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"12352439","productPharmForm":"CONCENTRATE FOR SOLUTION FOR INFUSION","euMpNumber":"PRD4323786","marketingAuthNumber":"EU/1/15/1024/002","prodAuthStatus":2,"prodName":"KEYTRUDA 25 mg/mL concentrate for solution for infusion","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"PEMBROLIZUMAB","euSubstNumber":"SUB167136","authorisationCountryCode":"NO","mrpNumber":"EMEA/H/C/003820","nameOrg":"MERCK SHARP & DOHME B.V.","productSubstances":[{"productPk":"12352439","substancePk":"387061","nameOrg":"MERCK SHARP & DOHME B.V.","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"PEMBROLIZUMAB","substanceEvCode":"SUB167136"}],"atcCode":"L01FF02","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"200","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"6.9","productChangedRelationMA":true,"productChangeDescription":"Relabeled for the clinical trial and administered with ficerasup alfa","maxTreatmentPeriod":24,"timeUnitCode":"3","evCode":"PRD4323786","miaNumber":"DE_BW_01_MIA_2023_0054","devices":[],"characteristics":["7","4"],"routes":["INTRAVENOUS USE"],"allSubstancesChemicals":false,"productName":"KEYTRUDA 25 mg/mL concentrate for solution for infusion","jsonActiveSubstanceNames":"pembrolizumab","pharmaceuticalFormDisplay":"SOLUTION FOR INFUSION"},{"id":562853,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB167136","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"PEMBROLIZUMAB","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"PEMBROLIZUMAB","euSubstNumber":"SUB167136","productSubstances":[{"substancePk":"387061","actSubstOrigin":"Protein - Other","actSubstName":"PEMBROLIZUMAB","substanceEvCode":"SUB167136"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"2","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"200","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"6.9","productChangedRelationMA":true,"productChangeDescription":"Relabeled for the clinical trial","maxTreatmentPeriod":42,"timeUnitCode":"2","miaNumber":"DE_BW_01_MIA_2023_0054","scientificProductEvCode":"SUB167136","devices":[],"characteristics":["7","4"],"routes":["INTRAVENOUS USE"],"allSubstancesChemicals":false,"productName":"PEMBROLIZUMAB","jsonActiveSubstanceNames":"pembrolizumab"},{"id":562852,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"12980657","productPharmForm":"POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION","euMpNumber":"PRD12980657","prodAuthStatus":1,"prodName":"Ficerafusp Alfa","pharmForm":"POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION","sponsorProductCode":"BCA101","activeSubstanceName":"FICERAFUSP ALFA","euSubstNumber":"SUB301432","nameOrg":"BICARA","productSubstances":[{"productPk":"12980657","substancePk":"404854","nameOrg":"BICARA","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"FICERAFUSP ALFA","substanceEvCode":"SUB301432","synonyms":["Bifunctional monoclonal antibody against epidermal growth factor receptor and transforming growth factor beta","BCA101","Ficerafusp alpha"]}],"activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"1500","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"156","maxTreatmentPeriod":24,"timeUnitCode":"3","evCode":"PRD12980657","sponsorProductCodeEdit":"BCA101","miaNumber":"DE_BW_01_MIA_2023_0054","devices":[],"characteristics":["7"],"routes":["SOLUTION FOR INFUSION"],"allSubstancesChemicals":false,"productName":"Ficerafusp Alfa","jsonActiveSubstanceNames":"ficerafusp alfa","pharmaceuticalFormDisplay":"POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION"},{"id":562846,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"12352437","productPharmForm":"CONCENTRATE FOR SOLUTION FOR INFUSION","euMpNumber":"PRD4323784","marketingAuthNumber":"EU/1/15/1024/002","prodAuthStatus":2,"prodName":"KEYTRUDA 25 mg/mL concentrate for solution for infusion","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"PEMBROLIZUMAB","euSubstNumber":"SUB167136","authorisationCountryCode":"IS","mrpNumber":"EMEA/H/C/003820","nameOrg":"MERCK SHARP & DOHME B.V.","productSubstances":[{"productPk":"12352437","substancePk":"387061","nameOrg":"MERCK SHARP & DOHME B.V.","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"PEMBROLIZUMAB","substanceEvCode":"SUB167136"}],"atcCode":"L01FF02","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"200","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"6.9","productChangedRelationMA":true,"productChangeDescription":"Relabeled for the clinical trial and administered with ficerasup alfa","maxTreatmentPeriod":24,"timeUnitCode":"3","evCode":"PRD4323784","miaNumber":"DE_BW_01_MIA_2023_0054","devices":[],"characteristics":["4","7"],"routes":["INTRAVENOUS USE"],"allSubstancesChemicals":false,"productName":"KEYTRUDA 25 mg/mL concentrate for solution for infusion","jsonActiveSubstanceNames":"pembrolizumab","pharmaceuticalFormDisplay":"SOLUTION FOR INFUSION"},{"id":562849,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"12352440","productPharmForm":"CONCENTRATE FOR SOLUTION FOR INFUSION","euMpNumber":"PRD12081132","marketingAuthNumber":"EU/1/15/1024/003","prodAuthStatus":2,"prodName":"KEYTRUDA 25 mg/mL concentrate for solution for infusion","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"PEMBROLIZUMAB","euSubstNumber":"SUB167136","authorisationCountryCode":"EU","mrpNumber":"EMEA/H/C/003820","nameOrg":"MERCK SHARP & DOHME B.V.","productSubstances":[{"productPk":"12352440","substancePk":"387061","nameOrg":"MERCK SHARP & DOHME B.V.","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"PEMBROLIZUMAB","substanceEvCode":"SUB167136"}],"atcCode":"L01FF02","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"200","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"6.9","productChangedRelationMA":true,"productChangeDescription":"Relabeled for the clinical trial and administered with ficerasup alfa","maxTreatmentPeriod":24,"timeUnitCode":"3","evCode":"PRD12081132","miaNumber":"DE_BW_01_MIA_2023_0054","devices":[],"characteristics":["4","7"],"routes":["INTRAVENOUS USE"],"allSubstancesChemicals":false,"productName":"KEYTRUDA 25 mg/mL concentrate for solution for infusion","jsonActiveSubstanceNames":"pembrolizumab","pharmaceuticalFormDisplay":"SOLUTION FOR INFUSION"},{"id":562848,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"12352443","productPharmForm":"CONCENTRATE FOR SOLUTION FOR INFUSION","euMpNumber":"PRD12081135","marketingAuthNumber":"EU/1/15/1024/003","prodAuthStatus":2,"prodName":"KEYTRUDA 25 mg/mL concentrate for solution for infusion","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"PEMBROLIZUMAB","euSubstNumber":"SUB167136","authorisationCountryCode":"NO","mrpNumber":"EMEA/H/C/003820","nameOrg":"MERCK SHARP & DOHME B.V.","productSubstances":[{"productPk":"12352443","substancePk":"387061","nameOrg":"MERCK SHARP & DOHME B.V.","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"PEMBROLIZUMAB","substanceEvCode":"SUB167136"}],"atcCode":"L01FF02","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"200","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"6.9","productChangedRelationMA":true,"productChangeDescription":"Relabeled for the clinical trial and administered with ficerasup alfa","maxTreatmentPeriod":24,"timeUnitCode":"3","evCode":"PRD12081135","miaNumber":"DE_BW_01_MIA_2023_0054","devices":[],"characteristics":["4","7"],"routes":["INTRAVENOUS USE"],"allSubstancesChemicals":false,"productName":"KEYTRUDA 25 mg/mL concentrate for solution for infusion","jsonActiveSubstanceNames":"pembrolizumab","pharmaceuticalFormDisplay":"SOLUTION FOR INFUSION"},{"id":562844,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"12352436","productPharmForm":"CONCENTRATE FOR SOLUTION FOR INFUSION","euMpNumber":"PRD4323105","marketingAuthNumber":"EU/1/15/1024/002","prodAuthStatus":2,"prodName":"KEYTRUDA 25 mg/mL concentrate for solution for infusion","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"PEMBROLIZUMAB","euSubstNumber":"SUB167136","authorisationCountryCode":"EU","mrpNumber":"EMEA/H/C/003820","nameOrg":"MERCK SHARP & DOHME B.V.","productSubstances":[{"productPk":"12352436","substancePk":"387061","nameOrg":"MERCK SHARP & DOHME B.V.","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"PEMBROLIZUMAB","substanceEvCode":"SUB167136"}],"atcCode":"L01FF02","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"200","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"6.9","productChangedRelationMA":true,"productChangeDescription":"Relabeled for the clinical trial and administered with ficerasup alfa","maxTreatmentPeriod":24,"timeUnitCode":"3","evCode":"PRD4323105","miaNumber":"DE_BW_01_MIA_2023_0054","devices":[],"characteristics":["4","7"],"routes":["INTRAVENOUS USE"],"allSubstancesChemicals":false,"productName":"KEYTRUDA 25 mg/mL concentrate for solution for infusion","jsonActiveSubstanceNames":"pembrolizumab","pharmaceuticalFormDisplay":"SOLUTION FOR INFUSION"},{"id":562850,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"12352438","productPharmForm":"CONCENTRATE FOR SOLUTION FOR INFUSION","euMpNumber":"PRD4323785","marketingAuthNumber":"EU/1/15/1024/002","prodAuthStatus":2,"prodName":"KEYTRUDA 25 mg/mL concentrate for solution for infusion","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"PEMBROLIZUMAB","euSubstNumber":"SUB167136","authorisationCountryCode":"LI","mrpNumber":"EMEA/H/C/003820","nameOrg":"MERCK SHARP & DOHME B.V.","productSubstances":[{"productPk":"12352438","substancePk":"387061","nameOrg":"MERCK SHARP & DOHME B.V.","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"PEMBROLIZUMAB","substanceEvCode":"SUB167136"}],"atcCode":"L01FF02","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"200","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"6.9","productChangedRelationMA":true,"productChangeDescription":"Relabeled for the clinical trial and administered with ficerasup alfa","maxTreatmentPeriod":24,"timeUnitCode":"3","evCode":"PRD4323785","miaNumber":"DE_BW_01_MIA_2023_0054","devices":[],"characteristics":["4","7"],"routes":["INTRAVENOUS USE"],"allSubstancesChemicals":false,"productName":"KEYTRUDA 25 mg/mL concentrate for solution for infusion","jsonActiveSubstanceNames":"pembrolizumab","pharmaceuticalFormDisplay":"SOLUTION FOR INFUSION"},{"id":562854,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPharmForm":"N/A","euMpNumber":"N/A","marketingAuthNumber":"N/A","prodName":"Saline bag","pharmForm":"N/A","activeSubstanceName":"N/A","euSubstNumber":"N/A","productOtherName":"N/A","authorisationCountryCode":"IS","nameOrg":"N/A","sponsorSubstanceCode":"N/A","atcCode":"N/A","atcName":"N/A","atcTermLevel":"N/A","activeSubstanceOtherDescriptiveName":"N/A"},"isPaediatricFormulation":false,"mpRoleInTrial":"3","timeUnitCode":"2","evCode":"N/A","devices":[],"characteristics":[],"routes":[],"allSubstancesChemicals":false,"productName":"Saline bag","jsonActiveSubstanceNames":"n/a","pharmaceuticalFormDisplay":"N/A"}],"trialDetails":{"clinicalTrialIdentifiers":{"fullTitle":"A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (FORTIFI-HN01).","fullTitleTranslations":[{"id":11363953,"uuid":"924cef3c-3f09-4734-94e2-3857e19e1a56","attributeTranslation":"Wieloośrodkowe, randomizowane, prowadzone metodą podwójnie ślepej próby badanie fazy II/III dotyczące stosowania ficerafuspu alfa (BCA101) lub placebo w skojarzeniu z pembrolizumabem w leczeniu pierwszego rzutu nawrotowego lub przerzutowego raka płaskonabłonkowego głowy i szyi z dodatnim wskaźnikiem PD-L1 (FORTIFI-HN01).","language":19,"languageDescription":"Polish"},{"id":11363957,"uuid":"924cef3c-3f09-4734-94e2-3857e19e1a56","attributeTranslation":"Estudio de fase II/III, multicéntrico, aleatorizado, doble ciego de ficerafusp alfa (BCA101) o placebo en combinación con pembrolizumab para el tratamiento de primera línea del carcinoma epidermoide de cabeza y cuello positivo para el PD-L1 recidivante o metastásico (FORTIFI-HN01)","language":7,"languageDescription":"Spanish"},{"id":11363956,"uuid":"924cef3c-3f09-4734-94e2-3857e19e1a56","attributeTranslation":"Eine multizentrische, randomisierte, doppelblinde Studie der Phase II/III mit Ficerafusp Alfa (BCA101) oder Placebo in Kombination mit Pembrolizumab zur Erstlinienbehandlung von PD-L1-positivem, rezidivierendem oder metastasiertem Plattenepithelkarzinom im Kopf- und Halsbereich (FORTIFI-HN01).","language":27,"languageDescription":"German (Austria)"},{"id":11363958,"uuid":"924cef3c-3f09-4734-94e2-3857e19e1a56","attributeTranslation":"Étude de phase II/III multicentrique, randomisée, en double aveugle, portant sur le Ficerafusp alfa (BCA101) ou un Placebo en association avec le Pembrolizumab dans le traitement de première ligne du carcinome épidermoïde de la tête et du cou PD-L1 positif, récidivant ou métastatique (FORTIFI-HN01).","language":34,"languageDescription":"French (France)"},{"id":11363954,"uuid":"924cef3c-3f09-4734-94e2-3857e19e1a56","attributeTranslation":"Μια πολυκεντρική, τυχαιοποιημένη, διπλά τυφλή μελέτη Φάσης 2/3 του ficerafusp alfa (BCA101) ή εικονικού φαρμάκου σε συνδυασμό με πεμπρολιζουμάμπη για θεραπεία πρώτης γραμμής του PD-L1-θετικού, υποτροπιάζοντος ή μεταστατικού καρκινώματος κεφαλής και τραχήλου από πλακώδες επιθήλιο (FORTIFI-HN01).","language":32,"languageDescription":"Greek (Greece)"},{"id":11363955,"uuid":"924cef3c-3f09-4734-94e2-3857e19e1a56","attributeTranslation":"Estudo de Fase 2/3, multicêntrico, aleatorizado, em dupla ocultação, de Ficerafusp alfa (BCA101) ou Placebo em combinação com Pembrolizumab para o tratamento de primeira linha do carcinoma espinocelular da cabeça e pescoço PD L1-positivo, recidivante ou metastático (FORTIFI-HN01).","language":20,"languageDescription":"Portuguese"}],"publicTitle":"A trial to see if ficerafusp alfa given with pembrolizumab can treat participants with head and neck cancer.","publicTitleTranslations":[{"id":11364044,"uuid":"e95ad29c-1e8d-4eb6-a35c-3fb19314114f","attributeTranslation":"Eine Studie, um herauszufinden, ob Ficerafusp Alfa in Kombination mit Pembrolizumab bei Teilnehmern mit Kopf-Hals-Karzinom helfen kann.","language":27,"languageDescription":"German (Austria)"},{"id":11364047,"uuid":"e95ad29c-1e8d-4eb6-a35c-3fb19314114f","attributeTranslation":"Um estudo para verificar se ficerafusp alfa administrado com pembrolizumab pode tratar participantes com cancro da cabeça e pescoço.","language":20,"languageDescription":"Portuguese"},{"id":11364043,"uuid":"e95ad29c-1e8d-4eb6-a35c-3fb19314114f","attributeTranslation":"Μια δοκιμή για να διαπιστωθεί εάν το ficerafusp alfa που χορηγείται μαζί με πεμπρολιζουμάμπη μπορεί να θεραπεύσει τους συμμετέχοντες με καρκίνο κεφαλής και τραχήλου.","language":32,"languageDescription":"Greek (Greece)"},{"id":11364046,"uuid":"e95ad29c-1e8d-4eb6-a35c-3fb19314114f","attributeTranslation":"Étude visant à déterminer si le ficerafusp alfa administré en association avec le pembrolizumab peut traiter les participants atteints d’un cancer de la tête et du cou.","language":34,"languageDescription":"French (France)"},{"id":11364045,"uuid":"e95ad29c-1e8d-4eb6-a35c-3fb19314114f","attributeTranslation":"Ensayo para ver si el ficerafusp alfa administrado con pembrolizumab puede tratar a los participantes con cáncer de cabeza y cuello.","language":7,"languageDescription":"Spanish"},{"id":11364048,"uuid":"e95ad29c-1e8d-4eb6-a35c-3fb19314114f","attributeTranslation":"Badanie mające na celu sprawdzenie, czy podawanie ficerafuspu alfa w skojarzeniu z pembrolizumabem można stosować w leczeniu uczestników z rakiem głowy i szyi.","language":19,"languageDescription":"Polish"}],"shortTitle":"BCA101X301","secondaryIdentifyingNumbers":{"nctNumber":{"id":547081,"number":"NCT06788990"},"additionalRegistries":[]}},"trialInformation":{"trialCategory":{"isLowIntervention":false,"trialPhase":"10","trialCategory":"2","justificationForTrialCategory":"Phase II/phase III clinical trial","trialCategoryId":124853},"medicalCondition":{"partIMedicalConditions":[{"id":141540,"medicalCondition":"Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.","medicalConditionTranslations":[{"id":11363707,"uuid":"352e4f80-3b7a-46fe-bbdc-c2cbe875c0d3","attributeTranslation":"Nawracająca lub przerzutowa postać raka płaskonabłonkowego głowy i szyi (ang. recurrent or metastatic head and neck squamous cell carcinoma, R/M HNSCC).","language":19,"languageDescription":"Polish"},{"id":11363708,"uuid":"352e4f80-3b7a-46fe-bbdc-c2cbe875c0d3","attributeTranslation":"Υποτροπιάζον ή μεταστατικό καρκίνωμα κεφαλής και τραχήλου από πλακώδες επιθήλιο.","language":32,"languageDescription":"Greek (Greece)"},{"id":11363710,"uuid":"352e4f80-3b7a-46fe-bbdc-c2cbe875c0d3","attributeTranslation":"Carcinoma espinocelular da cabeça e pescoço recidivante ou metastático.","language":20,"languageDescription":"Portuguese"},{"id":11363709,"uuid":"352e4f80-3b7a-46fe-bbdc-c2cbe875c0d3","attributeTranslation":"Carcinome épidermoïde de la tête et du cou récidivant ou métastatique.","language":34,"languageDescription":"French (France)"},{"id":11363712,"uuid":"352e4f80-3b7a-46fe-bbdc-c2cbe875c0d3","attributeTranslation":"Rezidivierendes oder metastasiertes Plattenepithelkarzinom im Kopf- und Halsbereich.","language":27,"languageDescription":"German (Austria)"},{"id":11363711,"uuid":"352e4f80-3b7a-46fe-bbdc-c2cbe875c0d3","attributeTranslation":"Carcinoma epidermoide de cabeza y cuello recidivante o metastásico.","language":7,"languageDescription":"Spanish"}],"isConditionRareDisease":false}],"meddraConditionTerms":[{"termId":200000009936,"version":"27.0","level":"LLT","termName":"Squamous cell carcinoma of head and neck metastatic","classificationCode":"10082179","organClass":10029104,"active":false},{"termId":200000042781,"version":"27.0","level":"LLT","termName":"Squamous cell carcinoma of head and neck recurrent","classificationCode":"10090001","organClass":100000004864,"active":false}]},"trialObjective":{"trialScopes":[{"code":"3","trialScopeId":411098},{"code":"4","trialScopeId":411101},{"code":"6","trialScopeId":411096},{"code":"9","trialScopeId":411097},{"code":"7","trialScopeId":411099},{"code":"5","trialScopeId":411100}],"mainObjective":"Phase 2 Primary (Dose Selection):\nTo identify optimal biological dose (OBD) by:\n• Assessing safety and tolerability of ficerafusp alfa in participants randomized to ficerafusp alfa 1500 mg once weekly (QW) with pembrolizumab (Treatment Arm A) and ficerafusp alfa 750 mg QW with pembrolizumab (Treatment Arm B).\n• Assessing antitumor activity of ficerafusp alfa in participants randomized to ficerafusp alfa 1500 mg QW with pembrolizumab (Treatment Arm A) and ficerafusp alfa 750 mg QW and pembrolizumab (Treatment Arm B).\n\nPhase 3 Primary:\n• To compare efficacy in participants treated with ficerafusp alfa at the selected OBD in combination with pembrolizumab versus placebo plus pembrolizumab.","mainObjectiveTranslations":[{"id":11364042,"uuid":"5f6e94bf-6a5c-494e-aea2-397f3574ab40","attributeTranslation":"Primär in Phase II (Dosisauswahl):\nBestimmung der optimalen biologischen Dosis (OBD) durch:\n• Beurteilung der Sicherheit und Verträglichkeit von ficerafusp alfa bei Teilnehmern, die nach dem Zufallsprinzip ficerafusp alfa 1.500 mg einmal wöchentlich (QW) mit pembrolizumab (Behandlungsarm A) und ficerafusp alfa 750 mg QW mit Pembrolizumab (Behandlungsarm B) erhalten.\n• Beurteilung der Antitumoraktivität von ficerafusp alfa bei Teilnehmern, die nach dem Zufallsprinzip Ficerafusp alfa 1.500 mg QW mit pembrolizumab (Behandlungsarm A) und ficerafusp alfa 750 mg QW mit pembrolizumab (Behandlungsarm B) erhalten.\n\nPrimär in Phase III:\n• Vergleich der Wirksamkeit bei Teilnehmern, die mit ficerafusp alfa in der ausgewählten OBD in Kombination mit pembrolizumab behandelt wurden, gegenüber placebo plus pembrolizumab.","language":27,"languageDescription":"German (Austria)"},{"id":11364037,"uuid":"5f6e94bf-6a5c-494e-aea2-397f3574ab40","attributeTranslation":"Faza 2, pierwszorzędowa (wybór dawki):\nUstalenie optymalnej dawki biologicznej (ang. optimal biological dose, OBD) na podstawie:\n• oceny bezpieczeństwa i tolerancji stosowania ficerafuspu alfa u uczestników zrandomizowanych do grupy otrzymującej ficerafusp alfa w dawce 1500 mg raz w tygodniu w skojarzeniu z pembrolizumabem (Grupa leczenia A) i ficerafusp alfa w dawce 750 mg raz w tygodniu w skojarzeniu z pembrolizumabem (Grupa leczenia B);\n• oceny aktywności przeciwnowotworowej ficerafuspu alfa u uczestników zrandomizowanych do grupy otrzymującej ficerafusp alfa w dawce 1500 mg raz w tygodniu w skojarzeniu z pembrolizumabem (Grupa leczenia A) i ficerafusp alfa w dawce 750 mg raz w tygodniu oraz pembrolizumab (Grupa leczenia B).\n\nFaza 3, pierwszorzędowa:\n• Porównanie skuteczności u uczestników leczonych ficerafuspem alfa przy wybranych OBD w skojarzeniu z pembrolizumabem względem placebo w skojarzeniu z pembrolizumabem.","language":19,"languageDescription":"Polish"},{"id":11364039,"uuid":"5f6e94bf-6a5c-494e-aea2-397f3574ab40","attributeTranslation":"Principal de Phase II (sélection de dose) :\nIdentifier la dose biologique optimale (DBO) en :\n• Évaluant la sécurité d’emploi et la tolérabilité du ficerafusp alfa chez des participants randomisés pour recevoir 1 500 mg de ficerafusp alfa une fois par semaine (1x/sem.) avec le pembrolizumab (bras de traitement A) et 750 mg de ficerafusp alfa 1x/sem. avec le pembrolizumab (bras de traitement B).\n• Évaluant l’activité antitumorale du ficerafusp alfa chez les participants randomisés pour recevoir 1 500 mg de ficerafusp alfa 1x/sem. avec le pembrolizumab (bras de traitement A) et 750 mg de ficerafusp alfa 1x/sem. avec le pembrolizumab (bras de traitement B).\n\nPrincipal de Phase III :\n• Comparer l’efficacité chez les participants traités par ficerafusp alfa à la DBO sélectionnée en association avec le pembrolizumab par rapport au placebo plus pembrolizumab.","language":34,"languageDescription":"French (France)"},{"id":11364040,"uuid":"5f6e94bf-6a5c-494e-aea2-397f3574ab40","attributeTranslation":"Φάση 2, πρωτεύων (Επιλογή δόσης):\nΠροσδιορισμός της βέλτιστης βιολογικής δόσης (OBD) με:\n• Αξιολόγηση της ασφάλειας και της ανεκτικότητας του ficerafusp alfa σε συμμετέχοντες που τυχαιοποιήθηκαν για τη λήψη ficerafusp alfa 1500 mg μία φορά την εβδομάδα (QW) σε συνδυασμό με πεμπρολιζουμάμπη (Σκέλος θεραπείας Α) και ficerafusp alfa 750 mg QW σε συνδυασμό με πεμπρολιζουμάμπη (Σκέλος θεραπείας Β).\n• Αξιολόγηση της αντινεοπλασματικής δράσης του ficerafusp alfa σε συμμετέχοντες που τυχαιοποιήθηκαν για λήψη ficerafusp alfa 1500 mg QW σε συνδυασμό με πεμπρολιζουμάμπη (Σκέλος θεραπείας Α) και ficerafusp alfa 750 mg QW σε συνδυασμό με πεμπρολιζουμάμπη (Σκέλος θεραπείας Β).\n\nΦάση 3, πρωτεύων:\n• Σύγκριση της αποτελεσματικότητας σε συμμετέχοντες που έλαβαν θεραπεία με ficerafusp alfa στην επιλεγμένη OBD σε συνδυασμό με πεμπρολιζουμάμπη έναντι εικονικού φαρμάκου συν πεμπρολιζουμάμπη.","language":32,"languageDescription":"Greek (Greece)"},{"id":11364038,"uuid":"5f6e94bf-6a5c-494e-aea2-397f3574ab40","attributeTranslation":"Primário da Fase 2 (seleção da dose):\nIdentificar a dose biológica ideal (DBI) através da:\n• Avaliação da segurança e tolerabilidade de ficerafusp alfa em participantes aleatorizados para ficerafusp alfa 1500 mg uma vez por semana (QS) com pembrolizumab (braço de tratamento A) e ficerafusp alfa 750 mg QS com pembrolizumab (braço de tratamento B).\n• Avaliação da atividade antitumoral de ficerafusp alfa em participantes aleatorizados para ficerafusp alfa 1500 mg QS com pembrolizumab (braço de tratamento A) e ficerafusp alfa 750 mg QS e pembrolizumab (braço de tratamento B).\n\nPrimário da Fase 3:\n• Comparar a eficácia em participantes tratados com ficerafusp alfa na DBI selecionada em combinação com pembrolizumab versus placebo mais pembrolizumab.","language":20,"languageDescription":"Portuguese"},{"id":11364041,"uuid":"5f6e94bf-6a5c-494e-aea2-397f3574ab40","attributeTranslation":"Fase II principal (selección de la dosis):\nIdentificar la dosis biológica óptima (DBO) mediante:\n• La evaluación de la seguridad y la tolerabilidad de ficerafusp alfa en participantes aleatorizados a recibir 1500 mg de ficerafusp alfa una vez cada semana (CS) con pembrolizumab (grupo de tratamiento A) y 750 mg de ficerafusp alfa CS con pembrolizumab (grupo de tratamiento B).\n• La evaluación de la actividad antitumoral de ficerafusp alfa en participantes aleatorizados a recibir 1500 mg de ficerafusp alfa CS con pembrolizumab (grupo de tratamiento A) y 750 mg de ficerafusp alfa CS con pembrolizumab (grupo de tratamiento B).\n\nFase III principal:\n• Comparar la eficacia en participantes tratados con la DBO seleccionada de ficerafusp alfa en combinación con pembrolizumab frente a placebo más pembrolizumab.","language":7,"languageDescription":"Spanish"}],"secondaryObjectives":[{"id":481913,"number":1,"secondaryObjective":"Phase 2 secondary (Dose Selection): To further compare antitumor activity of ficerafusp alfa in participants randomized to ficerafusp alfa 1500 mg QW with pembrolizumab (Treatment Arm A) and ficerafusp alfa 750 mg QW and pembrolizumab (Treatment Arm B).","secondaryObjectiveTranslations":[{"id":11364050,"uuid":"92271847-478b-401e-9ce0-c5e5262c90fc","attributeTranslation":"Secondaire de Phase II (sélection de dose) : Comparer de manière plus approfondie l’activité antitumorale du ficerafusp alfa chez les participants randomisés pour recevoir 1 500 mg de ficerafusp alfa 1x/sem. avec le pembrolizumab (bras de traitement A) et 750 mg de ficerafusp alfa 1x/sem. avec le pembrolizumab (bras de traitement B).","language":34,"languageDescription":"French (France)"},{"id":11364053,"uuid":"92271847-478b-401e-9ce0-c5e5262c90fc","attributeTranslation":"Sekundär in Phase II (Dosisauswahl): Weiterer Vergleich der Antitumoraktivität von ficerafusp alfa bei Teilnehmern, die nach dem Zufallsprinzip ficerafusp alfa 1.500 mg QW mit pembrolizumab (Behandlungsarm A) und ficerafusp alfa 750 mg QW mit pembrolizumab (Behandlungsarm B) erhalten.","language":27,"languageDescription":"German (Austria)"},{"id":11364051,"uuid":"92271847-478b-401e-9ce0-c5e5262c90fc","attributeTranslation":"Secundário da Fase 2 (seleção da dose): Comparar adicionalmente a atividade antitumoral de ficerafusp alfa em participantes aleatorizados para ficerafusp alfa 1500 mg QS com pembrolizumab (braço de tratamento A) e ficerafusp alfa 750 mg QS e pembrolizumab (braço de tratamento B).","language":20,"languageDescription":"Portuguese"},{"id":11364054,"uuid":"92271847-478b-401e-9ce0-c5e5262c90fc","attributeTranslation":"Faza 2, drugorzędowa (wybór dawki): Dalsze porównanie działania przeciwnowotworowego ficerafuspu alfa u uczestników zrandomizowanych do grupy leczenia ficerafuspem alfa w dawce 1500 mg raz w tygodniu w skojarzeniu z pembrolizumabem (Grupa leczenia A) i ficerafuspem alfa w dawce 750 mg raz w tygodniu oraz pembrolizumabem (Grupa leczenia B).","language":19,"languageDescription":"Polish"},{"id":11364052,"uuid":"92271847-478b-401e-9ce0-c5e5262c90fc","attributeTranslation":"Fase II secundaria (selección de la dosis): comparar en mayor profundidad la actividad antitumoral de ficerafusp alfa en participantes aleatorizados a recibir 1500 mg de ficerafusp alfa CS con pembrolizumab (grupo de tratamiento A) y 750 mg de ficerafusp alfa CS con pembrolizumab (grupo de tratamiento B).","language":7,"languageDescription":"Spanish"},{"id":11364049,"uuid":"92271847-478b-401e-9ce0-c5e5262c90fc","attributeTranslation":"Φάση 2, δευτερεύων (Επιλογή δόσης): Περαιτέρω σύγκριση της αντινεοπλασματικής δράσης του ficerafusp alfa σε συμμετέχοντες που τυχαιοποιήθηκαν για τη λήψη ficerafusp alfa 1500 mg QW σε συνδυασμό με πεμπρολιζουμάμπη (Σκέλος θεραπείας Α) και ficerafusp alfa 750 mg QW σε συνδυασμό με πεμπρολιζουμάμπη (Σκέλος θεραπείας Β).","language":32,"languageDescription":"Greek (Greece)"}]},{"id":481914,"number":2,"secondaryObjective":"Phase 3 secondary: To compare safety and tolerability of participants treated with ficerafusp alfa at the selected OBD in combination with pembrolizumab versus placebo plus pembrolizumab.","secondaryObjectiveTranslations":[{"id":11364055,"uuid":"f68c5b19-ec8e-4d4d-b75f-d6ec4e065b9f","attributeTranslation":"Secundário da Fase 3: Comparar a segurança e tolerabilidade de participantes tratados com ficerafusp alfa na DBI selecionada em combinação com pembrolizumab versus placebo mais pembrolizumab.","language":20,"languageDescription":"Portuguese"},{"id":11364058,"uuid":"f68c5b19-ec8e-4d4d-b75f-d6ec4e065b9f","attributeTranslation":"Faza 3, drugorzędowa: Porównanie bezpieczeństwa i tolerancji u uczestników leczonych ficerafuspem alfa w skojarzeniu z pembrolizumabem względem placebo w skojarzeniu z pembrolizumabem.","language":19,"languageDescription":"Polish"},{"id":11364056,"uuid":"f68c5b19-ec8e-4d4d-b75f-d6ec4e065b9f","attributeTranslation":"Φάση 3, δευτερεύων: Σύγκριση της ασφάλειας και της ανεκτικότητας των συμμετεχόντων που έλαβαν θεραπεία με ficerafusp alfa στην επιλεγμένη OBD σε συνδυασμό με πεμπρολιζουμάμπη έναντι εικονικού φαρμάκου συν πεμπρολιζουμάμπη.","language":32,"languageDescription":"Greek (Greece)"},{"id":11364059,"uuid":"f68c5b19-ec8e-4d4d-b75f-d6ec4e065b9f","attributeTranslation":"Fase III secundaria: comparar la seguridad y la tolerabilidad en participantes tratados con la DBO seleccionada de ficerafusp alfa en combinación con pembrolizumab frente a placebo más pembrolizumab.","language":7,"languageDescription":"Spanish"},{"id":11364057,"uuid":"f68c5b19-ec8e-4d4d-b75f-d6ec4e065b9f","attributeTranslation":"Sekundär in Phase III: Vergleich der Sicherheit und Verträglichkeit bei Teilnehmern, die mit Ficerafusp alfa in der ausgewählten OBD in Kombination mit Pembrolizumab behandelt wurden, gegenüber Placebo plus pembrolizumab.","language":27,"languageDescription":"German (Austria)"},{"id":11364060,"uuid":"f68c5b19-ec8e-4d4d-b75f-d6ec4e065b9f","attributeTranslation":"Secondaire de Phase III : Comparer la sécurité d’emploi et la tolérabilité chez les participants traités par ficerafusp alfa à la DBO sélectionnée en association avec le pembrolizumab par rapport au placebo plus pembrolizumab.","language":34,"languageDescription":"French (France)"}]},{"id":481915,"number":3,"secondaryObjective":"Phase 3 secondary: To further compare efficacy in participants treated with ficerafusp alfa in combination with pembrolizumab versus placebo plus pembrolizumab.","secondaryObjectiveTranslations":[{"id":11364063,"uuid":"d439bae6-f839-40b9-a871-e89070abea15","attributeTranslation":"Secundário da Fase 3: Comparar adicionalmente a eficácia em participantes tratados com ficerafusp alfa em combinação com pembrolizumab versus placebo mais pembrolizumab.","language":20,"languageDescription":"Portuguese"},{"id":11364061,"uuid":"d439bae6-f839-40b9-a871-e89070abea15","attributeTranslation":"Φάση 3, δευτερεύων: Περαιτέρω σύγκριση της αποτελεσματικότητας σε συμμετέχοντες που έλαβαν θεραπεία με ficerafusp alfa σε συνδυασμό με πεμπρολιζουμάμπη έναντι εικονικού φαρμάκου συν πεμπρολιζουμάμπη.","language":32,"languageDescription":"Greek (Greece)"},{"id":11364062,"uuid":"d439bae6-f839-40b9-a871-e89070abea15","attributeTranslation":"Sekundär in Phase III: Weiterer Vergleich der Wirksamkeit bei Teilnehmern, die mit ficerafusp alfa in Kombination mit pembrolizumab behandelt wurden, gegenüber placebo plus pembrolizumab.","language":27,"languageDescription":"German (Austria)"},{"id":11364065,"uuid":"d439bae6-f839-40b9-a871-e89070abea15","attributeTranslation":"Fase III secundaria: comparar en mayor profundidad la eficacia en participantes tratados con ficerafusp alfa en combinación con pembrolizumab frente a placebo más pembrolizumab.","language":7,"languageDescription":"Spanish"},{"id":11364066,"uuid":"d439bae6-f839-40b9-a871-e89070abea15","attributeTranslation":"Secondaire de Phase III : Comparer de manière plus approfondie l’efficacité chez les participants traités par le ficerafusp alfa en association avec le pembrolizumab par rapport au placebo plus pembrolizumab.","language":33,"languageDescription":"French (Belgium)"},{"id":11364064,"uuid":"d439bae6-f839-40b9-a871-e89070abea15","attributeTranslation":"Faza 3, drugorzędowa: Dalsze porównanie skuteczności u uczestników leczonych ficerafuspem alfa w skojarzeniu z pembrolizumabem względem placebo w skojarzeniu z pembrolizumabem.","language":19,"languageDescription":"Polish"}]},{"id":481916,"number":4,"secondaryObjective":"Phase 3 secondary: To evaluate time to deterioration (TTD) in global health status/quality of life and pain in participants treated with ficerafusp alfa in combination with pembrolizumab versus placebo plus pembrolizumab.","secondaryObjectiveTranslations":[{"id":11364070,"uuid":"4287cb9b-4419-41f5-92cb-c9a254ca9164","attributeTranslation":"Secundário da Fase 3: Avaliar o tempo até à deterioração (TAD) do estado de saúde global/da qualidade de vida e a dor em participantes tratados com ficerafusp alfa em combinação com pembrolizumab versus placebo mais pembrolizumab.","language":20,"languageDescription":"Portuguese"},{"id":11364069,"uuid":"4287cb9b-4419-41f5-92cb-c9a254ca9164","attributeTranslation":"Sekundär in Phase III: Beurteilung der Zeit bis zur Verschlechterung (time to deterioration – TTD) in Bezug auf den allgemeinen Gesundheitszustand/die Lebensqualität und die Schmerzen bei Teilnehmern, die mit ficerafusp alfa in Kombination mit Pembrolizumab behandelt wurden, gegenüber placebo plus pembrolizumab.","language":27,"languageDescription":"German (Austria)"},{"id":11364068,"uuid":"4287cb9b-4419-41f5-92cb-c9a254ca9164","attributeTranslation":"Faza 3, drugorzędowa: Ocena czasu do pogorszenia (ang. time to deterioration, TTD) ogólnego stanu zdrowia/jakości życia i bólu u uczestników leczonych ficerafuspem alfa w skojarzeniu z pembrolizumabem w porównaniu z placebo w skojarzeniu z pembrolizumabem.","language":19,"languageDescription":"Polish"},{"id":11364067,"uuid":"4287cb9b-4419-41f5-92cb-c9a254ca9164","attributeTranslation":"Φάση 3, δευτερεύων: Αξιολόγηση του χρόνου έως την επιδείνωση (TTD) της καθολικής κατάστασης υγείας/ποιότητας ζωής και του πόνου σε συμμετέχοντες που έλαβαν θεραπεία με ficerafusp alfa σε συνδυασμό με πεμπρολιζουμάμπη έναντι εικονικού φαρμάκου συν πεμπρολιζουμάμπη.","language":32,"languageDescription":"Greek (Greece)"},{"id":11364072,"uuid":"4287cb9b-4419-41f5-92cb-c9a254ca9164","attributeTranslation":"Secondaire de Phase III : Évaluer le délai jusqu’à la détérioration (DJD) de l’état de santé global/la qualité de vie et la douleur chez les participants traités par ficerafusp alfa en association avec le pembrolizumab par rapport au placebo plus pembrolizumab.","language":34,"languageDescription":"French (France)"},{"id":11364071,"uuid":"4287cb9b-4419-41f5-92cb-c9a254ca9164","attributeTranslation":"Fase III secundaria: evaluar el tiempo hasta el deterioro (THD) del estado de salud general o la calidad de vida y el dolor en participantes tratados con ficerafusp alfa en combinación con pembrolizumab frente a placebo más pembrolizumab.","language":7,"languageDescription":"Spanish"}]}]},"eligibilityCriteria":{"principalInclusionCriteria":[{"id":919171,"number":1,"principalInclusionCriteria":"Participant or legally authorized representative, if applicable, has signed and dated informed consent form (ICF) indicating that the participant (or legally authorized representative, if applicable) has been informed of all the pertinent aspects of the study prior to enrollment and the participant must be willing to comply with all study procedures for the duration of the study.","principalInclusionCriteriaTranslations":[{"id":11363959,"uuid":"2e01a5b6-f68e-4ee7-9384-2b451c8ae985","attributeTranslation":"Le participant ou son représentant légal, le cas échéant, a signé et daté un formulaire de consentement éclairé (FCE) indiquant que le participant (ou son représentant légal, le cas échéant) a été informé de tous les aspects pertinents de l’étude avant son inclusion et le participant doit être disposé à se conformer à toutes les procédures de l’étude pendant la durée de celle-ci.","language":34,"languageDescription":"French (France)"},{"id":11363960,"uuid":"2e01a5b6-f68e-4ee7-9384-2b451c8ae985","attributeTranslation":"O(A) participante ou o representante legalmente autorizado, se aplicável, assinou e datou o formulário de consentimento informado (FCI) que indica que o(a) participante (ou o representante legalmente autorizado, se aplicável) foi informado(a) de todos os aspetos pertinentes do estudo antes da inscrição e que o(a) participante deve estar disposto a cumprir todos os procedimentos do estudo ao longo do período do estudo.","language":20,"languageDescription":"Portuguese"},{"id":11363961,"uuid":"2e01a5b6-f68e-4ee7-9384-2b451c8ae985","attributeTranslation":"Uczestnik (albo przedstawiciel ustawowy, jeżeli dotyczy) podpisał i opatrzył datą formularz świadomej zgody wskazujący, że uczestnik (albo jego przedstawiciel ustawowy, jeżeli dotyczy) został poinformowany o wszystkich stosownych aspektach badania przed włączeniem do badania, a uczestnik musi zobowiązać się do przestrzegania wszystkich procedur w ramach badania przez cały czas trwania badania.","language":19,"languageDescription":"Polish"},{"id":11363963,"uuid":"2e01a5b6-f68e-4ee7-9384-2b451c8ae985","attributeTranslation":"Ο ασθενής ή ο νομικά εξουσιοδοτημένος εκπρόσωπος, εάν ισχύει, έχει υπογράψει και χρονολογήσει το έντυπο συναίνεσης μετά από ενημέρωση (ICF) που υποδεικνύει ότι ο ασθενής (ή ο νομικά εξουσιοδοτημένος εκπρόσωπος, εάν ισχύει) έχει ενημερωθεί για όλες τις σχετικές πτυχές της μελέτης πριν από την εγγραφή και ότι ο ασθενής πρέπει να είναι πρόθυμος να συμμορφωθεί με όλες τις διαδικασίες της μελέτης κατά τη διάρκεια της μελέτης.","language":32,"languageDescription":"Greek (Greece)"},{"id":11363962,"uuid":"2e01a5b6-f68e-4ee7-9384-2b451c8ae985","attributeTranslation":"Der Teilnehmer oder ggf. sein gesetzlich bevollmächtigter Vertreter hat die Patienteninformation und Einwilligungserklärung datiert und unterzeichnet, aus der hervorgeht, dass der Teilnehmer (oder ggf. sein gesetzlich bevollmächtigter Vertreter) vor der Aufnahme in die Studie über alle relevanten Aspekte der Studie informiert wurde und dass der Teilnehmer bereit sein muss, alle Studienmaßnahmen für die Dauer der Studie einzuhalten.","language":27,"languageDescription":"German (Austria)"},{"id":11363964,"uuid":"2e01a5b6-f68e-4ee7-9384-2b451c8ae985","attributeTranslation":"El participante o el representante legal del participante, si procede, ha firmado y fechado el formulario de consentimiento informado (FCI) en donde se indica que se ha informado al participante (o al representante legal del participante, si procede) de todos los aspectos pertinentes del estudio antes de la inclusión y el participante debe estar dispuesto a cumplir todos los procedimientos del estudio durante la totalidad del estudio.","language":7,"languageDescription":"Spanish"}]},{"id":919172,"number":10,"principalInclusionCriteria":"Participant demonstrates adequate organ function, defined as follows: Hematological • Absolute neutrophil count (ANC) ≥1500/μL  • Platelets ≥100,000/μL • Hemoglobin ≥9 g/dL (90 g/L) or ≥5.6 mmol/L. Must be met without packed red blood cell transfusion in the prior 7 days. Renal •Creatinine clearance (CrCl) measured or calculated per institutional standards (CrCl or estimated glomerular filtration rate  Hepatic •Total serum bilirubin ≤1.5 x× upper limit of normal (ULN) (except for (Exception: Participants with documented Gilbert’s syndrome) may be eligible if total bilirubin is ≤3× ULN and direct bilirubin is within normal limits [≤ULN]) •Aspartate aminotransferase (AST ()(SGOT) and alanine aminotransferase (ALT) (SGPT) ≤2.5xULN5× ULN OR ≤5xULN5×  ULN for participants with liver metastases Coagulation •INRInternational normalized ratio, PT, partial thromboplastin time (PTT,), or activated partial thromboplastin time (aPTT) ≤1.5× ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants","principalInclusionCriteriaTranslations":[{"id":11363967,"uuid":"4d53cea4-2e90-42a0-aeb9-c53f010a4874","attributeTranslation":"Der Teilnehmer weist eine angemessene Organfunktion auf, die wie folgt definiert ist: \nHämatologie \n• Absolute Neutrophilenzahl (ANC) ≥ 1.500/μl \n• Thrombozyten ≥ 100.000/µl \n• Hämoglobin ≥ 9 g/dl oder ≥ 5,6 mmol/l. Muss ohne Transfusion von Erythrozytenkonzentrat in den letzten 7 Tagen erreicht werden. \nNiere \n• Kreatinin-Clearance (KrCl) gemessen oder berechnet gemäß institutionellen Standards (KrCl oder geschätzte glomeruläre Fitrationsrate)\nLeber \n• Gesamtserumbilirubin ≤ 1,5 x obere Normgrenze (upper limit of normal – ULN) (außer bei Teilnehmern mit dokumentiertem Gilbert-Syndrom) kann für eine Teilnahme infrage kommen, wenn das Gesamtserumbilirubin ≤ 3 x ULN ist und die Werte des direkten Bilirubins im normalen Bereich liegen (≤ ULN)\n• Aspartat-Aminotransferase (AST) (SGOT) und Alanin-Aminotransferase (ALT) (SGPT) ≤ 2,5 x ULN5 x ULN ODER ≤ 5 x ULN5 x ULN bei Teilnehmern mit Lebermetastasen \nGerinnung \n• INR International Normalized Ratio, PT, partielle Thromboplastinzeit (PTT) oder aktivierte partielle Thromboplastinzeit (aPTT) ≤ 1,5 × ULN, es sei denn, der Teilnehmer erhält eine Antikoagulationstherapie, solange PT oder aPTT innerhalb des therapeutischen Bereichs der beabsichtigten Anwendung von Antikoagulanzien liegt.","language":27,"languageDescription":"German (Austria)"},{"id":11363969,"uuid":"4d53cea4-2e90-42a0-aeb9-c53f010a4874","attributeTranslation":"U uczestnika występuje odpowiednia czynność narządów, definiowana w następujący sposób: \nHematologia \n• Bezwzględna liczba neutrofili (ang. absolute neutrophil count, ANC) ≥1500/μL. \n• Płytki krwi ≥100 000/μl. \n• Stężenie hemoglobiny ≥9 g/dl albo ≥5,6 mmol/l. Wskaźnik musi być osiągnięty bez przetoczenia krwinek czerwonych w ciągu poprzednich siedmiu dni. Nerki \n• Klirens kreatyniny (CrCl) mierzony albo obliczony zgodnie ze standardami leczenia w danym ośrodku. \nWątroba \n• Stężenie bilirubiny całkowitej w surowicy ≤1,5 x górna granica normy (GGN; z wyjątkiem pacjentów z udokumentowanym zespołem Gilberta). • AST (SGOT) i ALT (SGPT) ≤2,5 x GGN ALBO ≤5 x GGN w przypadku pacjentów z przerzutami do wątroby. \nKrzepliwość \n• INR, PT, PTT lub czas częściowej tromboplastyny po aktywacji (aPTT) ≤1,5 × GGN, chyba że pacjent otrzymuje leki przeciwzakrzepowe, o ile PT lub aPTT mieści się w zakresie terapeutycznym zamierzonego stosowania leków przeciwzakrzepowych.","language":19,"languageDescription":"Polish"},{"id":11363970,"uuid":"4d53cea4-2e90-42a0-aeb9-c53f010a4874","attributeTranslation":"Le participant présente une fonction adéquate des organes, définie comme suit : \nFonction hématologique \n• Numération absolue des neutrophiles (NAN) ≥ 1 500/µL. \n• Plaquettes ≥ 100 000/µL. \n• Hémoglobine ≥ 9 g/dl ou ≥ 5,6 mmol/l. Ce taux doit être atteint sans transfusion de concentré de globules rouges au cours des 7 derniers jours. \nFonction rénale \n• Clairance de la créatinine (ClCr) mesurée ou calculée selon les normes de l’établissement, ou débit de filtration glomérulaire estimé. \nFonction hépatique \n• Bilirubine sérique totale ≤ 1,5 × limite supérieure de la normale (LSN) (exception : les participants présentant un syndrome de Gilbert documenté pourraient être éligibles si la bilirubine totale est ≤ 3 × LSN et la bilirubine directe est dans les limites de la normale [≤ LSN]).\n• Aspartate aminotransférase (ASAT [SGOT]) et alanine aminotransférase (ALAT [SGPT]) ≤ 2,5 × LSN OU ≤ 5 × LSN pour les participants présentant des métastases hépatiques. \nCoagulation \n• Rapport normalisé international (INR), temps de prothrombine (TP) ou temps de céphaline activée (TCA) ≤ 1,5 × LSN, sauf si le participant est sous traitement anticoagulant, à condition que le TP ou le TCA se situent dans la plage thérapeutique de l’utilisation prévue des anticoagulants.","language":34,"languageDescription":"French (France)"},{"id":11363966,"uuid":"4d53cea4-2e90-42a0-aeb9-c53f010a4874","attributeTranslation":"El participante demuestra un funcionamiento orgánico satisfactorio, definido como sigue: \nHematológico \n• Cifra absoluta de neutrófilos (CAN) ≥1500/μl. \n• Plaquetas ≥100 000/μl. \n• Hemoglobina ≥9 g/dl o ≥5,6 mmol/l. Debe cumplirse sin transfusión de concentrado de hematíes en los 7 días previos. Renal \n• Aclaramiento de la creatinina (CrCl) medido o calculado según las normas del centro.\nHepática \n• Bilirrubina en suero total ≤1,5 veces el límite superior de la normalidad (LSN) (excepto en participantes con síndrome de Gilbert documentado).\n• AST (GOT sérica) y ALT (GPT sérica) ≤2,5 veces el LSN O ≤5 x LSN en participantes con metástasis hepática. \nCoagulación \n• IIN, TP, TTP o tiempo de tromboplastina parcial activada (TTPa) ≤1,5 veces el LSN, a menos que el participante reciba tratamiento anticoagulante, siempre y cuando el TP o el TTPa estén dentro del intervalo terapéutico de uso previsto de anticoagulantes.","language":7,"languageDescription":"Spanish"},{"id":11363965,"uuid":"4d53cea4-2e90-42a0-aeb9-c53f010a4874","attributeTranslation":"Ο συμμετέχων επιδεικνύει επαρκή λειτουργία οργάνων, που ορίζεται ως εξής: \nΑιματολογική \n• Απόλυτος αριθμός ουδετερόφιλων (ANC) ≥ 1500/μL.\n• Αιμοπετάλια ≥ 100.000/μL. \n• Αιμοσφαιρίνη ≥ 9 g/dL ή ≥ 5,6 mmol/L. Πρέπει να επιτυγχάνεται χωρίς μετάγγιση συμπυκνωμένων ερυθρών αιμοσφαιρίων τις προηγούμενες 7 ημέρες.\nΝεφρική\n• Μέτρηση ή υπολογισμός της κάθαρσης κρεατινίνης (CrCl) σύμφωνα με τα πρότυπα του ιδρύματος (CrCl ή εκτιμώμενος ρυθμός σπειραματικής διήθησης)\nΗπατική\n• Ολική χολερυθρίνη ορού ≤1,5 × ανώτατο όριο του φυσιολογικού (ULN) (Εξαίρεση: Συμμετέχοντες με τεκμηριωμένο σύνδρομο Gilbert μπορεί να είναι επιλέξιμοι εάν η ολική χολερυθρίνη είναι ≤3× ULN και η άμεση χολερυθρίνη είναι εντός των φυσιολογικών ορίων [≤ULN])\n• Ασπαρτική αμινοτρανσφεράση (AST) (SGOT) και αμινοτρανσφεράση της αλανίνης (ALT) (SGPT) ≤2,5× ULN Ή ≤5× ULN για συμμετέχοντες με ηπατικές μεταστάσεις\nΠήξη\n• Διεθνές κανονικοποιημένο πηλίκο (INR), PT, χρόνος μερικής θρομβοπλαστίνης (PTT) ή χρόνος ενεργοποιημένης μερικής θρομβοπλαστίνης (aPTT) ≤1,5 × ULN, εκτός εάν ο συμμετέχων λαμβάνει αντιπηκτική θεραπεία, εφόσον ο PT ή ο aPTT είναι εντός του θεραπευτικού εύρους της προβλεπόμενης χρήσης των αντιπηκτικών φαρμάκων","language":32,"languageDescription":"Greek (Greece)"},{"id":11363968,"uuid":"4d53cea4-2e90-42a0-aeb9-c53f010a4874","attributeTranslation":"O(A) participante demonstra uma função adequada dos órgãos, definida da seguinte forma: \nHematológica \n• Contagem absoluta de neutrófilos (CAN) ≥1500/μl.  \n• Plaquetas ≥100 000/μl. \n• Hemoglobina ≥9 g/dl ou ≥5,6 mmol/l. Deve ser atingida sem transfusão de concentrado de eritrócitos nos 7 dias anteriores. Renal \n• Depuração da creatinina (DC) medida ou calculada de acordo com os padrões institucionais.\nHepática \n• Bilirrubina sérica total ≤1,5 vezes o limite superior normal (LSN) (exceto para participantes com síndrome de Gilbert documentada). • AST (SGOT) e ALT (SGPT) ≤2,5 vezes o LSN OU ≤5 vezes o LSN para participantes com metástases hepáticas. \nCoagulação \n• INR, TP, TTP ou tempo de tromboplastina parcial ativada (TTPa) ≤1,5 vezes o LSN, exceto se o(a) participante estiver a receber terapêutica anticoagulante, desde que o TP ou TTPa esteja dentro do intervalo terapêutico da utilização prevista de anticoagulantes.","language":20,"languageDescription":"Portuguese"}]},{"id":919173,"number":11,"principalInclusionCriteria":"Women of childbearing potential (WOCBP) must have a negative blood highly sensitive serum pregnancy test within 7 days prior to receiving the first dose of study treatment. A urine pregnancy test can be considered if a blood test is not appropriate per local standard of care.","principalInclusionCriteriaTranslations":[{"id":11363976,"uuid":"ba5603fe-174e-477c-92b0-4adf07700f3e","attributeTranslation":"Kobiety zdolne do posiadania potomstwa muszą uzyskać ujemny wynik testu ciążowego o wysokiej czułości z surowicy krwi w ciągu 7 dni przed otrzymaniem pierwszej dawki leczenia stosowanego w badaniu. Jeżeli test ciążowy z krwi jest nieodpowiedni zgodnie z lokalnym standardem opieki, można rozważyć wykonanie testu ciążowego z moczu.","language":19,"languageDescription":"Polish"},{"id":11363975,"uuid":"ba5603fe-174e-477c-92b0-4adf07700f3e","attributeTranslation":"Las mujeres con posibilidad de quedarse embarazadas (MPE) deben presentar un resultado negativo en una prueba de embarazo en sangre en los 7 días anteriores a recibir la primera dosis del tratamiento del estudio. Se puede considerar una prueba de embarazo en orina si el análisis de sangre no resulta oportuno.","language":7,"languageDescription":"Spanish"},{"id":11363972,"uuid":"ba5603fe-174e-477c-92b0-4adf07700f3e","attributeTranslation":"Les femmes en capacité de procréer doivent présenter un test de grossesse sérique négatif réalisé dans les 7 jours précédant l’administration de la première dose du traitement à l’étude. Un test de grossesse urinaire peut être envisagé si un test sérique n’est pas approprié.","language":34,"languageDescription":"French (France)"},{"id":11363974,"uuid":"ba5603fe-174e-477c-92b0-4adf07700f3e","attributeTranslation":"As mulheres com potencial para engravidar (MCPPE) têm de apresentar um teste de gravidez de sangue negativo no período de 7 dias antes de receberem a primeira dose do tratamento do estudo. Pode considerar-se um teste de gravidez de urina se uma análise ao sangue não for apropriada.","language":20,"languageDescription":"Portuguese"},{"id":11363971,"uuid":"ba5603fe-174e-477c-92b0-4adf07700f3e","attributeTranslation":"Frauen im gebärfähigen Alter müssen innerhalb von 7 Tagen vor Erhalt der ersten Dosis der Studienbehandlung einen negativen hochsensitiven Blutserum-Schwangerschaftstest vorweisen. Wenn ein Bluttest gemäß dem lokalen Behandlungsstandard nicht geeignet ist, kann ein Urin-Schwangerschaftstest in Betracht gezogen werden.","language":27,"languageDescription":"German (Austria)"},{"id":11363973,"uuid":"ba5603fe-174e-477c-92b0-4adf07700f3e","attributeTranslation":"Οι γυναίκες με δυνατότητα τεκνοποίησης (WOCBP) πρέπει να έχουν αρνητικό τεστ εγκυμοσύνης ορού υψηλής ευαισθησίας εντός 7 ημερών πριν από τη λήψη της πρώτης δόσης της θεραπείας της μελέτης. Μπορεί να γίνει ένα τεστ εγκυμοσύνης ούρων, εάν το τεστ αίματος δεν είναι κατάλληλο σύμφωνα με το τοπικό πρότυπο φροντίδας.","language":32,"languageDescription":"Greek (Greece)"}]},{"id":919174,"number":12,"principalInclusionCriteria":"WOCBP should be willing to use highly effective contraception for birth control or be surgically sterile or abstain from heterosexual activity for the course of the study and are not permitted to donate oocytes during this time. WOCBP are those who have not been surgically sterilized or have not been free from menses for >1 year.","principalInclusionCriteriaTranslations":[{"id":11363979,"uuid":"8e06059e-891a-4d6c-827b-32a7a24b84bb","attributeTranslation":"Las MPE deben estar dispuestas a utilizar métodos anticonceptivos muy eficaces o ser quirúrgicamente estériles o abstenerse de mantener relaciones heterosexuales durante el transcurso del estudio y tampoco podrán donar óvulos en este periodo. Las MPE son aquellas que no han sido esterilizadas quirúrgicamente o que no han tenido ausencia de periodos menstruales durante >1 año.","language":7,"languageDescription":"Spanish"},{"id":11363982,"uuid":"8e06059e-891a-4d6c-827b-32a7a24b84bb","attributeTranslation":"Frauen im gebärfähigen Alter sollten, sofern sie nicht chirurgisch sterilisiert worden sind, bereit sein, zur Empfängnisverhütung hochwirksame Verhütungsmittel anzuwenden oder für die Dauer der Studie auf heterosexuelle Aktivitäten zu verzichten. Frauen im gebärfähigen Alter bezieht sich auf Frauen, die nicht chirurgisch sterilisiert sind bzw. die nicht seit > 1 Jahr keine Menstruation mehr hatten.","language":27,"languageDescription":"German (Austria)"},{"id":11363977,"uuid":"8e06059e-891a-4d6c-827b-32a7a24b84bb","attributeTranslation":"Les femmes en capacité de procréer doivent être disposées à utiliser une méthode de contraception hautement efficace, avoir été stérilisées par voie chirurgicale, ou être disposées à s’abstenir de tout rapport hétérosexuel pendant toute la durée de l’étude et ne sont pas autorisées à faire de don d’ovocytes pendant cette période. Les femmes en capacité de procréer sont celles qui n’ont pas été stérilisées par voie chirurgicale ou qui n’ont pas une absence de règles depuis plus de 1 an.","language":34,"languageDescription":"French (France)"},{"id":11363980,"uuid":"8e06059e-891a-4d6c-827b-32a7a24b84bb","attributeTranslation":"Kobiety zdolne do posiadania potomstwa powinny zobowiązać się do stosowania wysoce skutecznych metod antykoncepcji lub być bezpłodne w wyniku przeprowadzonego zabiegu chirurgicznego albo powstrzymywać się od aktywności heteroseksualnej przez cały czas trwania badania oraz. Ponadto w tym okresie nie wolno im oddawać komórek jajowych. Kobiety zdolne do posiadania potomstwa to te, które nie zostały poddane sterylizacji chirurgicznej ani nie zaprzestały miesiączkowania przez > jeden rok.","language":19,"languageDescription":"Polish"},{"id":11363981,"uuid":"8e06059e-891a-4d6c-827b-32a7a24b84bb","attributeTranslation":"As MCPPE devem estar dispostas a utilizar métodos contracetivos altamente eficazes para contraceção, serem cirurgicamente estéreis ou absterem se de atividade heterossexual durante o estudo e não estão autorizadas a doar ovócitos durante este período. São consideradas MCPPE as mulheres que não tenham sido esterilizadas cirurgicamente ou que não tenham estado sem menstruação durante mais de um ano.","language":20,"languageDescription":"Portuguese"},{"id":11363978,"uuid":"8e06059e-891a-4d6c-827b-32a7a24b84bb","attributeTranslation":"Οι WOCBP θα πρέπει να είναι πρόθυμες να χρησιμο-ποιήσουν αντισύλληψη υψηλής αποτελεσματικότητας ή να έχουν υποβληθεί σε χειρουργική στείρωση ή να απέχουν πλήρως από ετεροφυλοφιλική σεξουαλική δραστηριότητα κατά τη διάρκεια της μελέτης και δεν επιτρέπεται να προβαίνουν σε δωρεά ωοκυττάρων κατά τη διάρκεια αυτής της περιόδου. WOCBP είναι οι γυναίκες που δεν έχουν υποβληθεί σε χειρουργική στείρωση ή δεν έχουν αμηνόρροια για > 1 έτος.","language":32,"languageDescription":"Greek (Greece)"}]},{"id":919175,"number":13,"principalInclusionCriteria":"Male participants must agree to use a condom or to remain abstinent (refrain from heterosexual intercourse), and to not donate sperm starting with the first dose of study treatment after the last dose of study medication.","principalInclusionCriteriaTranslations":[{"id":11363987,"uuid":"ee26275e-7314-47e4-a530-cda4e10448b6","attributeTranslation":"Männliche Teilnehmer müssen sich bereit erklären, ab der ersten Dosis der Studienbehandlung bis nach der letzten Dosis der Studienmedikation ein Kondom zu verwenden oder auf heterosexuellen Geschlechtsverkehr zu verzichten und keinen Samen zu spenden.","language":27,"languageDescription":"German (Austria)"},{"id":11363983,"uuid":"ee26275e-7314-47e4-a530-cda4e10448b6","attributeTranslation":"Los participantes varones deben aceptar utilizar preservativos y no donar semen a partir de la primera dosis del tratamiento del estudio y hasta después de la última dosis del medicamento del estudio.","language":7,"languageDescription":"Spanish"},{"id":11363984,"uuid":"ee26275e-7314-47e4-a530-cda4e10448b6","attributeTranslation":"Mężczyźni muszą wyrazić zgodę na stosowanie prezerwatyw lub zachowanie wstrzemięźliwości (powstrzymywanie się od stosunków heteroseksualnych) oraz na nieoddawanie nasienia, począwszy od momentu przyjęcia pierwszej dawki leczenia stosowanego w badaniu aż do czasu po przyjęciu ostatniej dawki leku stosowanego w badaniu.","language":19,"languageDescription":"Polish"},{"id":11363985,"uuid":"ee26275e-7314-47e4-a530-cda4e10448b6","attributeTranslation":"Os participantes do sexo masculino devem concordar em utilizar preservativo e em não doar esperma a partir da primeira dose do tratamento do estudo após a última dose da medicação do estudo.","language":20,"languageDescription":"Portuguese"},{"id":11363986,"uuid":"ee26275e-7314-47e4-a530-cda4e10448b6","attributeTranslation":"Les participants de sexe masculin doivent accepter d’utiliser un préservatif ou de rester abstinents (s’abstenir de tout rapport hétérosexuel), et de ne pas faire de don de sperme à compter de la première dose du traitement à l’étude et jusqu’après la dernière dose du médicament à l’étude.","language":34,"languageDescription":"French (France)"},{"id":11363988,"uuid":"ee26275e-7314-47e4-a530-cda4e10448b6","attributeTranslation":"Οι άνδρες συμμετέχοντες πρέπει να συμφωνήσουν να χρησιμοποιούν προφυλακτικό ή να παραμένουν σε αποχή (να απέχουν από ετεροφυλοφιλικές σεξουαλικές επαφές) και να μην προβαίνουν σε δωρεά σπέρματος ξεκινώντας από την πρώτη δόση της θεραπείας της μελέτης έως και μετά την τελευταία δόση του φαρμάκου της μελέτης.","language":32,"languageDescription":"Greek (Greece)"}]},{"id":919176,"number":2,"principalInclusionCriteria":"Participant is >18 years of age or of an acceptable age according to local regulations, whichever is older on the day the ICF is signed.","principalInclusionCriteriaTranslations":[{"id":11363994,"uuid":"fd73c29e-356d-4bcc-93af-3772820e1522","attributeTranslation":"Ο ασθενής είναι >18 ετών ή αποδεκτής ηλικίας σύμφωνα με τους τοπικούς κανονισμούς, όποια είναι μεγαλύτερη κατά την ημέρα υπογραφής του ICF.","language":32,"languageDescription":"Greek (Greece)"},{"id":11363991,"uuid":"fd73c29e-356d-4bcc-93af-3772820e1522","attributeTranslation":"Der Teilnehmer ist am Tag der Unterzeichnung der Patienteninformation und Einwilligungserklärung mindestens 18 Jahre alt oder in einem Alter, das den diesbezüglichen lokalen Vorschriften entspricht, wobei das jeweils höhere Alter maßgeblich ist.","language":27,"languageDescription":"German (Austria)"},{"id":11363993,"uuid":"fd73c29e-356d-4bcc-93af-3772820e1522","attributeTranslation":"Le participant est âgé de > 18 ans ou d’un âge acceptable conformément aux réglementations locales, l’âge le plus avancé prévalant, le jour de la signature du FCE.","language":34,"languageDescription":"French (France)"},{"id":11363989,"uuid":"fd73c29e-356d-4bcc-93af-3772820e1522","attributeTranslation":"El participante tiene ≥18 años el día de la firma del FCI.","language":7,"languageDescription":"Spanish"},{"id":11363992,"uuid":"fd73c29e-356d-4bcc-93af-3772820e1522","attributeTranslation":"O(A) participante tem idade igual ou superior a 18 anos no dia em que o FCI é assinado.","language":20,"languageDescription":"Portuguese"},{"id":11363990,"uuid":"fd73c29e-356d-4bcc-93af-3772820e1522","attributeTranslation":"Uczestnik jest w wieku ≥18 lat w dniu podpisania formularza świadomej zgody.","language":19,"languageDescription":"Polish"}]},{"id":919177,"number":3,"principalInclusionCriteria":"Participant has histologically or cytologically confirmed R or M HNSCC. Eligible primary tumor locations are oral cavity, hypopharynx, larynx or oropharynx (with documented HPV-negative disease if presenting with OPSCC). Note: Primary tumor location of paranasal sinuses and nasopharynx, or tumor of any other histology are excluded.","principalInclusionCriteriaTranslations":[{"id":11363999,"uuid":"e28fde10-b731-4dcb-95d5-57cb9f1939e5","attributeTranslation":"Ο ασθενής έχει ιστολογικά ή κυτταρολογικά επιβεβαιωμένο υποτροπιάζον ή μεταστατικό καρκίνωμα κεφαλής και τραχήλου από πλακώδες επιθήλιο (HNSCC). Επιλέξιμες θέσεις πρωτοπαθούς όγκου είναι η στοματική κοιλότητα, ο υποφάρυγγας, ο λάρυγγας ή ο στοματοφάρυγγας (με τεκμηριωμένη HPV-αρνητική νόσο εάν ο ασθενής παρουσιάζει στοματοφαρυγγικό καρκίνωμα από πλακώδες επιθήλιο [OPSCC]). Σημείωση: Αποκλείονται η θέση πρωτοπαθούς όγκου σε παραρρίνιους κόλπους και ρινοφάρυγγα, οποιουδήποτε ιστολογικού τύπου.","language":32,"languageDescription":"Greek (Greece)"},{"id":11363998,"uuid":"e28fde10-b731-4dcb-95d5-57cb9f1939e5","attributeTranslation":"Le participant présente un CETC R/M confirmé par histologie ou cytologie. Les localisations éligibles de la tumeur primitive sont la cavité buccale, l’hypopharynx, le larynx ou l’oropharynx (avec une maladie négative au VPH documentée en cas de carcinome épidermoïde de l’oropharynx [CEOP]). Remarque : les localisations de la tumeur primitive dans les sinus paranasaux et le nasopharynx, ainsi que les tumeurs de toute autre histologie, sont exclues.","language":34,"languageDescription":"French (France)"},{"id":11363997,"uuid":"e28fde10-b731-4dcb-95d5-57cb9f1939e5","attributeTranslation":"U uczestnika potwierdzono histologicznie lub cytologicznie R/M HNSCC. Kwalifikująca się do badania lokalizacja guza pierwotnego to jama ustna, część krtaniowa gardła, krtań lub część ustna gardła (z udokumentowaną chorobą wykazującą ujemny wynik badania HPV w przypadku raka płaskonabłonkowego jamy ustnej i gardła [ang. oropharyngeal squamous cell carcinoma; OPSCC]). Uwaga: pierwotne lokalizacje nowotworu w zatokach przynosowych i nosogardzieli lub guzy o jakiejkolwiek innej histologii są wykluczone.","language":19,"languageDescription":"Polish"},{"id":11363996,"uuid":"e28fde10-b731-4dcb-95d5-57cb9f1939e5","attributeTranslation":"O(A) participante tem carcinoma espinocelular da cabeça e pescoço recidivante ou metastático (CECP R ou M) confirmado histologicamente ou citologicamente. As zonas de tumor primário elegíveis são a cavidade oral, hipofaringe, laringe ou orofaringe (com doença documentada como HPV-negativa, se apresentar carcinoma espinocelular da orofaringe [CEO]). Nota: a zona de tumor primário dos seios nasais e da nasofaringe, ou tumores de qualquer outra histologia, estão excluídos.","language":20,"languageDescription":"Portuguese"},{"id":11364000,"uuid":"e28fde10-b731-4dcb-95d5-57cb9f1939e5","attributeTranslation":"El participante tiene carcinoma epidermoide de cabeza y cuello (CECC) recurrente o metastásico confirmado histológica o citológicamente. Las localizaciones aptas del tumor primario son la cavidad bucal, la hipofaringe, la laringe o la orofaringe (con un resultado negativo documentado de VPH en caso de carcinoma epidermoide orofaríngeo [CEO]). Nota: Se excluyen los tumores primarios localizados en los senos paranasales y la nasofaringe, de cualquier histología.","language":7,"languageDescription":"Spanish"},{"id":11363995,"uuid":"e28fde10-b731-4dcb-95d5-57cb9f1939e5","attributeTranslation":"Der Teilnehmer hat ein histologisch oder zytologisch bestätigtes rezidivierendes oder metastasiertes HNSCC. Als Ort des Primärtumors kommen die Mundhöhle, der Hypopharynx, der Larynx oder der Oropharynx (mit dokumentierter HPV-negativer Erkrankung bei Vorliegen eines OPSCC) in Frage. Hinweis: Primärtumore mit Lokalisierung in den Nasennebenhöhlen und im Nasopharynx sind unabhängig von der Histologie ausgeschlossen.","language":27,"languageDescription":"German (Austria)"}]},{"id":919178,"number":4,"principalInclusionCriteria":"No prior systemic therapy administered in the R or M setting. Systemic therapy completed >6 months prior to signing ICF if given as part of multimodal treatment for locoregionally advanced disease is allowed.","principalInclusionCriteriaTranslations":[{"id":11364005,"uuid":"1a86bee3-9331-4d69-9127-88eacab5c727","attributeTranslation":"Nenhuma terapêutica sistémica anterior administrada no cenário R ou M. É permitida terapêutica sistémica concluída >6 meses antes da assinatura do FCI, se administrada como parte de tratamento multimodal para doença locorregionalmente avançada.","language":20,"languageDescription":"Portuguese"},{"id":11364006,"uuid":"1a86bee3-9331-4d69-9127-88eacab5c727","attributeTranslation":"Aucun traitement systémique antérieur administré dans le contexte récidivant ou métastatique ; et traitement systémique terminé plus de 6 mois au préalable s’il est administré dans le cadre d’un traitement multimodal pour une maladie locorégionale à un stade avancé dans le contexte adjuvant ou définitif.","language":34,"languageDescription":"French (France)"},{"id":11364001,"uuid":"1a86bee3-9331-4d69-9127-88eacab5c727","attributeTranslation":"Nieprzyjmowanie wcześniej leczenia ogólnoustrojowego w ramach leczenia postaci nawracającej albo przerzutowej oraz ukończenie leczenia ogólnoustrojowego > sześć miesięcy przed rozpoczęciem leczenia multimodalnego w ramach leczenia miejscowo zaawansowanej choroby w terapii adjuwantowej albo definitywnej.","language":19,"languageDescription":"Polish"},{"id":11364004,"uuid":"1a86bee3-9331-4d69-9127-88eacab5c727","attributeTranslation":"Δεν έχει χορηγηθεί προηγούμενη συστηματική θεραπεία στο πλαίσιο R ή M νόσου. H συστηματική θεραπεία που έχει ολοκληρωθεί >6 μήνες πριν από την υπογραφή του ICF, εφόσον έχει χορηγηθεί ως μέρος πολυτροπικής θεραπείας για τοποπεριοχικά προχωρημένη επιτρέπεται.","language":32,"languageDescription":"Greek (Greece)"},{"id":11364003,"uuid":"1a86bee3-9331-4d69-9127-88eacab5c727","attributeTranslation":"Sin tratamiento sistémico previo administrado para un carcinoma recidivante o metastásico; y tratamiento sistémico completado >6 meses antes de la firma del FCI si se administró como parte de un tratamiento multimodal para la enfermedad avanzada locorregionalmente como tratamiento adyuvante o definitivo.","language":7,"languageDescription":"Spanish"},{"id":11364002,"uuid":"1a86bee3-9331-4d69-9127-88eacab5c727","attributeTranslation":"Keine vorherige systemische Therapie bei rezidivierter oder metastasierter Erkrankung; eine systemische Therapie, die > 6 Monate vor der Unterzeichnung der Patienteninformation und Einwilligungserklärung abgeschlossen wurde, ist zulässig, wenn die Verabreichung im Rahmen einer multimodalen Behandlung einer lokoregionär fortgeschrittenen Erkrankung erfolgt.","language":27,"languageDescription":"German (Austria)"}]},{"id":919179,"number":5,"principalInclusionCriteria":"Participant is willing to provide archival tumor tissue as specified in the laboratory manual or willing to undergo pretreatment excisional or core needle biopsy (fine needle aspirates not acceptable) at Screening if archival tissue is insufficient or unavailable.","principalInclusionCriteriaTranslations":[{"id":11364011,"uuid":"058518b6-4cec-40d9-b3b1-3fa5f2f66a01","attributeTranslation":"Le participant est disposé à fournir du tissu tumoral archivé, conformément aux modalités précisées dans le manuel de laboratoire, ou à faire l’objet d’une biopsie de prétraitement excisionnelle ou au trocart (les ponctions à l’aiguille fine ne sont pas acceptables) à la sélection si le tissu archivé est insuffisant ou indisponible.","language":34,"languageDescription":"French (France)"},{"id":11364012,"uuid":"058518b6-4cec-40d9-b3b1-3fa5f2f66a01","attributeTranslation":"Ο ασθενής είναι πρόθυμος να παράσχει αρχειακό ιστό όγκου ή είναι πρόθυμος να υποβληθεί σε βιοψία πριν από τη θεραπεία κατά τη διαλογή, εάν ο αρχειακός ιστός είναι ανεπαρκής ή μη διαθέσιμος.","language":32,"languageDescription":"Greek (Greece)"},{"id":11364010,"uuid":"058518b6-4cec-40d9-b3b1-3fa5f2f66a01","attributeTranslation":"El participante está dispuesto a proporcionar tejido tumoral de archivo (un bloque de tejido tumoral incluido en parafina suficiente para obtener 20 secciones de 4 a 10 micras de grosor) o a que se le practique una biopsia previa al tratamiento en la selección, si no hay suficiente tejido de archivo o no estuviera disponible.","language":7,"languageDescription":"Spanish"},{"id":11364009,"uuid":"058518b6-4cec-40d9-b3b1-3fa5f2f66a01","attributeTranslation":"Der Teilnehmer ist bereit, archiviertes Tumorgewebe bereitzustellen oder beim Screening eine Biopsie vor der Behandlung durchführen zu lassen, wenn das archivierte Gewebe nicht ausreicht oder nicht verfügbar ist.","language":27,"languageDescription":"German (Austria)"},{"id":11364008,"uuid":"058518b6-4cec-40d9-b3b1-3fa5f2f66a01","attributeTranslation":"Uczestnik jest gotowy dostarczyć archiwalną próbkę tkanki nowotworowej zgodnie z opisem w podręczniku laboratoryjnym lub wyraża chęć poddania się biopsji chirurgicznej lub gruboigłowej (aspiraty z biopsji cienkoigłowej nie są dopuszczalne) przed rozpoczęciem leczenia podczas badania przesiewowego, jeżeli tkanka archiwalna jest niewystarczająca lub niedostępna.","language":19,"languageDescription":"Polish"},{"id":11364007,"uuid":"058518b6-4cec-40d9-b3b1-3fa5f2f66a01","attributeTranslation":"O(A) participante está disposto(a) a fornecer tecido tumoral de arquivo, conforme especificado no manual de laboratório, ou está disposto(a) a realizar uma biópsia excisional ou por agulha grossa (não são aceitáveis aspirados por agulha fina) pré-tratamento na seleção se o tecido de arquivo for insuficiente ou não estiver disponível.","language":20,"languageDescription":"Portuguese"}]},{"id":919180,"number":6,"principalInclusionCriteria":"Participant has documentation of HPV-negative disease per central testing performed if presenting with OPSCC. Tumor tissue from excisional/incisional or core biopsy (fine needle aspirates and bone biopsies are not acceptable) must be provided for central testing. Archival tumor tissue is acceptable. A fresh tumor biopsy, using a procedure that is safe for the participant on a lesion not previously irradiated (unless lesion progressed) will be required if tumor tissue is not available. Note: To be eligible to participate in this study, participants with OPSCC must have HPV-negative documentation.","principalInclusionCriteriaTranslations":[{"id":11364014,"uuid":"07c060ab-09cc-4aa9-9837-4f28dc3a6d14","attributeTranslation":"Im Falle einer OPSCC-Diagnose verfügt der Teilnehmer über einen Nachweis einer HPV-negativen Erkrankung durch einen zentralen Test. Für den zentralen Test muss Tumorgewebe aus einer Exzisions-/Inzisions- oder Kernbiopsie (Feinnadelaspirate und Knochenbiopsien sind nicht zulässig) bereitgestellt werden. Archiviertes Tumorgewebe ist zulässig. Ist kein Tumorgewebe verfügbar, muss eine frische Tumorbiopsie entnommen werden, und zwar unter Verwendung eines für den Teilnehmer sicheren Verfahrens an einer zuvor nicht bestrahlten Läsion (es sei denn, die Läsion ist fortgeschritten). Hinweis: Um an dieser Studie teilnehmen zu können, müssen Teilnehmer mit OPSCC einen Nachweis über einen HPV-negativen Befund vorlegen.","language":27,"languageDescription":"German (Austria)"},{"id":11364013,"uuid":"07c060ab-09cc-4aa9-9837-4f28dc3a6d14","attributeTranslation":"El participante tiene un resultado negativo documentado de VPH si presenta CEO. Para las pruebas centrales se debe proporcionar tejido tumoral de biopsias por escisión o incisión o con aguja gruesa (no se aceptan biopsias por punción con aguja fina ni biopsias óseas). Se acepta el tejido tumoral de archivo. Si no se dispone de tejido tumoral, se exigirá una biopsia tumoral reciente realizada con un procedimiento seguro para el participante en una lesión no irradiada anteriormente (a menos que la lesión haya progresado). Nota: A fin de ser aptos para participar en este estudio, los participantes con CEO deben presentar un resultado negativo documentado de VPH.","language":7,"languageDescription":"Spanish"},{"id":11364017,"uuid":"07c060ab-09cc-4aa9-9837-4f28dc3a6d14","attributeTranslation":"O(A) participante tem documentação de doença HPV-negativa por meio de testes centrais, se apresentar CEO. Deve ser fornecido tecido tumoral de biópsia excisional/incisional ou por agulha grossa (não são aceitáveis aspirados por agulha fina ou biópsias ósseas) para testes centrais. O tecido tumoral de arquivo é aceitável. Se não estiver disponível tecido tumoral, será necessária uma biópsia de tumor recente, utilizando um procedimento seguro para o(a) participante numa lesão não irradiada anteriormente (a menos que a lesão tenha progredido). Nota: para serem elegíveis para participar neste estudo, os participantes com CEO têm de apresentar documentação de doença HPV-negativa.","language":20,"languageDescription":"Portuguese"},{"id":11364018,"uuid":"07c060ab-09cc-4aa9-9837-4f28dc3a6d14","attributeTranslation":"Uczestnik posiada dokumentację dotyczącą choroby wykazującej ujemny wynik badania HPV zgodnie z badaniem centralnym, jeśli u uczestnika jest obecne OPSCC. Tkanka nowotworowa z biopsji wycinkowej/nacinającej lub biopsji gruboigłowej (biopsja aspiracyjna cienkoigłowa i biopsja kości są niedozwolone) musi zostać przekazana do badań w laboratorium centralnym. Dopuszczalna jest tkanka archiwalna tkanki nowotworowej. Nowa biopsja guza, przeprowadzana w ramach procedury bezpiecznej dla uczestnika na zmianie, której wcześniej nie poddano naświetlaniu (chyba że choroba wykazuje progresję zmiany) będzie wymagana, jeżeli tkanka guza jest niedostępna. Uwaga: aby kwalifikować się do udziału w tym badaniu, uczestnicy z OPSCC muszą mieć dokumentację potwierdzającą ujemny wynik badania HPV.","language":19,"languageDescription":"Polish"},{"id":11364015,"uuid":"07c060ab-09cc-4aa9-9837-4f28dc3a6d14","attributeTranslation":"Le participant présente une maladie négative au VPH documentée par une analyse centrale, en cas de CEOP. Du tissu tumoral provenant d’une biopsie excisionnelle/incisionnelle ou d’une biopsie au trocart (les ponctions à l’aiguille fine et les biopsies osseuses ne sont pas acceptables) doit être fourni pour une analyse centrale. Du tissu tumoral archivé est acceptable. Une biopsie tumorale fraîche, utilisant une procédure sans danger pour le participant sur une lésion qui n’a pas été précédemment irradiée (sauf si la lésion a progressé), sera nécessaire si aucun tissu tumoral n’est disponible. Remarque : pour pouvoir participer à cette étude, les participants atteints d’un CEOP doivent présenter un résultat négatif documenté au test de dépistage du VPH.","language":34,"languageDescription":"French (France)"},{"id":11364016,"uuid":"07c060ab-09cc-4aa9-9837-4f28dc3a6d14","attributeTranslation":"Ο συμμετέχων έχει τεκμηρίωση HPV-αρνητικής νόσου εάν παρουσιάζει OPSCC. Ιστός όγκου από βιοψία εκτομής/τμηματική βιοψία ή βιοψία με κόπτουσα βελόνα (οι αναρροφήσεις με λεπτή βελόνα και οι οστικές βιοψίες δεν είναι αποδεκτές) πρέπει να παρέχεται για κεντρική εξέταση. Ο αρχειακός ιστός όγκου είναι αποδεκτός. Εάν δεν είναι διαθέσιμος ιστός όγκου, θα απαιτηθεί νέα βιοψία όγκου με χρήση διαδικασίας που είναι ασφαλής για τον συμμετέχοντα σε προηγουμένως μη ακτινοβοληθείσα βλάβη (εκτός εάν η βλάβη έχει προχωρήσει). Σημείωση: Για να είναι επιλέξιμοι να συμμετάσχουν σε αυτήν τη μελέτη, οι συμμετέχοντες με OPSCC πρέπει να διαθέτουν τεκμηρίωση HPV-αρνητικής νόσου.","language":32,"languageDescription":"Greek (Greece)"}]},{"id":919181,"number":7,"principalInclusionCriteria":"Participant is eligible to receive pembrolizumab as frontline monotherapy with documented tumor PD-L1 CPS ≥1 (PD-L1 immunohistochemistry [IHC] via 22C3). If appropriate local documentation of PD-L1status is not available, tumor tissue from excisional or core biopsy (fine needle aspirates and bone biopsies are not acceptable) must be provided for central testing to determine eligibility.","principalInclusionCriteriaTranslations":[{"id":11364021,"uuid":"acec4a7b-c0c2-4db4-8db2-95219b667ea2","attributeTranslation":"Uczestnik kwalifikuje się do otrzymania pembrolizumabu w monoterapii pierwszego rzutu, jeżeli występuje u niego udokumentowany łączny wynik dodatni oceny guza z ekspresją PD-L1 (ang. combined positive score, CPS) ≥1 (na podstawie testu PD-L1 IHC 22C3\neśli odpowiednia lokalna dokumentacja statusu PD-L1 nie jest dostępna, wówczas należy przekazać tkankę guza z biopsji wycinkowej lub biopsji gruboigłowej (biopsja aspiracyjna cienkoigłowa i biopsja kości są niedozwolone) do badania centralnego w celu określenia spełniania kryteriów kwalifikacyjnych.","language":19,"languageDescription":"Polish"},{"id":11364024,"uuid":"acec4a7b-c0c2-4db4-8db2-95219b667ea2","attributeTranslation":"Ο συμμετέχων είναι κατάλληλος να λάβει πεμπρολιζουμάμπη ως μονοθεραπεία πρώτης γραμμής και έχει τεκμηριωμένη έκφραση PD-L1 όγκου με συνδυαστική θετική βαθμολογία (CPS) ≥1 (βάσει ανοσοϊστοχημικής [IHC] εξέτασης του PD-L1 με τη δοκιμασία 22C3). Εάν δεν είναι διαθέσιμη κατάλληλη τοπική τεκμηρίωση της κατάστασης έκφρασης του PD-L1, πρέπει να παρασχεθεί ιστός όγκου από βιοψία εκτομής ή βιοψία με κόπτουσα βελόνα (οι αναρροφήσεις με λεπτή βελόνα και οι οστικές βιοψίες δεν είναι αποδεκτές) προς κεντρική εξέταση για τον προσδιορισμό της επιλεξιμότητας.","language":32,"languageDescription":"Greek (Greece)"},{"id":11364023,"uuid":"acec4a7b-c0c2-4db4-8db2-95219b667ea2","attributeTranslation":"O(A) participante tem uma pontuação positiva combinada (Combined Positive Score, CPS) de PD L1 do tumor ≥1 documentada (ensaio imunohistoquímico [IHC] PD-L1 22C3).\nSe a documentação local adequada sobre o estado de PD L1 não estiver disponível, deve ser fornecido tecido tumoral de uma biópsia excisional ou por agulha grossa (não são aceitáveis aspirados por agulha fina ou biópsias ósseas) para testes centrais de modo a determinar a elegibilidade.","language":20,"languageDescription":"Portuguese"},{"id":11364022,"uuid":"acec4a7b-c0c2-4db4-8db2-95219b667ea2","attributeTranslation":"Le participant présente un score tumoral CPS PD-L1 documenté ≥ 1 (immunohistochimie [IHC] du PD-L1 réalisée à l’aide du test 22C3).\nSi aucune documentation locale appropriée du statut PD-L1 n’est disponible, du tissu tumoral provenant d’une biopsie excisionnelle ou au trocart (les ponctions à l’aiguille fine et les biopsies osseuses ne sont pas acceptables) doit être fourni pour une analyse centrale afin de déterminer l’éligibilité.","language":34,"languageDescription":"French (France)"},{"id":11364019,"uuid":"acec4a7b-c0c2-4db4-8db2-95219b667ea2","attributeTranslation":"El participante reúne los requisitos para recibir pembrolizumab como monoterapia en primera línea con una PPC documentada para PD-L1 tumoral ≥1 (según la prueba PD-L1 IHC 22C3). Si no se dispone de documentación local sobre PD-L1, se debe proporcionar tejido tumoral de biopsias por escisión o con aguja gruesa (no se aceptan biopsias por punción con aguja fina ni biopsias óseas) para realizar pruebas centrales a fin de determinar la idoneidad.","language":7,"languageDescription":"Spanish"},{"id":11364020,"uuid":"acec4a7b-c0c2-4db4-8db2-95219b667ea2","attributeTranslation":"Der Teilnehmer ist mit einem dokumentierten Tumor-PD-L1-CPS ≥ 1 (im PD-L1 IHC 22C3), der vor Ort oder zentral bestimmt wurde, dafür geeignet, Pembrolizumab als Erstlinien-Monotherapie zu erhalten. Wenn keine lokale Dokumentation des PD-L1-Status verfügbar ist, muss zur Bestimmung der Eignung Tumorgewebe aus einer Exzisions- oder Kernbiopsie (Feinnadelaspirate und Knochenbiopsien sind nicht zulässig) für einen zentralen Test bereitgestellt werden.","language":27,"languageDescription":"German (Austria)"}]},{"id":919182,"number":8,"principalInclusionCriteria":"Participant has measurable disease based on RECIST 1.1 as determined by BICR. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated. Baseline Scan must be transferred to BICR for assessment.","principalInclusionCriteriaTranslations":[{"id":11364025,"uuid":"6f2c21d7-1789-43ad-abb3-03391a6a8fb1","attributeTranslation":"El participante tiene una enfermedad medible conforme a los criterios RECIST 1.1, según lo determinado por la RCIE. Las lesiones tumorales situadas en una zona previamente irradiada se consideran medibles si se ha presentado progresión. La exploración inicial mediante escáner debe transferirse a la RCIE para su evaluación.","language":7,"languageDescription":"Spanish"},{"id":11364029,"uuid":"6f2c21d7-1789-43ad-abb3-03391a6a8fb1","attributeTranslation":"Ο συμμετέχων έχει μετρήσιμη νόσο με βάση τα κριτήρια RECIST 1.1, όπως προσδιορίζεται από τυφλοποιημένη ανεξάρτητη κεντρική ανασκόπηση (BICR). Οι νεοπλασματικές βλάβες με εντόπιση σε προηγουμένως ακτινοβοληθείσα περιοχή θεωρούνται μετρήσιμες εάν έχει καταδειχθεί εξέλιξη. Η τομογραφία αρχικής αξιολόγησης πρέπει να διαβιβαστεί προς αξιολόγηση από την BICR.","language":32,"languageDescription":"Greek (Greece)"},{"id":11364027,"uuid":"6f2c21d7-1789-43ad-abb3-03391a6a8fb1","attributeTranslation":"Der Teilnehmer hat eine messbare Erkrankung gemäß verblindeter unabhängiger zentraler Überprüfung (Blinded Independent Central Review – BICR) basierend auf RECIST 1.1. Tumorläsionen in einem zuvor bestrahlten Bereich gelten als messbar, wenn eine Progression nachgewiesen wurde. Der Baseline-Scan muss zur Beurteilung per BICR übermittelt werden.","language":27,"languageDescription":"German (Austria)"},{"id":11364026,"uuid":"6f2c21d7-1789-43ad-abb3-03391a6a8fb1","attributeTranslation":"U uczestnika występuje choroba mierzalna na podstawie kryteriów RECIST 1.1, określona na podstawie niezależnej zaślepionej oceny centralnej (ang. blinded independent central review, BICR). Zmiany nowotworowe usytuowane w poddawanych uprzednio naświetlaniu obszarach uznaje się za mierzalne, jeżeli wykazano progresję. Skan wyjściowy musi zostać przekazany do BICR w celu przeprowadzenia oceny.","language":19,"languageDescription":"Polish"},{"id":11364028,"uuid":"6f2c21d7-1789-43ad-abb3-03391a6a8fb1","attributeTranslation":"O(A) participante tem doença mensurável com base nos critérios de avaliação de resposta em tumores sólidos (Response Evaluation Criteria in Solid Tumors, RECIST) 1.1, conforme determinado por revisão central independente de forma oculta (Blinded Independent Central Review, BICR).\nLesões tumorais situadas numa zona previamente irradiada são consideradas mensuráveis se tiver sido demonstrada progressão. O exame basal deve ser transferido para BICR para avaliação.","language":20,"languageDescription":"Portuguese"},{"id":11364030,"uuid":"6f2c21d7-1789-43ad-abb3-03391a6a8fb1","attributeTranslation":"Le participant présente une maladie mesurable selon les critères RECIST 1.1, tel que déterminé par un examen central indépendant en aveugle (ECIA). Les lésions tumorales situées dans une zone précédemment irradiée sont considérées comme mesurables si une progression a été mise en évidence. Les clichés d’imagerie de référence doivent être transférés à l’ECIA pour évaluation.","language":34,"languageDescription":"French (France)"}]},{"id":919183,"number":9,"principalInclusionCriteria":"Participant has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.","principalInclusionCriteriaTranslations":[{"id":11364032,"uuid":"505a380a-713e-4e00-b648-f0b34808e943","attributeTranslation":"Ο ασθενής έχει κατάσταση απόδοσης 0 ή 1 σύμφωνα με τη Συνεργατική Ογκολογική Ομάδα Ανατολικών Πολιτειών των ΗΠΑ (Eastern Cooperative Oncology Group, ECOG).","language":32,"languageDescription":"Greek (Greece)"},{"id":11364033,"uuid":"505a380a-713e-4e00-b648-f0b34808e943","attributeTranslation":"El participante tiene un estado funcional de 0 o 1 según la escala de valoración del Grupo Oncológico Cooperativo de la Costa Este de los EE. UU. (ECOG).","language":7,"languageDescription":"Spanish"},{"id":11364034,"uuid":"505a380a-713e-4e00-b648-f0b34808e943","attributeTranslation":"O(A) participante tem um estado de desempenho do Eastern Cooperative Oncology Group (ECOG) de 0 ou 1.","language":20,"languageDescription":"Portuguese"},{"id":11364035,"uuid":"505a380a-713e-4e00-b648-f0b34808e943","attributeTranslation":"Le participant a un indice de performance ECOG (Eastern Cooperative Oncology Group) de 0 ou 1.","language":34,"languageDescription":"French (France)"},{"id":11364031,"uuid":"505a380a-713e-4e00-b648-f0b34808e943","attributeTranslation":"Stan sprawności według skali Wschodniej Grupy Współpracy Onkologicznej (ang. Eastern Cooperative Oncology Group, ECOG) 0 albo 1.","language":19,"languageDescription":"Polish"},{"id":11364036,"uuid":"505a380a-713e-4e00-b648-f0b34808e943","attributeTranslation":"Der Teilnehmer hat einen Leistungsstatus gemäß ECOG (Eastern Cooperative Oncology Group) von 0 oder 1.","language":27,"languageDescription":"German (Austria)"}]}],"principalExclusionCriteria":[{"id":1571457,"number":1,"principalExclusionCriteria":"Prior systemic therapy in the R or M setting.","principalExclusionCriteriaTranslations":[{"id":11363800,"uuid":"90605b4c-3a96-4d2f-b9c6-077383a76414","attributeTranslation":"Traitement systémique antérieur dans un contexte récidivant ou métastatique.","language":34,"languageDescription":"French (France)"},{"id":11363799,"uuid":"90605b4c-3a96-4d2f-b9c6-077383a76414","attributeTranslation":"Wcześniejsze leczenie ogólnoustrojowe w nawracającym lub przerzutowym wskazaniu.","language":19,"languageDescription":"Polish"},{"id":11363801,"uuid":"90605b4c-3a96-4d2f-b9c6-077383a76414","attributeTranslation":"Terapêutica sistémica anterior no cenário recidivante ou metastático.","language":20,"languageDescription":"Portuguese"},{"id":11363797,"uuid":"90605b4c-3a96-4d2f-b9c6-077383a76414","attributeTranslation":"Vorherige systemische Therapie bei rezidivierter oder metastasierter Erkrankung.","language":27,"languageDescription":"German (Austria)"},{"id":11363802,"uuid":"90605b4c-3a96-4d2f-b9c6-077383a76414","attributeTranslation":"Προηγούμενη συστηματική θεραπεία σε πλαίσιο R ή M νόσου.","language":32,"languageDescription":"Greek (Greece)"},{"id":11363798,"uuid":"90605b4c-3a96-4d2f-b9c6-077383a76414","attributeTranslation":"Tratamiento sistémico previo para recidivas o metástasis.","language":7,"languageDescription":"Spanish"}]},{"id":1571466,"number":10,"principalExclusionCriteria":"Participants who are at higher risk of bleeding including participants with known bleeding diathesis, or who have current active major bleeding, or a recent major bleeding episode within 4 weeks prior to enrollment. Note: • A major bleeding episode is defined according to the International Society on Thrombosis and Haemostasis criteria, which include fatal bleeding, symptomatic bleeding in a critical organ/area (e.g., intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal), hemoglobin drop ≥2 g/dL, or transfusion of ≥2 units of blood. • Cases of tumor-related bleeding within the last 4 weeks, or other risk factors potentially increasing the risk of bleeding, should be discussed with the Sponsor Medical Director prior to enrollment.","principalExclusionCriteriaTranslations":[{"id":11363851,"uuid":"5651cec9-3137-4233-a8bb-f186c0c78d2c","attributeTranslation":"Participantes con mayor riesgo hemorrágico, incluidos los participantes con diátesis hemorrágica conocida, o que presenten sangrado activo importante en la actualidad o un episodio hemorrágico grave reciente en las 4 semanas previas a la inclusión.\nNota: • Un episodio hemorrágico grave se define según los criterios de la Sociedad Internacional de Trombosis y Hemostasia, e incluye hemorragia mortal, hemorragia sintomática en un órgano o lugar crítico (p. ej., intracraneal, intrarraquídea, intraocular, pericárdica, intrarticular, intramuscular con síndrome compartimental, retroperitoneal), disminución de la concentración de hemoglobina ≥2 g/dl o transfusión de ≥2 unidades de sangre.\n• Los casos de hemorragia relacionada con el tumor en las últimas 4 semanas, u otros factores de riesgo que tengan la posibilidad de aumentar el riesgo de hemorragia, se deben analizar con el director médico del promotor antes de la inclusión","language":7,"languageDescription":"Spanish"},{"id":11363852,"uuid":"5651cec9-3137-4233-a8bb-f186c0c78d2c","attributeTranslation":"Συμμετέχοντες που διατρέχουν υψηλότερο κίνδυνο αιμορραγίας, συμπεριλαμβανομένων των συμμετεχόντων με γνωστή αιμορραγική διάθεση ή με τρέχουσα ενεργό μείζονα αιμορραγία ή πρόσφατο μείζον αιμορραγικό επεισόδιο εντός 4 εβδομάδων πριν από την εγγραφή.\nΣημείωση: Ένα επεισόδιο μείζονος αιμορραγίας ορίζεται σύμφωνα με τα κριτήρια της Διεθνούς Εταιρείας για τη Θρόμβωση και την Αιμόσταση, τα οποία περιλαμβάνουν θανατηφόρο αιμορραγία, συμπτωματική αιμορραγία σε κρίσιμο όργανο/περιοχή (π.χ., ενδοκρανιακή, ενδορραχιαία, ενδοφθάλμια, περικαρδιακή, ενδοαρθρική, ενδομυϊκή με σύνδρομο διαμερίσματος, οπισθοπεριτοναϊκή), πτώση αιμοσφαιρίνης ≥2 g/dL, ή μετάγγιση ≥2 μονάδων αίματος.\n• Περιστατικά σχετιζόμενης με τον όγκο αιμορραγίας εντός των τελευταίων 4 εβδομάδων, ή άλλοι παράγοντες κινδύνου που πιθανώς να αυξάνουν τον κίνδυνο αιμορραγίας, θα πρέπει να συζητούνται με τον Ιατρικό Διευθυντή του Χορηγού πριν από την εγγραφή","language":32,"languageDescription":"Greek (Greece)"},{"id":11363853,"uuid":"5651cec9-3137-4233-a8bb-f186c0c78d2c","attributeTranslation":"Participantes com maior risco de hemorragia, incluindo participantes com diátese hemorrágica conhecida, que tenham hemorragia major ativa atual ou que tenham tido um episódio recente de hemorragia major nas 4 semanas anteriores à inscrição.\nNota: um episódio de hemorragia major define-se de acordo com os critérios da Sociedade Internacional de Trombose e Hemostasia (International Society on Thrombosis and Haemostasis), que incluem hemorragia fatal, hemorragia sintomática num órgão/área crítica (p. ex. intracraniana, intraespinal, intraocular, pericárdica, intra-articular, intramuscular com síndrome do compartimento, retroperineal), uma descida da hemoglobina de ≥2 g/dl, ou transfusão de ≥2 unidades de sangue.\n• Casos de hemorragia relacionada com o tumor nas últimas 4 semanas ou outros fatores de risco que aumentam potencialmente o risco de hemorragia devem ser discutidos com o diretor clínico do Promotor antes da inscrição.","language":20,"languageDescription":"Portuguese"},{"id":11363856,"uuid":"5651cec9-3137-4233-a8bb-f186c0c78d2c","attributeTranslation":"Uczestnicy, u których ryzyko krwawienia jest wyższe, w tym uczestnik ze stwierdzoną skazą krwotoczną lub u którego występuje czynne duże krwawienie, lub u którego wystąpił niedawno poważny epizod krwawienia w ciągu czterech tygodni przed włączeniem do badania.\nUwaga: poważny epizod krwawienia definiuje się zgodnie z kryteriami Międzynarodowego Towarzystwa ds. Zakrzepicy i Hemostazy (ang. International Society on Thrombosis and Haemostasis), które obejmują krwawienie prowadzące do zgonu, objawowe krwawienie w krytycznym narządzie/obszarze (np. śródczaszkowe, śródrdzeniowe, śródgałkowe, osierdziowe, śródstawowe, śródmięśniowe z zespołem ciasnoty przedziałów powięziowych, zaotrzewnowe), spadek stężenia hemoglobiny ≥2 g/dl lub transfuzję ≥2 jednostek krwi.\n•Przypadki krwawień związanych z guzem w ciągu ostatnich 4 tygodni lub inne czynniki ryzyka potencjalnie zwiększające ryzyko krwawienia należy omówić z dyrektorem medycznym sponsora przed włączeniem pacjenta do badania.","language":19,"languageDescription":"Polish"},{"id":11363855,"uuid":"5651cec9-3137-4233-a8bb-f186c0c78d2c","attributeTranslation":"Participants présentant un risque accru de saignement, y compris tout participant atteint de diathèse hémorragique connue, ou présentant un saignement actif majeur en cours ou un épisode de saignement majeur récent dans les 4 semaines précédant l’inclusion.\nRemarque : un épisode de saignement majeur est défini selon les critères de la Société internationale de thrombose et d’hémostase, qui incluent un saignement mortel, un saignement symptomatique dans un organe ou une zone critique (p. ex. intracrânien, intrarachidien, intraoculaire, péricardique, intra-articulaire, intramusculaire avec syndrome des loges, rétropéritonéal), une chute d’hémoglobine de ≥ 2 g/dL ou la transfusion de ≥ 2 unités de sang.\nLes cas de saignement lié à la tumeur au cours des 4 dernières semaines ou autres facteurs de risque pouvant potentiellement augmenter le risque de saignement doivent être évoqués avec le directeur médical du promoteur avant l’inclusion.","language":34,"languageDescription":"French (France)"},{"id":11363854,"uuid":"5651cec9-3137-4233-a8bb-f186c0c78d2c","attributeTranslation":"Teilnehmer mit erhöhtem Blutungsrisiko, einschließlich Teilnehmer mit bekannter Blutungsneigung oder aktiver schwerer Blutung oder einer schweren Blutung innerhalb der letzten vier Wochen vor der Aufnahme.\n•\tFälle von tumorbedingten Blutungen innerhalb der vergangenen 4 Wochen oder sonstige Faktoren, die das Blutungsrisiko potenziell erhöhen, sollten vor der Aufnahme mit dem medizinischen Leiter des Sponsors besprochen werden.","language":27,"languageDescription":"German (Austria)"}]},{"id":1571467,"number":11,"principalExclusionCriteria":"Any of the following <6 months before starting study treatment: ST-elevation myocardial infarction, severe/unstable angina, uncontrolled cardiac ventricular arrythmia, coronary/peripheral artery bypass graft or stent, cerebrovascular accident/stroke less than 6 months prior to enrollment or New York Heart Association Class III/IV congestive heart failure. Participants with deep vein thrombosis who are hemodynamically stable can enroll if they are on a stable dose of anticoagulants for at least 3 months.","principalExclusionCriteriaTranslations":[{"id":11363858,"uuid":"8583e832-522d-44cd-8550-519aaeb7ef07","attributeTranslation":"Którekolwiek z poniższych schorzeń, występujące < sześć miesięcy przed rozpoczęciem leczenia stosowanego w badaniu: zawał mięśnia sercowego z uniesieniem odcinka ST, ciężka/niestabilna dusznica bolesna, niekontrolowana arytmia komorowa serca, pomostowanie tętnic wieńcowych/obwodowych czyli stent, zdarzenie mózgowo-naczyniowe/udar mózgu mniej niż sześć miesięcy przed włączeniem do badania lub zastoinowa niewydolność serca klasy III/IV wg klasyfikacji Nowojorskiego Towarzystwa Kardiologicznego (ang. New York Heart Association). Uczestnicy z zakrzepicą żył głębokich, którzy są stabilni hemodynamiczni, mogą zostać włączeni do badania, jeżeli przyjmują stabilną dawkę leków przeciwzakrzepowych przez co najmniej trzy miesiące.","language":19,"languageDescription":"Polish"},{"id":11363862,"uuid":"8583e832-522d-44cd-8550-519aaeb7ef07","attributeTranslation":"Qualquer um dos seguintes <6 meses antes do início do tratamento do estudo: enfarte do miocárdio com supradesnivelamento do segmento ST, angina grave/instável, arritmia ventricular cardíaca não controlada, enxerto ou stent de bypass de artéria coronária/periférica, acidente vascular cerebral/derrame menos de 6 meses antes da inscrição ou insuficiência cardíaca congestiva de classe III/IV da New York Heart Association. Participantes com trombose venosa profunda que estejam hemodinamicamente estáveis podem ser inscritos(as) se estiverem a tomar uma dose estável de anticoagulantes há, pelo menos, 3 meses.","language":20,"languageDescription":"Portuguese"},{"id":11363861,"uuid":"8583e832-522d-44cd-8550-519aaeb7ef07","attributeTranslation":"L’une des situations suivantes moins de 6 mois avant le début du traitement à l’étude : Infarctus du myocarde avec élévation du segment ST, angor sévère/instable, arythmie ventriculaire cardiaque non contrôlée, pontage ou stent coronarien/d’une artère périphérique, accident vasculaire cérébral/AVC moins de 6 mois avant l’inclusion ou insuffisance cardiaque congestive de classe III/IV selon la New York Heart Association. Les participants atteints de thrombose veineuse profonde qui sont stables sur le plan hémodynamique peuvent être inclus s’ils reçoivent une dose stable d’anticoagulants depuis au moins 3 mois.","language":34,"languageDescription":"French (France)"},{"id":11363859,"uuid":"8583e832-522d-44cd-8550-519aaeb7ef07","attributeTranslation":"Cualquiera de los siguientes <6 meses antes del inicio del tratamiento del estudio: Infarto de miocardio con elevación del segmento ST, angina grave o inestable, arritmia ventricular cardiaca no controlada, injerto o endoprótesis vascular de derivación de la arteria coronaria o periférica, accidente cerebrovascular o ictus menos de 6 meses antes de la inclusión o insuficiencia cardíaca congestiva de clase III o IV según la Asociación Cardiológica de Nueva York. Los participantes con trombosis venosa profunda que sean estables desde el punto de vista hemodinámico pueden inscribirse si reciben una dosis estable de anticoagulantes desde hace al menos 3 meses.","language":7,"languageDescription":"Spanish"},{"id":11363860,"uuid":"8583e832-522d-44cd-8550-519aaeb7ef07","attributeTranslation":"Eine der folgenden Erkrankungen in den < 6 Monaten vor Beginn der Studienbehandlung: ST-Hebungsinfarkt, schwere/instabile Angina pectoris, unkontrollierte ventrikuläre Herzrhythmusstörung, koronarer/peripherer Arterienbypass oder Stent, zerebrovaskulärer Unfall/Schlaganfall weniger als 6 Monate vor der Aufnahme oder kongestive Herzinsuffizienz der NYHA-Klasse III/IV. Teilnehmer mit tiefer Venenthrombose, die hämodynamisch stabil sind, können teilnehmen, wenn sie seit mindestens 3 Monaten eine stabile Dosis Antikoagulanzien erhalten.","language":27,"languageDescription":"German (Austria)"},{"id":11363857,"uuid":"8583e832-522d-44cd-8550-519aaeb7ef07","attributeTranslation":"Οποιοδήποτε από τα παρακάτω <6 μήνες πριν από την έναρξη της θεραπείας της μελέτης: Έμφραγμα μυοκαρδίου με ανάσπαση ST, βαριάς μορφής/ασταθής στηθάγχη, μη ελεγχόμενη καρδιακή κοιλιακή αρρυθμία, μόσχευμα ή ενδοπρόσθεση παράκαμψης στεφανιαίας/περιφερικής αρτηρίας, αγγειακό εγκεφαλικό επεισόδιο/εγκεφαλικό επεισόδιο εντός 6 μηνών πριν από την εγγραφή ή συμφορητική καρδιακή ανεπάρκεια κατηγορίας III/IV σύμφωνα με την Καρδιολογική Εταιρεία Νέας Υόρκης. Οι συμμετέχοντες με εν τω βάθει φλεβική θρόμβωση που είναι αιμοδυναμικά σταθεροί μπορούν να εγγραφούν εάν λαμβάνουν σταθερή δόση αντιπηκτικών για τουλάχιστον 3 μήνες.","language":32,"languageDescription":"Greek (Greece)"}]},{"id":1571468,"number":12,"principalExclusionCriteria":"Major surgery (including eye surgery) <2 weeks or palliative radiotherapy <1 week prior to randomization. Participants must have recovered adequately from any surgery (major or minor) or radiation and/or its complications before randomization.","principalExclusionCriteriaTranslations":[{"id":11363866,"uuid":"0516bd58-95e5-4668-840a-1a576532a8a0","attributeTranslation":"Cirurgia de grande porte (incluindo cirurgia ocular) ou radioterapia paliativa <2 semanas antes da aleatorização. Os(As) participantes têm de estar adequadamente recuperados(as) de qualquer cirurgia (de grande ou de pequeno porte), radiação e/ou das suas complicações antes da aleatorização..","language":20,"languageDescription":"Portuguese"},{"id":11363865,"uuid":"0516bd58-95e5-4668-840a-1a576532a8a0","attributeTranslation":"Cirugía mayor (cirugía ocular incluida) <2 semanas o radioterapia paliativa <2 semanas antes de la aleatorización. Los participantes deben haberse recuperado de manera adecuada de cualquier cirugía (mayor o menor) o radioterapia o de sus complicaciones antes de la aleatorización.","language":7,"languageDescription":"Spanish"},{"id":11363863,"uuid":"0516bd58-95e5-4668-840a-1a576532a8a0","attributeTranslation":"Intervention chirurgicale majeure (y compris chirurgie oculaire) moins de 2 semaines ou radiothérapie palliative moins de 2 semaines avant la randomisation. Les participants doivent s’être rétablis de façon adéquate de toute intervention chirurgicale (majeure ou mineure) ou de toute radiothérapie et/ou de ses complications avant la randomisation","language":34,"languageDescription":"French (France)"},{"id":11363864,"uuid":"0516bd58-95e5-4668-840a-1a576532a8a0","attributeTranslation":"Größere chirurgische Eingriffe (einschließlich Augenoperationen) < 2 Wochen oder palliative Strahlentherapie < 2 Wochen vor der Randomisierung. Die Teilnehmer müssen sich vor der Randomisierung ausreichend von allen chirurgischen Eingriffen (größere oder kleinere) oder Bestrahlungen und/oder deren Komplikationen erholt haben.","language":27,"languageDescription":"German (Austria)"},{"id":11363867,"uuid":"0516bd58-95e5-4668-840a-1a576532a8a0","attributeTranslation":"Poważny zabieg chirurgiczny (w tym zabieg chirurgiczny w obrębie oka) <2 tygodnie albo radioterapia paliatywna <2 tygodnie przed randomizacją. Przed randomizacją uczestnicy muszą odpowiednio wyzdrowieć po jakimkolwiek zabiegu chirurgicznym (większym lub mniejszym) lub napromienianiu i/lub jego powikłaniach.","language":19,"languageDescription":"Polish"},{"id":11363868,"uuid":"0516bd58-95e5-4668-840a-1a576532a8a0","attributeTranslation":"Μείζων χειρουργική επέμβαση (συμπεριλαμβανομένων των οφθαλμολογικών) < 2 εβδομάδες ή παρηγορητική ακτινοθεραπεία < 2 εβδομάδες πριν από την τυχαιοποίηση. Οι συμμετέχοντες πρέπει να έχουν αναρρώσει επαρκώς από οποιαδήποτε χειρουργική επέμβαση (μείζονα ή ελάσσονα) ή ακτινοβολία ή/και επιπλοκές της πριν από την τυχαιοποίηση.","language":32,"languageDescription":"Greek (Greece)"}]},{"id":1571469,"number":13,"principalExclusionCriteria":"Participants who participated in another clinical study or received treatment with another investigational drug must wait at least 5 half-lives of the treatment received or 4 weeks (whichever is shorter) following prior therapy or at least 4 weeks if the half-life of the agent received is not known before enrollment.","principalExclusionCriteriaTranslations":[{"id":11363872,"uuid":"43e5eac3-f468-4654-9bdc-4ccba81207c2","attributeTranslation":"Teilnehmer, die an einer anderen klinischen Studie teilgenommen oder eine Behandlung mit einem anderen Prüfpräparat erhalten haben, müssen nach der vorherigen Therapie mindestens 5 Halbwertszeiten der erhaltenen Behandlung oder 4 Wochen (je nachdem, welcher Zeitraum kürzer ist) abwarten oder mindestens 4 Wochen, wenn die Halbwertszeit des erhaltenen Wirkstoffs vor der Aufnahme in die Studie nicht bekannt ist.","language":27,"languageDescription":"German (Austria)"},{"id":11363870,"uuid":"43e5eac3-f468-4654-9bdc-4ccba81207c2","attributeTranslation":"El participante que haya participado en otro estudio clínico o que haya recibido tratamiento con otro fármaco en investigación debe esperar al menos 5 semividas del tratamiento recibido o 4 semanas (lo que sea más corto) después del tratamiento previo, o al menos 4 semanas si no se conoce la semivida del fármaco recibido, antes de la inclusión","language":7,"languageDescription":"Spanish"},{"id":11363874,"uuid":"43e5eac3-f468-4654-9bdc-4ccba81207c2","attributeTranslation":"Uczestnik, który brał udział w innym badaniu klinicznym albo był leczony innym lekiem eksperymentalnym, musi odczekać co najmniej pięć okresów półtrwania leku stosowanego wcześniej albo cztery tygodnie (w zależności od tego, który okres jest krótszy) po wcześniejszym leczeniu albo co najmniej cztery tygodnie, jeżeli okres półtrwania otrzymywanego leku nie jest znany, przed włączeniem do badania.","language":19,"languageDescription":"Polish"},{"id":11363869,"uuid":"43e5eac3-f468-4654-9bdc-4ccba81207c2","attributeTranslation":"Συμμετέχοντες που συμμετείχαν σε άλλη κλινική μελέτη ή έλαβαν θεραπεία με άλλο υπό έρευνα φάρμακο πρέπει, πριν από την εγγραφή, να περιμένουν τουλάχιστον 5 χρόνους ημιζωής της ληφθείσας θεραπείας ή 4 εβδομάδες (όποιο εκ των δύο διαστημάτων είναι μικρότερο) μετά την προηγούμενη θεραπεία ή τουλάχιστον 4 εβδομάδες εάν δεν είναι γνωστός ο χρόνος ημιζωής του παράγοντα που ελήφθη.","language":32,"languageDescription":"Greek (Greece)"},{"id":11363871,"uuid":"43e5eac3-f468-4654-9bdc-4ccba81207c2","attributeTranslation":"Un participant ayant pris part à une autre étude clinique ou ayant reçu un traitement par un autre médicament expérimental doit attendre au moins 5 demi-vies du traitement reçu ou 4 semaines (selon l’éventualité la plus courte) après le traitement antérieur ou au moins 4 semaines si la demi-vie de l’agent reçu n’est pas connue avant l’inclusion.","language":34,"languageDescription":"French (France)"},{"id":11363873,"uuid":"43e5eac3-f468-4654-9bdc-4ccba81207c2","attributeTranslation":"Um(a) participante que tenha participado noutro estudo clínico ou recebido tratamento com outro medicamento experimental tem de esperar, pelo menos, 5 semividas do tratamento recebido ou 4 semanas (o que tiver menor duração) após a terapêutica anterior ou, pelo menos, 4 semanas se a semivida do agente recebido não for conhecida, antes da inscrição.","language":20,"languageDescription":"Portuguese"}]},{"id":1571470,"number":14,"principalExclusionCriteria":"Active autoimmune disease requiring systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.","principalExclusionCriteriaTranslations":[{"id":11363879,"uuid":"5a6ce274-bc03-4950-b872-d5fcba8b0c42","attributeTranslation":"Czynna choroba autoimmunologiczna wymagająca leczenia ogólnoustrojowego w ciągu ostatnich dwóch lat (tj. zastosowania leków modyfikujących przebieg choroby, kortykosteroidów albo leków immunosupresyjnych). Terapia zastępcza (np. tyroksyną lub insuliną, lub stosowanie kortykosteroidów w dawkach fizjologicznych w ramach terapii zastępczej niewydolności nadnerczy lub przysadki mózgowej, itp.) nie jest uznawana za formę leczenia ogólnoustrojowego.","language":19,"languageDescription":"Polish"},{"id":11363880,"uuid":"5a6ce274-bc03-4950-b872-d5fcba8b0c42","attributeTranslation":"Enfermedad autoinmunitaria activa que requiera tratamiento sistémico en los últimos 2 años (p. ej., con fármacos modificadores de la enfermedad, corticoesteroides o fármacos inmunodepresores). El tratamiento de reposición (p. ej., tiroxina, insulina o tratamiento de reposición con corticoesteroides para la insuficiencia suprarrenal o hipofisaria, etc.) no se considera una forma de tratamiento sistémico.","language":7,"languageDescription":"Spanish"},{"id":11363876,"uuid":"5a6ce274-bc03-4950-b872-d5fcba8b0c42","attributeTranslation":"Aktive Autoimmunerkrankung, die in den letzten 2 Jahren eine systemische Behandlung erforderte (d. h. mit krankheitsmodifizierenden Wirkstoffen, Kortikosteroiden oder Immunsuppressiva). Eine Ersatztherapie (z. B. mit Thyroxin, Insulin oder physiologischen Dosen eines Kortikosteroids zur Behandlung einer Nebennierenrinden- oder Hypophyseninsuffizienz usw.) gilt nicht als systemische Therapie.","language":27,"languageDescription":"German (Austria)"},{"id":11363877,"uuid":"5a6ce274-bc03-4950-b872-d5fcba8b0c42","attributeTranslation":"Ενεργό αυτοάνοσο νόσημα που απαιτεί συστηματική θεραπεία τα τελευταία 2 χρόνια (δηλαδή με χρήση τροποποιητικών της νόσου παραγόντων, κορτικοστεροειδών ή ανοσοκατασταλτικών φαρμάκων). Η θεραπεία υποκατάστασης (π.χ. θυροξίνη, ινσουλίνη ή θεραπεία φυσιολογικής υποκατάστασης με κορτικοστεροειδή για ανεπάρκεια των επινεφριδίων ή της υπόφυσης κ.λπ.) δεν θεωρείται μορφή συστηματικής θεραπείας.","language":32,"languageDescription":"Greek (Greece)"},{"id":11363878,"uuid":"5a6ce274-bc03-4950-b872-d5fcba8b0c42","attributeTranslation":"Maladie auto-immune active nécessitant un traitement systémique au cours des 2 dernières années (c’est-à-dire l’utilisation d’agents modificateurs de la maladie, de corticostéroïdes ou d’immunosuppresseurs). Un traitement de substitution (p. ex., thyroxine, insuline, traitement de substitution physiologique par corticostéroïdes pour insuffisance surrénalienne ou hypophysaire, etc.) n’est pas considéré comme une forme de traitement systémique.","language":34,"languageDescription":"French (France)"},{"id":11363875,"uuid":"5a6ce274-bc03-4950-b872-d5fcba8b0c42","attributeTranslation":"Doença autoimune ativa que tenha necessitado de tratamento sistémico 2 anos anteriores (ou seja, com a utilização de agentes modificadores da doença, corticosteroides ou medicamentos imunossupressores). A terapêutica de reposição (p. ex., terapêutica de reposição de tiroxina, insulina ou corticosteroides fisiológicos para insuficiência adrenal ou hipofisária, etc.) não é considerada uma forma de tratamento sistémico.","language":20,"languageDescription":"Portuguese"}]},{"id":1571471,"number":15,"principalExclusionCriteria":"Serious systemic infection (bacterial, viral, or fungal) within 4 weeks before first dose of study treatment, or active systemic infection requiring either hospitalization or parenteral anti-infective therapy within 2 weeks before first dose of study treatment.","principalExclusionCriteriaTranslations":[{"id":11363885,"uuid":"f7f547ca-5ca7-4e36-956e-4d5e3f22575a","attributeTranslation":"Infeção sistémica grave (bacteriana, viral ou fúngica) no período de 4 semanas antes da primeira dose do tratamento do estudo, ou infeção sistémica ativa que exija hospitalização ou terapêutica anti infeciosa parentérica nas 2 semanas anteriores à primeira dose do tratamento do estudo.","language":20,"languageDescription":"Portuguese"},{"id":11363882,"uuid":"f7f547ca-5ca7-4e36-956e-4d5e3f22575a","attributeTranslation":"Poważne zakażenie ogólnoustrojowe (bakteryjne, wirusowe lub grzybicze) w okresie czterech tygodni przed otrzymaniem pierwszej dawki leczenia stosowanego w badaniu lub czynne zakażenie ogólnoustrojowe wymagające hospitalizacji lub pozajelitowego leczenia przeciwzakaźnego w okresie dwóch tygodni przed podaniem pierwszej dawki leczenia stosowanego w badaniu.","language":19,"languageDescription":"Polish"},{"id":11363884,"uuid":"f7f547ca-5ca7-4e36-956e-4d5e3f22575a","attributeTranslation":"Σοβαρή συστηματική λοίμωξη (βακτηριακή, ιογενής ή μυκητιασική) εντός 4 εβδομάδων πριν από την πρώτη δόση της θεραπείας της μελέτης ή ενεργή συστηματική λοίμωξη που χρήζει νοσηλείας ή παρεντερικής αντιλοιμώδους θεραπείας εντός 2 εβδομάδων πριν από την πρώτη δόση της θεραπείας της μελέτης.","language":32,"languageDescription":"Greek (Greece)"},{"id":11363883,"uuid":"f7f547ca-5ca7-4e36-956e-4d5e3f22575a","attributeTranslation":"nfection systémique grave (bactérienne, virale ou fongique) dans les 4 semaines précédant la première dose du traitement à l’étude, ou infection systémique active nécessitant une hospitalisation ou un traitement anti-infectieux parentéral dans les 2 semaines précédant la première dose du traitement à l’étude.","language":34,"languageDescription":"French (France)"},{"id":11363886,"uuid":"f7f547ca-5ca7-4e36-956e-4d5e3f22575a","attributeTranslation":"Infección sistémica grave (bacteriana, vírica o fúngica) en las 4 semanas anteriores a la primera dosis del tratamiento del estudio o infección sistémica activa que requiera hospitalización o terapia antiinfecciosa parenteral en las 2 semanas anteriores a la primera dosis del tratamiento del estudio.","language":7,"languageDescription":"Spanish"},{"id":11363881,"uuid":"f7f547ca-5ca7-4e36-956e-4d5e3f22575a","attributeTranslation":"Schwere systemische Infektion (bakteriell, viral oder durch Pilze) innerhalb von 4 Wochen vor der ersten Dosis der Studienbehandlung oder aktive systemische Infektion, die entweder einen Krankenhausaufenthalt oder eine parenterale antiinfektiöse Therapie innerhalb von 2 Wochen vor der ersten Dosis der Studienbehandlung erfordert.","language":27,"languageDescription":"German (Austria)"}]},{"id":1571472,"number":16,"principalExclusionCriteria":"Known psychiatric, behavioral, or substance abuse disorders that would interfere with cooperation of the study requirements.","principalExclusionCriteriaTranslations":[{"id":11363887,"uuid":"5400770d-f84c-4b42-a430-65c1e36bc06c","attributeTranslation":"Perturbações psiquiátricas, comportamentais ou de abuso de substâncias conhecidas que possam interferir na cooperação com os requisitos do estudo.","language":20,"languageDescription":"Portuguese"},{"id":11363892,"uuid":"5400770d-f84c-4b42-a430-65c1e36bc06c","attributeTranslation":"Bekannte psychiatrische, Verhaltens- oder Substanzmissbrauchsstörungen, die die Zusammenarbeit bei den Studienanforderungen beeinträchtigen würden.","language":27,"languageDescription":"German (Austria)"},{"id":11363891,"uuid":"5400770d-f84c-4b42-a430-65c1e36bc06c","attributeTranslation":"Troubles psychiatriques, comportementaux ou d’abus de substances connus qui interféreraient avec le respect des exigences de l’étude.","language":34,"languageDescription":"French (France)"},{"id":11363890,"uuid":"5400770d-f84c-4b42-a430-65c1e36bc06c","attributeTranslation":"Γνωστές ψυχιατρικές ή συμπεριφορικές διαταραχές ή διαταραχές κατάχρησης ουσιών που θα μπορούσαν να επηρεάσουν αρνητικά τη συμμόρφωση με τις απαιτήσεις της μελέτης.","language":32,"languageDescription":"Greek (Greece)"},{"id":11363889,"uuid":"5400770d-f84c-4b42-a430-65c1e36bc06c","attributeTranslation":"Stwierdzone zaburzenia psychiatryczne, behawioralne albo związane z nadużywaniem substancji, które mogłyby niekorzystnie wpływać na przestrzeganie wymogów badania","language":19,"languageDescription":"Polish"},{"id":11363888,"uuid":"5400770d-f84c-4b42-a430-65c1e36bc06c","attributeTranslation":"Trastornos psiquiátricos, de comportamiento o de abuso de sustancias conocidos que podrían interferir en la cooperación en relación con los requisitos del estudio.","language":7,"languageDescription":"Spanish"}]},{"id":1571473,"number":17,"principalExclusionCriteria":"Participants with chronic hepatitis B virus (HBV) infection with active disease who meet the criteria for anti-HBV therapy and are not on a suppressive antiviral therapy prior to initiation of study treatment. Participants who are hepatitis B surface antigen positive must have initiated HBV antiviral therapy for at least two weeks and have undetectable HBV DNA levels prior to randomization. Note: Participants should remain on antiviral therapy throughout the Treatment period and follow local guidelines for HBV antiviral therapy post completion of study treatment.","principalExclusionCriteriaTranslations":[{"id":11363893,"uuid":"516c6170-f023-4452-b3d0-181023605699","attributeTranslation":"Uczestnicy z przewlekłym zakażeniem wirusem zapalenia wątroby typu B (HBV) z czynną postacią choroby spełniającej kryteria leczenia anty-HBV i którzy nie przyjmują leczenia supresyjnego przed rozpoczęciem leczenia stosowanego w badaniu. Uczestnicy z dodatnim wynikiem badania w kierunku antygenu powierzchniowego wirusa zapalenia wątroby typu muszą mieć w wywiadzie przyjmowanie leków przeciwwirusowych przeciwko HBV przez co najmniej dwa tygodnie przed randomizacją oraz muszą mieć niewykrywalną wiremię HBV przed randomizacją. Uwaga: uczestnicy powinni stosować leczenie przeciwwirusowe przez cały okres leczenia oraz stosować się do miejscowych wytycznych dotyczących leczenia przeciwwirusowego HBV po zakończeniu leczenia stosowanego w badaniu.","language":19,"languageDescription":"Polish"},{"id":11363897,"uuid":"516c6170-f023-4452-b3d0-181023605699","attributeTranslation":"Συμμετέχοντες με χρόνια λοίμωξη από τον ιό της ηπατίτιδας Β (HBV) με ενεργή νόσο οι οποίοι πληρούν τα κριτήρια για θεραπεία κατά του HBV και δεν υποβάλλονται σε κατασταλτική αντιιική θεραπεία πριν από την έναρξη της θεραπείας της μελέτης. Οι συμμετέχοντες που είναι θετικοί στο επιφανειακό αντιγόνο της ηπατίτιδας Β πρέπει να έχουν λάβει αντιιική θεραπεία έναντι του HBV για τουλάχιστον δύο εβδομάδες και έχουν μη ανιχνεύσιμο ιικό φορτίο HBV πριν από την τυχαιοποίηση. Σημείωση: Οι συμμετέχοντες θα πρέπει να εξακολουθήσουν να λαμβάνουν αντιιική θεραπεία καθ' όλη τη διάρκεια της περιόδου θεραπείας και να ακολουθούν τις τοπικές οδηγίες για την αντιιική θεραπεία έναντι του HBV μετά την ολοκλήρωση της θεραπείας της μελέτης.","language":32,"languageDescription":"Greek (Greece)"},{"id":11363894,"uuid":"516c6170-f023-4452-b3d0-181023605699","attributeTranslation":"Teilnehmer mit chronischer Infektion mit dem Hepatitis-B-Virus (HBV) und aktiver Erkrankung, die die Kriterien für eine Anti-HBV-Therapie erfüllen und vor Beginn der Studienbehandlung keine suppressive antivirale Therapie erhalten haben. Teilnehmer, die positiv für das Hepatitis-B-Oberflächenantigen sind, müssen mindestens zwei Wochen lang eine antivirale HBV-Therapie erhalten haben und vor der Randomisierung darf bei ihnen keine HBV-Viruslast nachweisbar sein. Hinweis: Die Teilnehmer sollten während des gesamten Behandlungszeitraums die antivirale Therapie fortsetzen und nach Abschluss der Studienbehandlung die vor Ort geltenden Richtlinien für die antivirale HBV-Therapie befolgen.","language":27,"languageDescription":"German (Austria)"},{"id":11363895,"uuid":"516c6170-f023-4452-b3d0-181023605699","attributeTranslation":"Participantes com infeção crónica pelo vírus da hepatite B (VHB) com doença ativa que cumprem os critérios para terapêutica anti VHB e não estejam a receber uma terapêutica antiviral supressiva antes do início do tratamento do estudo. Os(As) participantes positivos(as) para o antigénio de superfície da hepatite B devem ter recebido terapêutica antiviral para o VHB durante, pelo menos, duas semanas e tiverem uma carga viral de VHB indetetável antes da aleatorização. Nota: os(as) participantes devem manter a terapêutica antiviral durante todo o período de tratamento e seguir as orientações locais para a terapêutica antiviral para o VHB após a conclusão do tratamento do estudo.","language":20,"languageDescription":"Portuguese"},{"id":11363898,"uuid":"516c6170-f023-4452-b3d0-181023605699","attributeTranslation":"Participantes con infección crónica por el virus de la hepatitis B (VHB) con enfermedad activa que cumplan los criterios de tratamiento anti-VHB y no reciban tratamiento antivírico supresor antes del inicio del tratamiento del estudio. Los participantes que tengan antígenos de superficie de la hepatitis B positivos deben haber recibido tratamiento antivírico para el VHB durante al menos dos semanas y tener una concentración vírica indetectable de VHB antes de la aleatorización. Nota: Los participantes deben permanecer en tratamiento antivírico durante el periodo de tratamiento y seguir las directrices locales sobre tratamiento antivírico para el VHB después de la finalización del tratamiento del estudio.","language":7,"languageDescription":"Spanish"},{"id":11363896,"uuid":"516c6170-f023-4452-b3d0-181023605699","attributeTranslation":"Participants atteints d’une infection chronique par le virus de l’hépatite B (VHB) avec une maladie active qui remplissent les critères pour un traitement anti-VHB et qui ne reçoivent pas de traitement antiviral suppresseur avant l’instauration du traitement à l’étude. Les participants positifs pour l’antigène de surface du virus de l’hépatite B doivent avoir reçu un traitement antiviral contre le VHB pendant au moins deux semaines et s’ils présentent une charge virale du VHB indétectable avant la randomisation. Remarque : les participants doivent poursuivre le traitement antiviral tout au long de la période de traitement et suivre les directives locales pour le traitement antiviral contre le VHB après la fin du traitement à l’étude.","language":34,"languageDescription":"French (France)"}]},{"id":1571474,"number":18,"principalExclusionCriteria":"Participants with a known history of hepatitis C virus (HCV) who have not completed curative antiviral treatment or have an HCV viral load above the limit of quantification at Screening. Note: Participants must have completed curative antiviral therapy at least 4 weeks prior to randomization.","principalExclusionCriteriaTranslations":[{"id":11363900,"uuid":"8e256342-a95e-44df-8568-9cd8142f5ab4","attributeTranslation":"Participantes com histórico conhecido de vírus da hepatite C (VHC) que não tenham concluído o tratamento antiviral curativo ou que apresentem uma carga viral de VHC acima do limite de quantificação na seleção. Nota: os(as) participantes têm de ter concluído a terapêutica antiviral curativa pelo menos 4 semanas antes da aleatorização.","language":20,"languageDescription":"Portuguese"},{"id":11363904,"uuid":"8e256342-a95e-44df-8568-9cd8142f5ab4","attributeTranslation":"Participants ayant des antécédents connus d’infection par le virus de l’hépatite C (VHC) qui n’ont pas achevé de traitement antiviral curatif ou qui présentent une charge virale du VHC supérieure à la limite de quantification à la sélection. Remarque : les participants doivent avoir achevé le traitement antiviral curatif au moins 4 semaines avant la randomisation.","language":34,"languageDescription":"French (France)"},{"id":11363901,"uuid":"8e256342-a95e-44df-8568-9cd8142f5ab4","attributeTranslation":"Συμμετέχοντες με γνωστό ιστορικό λοίμωξης από τον ιό της ηπατίτιδας C (HCV) οι οποίοι δεν έχουν ολοκληρώσει την οριστική αντιιική θεραπεία ή έχουν ιικό φορτίο HCV πάνω από το όριο ποσοτικοποίησης κατά τη διαλογή. Σημείωση: οι συμμετέχοντες πρέπει να έχουν ολοκληρώσει την οριστική αντιιική θεραπεία τουλάχιστον 4 εβδομάδες πριν από την τυχαιοποίηση.","language":32,"languageDescription":"Greek (Greece)"},{"id":11363902,"uuid":"8e256342-a95e-44df-8568-9cd8142f5ab4","attributeTranslation":"Teilnehmer mit bekannter Hepatitis-C-Virus(HCV)-Anamnese, die keine kurative antivirale Behandlung abgeschlossen haben oder bei denen die HCV-Viruslast beim Screening über der Bestimmungsgrenze liegt. Hinweis: Die Teilnehmer müssen die kurative antivirale Therapie mindestens 4 Wochen vor der Randomisierung abgeschlossen haben","language":27,"languageDescription":"German (Austria)"},{"id":11363899,"uuid":"8e256342-a95e-44df-8568-9cd8142f5ab4","attributeTranslation":"Uczestnicy z dodatnim wywiadem w kierunku wirusa zapalenia wątroby typu C (HCV), którzy nie ukończyli leczenia przeciwwirusowego lub z poziomem wiremii HCV powyżej granicy oznaczalności podczas badań przesiewowych. Uwaga: uczestnik musi zakończyć leczenie przeciwwirusowe co najmniej cztery tygodnie przed randomizacją.","language":19,"languageDescription":"Polish"},{"id":11363903,"uuid":"8e256342-a95e-44df-8568-9cd8142f5ab4","attributeTranslation":"Participantes con antecedentes conocidos de virus de la hepatitis C (VHC) que no hayan completado el tratamiento antivírico curativo o que tengan una concentración vírica de VHC por encima del límite de cuantificación en la selección. Nota: Los participantes deben haber completado el tratamiento antivírico curativo al menos 4 semanas antes de la aleatorización.","language":7,"languageDescription":"Spanish"}]},{"id":1571475,"number":19,"principalExclusionCriteria":"Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies). HIV testing is not required unless mandated by local health authority.","principalExclusionCriteriaTranslations":[{"id":11363908,"uuid":"902ebbf9-773a-4809-983b-270ad9dfe810","attributeTranslation":"Anamnestisch bekannte Infektion mit dem humanen Immundefizienzvirus (HIV) (HIV-1/2-Antikörper). Ein HIV-Test ist nicht erforderlich, es sei denn, die örtliche Gesundheitsbehörde schreibt ihn vor.","language":27,"languageDescription":"German (Austria)"},{"id":11363909,"uuid":"902ebbf9-773a-4809-983b-270ad9dfe810","attributeTranslation":"Antécédents connus d’infection par le virus de l’immunodéficience humaine (VIH) (anticorps anti-VIH 1/2). Un test de dépistage du VIH n’est pas requis, sauf si prescrit par l’autorité sanitaire locale.","language":34,"languageDescription":"French (France)"},{"id":11363907,"uuid":"902ebbf9-773a-4809-983b-270ad9dfe810","attributeTranslation":"Antecedentes conocidos de virus de la inmunodeficiencia humana (anticuerpos contra el VIH-1/2). No es obligatorio realizar pruebas del VIH, a menos que lo exija la autoridad sanitaria.","language":7,"languageDescription":"Spanish"},{"id":11363905,"uuid":"902ebbf9-773a-4809-983b-270ad9dfe810","attributeTranslation":"Γνωστό ιστορικό λοίμωξης από τον ιό της ανθρώπινης ανοσοανεπάρκειας (HIV) (HIV 1/2 αντισώματα). Η εξέταση για τον HIV δεν απαιτείται, εκτός εάν επιβάλλεται από την τοπική υγειονομική αρχή.","language":32,"languageDescription":"Greek (Greece)"},{"id":11363906,"uuid":"902ebbf9-773a-4809-983b-270ad9dfe810","attributeTranslation":"Tem histórico conhecido de vírus da imunodeficiência humana (VIH) (anticorpos de VIH 1/2). O teste do VIH não é necessário, exceto se exigido pela autoridade de saúde local.","language":20,"languageDescription":"Portuguese"},{"id":11363910,"uuid":"902ebbf9-773a-4809-983b-270ad9dfe810","attributeTranslation":"Stwierdzone w wywiadzie zakażenie ludzkim wirusem upośledzenia odporności (HIV; przeciwciała przeciwko HIV 1/2). HIV: test na obecność ludzkiego wirusa niedoboru odporności nie jest wymagany, chyba że jego wykonanie nakazują lokalne władze służby zdrowia.","language":19,"languageDescription":"Polish"}]},{"id":1571458,"number":2,"principalExclusionCriteria":"Disease suitable for local therapy administered with curative intent.","principalExclusionCriteriaTranslations":[{"id":11363803,"uuid":"9ad91058-063c-4c72-b31b-3a28e957e400","attributeTranslation":"Νόσος κατάλληλη για τοπική θεραπεία που χορηγείται με πρόθεση ίασης.","language":32,"languageDescription":"Greek (Greece)"},{"id":11363804,"uuid":"9ad91058-063c-4c72-b31b-3a28e957e400","attributeTranslation":"Vorliegen einer Erkrankung, die sich für eine lokale Therapie mit kurativer Absicht eignet.","language":27,"languageDescription":"German (Austria)"},{"id":11363807,"uuid":"9ad91058-063c-4c72-b31b-3a28e957e400","attributeTranslation":"Choroba kwalifikująca się do leczenia miejscowego prowadzonego z zamiarem wyleczenia.","language":19,"languageDescription":"Polish"},{"id":11363805,"uuid":"9ad91058-063c-4c72-b31b-3a28e957e400","attributeTranslation":"Doença adequada para terapêutica local administrada com intenção curativa.","language":20,"languageDescription":"Portuguese"},{"id":11363808,"uuid":"9ad91058-063c-4c72-b31b-3a28e957e400","attributeTranslation":"Enfermedad adecuada para tratamiento local administrado con intención curativa.","language":7,"languageDescription":"Spanish"},{"id":11363806,"uuid":"9ad91058-063c-4c72-b31b-3a28e957e400","attributeTranslation":"Maladie adaptée à un traitement local administré avec une intention curative.","language":34,"languageDescription":"French (France)"}]},{"id":1571476,"number":20,"principalExclusionCriteria":"Receipt of any organ transplantation, including autologous and allogeneic stem cell transplantation, with the exception of transplants that do not require immunosuppression.","principalExclusionCriteriaTranslations":[{"id":11363913,"uuid":"1df883e7-a7df-453c-b843-5dbefdc4e154","attributeTranslation":"Recepción de cualquier trasplante de órgano, incluidos el autotrasplante y el trasplante alogénico de células madre, con excepción de los trasplantes que no precisen inmunodepresión.","language":7,"languageDescription":"Spanish"},{"id":11363916,"uuid":"1df883e7-a7df-453c-b843-5dbefdc4e154","attributeTranslation":"Erhalt einer Organtransplantation jeglicher Art, einschließlich autologer und allogener Stammzelltransplantation, mit Ausnahme von Transplantationen, die keine Immunsuppression erfordern.","language":27,"languageDescription":"German (Austria)"},{"id":11363915,"uuid":"1df883e7-a7df-453c-b843-5dbefdc4e154","attributeTranslation":"Receção de qualquer transplante de órgão, incluindo transplante autólogo e alogénico de células estaminais, com exceção de transplantes que não exijam imunossupressão.","language":20,"languageDescription":"Portuguese"},{"id":11363912,"uuid":"1df883e7-a7df-453c-b843-5dbefdc4e154","attributeTranslation":"Μεταμόσχευση οργάνου οποιουδήποτε τύπου, συμπεριλαμβανομένων της αυτόλογης και της αλλογενούς μεταμόσχευσης βλαστοκυττάρων, με εξαίρεση τις μεταμοσχεύσεις που δεν απαιτούν ανοσοκαταστολή.","language":32,"languageDescription":"Greek (Greece)"},{"id":11363911,"uuid":"1df883e7-a7df-453c-b843-5dbefdc4e154","attributeTranslation":"Réception d’une greffe d’organe, y compris d’une greffe de cellules souches allogéniques ou autologues, à l’exception des greffes qui ne nécessitent pas d’immunosuppression.","language":34,"languageDescription":"French (France)"},{"id":11363914,"uuid":"1df883e7-a7df-453c-b843-5dbefdc4e154","attributeTranslation":"Przeszczep jakiegokolwiek narządu, w tym autologiczny i allogeniczny przeszczep komórek macierzystych, z wyjątkiem przeszczepów niewymagających immunosupresji.","language":19,"languageDescription":"Polish"}]},{"id":1571477,"number":21,"principalExclusionCriteria":"Known to be diagnosed and/or treated for any other additional malignancy within 2 years prior to randomization with the exception of the following: curatively treated basal cell carcinoma or squamous cell carcinoma of the skin, and curatively resected in situ cervical cancer, and curatively resected in situ breast cancer, and low-risk early stage prostate cancer defined as follows: Stage T1c or T2a with a Gleason score ≤6 and prostatic-specific antigen <10 ng/mL either treated with definitive intent or untreated in active surveillance that has been stable for the past year prior to randomization. Other exceptions may be considered with the Sponsor’s consultation. The time requirement for no malignancy for 2 years does not apply to the cancer for which a participant is enrolled in the study.","principalExclusionCriteriaTranslations":[{"id":11363918,"uuid":"4579e921-03a2-4aaa-b4f7-e236513434d4","attributeTranslation":"Diagnostic et/ou traitement connus de toute autre tumeur maligne supplémentaire dans les 2 ans précédant la randomisation, à l’exception d’un carcinome basocellulaire ou d’un carcinome épidermoïde cutané traités de manière curative, d’un cancer du col de l’utérus in situ réséqué de manière curative, d’un cancer du sein in situ réséqué de manière curative et d’un cancer de la prostate de stade précoce à faible risque, défini comme suit : Stade T1c ou T2a avec score de Gleason ≤ 6 et antigène prostatique spécifique < 10 ng/ml, traité avec intention définitive ou non traité sous surveillance active et ayant été stable au cours de l’année précédant la randomisation. D’autres exceptions pourront être envisagées après consultation avec le promoteur. L’exigence de durée d’absence de tumeur maligne de 2 ans ne s’applique pas au cancer pour lequel un participant est inclus dans l’étude.","language":34,"languageDescription":"French (France)"},{"id":11363922,"uuid":"4579e921-03a2-4aaa-b4f7-e236513434d4","attributeTranslation":"Con diagnóstico o tratamiento conocido para cualquier otra neoplasia maligna adicional en los 2 años anteriores a la aleatorización, con excepción de lo siguiente: carcinoma basocelular o carcinoma epidermoide de la piel tratado y curado y cáncer cervicouterino in situ resecado y curado, cáncer de mama in situ resecado y curado y cáncer de próstata de bajo riesgo en estadio inicial, definido de la siguiente manera: Estadio T1c o T2a con puntuación en la escala de Gleason ≤6 y antígeno prostático específico <10 ng/ml tratado con intención definitiva o no tratado, pero objeto de vigilancia activa y que haya sido estable durante el año anterior a la aleatorización. Se podrían considerar otras excepciones tras consulta con el promotor. El requisito de tiempo de no tener ningún tumor maligno durante 2 años no se aplica al cáncer por el que el participante se incluye en el estudio.","language":7,"languageDescription":"Spanish"},{"id":11363919,"uuid":"4579e921-03a2-4aaa-b4f7-e236513434d4","attributeTranslation":"Diagnóstico e/ou tratamento conhecido para qualquer outra neoplasia maligna adicional nos 2 anos anteriores à aleatorização, com exceção dos seguintes: carcinoma basocelular ou carcinoma espinocelular da pele tratado curativamente, cancro do colo do útero in situ ressecado curativamente, cancro da mama in situ ressecado curativamente e cancro da próstata em estágio inicial de baixo risco definido da seguinte forma: estágio T1c ou T2a com uma pontuação de Gleason ≤6 e antigénio específico da próstata <10 ng/ml tratado com intenção definitiva ou não tratado em vigilância ativa que tenha permanecido estável durante o último ano antes da aleatorização. Poderão ser consideradas outras exceções mediante consulta com o Promotor. O requisito de tempo para ausência de neoplasia maligna durante 2 anos não se aplica ao cancro pelo qual o(a) participante está a ser inscrito(a) no estudo.","language":20,"languageDescription":"Portuguese"},{"id":11363921,"uuid":"4579e921-03a2-4aaa-b4f7-e236513434d4","attributeTranslation":"Γνωστή διάγνωση ή/και θεραπεία για οποιαδήποτε άλλη πρόσθετη κακοήθεια εντός 2 ετών πριν από την τυχαιοποίηση, με εξαίρεση τα ακόλουθα: το οριστικά αντιμετωπισθέν βασικοκυτταρικό καρκίνωμα ή καρκίνωμα από πλακώδες επιθήλιο του δέρματος, το οριστικά εξαιρεθέν in situ καρκίνωμα του τραχήλου της μήτρας, τον οριστικά εξαιρεθέντα in situ καρκίνο του μαστού και τον χαμηλού κινδύνου καρκίνο του προστάτη πρώιμου σταδίου που ορίζεται ως εξής: Στάδιο T1c ή T2a με βαθμολογία Gleason ≤ 6 και ειδικό προστατικό αντιγόνο < 10 ng/mL είτε έχει υποβληθεί σε θεραπεία με πρόθεση ίασης είτε δεν έχει υποβληθεί σε θεραπεία και τελεί υπό ενεργή επιτήρηση, και η νόσος έχει παραμείνει σταθερή κατά το τελευταίο έτος πριν από την τυχαιοποίηση. Άλλες εξαιρέσεις μπορούν να ληφθούν υπόψη κατόπιν διαβούλευσης με τον Χορηγό. Η χρονική απαίτηση απουσίας κακοήθειας για 2 έτη δεν ισχύει για τον καρκίνο για τον οποίο ένας συμμετέχων εγγράφεται στη μελέτη.","language":31,"languageDescription":"Greek (Cyprus)"},{"id":11363917,"uuid":"4579e921-03a2-4aaa-b4f7-e236513434d4","attributeTranslation":"Bei dem Teilnehmer wurde bekanntermaßen innerhalb von 2 Jahren vor der Randomisierung eine andere zusätzliche maligne Erkrankung diagnostiziert und/oder behandelt, mit Ausnahme der folgenden: kurativ behandeltes Basalzellkarzinom oder Plattenepithelkarzinom der Haut und kurativ reseziertes In-situ-Zervixkarzinom und kurativ reseziertes In-situ-Mammakarzinom und Prostatakarzinom im Frühstadium mit geringem Risiko, definiert wie folgt: Stadium T1c oder T2a mit einem Gleason-Score ≤ 6 und prostataspezifischem Antigen < 10 ng/ml, entweder mit definitiver Absicht behandelt oder unbehandelt in aktiver Überwachung, die seit einem Jahr vor der Randomisierung stabil ist. Andere Ausnahmen können nach Rücksprache mit dem Sponsor in Betracht gezogen werden. Die Anforderung für das Nichtvorliegen einer malignen Erkrankung für 2 Jahre gilt nicht für den Krebs, wegen dem ein Teilnehmer in die Studie aufgenommen wurde.","language":27,"languageDescription":"German (Austria)"},{"id":11363920,"uuid":"4579e921-03a2-4aaa-b4f7-e236513434d4","attributeTranslation":"U uczestnika rozpoznano / lub uczestnika leczono w związku z jakimkolwiek innym nowotworem dodatkowym w okresie dwóch lat poprzedzających randomizację, z wyjątkiem: skutecznie wyleczonego raka podstawnokomórkowego lub płaskonabłonkowego skóry, wyleczonego raka szyjki macicy w postaci przedinwazyjnej, a także usuniętego z zamiarem wyleczenia raka piersi w postaci przedinwazyjnej oraz raka prostaty we wczesnym stadium ryzyka, definiowanego jako: stadium T1c lub T2a z wynikiem w skali Gleasona ≤6 i stężeniem swoistego antygenu sterczowego <10 ng/ml leczonego z zamiarem definitywnym lub nieleczonego w ramach kontroli substancji czynnej, który był stabilny przez ostatni rok przed randomizacją. Inne wyjątki mogą być brane pod uwagę po skonsultowaniu się ze Sponsorem. Brak nowotworu przez 2 lata nie dotyczy nowotworu, w przypadku którego uczestnik został włączony do badania.","language":19,"languageDescription":"Polish"}]},{"id":1571478,"number":22,"principalExclusionCriteria":"Any condition requiring systemic treatment with either corticosteroids (>10 mg daily of prednisone or equivalent) or other immunosuppressive medication within 7 days prior to the first dose of study treatment, except for topical, intranasal, intrabronchial, or ocular steroids. Corticosteroid use as premedication for allergic reactions (e.g., intravenous contrast), or as a prophylactic management of AEs related to the therapies specified in the protocol is allowed. The use of physiologic doses of corticosteroids may be approved after consultation with the Sponsor.","principalExclusionCriteriaTranslations":[{"id":11363924,"uuid":"4f7b4c71-03a8-40e6-9517-172b8fa16ac2","attributeTranslation":"Dowolny stan wymagający leczenia ogólnoustrojowego kortykosteroidami (>10 mg prednizonu na dobę lub równoważna dawka innego leku) lub innymi lekami immunosupresyjnymi w ciągu siedmiu dni przed pierwszą dawką leczenia stosowanego w badaniu, z wyjątkiem steroidów miejscowych, donosowych, dooskrzelowych lub ocznych. Dozwolone jest stosowanie kortykosteroidów w ramach premedykacji w związku z reakcjami alergicznymi (np. dożylnym podaniem środka kontrastującego) lub w ramach profilaktycznego leczenia zdarzeń niepożądanych związanych ze stosowaniem leków określonych w protokole. Stosowanie fizjologicznych dawek kortykosteroidów może zostać zatwierdzone po konsultacji ze Sponsorem.","language":19,"languageDescription":"Polish"},{"id":11363925,"uuid":"4f7b4c71-03a8-40e6-9517-172b8fa16ac2","attributeTranslation":"Cualquier afección que requiera tratamiento sistémico con corticoesteroides (>10 mg al día de prednisolona o equivalente) o con otro medicamento inmunodepresor en los 7 días previos a la primera dosis del tratamiento del estudio, excepto corticoesteroides tópicos, intranasales, intrabronquiales u oculares. Se permite el uso de corticoesteroides como medicación prequimioterápica para prevenir reacciones alérgicas (p. ej., contraste intravenoso) o como tratamiento profiláctico de AA relacionados con los tratamientos especificados en el protocolo. El uso de dosis fisiológicas de corticoesteroides podría aprobarse tras consulta con el promotor.","language":7,"languageDescription":"Spanish"},{"id":11363923,"uuid":"4f7b4c71-03a8-40e6-9517-172b8fa16ac2","attributeTranslation":"Οποιαδήποτε πάθηση που απαιτεί συστηματική θεραπεία είτε με κορτικοστεροειδή (> 10 mg πρεδνιζόνης ή ισοδύναμου ημερησίως) είτε με άλλο ανοσοκατασταλτικό φάρμακο εντός 7 ημερών πριν από την πρώτη δόση της θεραπείας της μελέτης, εκτός από τοπικά, ενδορινικά, ενδοβρογχικά ή οφθαλμικά στεροειδή. Επιτρέπεται η χρήση κορτικοστεροειδών ως προκαταρκτική αγωγή για αλλεργικές αντιδράσεις (π.χ. ενδοφλέβια σκιαγραφική ουσία) ή για την προφυλακτική αντιμετώπιση των ΑΣ που σχετίζονται με τις θεραπείες που καθορίζονται στο πρωτόκολλο. Η χρήση φυσιολογικών δόσεων κορτικοστεροειδών μπορεί να εγκριθεί μετά από διαβούλευση με τον Χορηγό.","language":32,"languageDescription":"Greek (Greece)"},{"id":11363927,"uuid":"4f7b4c71-03a8-40e6-9517-172b8fa16ac2","attributeTranslation":"Qualquer condição que necessite de tratamento sistémico com corticosteroides (>10 mg diários de prednisona ou equivalente) ou outro medicamento imunossupressor nos 7 dias anteriores à primeira dose do tratamento do estudo, exceto esteroides tópicos, intranasais, intrabrônquicos ou oculares. É permitida a utilização de corticosteroides como pré medicação para reações alérgicas (p. ex., contraste intravenoso) ou para gestão profilática de eventos adversos (EA) relacionados com as terapêuticas especificadas no protocolo. A utilização de doses fisiológicas de corticosteroides poderá ser aprovada após consulta com o Promotor.","language":20,"languageDescription":"Portuguese"},{"id":11363926,"uuid":"4f7b4c71-03a8-40e6-9517-172b8fa16ac2","attributeTranslation":"Jede Erkrankung, die eine systemische Behandlung mit Kortikosteroiden (> 10 mg Prednison oder Äquivalent täglich) oder anderen Immunsuppressiva innerhalb von 7 Tagen vor der ersten Dosis der Studienbehandlung erfordert, ausgenommen topische, intranasale, intrabronchiale oder okuläre Steroide. Die Verwendung von Kortikosteroiden als Prämedikation bei allergischen Reaktionen (z. B. intravenöses Kontrastmittel) oder zur prophylaktischen Behandlung von unerwünschten Ereignissen (UE) im Zusammenhang mit den im Prüfplan angegebenen Therapien ist zulässig. Die Anwendung physiologischer Dosen von Kortikosteroiden kann nach Rücksprache mit dem Sponsor genehmigt werden.","language":27,"languageDescription":"German (Austria)"},{"id":11363928,"uuid":"4f7b4c71-03a8-40e6-9517-172b8fa16ac2","attributeTranslation":"Toute affection nécessitant un traitement systémique par corticostéroïdes (> 10 mg par jour de prednisone ou équivalent) ou tout autre immunosuppresseur dans les 7 jours précédant la première dose du traitement à l’étude, à l’exception des stéroïdes topiques, intranasaux, intrabronchiques ou oculaires. L’utilisation de corticostéroïdes en prémédication pour les réactions allergiques (p. ex., au produit de contraste intraveineux) ou en tant que prise en charge prophylactique des EI liés aux traitements spécifiés dans le protocole est autorisée. L’utilisation de doses physiologiques de corticostéroïdes pourra être approuvée après consultation avec le promoteur.","language":34,"languageDescription":"French (France)"}]},{"id":1571479,"number":23,"principalExclusionCriteria":"Use of a live or live attenuated vaccine within 4 weeks prior to Screening. Note: Administration of killed, recombinant or inactivated vaccines is allowed.","principalExclusionCriteriaTranslations":[{"id":11363930,"uuid":"a684884c-22a0-4a07-abd2-6d8259ae514f","attributeTranslation":"Administração de uma vacina viva ou viva atenuada no período de 4 semanas antes da seleção. Nota: é permitida a administração de vacinas mortas, recombinantes ou inativadas.","language":20,"languageDescription":"Portuguese"},{"id":11363933,"uuid":"a684884c-22a0-4a07-abd2-6d8259ae514f","attributeTranslation":"Stosowanie żywej lub żywej atenuowanej szczepionki w okresie czterech tygodni poprzedzających badania przesiewowe. Uwaga: dozwolone jest podawanie szczepionek zabitych, rekombinowanych lub inaktywowanych.","language":19,"languageDescription":"Polish"},{"id":11363931,"uuid":"a684884c-22a0-4a07-abd2-6d8259ae514f","attributeTranslation":"Erhalt eines Lebendimpfstoffs oder eines abgeschwächten Lebendimpfstoffs innerhalb von 4 Wochen vor dem Screening. Hinweis: Der Erhalt von abgetöteten, rekombinanten oder inaktivierten Impfstoffen ist zulässig.","language":27,"languageDescription":"German (Austria)"},{"id":11363929,"uuid":"a684884c-22a0-4a07-abd2-6d8259ae514f","attributeTranslation":"Haber recibido una vacuna elaborada con microbios vivos o atenuada en las 4 semanas anteriores a la selección. Nota: Se permite la administración de vacunas elaboradas con microbios muertos, recombinantes o inactivadas.","language":7,"languageDescription":"Spanish"},{"id":11363934,"uuid":"a684884c-22a0-4a07-abd2-6d8259ae514f","attributeTranslation":"Χρήση εμβολίου ζώντος ή ζώντος εξασθενημένου ιού εντός 4 εβδομάδων πριν από τη διαλογή. Σημείωση: Επιτρέπεται η χορήγηση νεκρών, ανασυνδυασμένων ή αδρανοποιημένων εμβολίων.","language":32,"languageDescription":"Greek (Greece)"},{"id":11363932,"uuid":"a684884c-22a0-4a07-abd2-6d8259ae514f","attributeTranslation":"Utilisation d’un vaccin vivant ou vivant atténué dans les 4 semaines précédant la sélection. Remarque : l’administration de vaccins non vivants, recombinants ou inactivés est autorisée.","language":34,"languageDescription":"French (France)"}]},{"id":1571480,"number":24,"principalExclusionCriteria":"Active pregnancy or breastfeeding.","principalExclusionCriteriaTranslations":[{"id":11363938,"uuid":"dd0eead6-55cc-4253-a90d-963cfee7eddf","attributeTranslation":"Ενεργή εγκυμοσύνη ή θηλασμός.","language":32,"languageDescription":"Greek (Greece)"},{"id":11363937,"uuid":"dd0eead6-55cc-4253-a90d-963cfee7eddf","attributeTranslation":"Estar embarazada o en periodo de lactancia.","language":7,"languageDescription":"Spanish"},{"id":11363939,"uuid":"dd0eead6-55cc-4253-a90d-963cfee7eddf","attributeTranslation":"Grossesse ou allaitement en cours.","language":34,"languageDescription":"French (France)"},{"id":11363936,"uuid":"dd0eead6-55cc-4253-a90d-963cfee7eddf","attributeTranslation":"Gravidez ou amamentação ativas.","language":20,"languageDescription":"Portuguese"},{"id":11363935,"uuid":"dd0eead6-55cc-4253-a90d-963cfee7eddf","attributeTranslation":"Aktive Schwangerschaft oder Stillzeit.","language":27,"languageDescription":"German (Austria)"},{"id":11363940,"uuid":"dd0eead6-55cc-4253-a90d-963cfee7eddf","attributeTranslation":"Ciąża lub karmienie piersią.","language":19,"languageDescription":"Polish"}]},{"id":1571481,"number":25,"principalExclusionCriteria":"History of (noninfectious) pneumonitis/interstitial lung disease or has current pneumonitis/interstitial lung disease.","principalExclusionCriteriaTranslations":[{"id":11363944,"uuid":"397e8e3a-9030-4284-9747-3753c849a70e","attributeTranslation":"Histórico de pneumonite/doença pulmonar intersticial (não infeciosa) ou com pneumonite/doença pulmonar intersticial atual.","language":20,"languageDescription":"Portuguese"},{"id":11363942,"uuid":"397e8e3a-9030-4284-9747-3753c849a70e","attributeTranslation":"Antécédents de pneumopathie inflammatoire/pneumopathie interstitielle diffuse (non infectieuse) ou présence actuelle d’une pneumopathie inflammatoire/pneumopathie interstitielle diffuse.","language":34,"languageDescription":"French (France)"},{"id":11363941,"uuid":"397e8e3a-9030-4284-9747-3753c849a70e","attributeTranslation":"Obecność w wywiadzie (niezakaźnego) zapalenia płuc / śródmiąższowej choroby płuc lub występowanie obecnie zapalenia płuc / śródmiąższowej choroby płuc.","language":19,"languageDescription":"Polish"},{"id":11363945,"uuid":"397e8e3a-9030-4284-9747-3753c849a70e","attributeTranslation":"Ιστορικό (μη λοιμώδους) πνευμονίτιδας/διάμεσης πνευμονοπάθειας ή τρέχουσα πνευμονίτιδα/διάμεση πνευμονοπάθεια.","language":32,"languageDescription":"Greek (Greece)"},{"id":11363946,"uuid":"397e8e3a-9030-4284-9747-3753c849a70e","attributeTranslation":"Antecedentes de enfermedad pulmonar intersticial o neumonitis (no infecciosa) o neumonitis o enfermedad pulmonar intersticial en la actualidad.","language":7,"languageDescription":"Spanish"},{"id":11363943,"uuid":"397e8e3a-9030-4284-9747-3753c849a70e","attributeTranslation":"(Nichtinfektiöse) Pneumonitis/interstitielle Lungenerkrankung in der Vorgeschichte oder aktuelles Vorliegen einer Pneumonitis/interstitiellen Lungenerkrankung.","language":27,"languageDescription":"German (Austria)"}]},{"id":1571482,"number":26,"principalExclusionCriteria":"History of any of the following drug-induced severe cutaneous adverse reactions including, but not limited to, Stevens-Johnson syndrome/toxic epidermal necrolysis, or drug-reaction with eosinophilia and systemic symptoms, or dose-limiting immune-mediated reactions.","principalExclusionCriteriaTranslations":[{"id":11363951,"uuid":"d4292268-e69d-4f80-8c8a-6d12b521839c","attributeTranslation":"Obecność w wywiadzie dowolnej z następujących ciężkich reakcji niepożądanych ze strony skóry wywołanych przez leki, takich jak między innymi zespół Stevensa-Johnsona / toksyczna nekroliza naskórka lub reakcja na lek z eozynofilią i objawami ogólnoustrojowymi lub reakcje o podłożu immunologicznym ograniczające dawkę..","language":19,"languageDescription":"Polish"},{"id":11363949,"uuid":"d4292268-e69d-4f80-8c8a-6d12b521839c","attributeTranslation":"Antecedentes de cualquiera de las siguientes reacciones adversas cutáneas graves farmacógenas, incluidas, entre otras, síndrome de Stevens-Johnson, necrólisis epidérmica tóxica o reacción farmacológica con eosinofilia y síntomas generalizados, o reacciones inmunomediadas limitantes de la dosis.","language":7,"languageDescription":"Spanish"},{"id":11363952,"uuid":"d4292268-e69d-4f80-8c8a-6d12b521839c","attributeTranslation":"Eine der folgenden arzneimittelinduzierten schweren unerwünschten Hautreaktionen in der Vorgeschichte, einschließlich unter anderem Stevens-Johnson-Syndrom/toxisch epidermale Nekrolyse oder Arzneimittelreaktion mit Eosinophilie und systemischen Symptomen oder dosislimitierende immunvermittelte Reaktionen.","language":27,"languageDescription":"German (Austria)"},{"id":11363947,"uuid":"d4292268-e69d-4f80-8c8a-6d12b521839c","attributeTranslation":"Antécédents de tout effet indésirable cutané sévère d’origine médicamenteuse parmi les suivants, notamment le syndrome de Stevens-Johnson/érythrodermie bulleuse avec épidermolyse, ou une réaction médicamenteuse avec éosinophilie et symptômes systémiques, ou des réactions immunitaires limitant la dose.","language":34,"languageDescription":"French (France)"},{"id":11363948,"uuid":"d4292268-e69d-4f80-8c8a-6d12b521839c","attributeTranslation":"Ιστορικό οποιασδήποτε εκ των ακόλουθων φαρμακοεπαγόμενων δερματικών ανεπιθύμητων αντιδράσεων βαριάς μορφής συμπεριλαμβανομένων, ενδεικτικά, συνδρόμου Stevens-Johnson/τοξικής επιδερμικής νεκρόλυσης ή αντίδρασης σε φάρμακο με ηωσινοφιλία και συστηματικά συμπτώματα, ή των δοσοπεριοριστικών ανοσομεσολαβούμενων αντιδράσεων.","language":32,"languageDescription":"Greek (Greece)"},{"id":11363950,"uuid":"d4292268-e69d-4f80-8c8a-6d12b521839c","attributeTranslation":"Histórico de qualquer uma das seguintes reações adversas graves cutâneas induzidas pelo medicamento, incluindo, entre outras, síndrome de Stevens-Johnson/necrólise epidérmica tóxica, ou reação ao medicamento com eosinofilia e sintomas sistémicos, ou reações mediadas pelo sistema imunitário limitadoras de dose.","language":20,"languageDescription":"Portuguese"}]},{"id":1603831,"number":27,"principalExclusionCriteria":"Any condition that, in the opinion of the investigator, could prevent, limit, or confound the protocol-specified assessments.","principalExclusionCriteriaTranslations":[{"id":11700198,"uuid":"3efd1afa-5072-4ef7-869a-065d7a420087","attributeTranslation":"Qualquer condição que, na opinião do investigador, possa impedir, limitar ou confundir as avaliações especificadas no protocolo.","language":20,"languageDescription":"Portuguese"},{"id":11700157,"uuid":"3efd1afa-5072-4ef7-869a-065d7a420087","attributeTranslation":"Toute affection qui, de l’avis de l'investigateur, pourrait empêcher, limiter ou compromettre les évaluations prévues par le protocole.","language":34,"languageDescription":"French (France)"},{"id":11699419,"uuid":"3efd1afa-5072-4ef7-869a-065d7a420087","attributeTranslation":"Toda afección que, a juicio del investigador, pudiera impedir, limitar u obstaculizar las evaluaciones especificadas en el protocolo.","language":7,"languageDescription":"Spanish"},{"id":11706134,"uuid":"3efd1afa-5072-4ef7-869a-065d7a420087","attributeTranslation":"Jegliche Erkrankung, die nach Ansicht des Prüfarztes die im Prüfplan festgelegten Beurteilungen verhindern, einschränken oder verfälschen könnte.","language":27,"languageDescription":"German (Austria)"},{"id":11706993,"uuid":"3efd1afa-5072-4ef7-869a-065d7a420087","attributeTranslation":"Każde schorzenie, które w opinii badacza może uniemożliwić, ograniczyć lub zakłócić oceny wymagane przez protokół.","language":19,"languageDescription":"Polish"},{"id":11706646,"uuid":"3efd1afa-5072-4ef7-869a-065d7a420087","attributeTranslation":"Οποιαδήποτε κατάσταση η οποία, κατά την κρίση του ερευνητή, θα μπορούσε να αποτρέψει, να περιορίσει ή να προκαλέσει σύγχυση στις αξιολογήσεις που καθορίζονται από το πρωτόκολλο.","language":32,"languageDescription":"Greek (Greece)"}]},{"id":1571459,"number":3,"principalExclusionCriteria":"Prior treatment with anti-TGF-β therapy.","principalExclusionCriteriaTranslations":[{"id":11363809,"uuid":"439ed7dc-f365-4520-87d1-cec808d8f794","attributeTranslation":"Tratamento anterior com terapêutica anti TGFβ.","language":20,"languageDescription":"Portuguese"},{"id":11363810,"uuid":"439ed7dc-f365-4520-87d1-cec808d8f794","attributeTranslation":"Wcześniejsze leczenie anty-TGFβ.","language":19,"languageDescription":"Polish"},{"id":11363811,"uuid":"439ed7dc-f365-4520-87d1-cec808d8f794","attributeTranslation":"Vorherige Behandlung mit einer Anti-TGFβ-Therapie.","language":27,"languageDescription":"German (Austria)"},{"id":11363814,"uuid":"439ed7dc-f365-4520-87d1-cec808d8f794","attributeTranslation":"Traitement antérieur par anti-TGFβ.","language":34,"languageDescription":"French (France)"},{"id":11363813,"uuid":"439ed7dc-f365-4520-87d1-cec808d8f794","attributeTranslation":"Tratamiento previo con un anticuerpo anti-EGFR.","language":7,"languageDescription":"Spanish"},{"id":11363812,"uuid":"439ed7dc-f365-4520-87d1-cec808d8f794","attributeTranslation":"Προηγούμενη λήψη αντι-TGFβ θεραπείας.","language":32,"languageDescription":"Greek (Greece)"}]},{"id":1571460,"number":4,"principalExclusionCriteria":"Prior therapy with an anti-EGFR antibody.","principalExclusionCriteriaTranslations":[{"id":11363815,"uuid":"d65219a2-cf4b-4067-9d46-1e9ab2a92ba9","attributeTranslation":"Wcześniejsze leczenie z zastosowaniem anty-EGFR.","language":19,"languageDescription":"Polish"},{"id":11363819,"uuid":"d65219a2-cf4b-4067-9d46-1e9ab2a92ba9","attributeTranslation":"Vorherige Therapie mit einem Anti-EGFR-Antikörper","language":27,"languageDescription":"German (Austria)"},{"id":11363818,"uuid":"d65219a2-cf4b-4067-9d46-1e9ab2a92ba9","attributeTranslation":"Tratamiento previo con un anticuerpo anti-EGFR.","language":7,"languageDescription":"Spanish"},{"id":11363817,"uuid":"d65219a2-cf4b-4067-9d46-1e9ab2a92ba9","attributeTranslation":"Traitement antérieur par un anticorps anti-EGFR.","language":34,"languageDescription":"French (France)"},{"id":11363816,"uuid":"d65219a2-cf4b-4067-9d46-1e9ab2a92ba9","attributeTranslation":"Προηγούμενη θεραπεία με αντίσωμα έναντι του EGFR","language":32,"languageDescription":"Greek (Greece)"},{"id":11363820,"uuid":"d65219a2-cf4b-4067-9d46-1e9ab2a92ba9","attributeTranslation":"Terapêutica anterior com um anticorpo anti-EGFR.","language":20,"languageDescription":"Portuguese"}]},{"id":1571461,"number":5,"principalExclusionCriteria":"Prior history of Grade ≥2 intolerance or hypersensitivity reaction.","principalExclusionCriteriaTranslations":[{"id":11363826,"uuid":"cc029e22-b864-4989-9c67-9ffa78ea0202","attributeTranslation":"Προηγούμενο ιστορικό δυσανεξίας ή αντίδρασης υπερευαισθησίας Βαθμού ≥ 2.","language":32,"languageDescription":"Greek (Greece)"},{"id":11363824,"uuid":"cc029e22-b864-4989-9c67-9ffa78ea0202","attributeTranslation":"Unverträglichkeit oder Überempfindlichkeitsreaktion Grad ≥ 2 in der Vorgeschichte.","language":27,"languageDescription":"German (Austria)"},{"id":11363823,"uuid":"cc029e22-b864-4989-9c67-9ffa78ea0202","attributeTranslation":"Antecedentes de intolerancia o reacción de hipersensibilidad de grado ≥2.","language":7,"languageDescription":"Spanish"},{"id":11363821,"uuid":"cc029e22-b864-4989-9c67-9ffa78ea0202","attributeTranslation":"Obecność w wywiadzie nietolerancji lub reakcji nadwrażliwości stopnia ≥2.","language":19,"languageDescription":"Polish"},{"id":11363825,"uuid":"cc029e22-b864-4989-9c67-9ffa78ea0202","attributeTranslation":"Antécédents d’intolérance ou de réaction d’hypersensibilité de grade ≥ 2.","language":34,"languageDescription":"French (France)"},{"id":11363822,"uuid":"cc029e22-b864-4989-9c67-9ffa78ea0202","attributeTranslation":"Histórico prévio de intolerância de grau ≥2 ou de reação de hipersensibilidade.","language":20,"languageDescription":"Portuguese"}]},{"id":1571462,"number":6,"principalExclusionCriteria":"Prior (neoadjuvant and/or adjuvant) therapy with an immune checkpoint inhibitor completed within 6 months prior to study treatment initiation.","principalExclusionCriteriaTranslations":[{"id":11363832,"uuid":"c7deefb5-87ab-4682-a164-9b99c7cfd147","attributeTranslation":"Προηγούμενη (νεοεπικουρική ή/και επικουρική) θεραπεία με αναστολείς ανοσολογικού σημείου ελέγχου που ολοκληρώθηκε εντός 6 μηνών πριν από την έναρξη της θεραπείας της μελέτης.","language":32,"languageDescription":"Greek (Greece)"},{"id":11363830,"uuid":"c7deefb5-87ab-4682-a164-9b99c7cfd147","attributeTranslation":"Terapêutica (neoadjuvante e/ou adjuvante) anterior com inibidores de checkpoint imunológico concluída no período de 6 meses antes do início do tratamento do estudo.","language":20,"languageDescription":"Portuguese"},{"id":11363827,"uuid":"c7deefb5-87ab-4682-a164-9b99c7cfd147","attributeTranslation":"Vorherige (neoadjuvante und/oder adjuvante) Therapie mit einem Immun-Checkpoint-Inhibitor, die innerhalb von 6 Monaten vor Beginn der Studienbehandlung abgeschlossen wurde.","language":27,"languageDescription":"German (Austria)"},{"id":11363831,"uuid":"c7deefb5-87ab-4682-a164-9b99c7cfd147","attributeTranslation":"Traitement antérieur (néoadjuvant et/ou adjuvant) par des inhibiteurs de point de contrôle immunitaire achevé dans les 6 mois précédant l’instauration du traitement à l’étude.","language":34,"languageDescription":"French (France)"},{"id":11363828,"uuid":"c7deefb5-87ab-4682-a164-9b99c7cfd147","attributeTranslation":"Wcześniejsze leczenie (neoadjuwantowe lub adjuwantowe) z inhibitorami punktów kontrolnych układu odpornościowego zakończone w ciągu sześciu miesięcy przed rozpoczęciem leczenia stosowanego w badaniu.","language":19,"languageDescription":"Polish"},{"id":11363829,"uuid":"c7deefb5-87ab-4682-a164-9b99c7cfd147","attributeTranslation":"Tratamiento previo (neoadyuvante o complementario) con inhibidores del punto de control inmunitario completado en los 6 meses anteriores al inicio del tratamiento del estudio.","language":7,"languageDescription":"Spanish"}]},{"id":1571463,"number":7,"principalExclusionCriteria":"PD (radiologically or pathologically confirmed) <6 months from completion of curative intent systemic therapy for locoregionally advanced HNSCC.","principalExclusionCriteriaTranslations":[{"id":11363833,"uuid":"0038c44b-9b72-4232-99aa-39a08ebea1eb","attributeTranslation":"Progression de la maladie (confirmée par examen radiologique ou pathologique) moins de 6 mois après la fin du traitement systémique en intention curative pour le CETC avancé au niveau locorégional.","language":34,"languageDescription":"French (France)"},{"id":11363834,"uuid":"0038c44b-9b72-4232-99aa-39a08ebea1eb","attributeTranslation":"Προϊούσα νόσος (ακτινολογικά ή παθολογικά επιβεβαιωμένη) <6 μήνες από την ολοκλήρωση της συστηματικής θεραπείας με πρόθεση ίασης για το τοπικοπεριοχικά προχωρημένο HNSCC.","language":32,"languageDescription":"Greek (Greece)"},{"id":11363838,"uuid":"0038c44b-9b72-4232-99aa-39a08ebea1eb","attributeTranslation":"Fortschreitende Erkrankung (progressive disease – PD) (radiologisch oder pathologisch bestätigt) < 6 Monate nach Abschluss einer systemischen Therapie mit kurativer Absicht bei lokoregionär fortgeschrittenem HNSCC.","language":27,"languageDescription":"German (Austria)"},{"id":11363836,"uuid":"0038c44b-9b72-4232-99aa-39a08ebea1eb","attributeTranslation":"PC (confirmada radiológica o patológicamente) <6 meses desde la finalización del tratamiento sistémico con intención curativa para el CECC avanzado locorregionalmente.","language":7,"languageDescription":"Spanish"},{"id":11363835,"uuid":"0038c44b-9b72-4232-99aa-39a08ebea1eb","attributeTranslation":"Progressão da doença (PD) (confirmada radiológica ou patologicamente) <6 meses após a conclusão da terapêutica sistémica com intenção curativa para CECP locorregionalmente avançado.","language":20,"languageDescription":"Portuguese"},{"id":11363837,"uuid":"0038c44b-9b72-4232-99aa-39a08ebea1eb","attributeTranslation":"ChP (potwierdzona radiologicznie lub patologicznie) < sześć miesięcy od zakończenia leczenia ogólnoustrojowego z zamiarem wyleczenia miejscowo zaawansowanego HNSCC.","language":19,"languageDescription":"Polish"}]},{"id":1571464,"number":8,"principalExclusionCriteria":"Life expectancy of less than 3 months and/or has rapidly progressing disease in the treating investigator's opinion.","principalExclusionCriteriaTranslations":[{"id":11363843,"uuid":"4e2a9e39-eb8b-4b73-8214-f3b0f6ce771e","attributeTranslation":"Espérance de vie inférieure à 3 mois et/ou maladie progressant rapidement selon l’avis de l’investigateur traitant.","language":34,"languageDescription":"French (France)"},{"id":11363840,"uuid":"4e2a9e39-eb8b-4b73-8214-f3b0f6ce771e","attributeTranslation":"Lebenserwartung von weniger als 3 Monaten und/oder nach Ansicht des behandelnden Prüfarztes rasch fortschreitende Erkrankung.","language":27,"languageDescription":"German (Austria)"},{"id":11363844,"uuid":"4e2a9e39-eb8b-4b73-8214-f3b0f6ce771e","attributeTranslation":"Oczekiwana długość życia krótsza niż trzy miesiące i/lub choroba szybko postępująca w opinii badacza prowadzącego.","language":19,"languageDescription":"Polish"},{"id":11363841,"uuid":"4e2a9e39-eb8b-4b73-8214-f3b0f6ce771e","attributeTranslation":"Esperanza de vida inferior a 3 meses o progresión rápida de la enfermedad según la opinión del investigador encargado del tratamiento.","language":7,"languageDescription":"Spanish"},{"id":11363839,"uuid":"4e2a9e39-eb8b-4b73-8214-f3b0f6ce771e","attributeTranslation":"Προσδόκιμο ζωής μικρότερο από 3 μήνες ή/και ταχέως προϊούσα νόσος κατά τη γνώμη του θεράποντος ερευνητή.","language":32,"languageDescription":"Greek (Greece)"},{"id":11363842,"uuid":"4e2a9e39-eb8b-4b73-8214-f3b0f6ce771e","attributeTranslation":"Esperança de vida inferior a 3 meses e/ou com doença de rápida progressão, na opinião do investigador responsável.","language":20,"languageDescription":"Portuguese"}]},{"id":1571465,"number":9,"principalExclusionCriteria":"Known active central nervous system metastases, history of spinal cord compression from tumor involvement, a history of carcinomatous meningitis, and leptomeningeal disease are excluded. Participants with a history of treated central nervous system metastases (by surgery or radiation therapy) may be eligible if central nervous system metastases have been stable for at least 4 weeks, i.e., without evidence of progression by repeat imaging and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.","principalExclusionCriteriaTranslations":[{"id":11363849,"uuid":"f0377a7a-2c4c-4577-8221-2caa0cd020f7","attributeTranslation":"Znane czynne przerzuty do ośrodkowego układu nerwowego, ucisk na rdzeń kręgowy w wywiadzie z powodu zajęcia nowotworem, nowotworowe zapalenie opon mózgowo-rdzeniowych i choroba opon mózgowo-rdzeniowych są wyłączone. Uczestnicy, u których w wywiadzie leczono przerzuty do ośrodkowego układu nerwowego (w ramach zabiegu chirurgicznego lub radioterapii) mogą kwalifikować się do udziału, jeżeli przerzuty do ośrodkowego układu nerwowego były stabilne przez co najmniej 4 tygodnie, tj. bez oznak progresji w ramach powtarzanego badania obrazowego oraz bez konieczności leczenia steroidami przez co najmniej 14 dni przed podaniem pierwszej dawki leczenia stosowanego w badaniu.","language":19,"languageDescription":"Polish"},{"id":11363850,"uuid":"f0377a7a-2c4c-4577-8221-2caa0cd020f7","attributeTranslation":"Εξαιρούνται οι γνωστές ενεργές μεταστάσεις του κεντρικού νευρικού συστήματος, το ιστορικό συμπίεσης του νωτιαίου μυελού από ύπαρξη όγκου, το ιστορικό καρκινωματώδους μηνιγγίτιδας και η λεπτομηνιγγική νόσος. Οι συμμετέχοντες με ιστορικό θεραπευμένων μεταστάσεων του κεντρικού νευρικού συστήματος (με χειρουργική επέμβαση ή ακτινοθεραπεία) μπορεί να είναι επιλέξιμοι εάν οι μεταστάσεις του κεντρικού νευρικού συστήματος έχουν παραμείνει σταθερές για τουλάχιστον 4 εβδομάδες, δηλαδή χωρίς ένδειξη εξέλιξης σε επαναληπτική απεικόνιση και χωρίς απαίτηση θεραπείας με στεροειδή για τουλάχιστον 14 ημέρες πριν από την πρώτη δόση της θεραπείας της μελέτης.","language":32,"languageDescription":"Greek (Greece)"},{"id":11363848,"uuid":"f0377a7a-2c4c-4577-8221-2caa0cd020f7","attributeTranslation":"Metástases ativas conhecidas do sistema nervoso central, histórico de compressão da medula espinal por envolvimento do tumor, histórico de meningite carcinomatosa ou doença leptomeníngea são excluídos. Participantes com histórico de metástases do sistema nervoso central tratados(as) (através de cirurgia ou radioterapia) podem ser elegíveis se as metástases do sistema nervoso central estiverem estáveis durante, pelo menos, 4 semanas, ou seja, sem evidência de progressão por imagiologia repetida e sem necessidade de tratamento com esteroides durante, pelo menos, 14 dias antes da primeira dose do tratamento do estudo.","language":20,"languageDescription":"Portuguese"},{"id":11363847,"uuid":"f0377a7a-2c4c-4577-8221-2caa0cd020f7","attributeTranslation":"Ausgeschlossen sind bekannte aktive Metastasen im zentralen Nervensystem, Rückenmarkskompression durch Tumorbeteiligung in der Vorgeschichte, karzinomatöse Meningitis oder leptomeningeale Erkrankung in der Vorgeschichte. Teilnehmer mit behandelten Metastasen im zentralen Nervensystem in der Vorgeschichte (durch Operation oder Strahlentherapie) können geeignet sein, wenn die Metastasen im zentralen Nervensystem seit mindestens 4 Wochen stabil sind, d. h. ohne Anzeichen einer Progression durch wiederholte Bildgebung und ohne Notwendigkeit einer Steroidbehandlung für mindestens 14 Tage vor der ersten Dosis der Studienbehandlung.","language":27,"languageDescription":"German (Austria)"},{"id":11363845,"uuid":"f0377a7a-2c4c-4577-8221-2caa0cd020f7","attributeTranslation":"Les participants présentant des métastases actives connues du système nerveux central, des antécédents de compression de la moelle épinière due à la tumeur, des antécédents de méningite carcinomateuse et une maladie leptoméningée sont exclus. Les participants ayant des antécédents de métastases du système nerveux central traitées (par chirurgie ou radiothérapie) peuvent être éligibles si les métastases du système nerveux central ont été stables pendant au moins 4 semaines, c’est-à-dire sans preuve de progression par de nouveaux examens d’imagerie et sans nécessité de traitement stéroïdien pendant au moins 14 jours avant la première dose du traitement à l’étude.","language":34,"languageDescription":"French (France)"},{"id":11363846,"uuid":"f0377a7a-2c4c-4577-8221-2caa0cd020f7","attributeTranslation":"Quedan excluidos las metástasis activas en el sistema nervioso central, los antecedentes de compresión medular por afectación tumoral, los antecedentes de meningitis carcinomatosa o la carcinomatosis leptomeníngea. Los participantes con antecedentes de metástasis en el sistema nervioso central tratadas (mediante cirugía o radioterapia) pueden ser aptos si las metástasis en el sistema nervioso central han permanecido estables durante al menos 4 semanas, p. ej., sin pruebas de progresión en imágenes diagnósticas repetidas y sin necesidad de tratamiento con esteroides durante al menos 14 días antes de la primera dosis del tratamiento del estudio.","language":7,"languageDescription":"Spanish"}]}]},"endPoint":{"primaryEndPoints":[{"id":1073587,"number":1,"endPoint":"Phase 2 (Dose Selection) - Safety: Incidence and severity of TEAEs, treatment-emergent SAEs.","isPrimary":true,"endPointTranslations":[{"id":11363717,"uuid":"18e6abc4-417d-41c5-a4ba-4e1904f2d31d","attributeTranslation":"Fase 2 (seleção da dose) – Segurança: incidência e gravidade de eventos adversos decorrentes do tratamento (EADT) e eventos adversos graves (EAG) decorrentes do tratamento.","language":20,"languageDescription":"Portuguese"},{"id":11363715,"uuid":"18e6abc4-417d-41c5-a4ba-4e1904f2d31d","attributeTranslation":"Fase II (selección de la dosis) - Seguridad: incidencia e intensidad de los AADT, AAG durante el tratamiento.","language":7,"languageDescription":"Spanish"},{"id":11363718,"uuid":"18e6abc4-417d-41c5-a4ba-4e1904f2d31d","attributeTranslation":"Phase II (Dosisauswahl) – Sicherheit: Inzidenz und Schwere von behandlungsbedingten unerwünschten Ereignissen (treatment-emergent adverse events, TEAE), behandlungsbedingten schwerwiegenden unerwünschten Ereignissen (SUE).","language":27,"languageDescription":"German (Austria)"},{"id":11363714,"uuid":"18e6abc4-417d-41c5-a4ba-4e1904f2d31d","attributeTranslation":"Phase II (sélection de dose) – Sécurité d’emploi : Incidence et sévérité des EIT et des EIG liés au traitement.","language":34,"languageDescription":"French (France)"},{"id":11363716,"uuid":"18e6abc4-417d-41c5-a4ba-4e1904f2d31d","attributeTranslation":"Faza 2 (wybór dawki) – bezpieczeństwo: częstość występowania i nasilenie zdarzeń niepożądanych zaobserwowanych w czasie leczenia (ang. treatment-emergent adverse events, TEAE).","language":19,"languageDescription":"Polish"},{"id":11363713,"uuid":"18e6abc4-417d-41c5-a4ba-4e1904f2d31d","attributeTranslation":"Φάση 2 (επιλογή δόσης) - Ασφάλεια: Επίπτωση και βαρύτητα εμφανιζόμενων κατά τη θεραπεία ΑΣ (ΤΕΑΕ), εμφανιζόμενων κατά τη θεραπεία ΣΑΣ.","language":32,"languageDescription":"Greek (Greece)"}]},{"id":1073588,"number":2,"endPoint":"Phase 2 (Dose Selection) - Tolerability: TEAEs leading to dose interruption, dose reduction or permanent discontinuation.","isPrimary":true,"endPointTranslations":[{"id":11363722,"uuid":"f61d74ec-fc3a-423f-8630-c7b21a7aee8b","attributeTranslation":"Φάση 2 (επιλογή δόσης) - Ανεκτικότητα: TEAE που οδηγούν σε προσωρινή διακοπή της δόσης, μείωση δόσης ή οριστική διακοπή.","language":32,"languageDescription":"Greek (Greece)"},{"id":11363723,"uuid":"f61d74ec-fc3a-423f-8630-c7b21a7aee8b","attributeTranslation":"Fase II (selección de la dosis) - Tolerabilidad: AADT que provoquen la interrupción de la dosis, la reducción de la dosis o la suspensión permanente del tratamiento.","language":7,"languageDescription":"Spanish"},{"id":11363720,"uuid":"f61d74ec-fc3a-423f-8630-c7b21a7aee8b","attributeTranslation":"Faza 2 (wybór dawki) – tolerancja: TEAE prowadzące do przerwania podawania dawki, zmniejszenia dawki lub trwałego przerwania leczenia.","language":19,"languageDescription":"Polish"},{"id":11363724,"uuid":"f61d74ec-fc3a-423f-8630-c7b21a7aee8b","attributeTranslation":"Phase II (Dosisauswahl) – Verträglichkeit: TEAE, die zu einer Unterbrechung, Reduzierung oder dauerhaften Einstellung der Dosis führen.","language":27,"languageDescription":"German (Austria)"},{"id":11363719,"uuid":"f61d74ec-fc3a-423f-8630-c7b21a7aee8b","attributeTranslation":"Phase II (sélection de dose) – Tolérabilité : EIT entraînant l’interruption des administrations, une réduction de la dose ou l’arrêt définitif du traitement.","language":34,"languageDescription":"French (France)"},{"id":11363721,"uuid":"f61d74ec-fc3a-423f-8630-c7b21a7aee8b","attributeTranslation":"Fase 2 (seleção da dose) – Tolerabilidade: EADT que levam à interrupção da dose, redução da dose ou descontinuação permanente.","language":20,"languageDescription":"Portuguese"}]},{"id":1073589,"number":3,"endPoint":"Phase 2 (Dose Selection) - ORR is defined as the proportion of participants in the DDS who have a confirmed CR or PR per RECIST 1.1. by BICR.","isPrimary":true,"endPointTranslations":[{"id":11363728,"uuid":"deb7e252-d807-4c94-acb2-9020a9938836","attributeTranslation":"Fase II (selección de la dosis): la TRO se define como la proporción de participantes en la población de determinación de la dosis (PDD) con respuesta confirmada de RC o RP según los criterios RECIST 1.1. determinada por la RCIE.","language":7,"languageDescription":"Spanish"},{"id":11363726,"uuid":"deb7e252-d807-4c94-acb2-9020a9938836","attributeTranslation":"Φάση 2 (επιλογή δόσης) - το ποσοστό αντικειμενικής ανταπόκρισης (ORR) ορίζεται ως το ποσοστό των συμμετεχόντων στο σύνολο προσδιορισμού της δόσης (DDS) με επιβεβαιωμένη πλήρη ανταπόκριση (CR) ή μερική ανταπόκριση (PR) σύμφωνα με τα κριτήρια RECIST 1.1. από την BICR.","language":32,"languageDescription":"Greek (Greece)"},{"id":11363730,"uuid":"deb7e252-d807-4c94-acb2-9020a9938836","attributeTranslation":"Fase 2 (seleção da dose) – A taxa de resposta objetiva (TRO) é definida como a proporção de participantes no conjunto de determinação da dose (CDD) que têm uma resposta completa (RC) ou resposta parcial (RP) confirmada de acordo com os RECIST 1.1 por BICR","language":20,"languageDescription":"Portuguese"},{"id":11363729,"uuid":"deb7e252-d807-4c94-acb2-9020a9938836","attributeTranslation":"Phase II (Dosisauswahl) – Die objektive Ansprechrate (objective response rate – ORR) ist definiert als der Anteil der Teilnehmer in der DDS, die ein bestätigtes komplettes Ansprechen (complete response – CR) oder partielles Ansprechen (partial response – PR) gemäß BICR basierend auf RECIST 1.1","language":27,"languageDescription":"German (Austria)"},{"id":11363727,"uuid":"deb7e252-d807-4c94-acb2-9020a9938836","attributeTranslation":"Phase II (sélection de dose) – TRO : Défini comme la proportion de participants dans l’EDD qui présentent une RC ou une RP confirmée selon les critères RECIST 1.1 par l’ECIA.","language":34,"languageDescription":"French (France)"},{"id":11363725,"uuid":"deb7e252-d807-4c94-acb2-9020a9938836","attributeTranslation":"Faza 2 (wybór dawki) – wskaźnik obiektywnych odpowiedzi (ang. Objective Response Rate, ORR) jest definiowany jako odsetek uczestników z DDS, u których wystąpiła potwierdzona odpowiedź całkowita albo odpowiedź częściowa według kryteriów RECIST w wersji 1.1.","language":19,"languageDescription":"Polish"}]},{"id":1073590,"number":4,"endPoint":"Phase 3 - OS: Defined as the time from the randomization to death due to any cause.","isPrimary":true,"endPointTranslations":[{"id":11363731,"uuid":"5428ab00-d3eb-4f2f-bc36-8961048ae8b5","attributeTranslation":"Phase III – Gesamtüberleben (overall survival – OS): Definiert als die Zeit von der Randomisierung bis zum Tod jeglicher Ursache.","language":27,"languageDescription":"German (Austria)"},{"id":11363735,"uuid":"5428ab00-d3eb-4f2f-bc36-8961048ae8b5","attributeTranslation":"Faza 3 – całkowity współczynnik przeżycia (ang. Overall Survival, OS): definiowany jako czas od randomizacji do zgonu z dowolnej przyczyny.","language":19,"languageDescription":"Polish"},{"id":11363736,"uuid":"5428ab00-d3eb-4f2f-bc36-8961048ae8b5","attributeTranslation":"Fase III - SG: definida como el tiempo transcurrido desde la aleatorización hasta la muerte por cualquier causa.","language":7,"languageDescription":"Spanish"},{"id":11363733,"uuid":"5428ab00-d3eb-4f2f-bc36-8961048ae8b5","attributeTranslation":"Phase III – SG : Définie comme le délai entre la randomisation et le décès toutes causes confondues.","language":34,"languageDescription":"French (France)"},{"id":11363732,"uuid":"5428ab00-d3eb-4f2f-bc36-8961048ae8b5","attributeTranslation":"Fase 3 – Sobrevivência global (SG): definida como o tempo desde a aleatorização até à morte por qualquer causa.","language":20,"languageDescription":"Portuguese"},{"id":11363734,"uuid":"5428ab00-d3eb-4f2f-bc36-8961048ae8b5","attributeTranslation":"Φάση 3 - OS: Ορίζεται ως ο χρόνος από την τυχαιοποίηση έως τον θάνατο από οποιαδήποτε αιτία.","language":32,"languageDescription":"Greek (Greece)"}]},{"id":1073591,"number":5,"endPoint":"Phase 3 - ORR: Defined as the proportion of the partcipants in the FAS who have confirmed CR or PR by BICR per RECIST 1.1. (Subset of FAS).","isPrimary":true,"endPointTranslations":[{"id":11363739,"uuid":"bc16ad62-af19-436d-9fa2-142ee74a1b8c","attributeTranslation":"Phase III – TRO : Défini comme la proportion de participants dans l’EAC présentant une RC ou une RP confirmée par l’ECIA selon les critères RECIST 1.1. (Sous-ensemble de l’EAC.)","language":34,"languageDescription":"French (France)"},{"id":11363742,"uuid":"bc16ad62-af19-436d-9fa2-142ee74a1b8c","attributeTranslation":"Faza 3 – ORR: definiowany jako odsetek uczestników w zbiorze pełnej analizy, u których wystąpiła potwierdzona odpowiedź całkowita lub odpowiedź częściowa potwierdzona na podstawie oceny BICR według kryteriów RECIST 1.1. (podgrupa FAS).","language":19,"languageDescription":"Polish"},{"id":11363740,"uuid":"bc16ad62-af19-436d-9fa2-142ee74a1b8c","attributeTranslation":"Phase III – ORR: Definiert als Anteil der Teilnehmer in der Gesamtgruppe (full analysis set – FAS), bei denen gemäß BICR basierend auf RECIST 1.1 ein CR oder PR bestätigt wurde. (Teilmenge der FAS).","language":27,"languageDescription":"German (Austria)"},{"id":11363737,"uuid":"bc16ad62-af19-436d-9fa2-142ee74a1b8c","attributeTranslation":"Fase III - TRO: se define como la proporción de los participantes de la PCA con respuesta confirmada de RC o RP determinada por la RCIE según los criterios RECIST 1.1. (Subconjunto de la PCA).","language":7,"languageDescription":"Spanish"},{"id":11363738,"uuid":"bc16ad62-af19-436d-9fa2-142ee74a1b8c","attributeTranslation":"Φάση 3 - ORR: Ορίζεται ως το ποσοστό των συμμετεχόντων στο σύνολο πλήρους ανάλυσης (FAS) που έχουν επιβεβαιωμένη CR ή PR από την BICR σύμφωνα με τα κριτήρια RECIST 1.1. (Υποσύνολο του FAS).","language":32,"languageDescription":"Greek (Greece)"},{"id":11363741,"uuid":"bc16ad62-af19-436d-9fa2-142ee74a1b8c","attributeTranslation":"Fase 3 – TRO: definida como a proporção de participantes no conjunto de análise completo (CAC) que têm RC ou RP confirmada por BICR de acordo com os RECIST 1.1. (subconjunto do CAC).","language":20,"languageDescription":"Portuguese"}]}],"secondaryEndPoints":[{"id":1073592,"number":1,"endPoint":"Phase 2 - DOR: For participants who demonstrated CR or PR, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death, whichever occurs first, per RECIST 1.1 by BICR.","isPrimary":false,"endPointTranslations":[{"id":11363744,"uuid":"f006d0eb-294b-4c0c-bf15-105d4e5fd785","attributeTranslation":"Φάση 2 (επιλογή δόσης) - DOR: Για τους ασθενείς που επέδειξαν CR ή PR, η διάρκεια της ανταπόκρισης (DOR) ορίζεται ως ο χρόνος από την πρώτη τεκμηριωμένη ένδειξη CR ή PR μέχρι την εξέλιξη της νόσου ή τον θάνατο, όποιο από τα δύο συμβεί πρώτο, σύμφωνα με τα κριτήρια RECIST 1.1 από την BICR.","language":32,"languageDescription":"Greek (Greece)"},{"id":11363745,"uuid":"f006d0eb-294b-4c0c-bf15-105d4e5fd785","attributeTranslation":"Fase II (selección de la dosis) - DR: en los participantes que hayan demostrado una respuesta de RC o RP, la DR se define como el tiempo transcurrido desde la primera prueba documentada de RC o RP hasta la progresión del cáncer o la muerte, lo que ocurra primero, según los criterios RECIST 1.1 y determinado por la RCIE.","language":7,"languageDescription":"Spanish"},{"id":11363743,"uuid":"f006d0eb-294b-4c0c-bf15-105d4e5fd785","attributeTranslation":"Phase II (Dosisauswahl) – Dauer des Ansprechens (duration of response – DOR): Bei Teilnehmern, bei denen ein CR oder PR nachgewiesen wurde, wird die DOR gemäß BICR basierend auf RECIST 1.1 als die Zeit vom ersten dokumentierten Nachweis eines CR oder PR bis zum Fortschreiten der Krankheit oder bis zum Tod definiert, je nachdem, was zuerst eintritt.","language":27,"languageDescription":"German (Austria)"},{"id":11363748,"uuid":"f006d0eb-294b-4c0c-bf15-105d4e5fd785","attributeTranslation":"Faza 2 (wybór dawki) – DOR: w przypadku uczestników, u których wystąpiła odpowiedź całkowita albo odpowiedź częściowa, czas trwania odpowiedzi (ang. Duration of Response, DOR) definiowany jest jako czas od wystąpienia pierwszych udokumentowanych objawów odpowiedzi całkowitej albo odpowiedzi częściowej do momentu wystąpienia progresji choroby albo zgonu, w zależności od tego, co nastąpi jako pierwsze, zgodnie z kryteriami RECIST w wersji 1.1 na podstawie oceny BICR.","language":19,"languageDescription":"Polish"},{"id":11363747,"uuid":"f006d0eb-294b-4c0c-bf15-105d4e5fd785","attributeTranslation":"Phase II (sélection de dose) – DR : Pour les participants ayant présenté une RC ou une RP, la DR est définie comme le délai entre la première preuve documentée de RC ou de RP et la progression de la maladie ou le décès, selon la première éventualité, selon les critères RECIST 1.1 par l’ECIA","language":34,"languageDescription":"French (France)"},{"id":11363746,"uuid":"f006d0eb-294b-4c0c-bf15-105d4e5fd785","attributeTranslation":"Fase 2 (seleção da dose) – Duração da resposta (DR): para participantes que demonstraram RC ou RP, a DR é definida como o tempo desde a primeira evidência documentada de RC ou RP até à progressão da doença ou morte, o que ocorrer primeiro, de acordo com os RECIST 1.1 por BICR.","language":20,"languageDescription":"Portuguese"}]},{"id":1073593,"number":2,"endPoint":"Phase 3 - Safety: Incidence and severity of TEAEs, and treatment-emergent SAEs.","isPrimary":false,"endPointTranslations":[{"id":11363754,"uuid":"58de2ae5-bdd2-40d6-aef7-b1e1918625fb","attributeTranslation":"Φάση 3 - Ασφάλεια: Επίπτωση και βαρύτητα των ΤΕΑΕ και των εμφανιζόμενων κατά τη θεραπεία ΣΑΣ.","language":32,"languageDescription":"Greek (Greece)"},{"id":11363753,"uuid":"58de2ae5-bdd2-40d6-aef7-b1e1918625fb","attributeTranslation":"Phase III – Sicherheit: Inzidenz und Schwere von TEAE und behandlungsbedingten SUE.","language":27,"languageDescription":"German (Austria)"},{"id":11363752,"uuid":"58de2ae5-bdd2-40d6-aef7-b1e1918625fb","attributeTranslation":"Fase III - Seguridad: incidencia e intensidad de los AADT y los AAG durante el tratamiento.","language":7,"languageDescription":"Spanish"},{"id":11363749,"uuid":"58de2ae5-bdd2-40d6-aef7-b1e1918625fb","attributeTranslation":"Faza 3 – bezpieczeństwo: częstość występowania i nasilenie TEAE oraz CZN zaobserwowanych w czasie leczenia.","language":19,"languageDescription":"Polish"},{"id":11363751,"uuid":"58de2ae5-bdd2-40d6-aef7-b1e1918625fb","attributeTranslation":"Phase III – Sécurité d’emploi : Incidence et sévérité des EIT et des EIG liés au traitement.","language":34,"languageDescription":"French (France)"},{"id":11363750,"uuid":"58de2ae5-bdd2-40d6-aef7-b1e1918625fb","attributeTranslation":"Fase 3 – Segurança: incidência e gravidade de EADT e EAG decorrentes do tratamento.","language":20,"languageDescription":"Portuguese"}]},{"id":1073594,"number":3,"endPoint":"Phase 3 - Tolerability: TEAEs leading to dose interruption, dose reduction, or permanent discontinuation.","isPrimary":false,"endPointTranslations":[{"id":11363756,"uuid":"a9aec207-9dc9-4d81-b005-5f01b4455c56","attributeTranslation":"Fase III - Tolerabilidad: los AADT que provoquen la interrupción de la dosis, la reducción de la dosis o la interrupción permanente del tratamiento.","language":7,"languageDescription":"Spanish"},{"id":11363758,"uuid":"a9aec207-9dc9-4d81-b005-5f01b4455c56","attributeTranslation":"Φάση 3 - Ανεκτικότητα: TEAE που οδηγούν σε διακοπή της δόσης, μείωση δόσης ή οριστική διακοπή.","language":32,"languageDescription":"Greek (Greece)"},{"id":11363755,"uuid":"a9aec207-9dc9-4d81-b005-5f01b4455c56","attributeTranslation":"Phase III – Verträglichkeit: TEAE, die zu einer Unterbrechung, Reduzierung oder dauerhaften Einstellung der Dosis führen.","language":27,"languageDescription":"German (Austria)"},{"id":11363759,"uuid":"a9aec207-9dc9-4d81-b005-5f01b4455c56","attributeTranslation":"Fase 3 – Tolerabilidade: EADT que levam à interrupção da dose, redução da dose ou descontinuação permanente.","language":20,"languageDescription":"Portuguese"},{"id":11363757,"uuid":"a9aec207-9dc9-4d81-b005-5f01b4455c56","attributeTranslation":"Faza 3 – tolerancja: TEAE prowadzące do przerwania podawania dawki, zmniejszenia dawki albo trwałego przerwania przyjmowania leku.","language":19,"languageDescription":"Polish"},{"id":11363760,"uuid":"a9aec207-9dc9-4d81-b005-5f01b4455c56","attributeTranslation":"Phase III – Tolérabilité : EIT entraînant l’interruption des administrations, une réduction de la dose ou l’arrêt définitif du traitement.","language":34,"languageDescription":"French (France)"}]},{"id":1073595,"number":4,"endPoint":"Phase 3 - PFS: Defined as the time from randomization to the first documented PD per RECIST 1.1 as determined by BICR or death due to any cause, whichever occurs first.","isPrimary":false,"endPointTranslations":[{"id":11363764,"uuid":"c0b21124-6d43-4e2b-a36f-72d119e84faf","attributeTranslation":"Fase III - SSP: definida como el tiempo desde la aleatorización hasta la primera PC documentada según los criterios RECIST 1.1, determinado por la RCIE, o la muerte por cualquier causa, lo que ocurra primero.","language":7,"languageDescription":"Spanish"},{"id":11363765,"uuid":"c0b21124-6d43-4e2b-a36f-72d119e84faf","attributeTranslation":"Phase III – Progressionsfreies Überleben (progression-free survival – PFS): Definiert als die Zeit von der Randomisierung bis zur ersten dokumentierten PD gemäß BICR basierend auf RECIST 1.1 oder bis zum Tod jeglicher Ursache, je nachdem, was zuerst eintritt.","language":27,"languageDescription":"German (Austria)"},{"id":11363766,"uuid":"c0b21124-6d43-4e2b-a36f-72d119e84faf","attributeTranslation":"Faza 3 – PFS: definiowany jako czas od randomizacji do pierwszej udokumentowanej progresji choroby (ang. Progression-Free Survival, PFS) według kryteriów RECIST w wersji 1.1 określony na podstawie oceny BICR albo do zgonu z dowolnej przyczyny, w zależności od tego, co nastąpi wcześniej.","language":19,"languageDescription":"Polish"},{"id":11363762,"uuid":"c0b21124-6d43-4e2b-a36f-72d119e84faf","attributeTranslation":"Phase III – SSP : Définie comme le délai entre la randomisation et la première PM documentée selon les critères RECIST 1.1, tel que déterminé par l’ECIA, ou le décès toutes causes confondues, selon la première éventualité.","language":34,"languageDescription":"French (France)"},{"id":11363763,"uuid":"c0b21124-6d43-4e2b-a36f-72d119e84faf","attributeTranslation":"Fase 3 – Sobrevivência livre de progressão (SLP): definida como o tempo desde a aleatorização até à primeira PD documentada de acordo com os RECIST 1.1, conforme determinado por BICR, ou morte por qualquer causa, o que ocorrer primeiro.","language":20,"languageDescription":"Portuguese"},{"id":11363761,"uuid":"c0b21124-6d43-4e2b-a36f-72d119e84faf","attributeTranslation":"Φάση 3 - PFS: Ορίζεται ως ο χρόνος από την τυχαιοποίηση έως την πρώτη τεκμηριωμένη PD σύμφωνα με τα κριτήρια RECIST 1.1 όπως προσδιορίζεται από την BICR ή τον θάνατο από οποιαδήποτε αιτία, όποιο από τα δύο συμβεί πρώτο.","language":32,"languageDescription":"Greek (Greece)"}]},{"id":1073596,"number":5,"endPoint":"Phase 3 - ORR: Defined as confirmed CR + PR per RECIST 1.1 by BICR. (FAS).","isPrimary":false,"endPointTranslations":[{"id":11363768,"uuid":"e795078b-1861-4c97-abf8-c0d09aac682b","attributeTranslation":"Fase III - TRO: definida como RC + RP confirmada según los criterios RECIST 1.1 determinados por la RCIE. (PCA).","language":7,"languageDescription":"Spanish"},{"id":11363767,"uuid":"e795078b-1861-4c97-abf8-c0d09aac682b","attributeTranslation":"Faza 3 – ORR: definiowany jako potwierdzona odpowiedź całkowita + odpowiedź częściowa według kryteriów RECIST w wersji 1.1 na podstawie oceny BICR. (FAS).","language":19,"languageDescription":"Polish"},{"id":11363769,"uuid":"e795078b-1861-4c97-abf8-c0d09aac682b","attributeTranslation":"Phase III – ORR: Definiert als bestätigtes CR + PR gemäß BICR basierend auf RECIST 1.1. (FAS).","language":27,"languageDescription":"German (Austria)"},{"id":11363772,"uuid":"e795078b-1861-4c97-abf8-c0d09aac682b","attributeTranslation":"Phase III – TRO : Défini comme une RC + RP confirmée selon les critères RECIST 1.1 par l’ECIA. (EAC.)","language":34,"languageDescription":"French (France)"},{"id":11363771,"uuid":"e795078b-1861-4c97-abf8-c0d09aac682b","attributeTranslation":"Fase 3 – TRO: definida como RC + RP confirmada de acordo com os RECIST 1.1 por BICR. (CAC).","language":20,"languageDescription":"Portuguese"},{"id":11363770,"uuid":"e795078b-1861-4c97-abf8-c0d09aac682b","attributeTranslation":"Φάση 3 - ORR: Ορίζεται ως η επιβεβαιωμένη CR + PR σύμφωνα με τα κριτήρια RECIST 1.1 από την BICR. (FAS).","language":32,"languageDescription":"Greek (Greece)"}]},{"id":1073597,"number":6,"endPoint":"Phase 3  - DOR: For participants who demonstrated CR or PR, DOR is defined as the time from first documented evidence of CR or PR until disease progression or death, whichever occurs first per RECIST 1.1 by BICR.","isPrimary":false,"endPointTranslations":[{"id":11363775,"uuid":"5d75140c-6f6d-4ab5-ab10-538b52028f90","attributeTranslation":"Φάση 3 - DOR: Για τους συμμετέχοντες που επέδειξαν CR ή PR, η διάρκεια της ανταπόκρισης (DOR) ορίζεται ως ο χρόνος από την πρώτη τεκμηριωμένη ένδειξη CR ή PR μέχρι την εξέλιξη της νόσου ή τον θάνατο, όποιο από τα δύο συμβεί πρώτο, σύμφωνα με τα κριτήρια RECIST 1.1 από την BICR.","language":32,"languageDescription":"Greek (Greece)"},{"id":11363777,"uuid":"5d75140c-6f6d-4ab5-ab10-538b52028f90","attributeTranslation":"Fase 3 – DR: para participantes que demonstraram RC ou RP, a DR é definida como o tempo desde a primeira evidência documentada de RC ou RP até à progressão da doença ou morte, o que ocorrer primeiro, de acordo com os RECIST 1.1 por BICR.","language":20,"languageDescription":"Portuguese"},{"id":11363774,"uuid":"5d75140c-6f6d-4ab5-ab10-538b52028f90","attributeTranslation":"Phase III – DOR: Bei Teilnehmern mit Nachweis eines CR oder PR ist die DOR gemäß BICR basierend auf RECIST 1.1 als die Zeit vom ersten dokumentierten Nachweis eines CR oder PR bis zum Fortschreiten der Krankheit oder dem Tod definiert, je nachdem, was zuerst eintritt.","language":27,"languageDescription":"German (Austria)"},{"id":11363778,"uuid":"5d75140c-6f6d-4ab5-ab10-538b52028f90","attributeTranslation":"Fase III - DR: en los participantes que hayan demostrado una respuesta de RC o RP, la DR se define como el tiempo transcurrido desde la primera prueba documentada de RC o RP hasta la progresión del cáncer o la muerte, lo que ocurra primero, según los criterios RECIST 1.1 y determinado por la RCIE.","language":7,"languageDescription":"Spanish"},{"id":11363773,"uuid":"5d75140c-6f6d-4ab5-ab10-538b52028f90","attributeTranslation":"Phase III – DR : Pour les participants ayant présenté une RC ou une RP, la DR est définie comme le délai entre la première preuve documentée de RC ou de RP et la progression de la maladie ou le décès, selon la première éventualité, selon les critères RECIST 1.1 par l’ECIA.","language":34,"languageDescription":"French (France)"},{"id":11363776,"uuid":"5d75140c-6f6d-4ab5-ab10-538b52028f90","attributeTranslation":"Faza 3 – DOR: w przypadku uczestników, u których wystąpiła odpowiedź całkowita albo odpowiedź częściowa, czas trwania odpowiedzi definiowany jest jako czas od wystąpienia pierwszych udokumentowanych objawów odpowiedzi całkowitej albo odpowiedzi częściowej do momentu wystąpienia progresji choroby albo zgonu, w zależności od tego, co nastąpi jako pierwsze według kryteriów RECIST w wersji 1.1 na podstawie niezależnej zaślepionej oceny centralnej.","language":19,"languageDescription":"Polish"}]},{"id":1073598,"number":7,"endPoint":"Phase 3 - Clinical Benefit Rate: For subject who demonstrated CR + PR + SD","isPrimary":false,"endPointTranslations":[{"id":11363779,"uuid":"46a572b9-0a71-4b63-b3f0-ee5db6daff84","attributeTranslation":"Fase 3 – Taxa de benefício clínico: para participantes que demonstraram RC + RP + SD","language":20,"languageDescription":"Portuguese"},{"id":11363782,"uuid":"46a572b9-0a71-4b63-b3f0-ee5db6daff84","attributeTranslation":"Φάση 3 - Ποσοστό κλινικού οφέλους: Για τους ασθενείς που επέδειξαν CR + PR + SD για","language":32,"languageDescription":"Greek (Greece)"},{"id":11363781,"uuid":"46a572b9-0a71-4b63-b3f0-ee5db6daff84","attributeTranslation":"Phase III – Klinische Benefitrate: Definiert als Teilnehmer mit CR + PR + SD","language":27,"languageDescription":"German (Austria)"},{"id":11363783,"uuid":"46a572b9-0a71-4b63-b3f0-ee5db6daff84","attributeTranslation":"Faza 3 – Wskaźnik korzyści klinicznej: w przypadku uczestników, u których wystąpiła CR + PR + SD","language":19,"languageDescription":"Polish"},{"id":11363780,"uuid":"46a572b9-0a71-4b63-b3f0-ee5db6daff84","attributeTranslation":"Phase III – Taux de bénéfice clinique : Pour les patients ayant présenté une RC + RP + MS","language":34,"languageDescription":"French (France)"},{"id":11363784,"uuid":"46a572b9-0a71-4b63-b3f0-ee5db6daff84","attributeTranslation":"Fase III - Tasa de beneficio clínico: en los participantes que hayan demostrado una respuesta de RC + RP + CE","language":7,"languageDescription":"Spanish"}]},{"id":1073599,"number":8,"endPoint":"Phase 3 - ORR, DOR, and PFS per RECIST 1.1 as determined by investigator’s assessment.","isPrimary":false,"endPointTranslations":[{"id":11363786,"uuid":"e00a5705-7ccc-46fa-a8c2-608e85a156aa","attributeTranslation":"Fase III: TRO, DR y SSP según los criterios RECIST 1.1 determinados por la evaluación del investigador.","language":7,"languageDescription":"Spanish"},{"id":11363789,"uuid":"e00a5705-7ccc-46fa-a8c2-608e85a156aa","attributeTranslation":"Φάση 3 - ORR, DOR και επιβίωση χωρίς εξέλιξη της νόσου (PFS) σύμφωνα με τα κριτήρια RECIST 1.1 όπως προσδιορίζονται από την αξιολόγηση του ερευνητή.","language":32,"languageDescription":"Greek (Greece)"},{"id":11363787,"uuid":"e00a5705-7ccc-46fa-a8c2-608e85a156aa","attributeTranslation":"Faza 3 – ORR, DOR i PFS według kryteriów RECIST w wersji 1.1, na podstawie oceny badacza.","language":19,"languageDescription":"Polish"},{"id":11363785,"uuid":"e00a5705-7ccc-46fa-a8c2-608e85a156aa","attributeTranslation":"Fase 3 – TRO, DR e SLP de acordo com os RECIST 1.1, conforme determinado pela avaliação do investigador.","language":20,"languageDescription":"Portuguese"},{"id":11363788,"uuid":"e00a5705-7ccc-46fa-a8c2-608e85a156aa","attributeTranslation":"Phase III – ORR, DOR und PFS gemäß RECIST 1.1 per Einschätzung durch den Prüfarzt.","language":27,"languageDescription":"German (Austria)"},{"id":11363790,"uuid":"e00a5705-7ccc-46fa-a8c2-608e85a156aa","attributeTranslation":"Phase III – TRO, DR et SSP selon les critères RECIST 1.1, tels que déterminés par l’évaluation de l’investigateur.","language":34,"languageDescription":"French (France)"}]},{"id":1073600,"number":9,"endPoint":"Phase 3 - The TTD in global health status measured by","isPrimary":false,"endPointTranslations":[{"id":11363796,"uuid":"8ff88d23-956a-4d5f-9d4a-40d611d4c714","attributeTranslation":"Fase 3 – O TAD no estado de saúde global medido pelos","language":20,"languageDescription":"Portuguese"},{"id":11363793,"uuid":"8ff88d23-956a-4d5f-9d4a-40d611d4c714","attributeTranslation":"Phase III – Die Zeit bis zur Verschlechterung (TTD) des allgemeinen Gesundheitszustands, gemessen anhand","language":27,"languageDescription":"German (Austria)"},{"id":11363795,"uuid":"8ff88d23-956a-4d5f-9d4a-40d611d4c714","attributeTranslation":"Faza 3 – Kwestionariusz TTD dotyczący ogólnego stanu zdrowia i jakości życia, mierzonych za","language":19,"languageDescription":"Polish"},{"id":11363794,"uuid":"8ff88d23-956a-4d5f-9d4a-40d611d4c714","attributeTranslation":"Fase III: el THD del estado de salud general medido por","language":7,"languageDescription":"Spanish"},{"id":11363791,"uuid":"8ff88d23-956a-4d5f-9d4a-40d611d4c714","attributeTranslation":"Φάση 3 - Ο TTD στην καθολική κατάσταση υγείας όπως μετράται από τα","language":32,"languageDescription":"Greek (Greece)"},{"id":11363792,"uuid":"8ff88d23-956a-4d5f-9d4a-40d611d4c714","attributeTranslation":"Phase III – Le DJD de l’état de santé global mesuré par","language":34,"languageDescription":"French (France)"}]}]},"trialDuration":{"estimatedGlobalEndDate":"2029-07-31","estimatedEndDate":"2029-07-31","estimatedRecruitmentStartDate":"2025-11-01"},"sourceOfMonetarySupport":[{"id":99399,"organisationName":"Bicara Therapeutics Inc."}],"populationOfTrialSubjects":{"ageRanges":[{"id":371910,"ageRangeCategoryCode":"3","ageRangeCategory":"3"},{"id":371909,"ageRangeCategoryCode":"4","ageRangeCategory":"4"}],"ageRangeSecondaryIds":[{"id":371912,"ageRangeCategoryCode":"4","ctAgeRangeCode":"8","ctAgeRange":"8","ageRangeCategory":"4"},{"id":371911,"ageRangeCategoryCode":"4","ctAgeRangeCode":"7","ctAgeRange":"7","ageRangeCategory":"4"}],"clinicalTrialGroups":[{"code":"2","name":"Patients"}],"isFemaleSubjects":true,"isMaleSubjects":true,"isVulnerablePopulationSelected":false},"individualParticipantData":{"planToShareIPD":"3"}},"protocolInformation":{"studyDesign":{"periodDetails":[{"id":194331,"businessKey":"1","title":"Phase 2","description":"Subjects will be randomized to one of three treatment arms at a 1:1:1 ratio.","blindingMethodCode":"2","blindedRoles":[{"id":194332,"code":2,"name":"Investigator"},{"id":194333,"code":3,"name":"Monitor"},{"id":194335,"code":1,"name":"Subject"},{"id":194334,"code":4,"name":"Analyst"}],"blindingDetails":"Treatment will be blinded to subjects, investigator staff, persons performing the assessments, and the clinical study team. Blinding is not to be broken during the study unless considered necessary by the investigator for emergency situations for reasons of subject safety.\nTreatment identification information is to be unblinded only for the welfare of the subject, if necessary.","armDetails":[{"description":"Ficerafusp alfa 1500 mg QW + pembrolizumab 200 mg every 3 weeks (Q3W)","title":"Arm A","id":107972},{"description":"Ficerafusp alfa 750 mg QW + pembrolizumab 200 mg Q3W","title":"Arm B","id":107973},{"description":"Placebo QW + pembrolizumab 200 mg Q3W","title":"Arm C (control)","id":107974}],"allocationMethod":"1"},{"id":194336,"businessKey":"2","title":"Phase 3","description":"Once the OBD is determined, additional subjects will be randomized 2:1 in the treatment versus control arm.","blindingMethodCode":"2","blindedRoles":[{"id":194337,"code":1,"name":"Subject"},{"id":194339,"code":4,"name":"Analyst"},{"id":194338,"code":2,"name":"Investigator"},{"id":194340,"code":3,"name":"Monitor"}],"blindingDetails":"Treatment will be blinded to subjects, investigator staff, persons performing the assessments, and the clinical study team. Blinding is not to be broken during the study unless considered necessary by the investigator for emergency situations for reasons of subject safety.","armDetails":[{"description":"Ficerafusp alfa OBD + pembrolizumab 200 mg Q3W","title":"OBD Arm","id":107975},{"description":"Placebo QW + pembrolizumab 200 mg Q3W.","title":"Arm C (control)","id":107976}],"allocationMethod":"1"}]}},"scientificAdviceAndPip":{"scientificAdvices":[{"id":58408,"competentAuthority":{"id":777570,"organisation":{"id":816327,"type":"EU Institution/Body/Agency","typeCode":"14","name":"European Medicines Agency","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100013412","organisationLocationStatus":"Active"},"address":{"addressId":858248,"oneLine":"Domenico Scarlattilaan 6","addressLine1":"Domenico Scarlattilaan 6","addressLine2":"","addressLine3":"","addressLine4":"","city":"Amsterdam","postcode":"1083 HS","country":2029,"countryName":"Netherlands"},"isBusinessKeyValidated":true,"businessKey":"ORG-100013412"}}],"paediatricInvestigationPlan":[]},"associatedClinicalTrials":[],"references":[],"pubmedCode":[],"pubmedUrl":[]},"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-09-01","conclusionDate":"2026-09-01","therapeuticAreas":[{"code":"4","name":"Diseases [C] - Neoplasms [C04]"}],"medicalConditions":[{"id":141540,"medicalCondition":"Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.","isConditionRareDisease":false}],"sponsors":[{"id":153971,"primary":true,"publicContacts":[{"id":454354,"type":"Public","functionalName":"Clinical Operations","functionalEmailAddress":"fortifi_inquiries@bicara.com","telephone":"0016174684219","organisation":{"id":688028,"type":"Pharmaceutical company","typeCode":"10","name":"Bicara Therapeutics Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100049097","organisationLocationStatus":"Active"}}],"scientificContacts":[{"id":454355,"type":"Scientific","functionalName":"Clinical Operations","functionalEmailAddress":"fortifi_inquiries@bicara.com","telephone":"0016174684219","organisation":{"id":688028,"type":"Pharmaceutical company","typeCode":"10","name":"Bicara Therapeutics Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100049097","organisationLocationStatus":"Active"}}],"thirdParties":[{"id":699809,"organisationAddress":{"id":759055,"organisation":{"id":797718,"type":"Pharmaceutical company","typeCode":"10","name":"Certara USA Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100042611","organisationLocationStatus":"Active"},"address":{"addressId":836394,"oneLine":"100 Overlook Center Suite 101","addressLine1":"100 Overlook Center Suite 101","addressLine2":"","addressLine3":"","addressLine4":"","city":"Princeton","postcode":"08540-7814","country":840,"countryName":"United States"},"phone":"+9198524620","email":"support@certara.com","isBusinessKeyValidated":true,"businessKey":"ORG-100042611"},"sponsorDuties":[{"id":1085608,"code":"10"}],"phoneNumber":"+9198524620","email":"support@certara.com"},{"id":699808,"organisationAddress":{"id":707025,"organisation":{"id":745240,"type":"Non-Pharmaceutical company","typeCode":"11","name":"Greenphire LLC","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100041621","organisationLocationStatus":"Active"},"address":{"addressId":773579,"oneLine":"1018 West 9th Avenue Suite 200","addressLine1":"1018 West 9th Avenue Suite 200","addressLine2":"","addressLine3":"","addressLine4":"","city":"King Of Prussia","postcode":"19406-1225","country":840,"countryName":"United States"},"phone":"+12156094365","email":"ctis_inquiry@greenphire.com","isBusinessKeyValidated":true,"businessKey":"ORG-100041621"},"sponsorDuties":[{"id":1085607,"code":"15","value":"Patient concierge"}],"phoneNumber":"+12156094365","email":"ctis_inquiry@greenphire.com"},{"id":699812,"organisationAddress":{"id":707013,"organisation":{"id":745228,"type":"Laboratory/Research/Testing facility","typeCode":"9","name":"Bioclinica Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100033079","organisationLocationStatus":"Active"},"address":{"addressId":773566,"oneLine":"1818 Market Street Suite 2600","addressLine1":"1818 Market Street Suite 2600","addressLine2":"","addressLine3":"","addressLine4":"","city":"Philadelphia","postcode":"19103-3600","country":840,"countryName":"United States"},"phone":"+12159720420","email":"BCA101X301@clario.com","isBusinessKeyValidated":true,"businessKey":"ORG-100033079"},"sponsorDuties":[{"id":1085611,"code":"15","value":"Medical imagining Core Laboratory Services"}],"phoneNumber":"+12159720420","email":"BCA101X301@clario.com"},{"id":699814,"organisationAddress":{"id":705258,"organisation":{"id":743469,"type":"Pharmaceutical company","typeCode":"10","name":"Iqvia Biotech Limited","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100008726","organisationLocationStatus":"Active"},"address":{"addressId":771552,"oneLine":"3 Forbury Place, 23 Forbury Road","addressLine1":"3 Forbury Place","addressLine2":"23 Forbury Road","addressLine3":"","addressLine4":"","city":"Reading","postcode":"RG1 3JH","country":826,"countryName":"United Kingdom"},"phone":"+441438310000","email":"Biotech-EUCTR-Support@iqvia.com","isBusinessKeyValidated":true,"businessKey":"ORG-100008726"},"sponsorDuties":[{"id":1085613,"code":"1"},{"id":1085614,"code":"10"},{"id":1085615,"code":"11"},{"id":1085616,"code":"12"},{"id":1085617,"code":"15","value":"SUSAR Reporting; Vendor Affiliate Management;"},{"id":1085618,"code":"15","value":"Patients reimbursement."},{"id":1085619,"code":"2"},{"id":1085620,"code":"8"},{"id":1085621,"code":"9"}],"phoneNumber":"+441438310000","email":"Biotech-EUCTR-Support@iqvia.com"},{"id":699821,"organisationAddress":{"id":758797,"organisation":{"id":797459,"type":"Pharmaceutical company","typeCode":"10","name":"Precision For Medicine Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100041895","organisationLocationStatus":"Active"},"address":{"addressId":836078,"oneLine":"8425 Precision Way Suite M","addressLine1":"8425 Precision Way Suite M","addressLine2":"","addressLine3":"","addressLine4":"","city":"Frederick","postcode":"21701-2903","country":840,"countryName":"United States"},"phone":"+12406540730","email":"info@precisionmedicine.com","isBusinessKeyValidated":true,"businessKey":"ORG-100041895"},"sponsorDuties":[{"id":1085628,"code":"10"}],"phoneNumber":"+12406540730","email":"info@precisionmedicine.com"},{"id":699818,"organisationAddress":{"id":758786,"organisation":{"id":797448,"type":"Pharmaceutical company","typeCode":"10","name":"Fisher Clinical Services GmbH","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100012942","organisationLocationStatus":"Active"},"address":{"addressId":836065,"oneLine":"Steinbuhlweg 69","addressLine1":"Steinbuhlweg 69","addressLine2":"","addressLine3":"","addressLine4":"","city":"Allschwil","postcode":"4123","country":756,"countryName":"Switzerland"},"phone":"+18005562323","email":"rheinfelden.and.weil.reception@thermofisher.com","isBusinessKeyValidated":true,"businessKey":"ORG-100012942"},"sponsorDuties":[{"id":1085625,"code":"15","value":"Drug storage and distribution"}],"phoneNumber":"+18005562323","email":"rheinfelden.and.weil.reception@thermofisher.com"},{"id":699819,"organisationAddress":{"id":881684,"organisation":{"id":923701,"type":"Health care","typeCode":"2","name":"Auxilius, Inc.","commercial":false,"isBusinessKeyValidated":false,"businessKey":"ORL-000017162","organisationLocationStatus":"Active"},"address":{"addressId":984308,"oneLine":"249 Smith Street #4020","addressLine1":"249 Smith Street #4020","addressLine2":"","addressLine3":"","addressLine4":"","city":"Brooklyn","postcode":"NY 11231","country":840,"countryName":"United States"},"phone":"0012013804453","email":"info@auxili.us","isBusinessKeyValidated":false,"businessKey":"ORL-000017162"},"sponsorDuties":[{"id":1085626,"code":"15","value":"Financial and operational support platform"}],"phoneNumber":"0012013804453","email":"info@auxili.us"},{"id":699810,"organisationAddress":{"id":718578,"organisation":{"id":756836,"type":"Pharmaceutical company","typeCode":"10","name":"IQVIA Limited","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100008655","organisationLocationStatus":"Active"},"address":{"addressId":787454,"oneLine":"3 Forbury Place, 23 Forbury Road","addressLine1":"3 Forbury Place","addressLine2":"23 Forbury Road","addressLine3":"","addressLine4":"","city":"Reading","postcode":"RG1 3JH","country":826,"countryName":"United Kingdom"},"phone":"+441438310000","email":"eu_clinical_trials_information@iqvia.com","isBusinessKeyValidated":true,"businessKey":"ORG-100008655"},"sponsorDuties":[{"id":1085609,"code":"15","value":"eCOA + IRT system"}],"phoneNumber":"+441438310000","email":"eu_clinical_trials_information@iqvia.com"},{"id":699815,"organisationAddress":{"id":717924,"organisation":{"id":756182,"type":"Laboratory/Research/Testing facility","typeCode":"9","name":"Q Squared Solutions LLC","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100043195","organisationLocationStatus":"Active"},"address":{"addressId":786685,"oneLine":"2400 Ellis Road","addressLine1":"2400 Ellis Road","addressLine2":"","addressLine3":"","addressLine4":"","city":"Durham","postcode":"27703-5543","country":840,"countryName":"United States"},"phone":"+441184501088","email":"q2_eu_clinical_trials_information@q2labsolutions.com","isBusinessKeyValidated":true,"businessKey":"ORG-100043195"},"sponsorDuties":[{"id":1085622,"code":"15","value":"PK/ADA Analyses"}],"phoneNumber":"+441184501088","email":"q2_eu_clinical_trials_information@q2labsolutions.com"},{"id":699822,"organisationAddress":{"id":708266,"organisation":{"id":746483,"type":"Non-Pharmaceutical company","typeCode":"11","name":"Q Squared Solutions Limited","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100042527","organisationLocationStatus":"Active"},"address":{"addressId":774983,"oneLine":"3 Forbury Place, 23 Forbury Road","addressLine1":"3 Forbury Place","addressLine2":"23 Forbury Road","addressLine3":"","addressLine4":"","city":"Reading","postcode":"RG1 3JH","country":826,"countryName":"United Kingdom"},"phone":"+441184501088","email":"q2_eu_clinical_trials_information@q2labsolutions.com","isBusinessKeyValidated":true,"businessKey":"ORG-100042527"},"sponsorDuties":[{"id":1085629,"code":"15","value":"Central Lab"}],"phoneNumber":"+441184501088","email":"q2_eu_clinical_trials_information@q2labsolutions.com"},{"id":699811,"organisationAddress":{"id":758817,"organisation":{"id":797479,"type":"Non-Pharmaceutical company","typeCode":"11","name":"Revvity Signals Software Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100046158","organisationLocationStatus":"Active"},"address":{"addressId":836100,"oneLine":"940 Winter Street","addressLine1":"940 Winter Street","addressLine2":"","addressLine3":"","addressLine4":"","city":"Waltham","postcode":"02451-1457","country":840,"countryName":"United States"},"phone":"+7816636900","email":"x@xx.com","isBusinessKeyValidated":true,"businessKey":"ORG-100046158"},"sponsorDuties":[{"id":1085610,"code":"15","value":"Data Visualization"}],"phoneNumber":"+7816636900","email":"x@xx.com"},{"id":699813,"organisationAddress":{"id":881671,"organisation":{"id":923688,"type":"Health care","typeCode":"2","name":"Ascopharm","commercial":false,"isBusinessKeyValidated":false,"businessKey":"ORL-000017161","organisationLocationStatus":"Active"},"address":{"addressId":984295,"oneLine":"56 Rue de Londres","addressLine1":"56 Rue de Londres","addressLine2":"","addressLine3":"","addressLine4":"","city":"Paris","postcode":"75008","country":2012,"countryName":"France"},"phone":"0033156333540","email":"ascopharm@ascopharm.com","isBusinessKeyValidated":false,"businessKey":"ORL-000017161"},"sponsorDuties":[{"id":1085612,"code":"15","value":"Patient concierge"}],"phoneNumber":"0033156333540","email":"ascopharm@ascopharm.com"},{"id":699816,"organisationAddress":{"id":110113,"organisation":{"id":113022,"type":"Industry","typeCode":"3","name":"IQVIA HELLAS S.A.","commercial":true,"isBusinessKeyValidated":false,"businessKey":"ORL-000000942","organisationLocationStatus":"Active"},"address":{"addressId":115736,"oneLine":"284 Kifisias Avenue","addressLine1":"284 Kifisias Avenue","addressLine2":"","addressLine3":"","addressLine4":"","city":"Halandri","postcode":"15232","country":2014,"countryName":"Greece"},"phone":"+441438310000","email":"Biotech-EUCTR-Support@iqvia.com","isBusinessKeyValidated":false,"businessKey":"ORL-000000942"},"sponsorDuties":[{"id":1085623,"code":"1"}],"phoneNumber":"+441438310000","email":"Biotech-EUCTR-Support@iqvia.com"},{"id":699820,"organisationAddress":{"id":707011,"organisation":{"id":745226,"type":"Non-Pharmaceutical company","typeCode":"11","name":"Medidata Solutions Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100016256","organisationLocationStatus":"Active"},"address":{"addressId":773564,"oneLine":"350 Hudson Street","addressLine1":"350 Hudson Street","addressLine2":"","addressLine3":"","addressLine4":"","city":"New York","postcode":"10014-4504","country":840,"countryName":"United States"},"phone":"000000","email":"info@medidata.com","isBusinessKeyValidated":true,"businessKey":"ORG-100016256"},"sponsorDuties":[{"id":1085627,"code":"7"}],"phoneNumber":"000000","email":"info@medidata.com"},{"id":699817,"organisationAddress":{"id":758781,"organisation":{"id":797443,"type":"Pharmaceutical company","typeCode":"10","name":"Qiagen Manchester Limited","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100050466","organisationLocationStatus":"Active"},"address":{"addressId":836060,"oneLine":"200 Hathersage Road","addressLine1":"200 Hathersage Road","addressLine2":"","addressLine3":"","addressLine4":"","city":"Manchester","postcode":"M13 0BH","country":826,"countryName":"United Kingdom"},"phone":"+4408082343974","email":"competentauthoritysubmissions@qiagen.com","isBusinessKeyValidated":true,"businessKey":"ORG-100050466"},"sponsorDuties":[{"id":1085624,"code":"15","value":"Development of HPV DNA Assay"}],"phoneNumber":"+4408082343974","email":"competentauthoritysubmissions@qiagen.com"}],"organisation":{"id":688028,"type":"Pharmaceutical company","typeCode":"10","name":"Bicara Therapeutics Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100049097","organisationLocationStatus":"Active"},"addresses":[{"id":650029,"organisation":{"id":688028,"type":"Pharmaceutical company","typeCode":"10","name":"Bicara Therapeutics Inc.","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100049097","organisationLocationStatus":"Active"},"address":{"addressId":705519,"oneLine":"116 Huntington Avenue Suite 703","addressLine1":"116 Huntington Avenue Suite 703","addressLine2":"","addressLine3":"","addressLine4":"","city":"Boston","postcode":"02116-5784","country":840,"countryName":"United States"},"isBusinessKeyValidated":true,"businessKey":"ORG-100049097"}],"isCommercial":true,"commercial":"Commercial"}],"trialCategoryCode":"2","trialCategoryJustificationComment":"Phase II/phase III clinical trial","partOneTherapeuticAreas":[{"id":1216851,"therapeuticArea":{"code":"4","name":"Diseases [C] - Neoplasms [C04]"}}],"productRoleGroupInfos":[{"id":418803,"comments":"PEMBROLIZUMAB","miaNumber":"DE_BW_01_MIA_2023_0054","productRoleCode":"2","productRoleName":"Comparator","products":[{"id":562853,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB167136","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"PEMBROLIZUMAB","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"PEMBROLIZUMAB","euSubstNumber":"SUB167136","productSubstances":[{"substancePk":"387061","actSubstOrigin":"Protein - Other","actSubstName":"PEMBROLIZUMAB","substanceEvCode":"SUB167136"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"2","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"200","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"6.9","productChangedRelationMA":true,"productChangeDescription":"Relabeled for the clinical trial","maxTreatmentPeriod":42,"timeUnitCode":"2","miaNumber":"DE_BW_01_MIA_2023_0054","scientificProductEvCode":"SUB167136","devices":[],"characteristics":["7","4"],"routes":["INTRAVENOUS USE"],"allSubstancesChemicals":false,"productName":"PEMBROLIZUMAB","jsonActiveSubstanceNames":"pembrolizumab"}]},{"id":418800,"comments":"Ficerafusp Alfa","miaNumber":"DE_BW_01_MIA_2023_0054","productRoleCode":"1","productRoleName":"Test","products":[{"id":562843,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"12408372","productPharmForm":"VIAL FOR INTRAVENOUS USE","euMpNumber":"PRD12408372","prodAuthStatus":1,"prodName":"Ficerafusp Alfa","pharmForm":"VIAL FOR INTRAVENOUS USE","sponsorProductCode":"BCA101","activeSubstanceName":"FICERAFUSP ALFA","euSubstNumber":"SUB301432","nameOrg":"BICARA","productSubstances":[{"productPk":"12408372","substancePk":"404854","nameOrg":"BICARA","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"FICERAFUSP ALFA","substanceEvCode":"SUB301432","synonyms":["Bifunctional monoclonal antibody against epidermal growth factor receptor and transforming growth factor beta","BCA101","Ficerafusp alpha"]}],"activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"1500","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"156","maxTreatmentPeriod":24,"timeUnitCode":"3","evCode":"PRD12408372","sponsorProductCodeEdit":"BCA101","miaNumber":"DE_BW_01_MIA_2023_0054","devices":[],"characteristics":["7"],"routes":["SOLUTION FOR INFUSION"],"allSubstancesChemicals":false,"productName":"Ficerafusp Alfa","jsonActiveSubstanceNames":"ficerafusp alfa","pharmaceuticalFormDisplay":"VIAL FOR INTRAVENOUS USE"}]},{"id":418802,"comments":"Ficerafusp Alfa","miaNumber":"DE_BW_01_MIA_2023_0054","productRoleCode":"1","productRoleName":"Test","products":[{"id":562852,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"12980657","productPharmForm":"POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION","euMpNumber":"PRD12980657","prodAuthStatus":1,"prodName":"Ficerafusp Alfa","pharmForm":"POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION","sponsorProductCode":"BCA101","activeSubstanceName":"FICERAFUSP ALFA","euSubstNumber":"SUB301432","nameOrg":"BICARA","productSubstances":[{"productPk":"12980657","substancePk":"404854","nameOrg":"BICARA","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"FICERAFUSP ALFA","substanceEvCode":"SUB301432","synonyms":["Bifunctional monoclonal antibody against epidermal growth factor receptor and transforming growth factor beta","BCA101","Ficerafusp alpha"]}],"activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"1500","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"156","maxTreatmentPeriod":24,"timeUnitCode":"3","evCode":"PRD12980657","sponsorProductCodeEdit":"BCA101","miaNumber":"DE_BW_01_MIA_2023_0054","devices":[],"characteristics":["7"],"routes":["SOLUTION FOR INFUSION"],"allSubstancesChemicals":false,"productName":"Ficerafusp Alfa","jsonActiveSubstanceNames":"ficerafusp alfa","pharmaceuticalFormDisplay":"POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION"}]},{"id":418804,"comments":"Saline bag","productRoleCode":"3","productRoleName":"Placebo","products":[{"id":562854,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPharmForm":"N/A","euMpNumber":"N/A","marketingAuthNumber":"N/A","prodName":"Saline bag","pharmForm":"N/A","activeSubstanceName":"N/A","euSubstNumber":"N/A","productOtherName":"N/A","authorisationCountryCode":"IS","nameOrg":"N/A","sponsorSubstanceCode":"N/A","atcCode":"N/A","atcName":"N/A","atcTermLevel":"N/A","activeSubstanceOtherDescriptiveName":"N/A"},"isPaediatricFormulation":false,"mpRoleInTrial":"3","timeUnitCode":"2","evCode":"N/A","devices":[],"characteristics":[],"routes":[],"allSubstancesChemicals":false,"productName":"Saline bag","jsonActiveSubstanceNames":"n/a","pharmaceuticalFormDisplay":"N/A"}]},{"id":418801,"comments":"KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion","miaNumber":"DE_BW_01_MIA_2023_0054","productRoleCode":"1","productRoleName":"Test","products":[{"id":562844,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"12352436","productPharmForm":"CONCENTRATE FOR SOLUTION FOR INFUSION","euMpNumber":"PRD4323105","marketingAuthNumber":"EU/1/15/1024/002","prodAuthStatus":2,"prodName":"KEYTRUDA 25 mg/mL concentrate for solution for infusion","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"PEMBROLIZUMAB","euSubstNumber":"SUB167136","authorisationCountryCode":"EU","mrpNumber":"EMEA/H/C/003820","nameOrg":"MERCK SHARP & DOHME B.V.","productSubstances":[{"productPk":"12352436","substancePk":"387061","nameOrg":"MERCK SHARP & DOHME B.V.","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"PEMBROLIZUMAB","substanceEvCode":"SUB167136"}],"atcCode":"L01FF02","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"200","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"6.9","productChangedRelationMA":true,"productChangeDescription":"Relabeled for the clinical trial and administered with ficerasup alfa","maxTreatmentPeriod":24,"timeUnitCode":"3","evCode":"PRD4323105","miaNumber":"DE_BW_01_MIA_2023_0054","devices":[],"characteristics":["4","7"],"routes":["INTRAVENOUS USE"],"allSubstancesChemicals":false,"productName":"KEYTRUDA 25 mg/mL concentrate for solution for infusion","jsonActiveSubstanceNames":"pembrolizumab","pharmaceuticalFormDisplay":"SOLUTION FOR INFUSION"},{"id":562845,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"12352439","productPharmForm":"CONCENTRATE FOR SOLUTION FOR INFUSION","euMpNumber":"PRD4323786","marketingAuthNumber":"EU/1/15/1024/002","prodAuthStatus":2,"prodName":"KEYTRUDA 25 mg/mL concentrate for solution for infusion","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"PEMBROLIZUMAB","euSubstNumber":"SUB167136","authorisationCountryCode":"NO","mrpNumber":"EMEA/H/C/003820","nameOrg":"MERCK SHARP & DOHME B.V.","productSubstances":[{"productPk":"12352439","substancePk":"387061","nameOrg":"MERCK SHARP & DOHME B.V.","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"PEMBROLIZUMAB","substanceEvCode":"SUB167136"}],"atcCode":"L01FF02","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"200","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"6.9","productChangedRelationMA":true,"productChangeDescription":"Relabeled for the clinical trial and administered with ficerasup alfa","maxTreatmentPeriod":24,"timeUnitCode":"3","evCode":"PRD4323786","miaNumber":"DE_BW_01_MIA_2023_0054","devices":[],"characteristics":["7","4"],"routes":["INTRAVENOUS USE"],"allSubstancesChemicals":false,"productName":"KEYTRUDA 25 mg/mL concentrate for solution for infusion","jsonActiveSubstanceNames":"pembrolizumab","pharmaceuticalFormDisplay":"SOLUTION FOR INFUSION"},{"id":562846,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"12352437","productPharmForm":"CONCENTRATE FOR SOLUTION FOR INFUSION","euMpNumber":"PRD4323784","marketingAuthNumber":"EU/1/15/1024/002","prodAuthStatus":2,"prodName":"KEYTRUDA 25 mg/mL concentrate for solution for infusion","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"PEMBROLIZUMAB","euSubstNumber":"SUB167136","authorisationCountryCode":"IS","mrpNumber":"EMEA/H/C/003820","nameOrg":"MERCK SHARP & DOHME B.V.","productSubstances":[{"productPk":"12352437","substancePk":"387061","nameOrg":"MERCK SHARP & DOHME B.V.","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"PEMBROLIZUMAB","substanceEvCode":"SUB167136"}],"atcCode":"L01FF02","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"200","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"6.9","productChangedRelationMA":true,"productChangeDescription":"Relabeled for the clinical trial and administered with ficerasup alfa","maxTreatmentPeriod":24,"timeUnitCode":"3","evCode":"PRD4323784","miaNumber":"DE_BW_01_MIA_2023_0054","devices":[],"characteristics":["4","7"],"routes":["INTRAVENOUS USE"],"allSubstancesChemicals":false,"productName":"KEYTRUDA 25 mg/mL concentrate for solution for infusion","jsonActiveSubstanceNames":"pembrolizumab","pharmaceuticalFormDisplay":"SOLUTION FOR INFUSION"},{"id":562847,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"12352442","productPharmForm":"CONCENTRATE FOR SOLUTION FOR INFUSION","euMpNumber":"PRD12081134","marketingAuthNumber":"EU/1/15/1024/003","prodAuthStatus":2,"prodName":"KEYTRUDA 25 mg/mL concentrate for solution for infusion","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"PEMBROLIZUMAB","euSubstNumber":"SUB167136","authorisationCountryCode":"LI","mrpNumber":"EMEA/H/C/003820","nameOrg":"MERCK SHARP & DOHME B.V.","productSubstances":[{"productPk":"12352442","substancePk":"387061","nameOrg":"MERCK SHARP & DOHME B.V.","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"PEMBROLIZUMAB","substanceEvCode":"SUB167136"}],"atcCode":"L01FF02","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"200","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"6.9","productChangedRelationMA":true,"productChangeDescription":"Relabeled for the clinical trial and administered with ficerasup alfa","maxTreatmentPeriod":24,"timeUnitCode":"3","evCode":"PRD12081134","miaNumber":"DE_BW_01_MIA_2023_0054","devices":[],"characteristics":["7","4"],"routes":["INTRAVENOUS USE"],"allSubstancesChemicals":false,"productName":"KEYTRUDA 25 mg/mL concentrate for solution for infusion","jsonActiveSubstanceNames":"pembrolizumab","pharmaceuticalFormDisplay":"SOLUTION FOR INFUSION"},{"id":562848,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"12352443","productPharmForm":"CONCENTRATE FOR SOLUTION FOR INFUSION","euMpNumber":"PRD12081135","marketingAuthNumber":"EU/1/15/1024/003","prodAuthStatus":2,"prodName":"KEYTRUDA 25 mg/mL concentrate for solution for infusion","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"PEMBROLIZUMAB","euSubstNumber":"SUB167136","authorisationCountryCode":"NO","mrpNumber":"EMEA/H/C/003820","nameOrg":"MERCK SHARP & DOHME B.V.","productSubstances":[{"productPk":"12352443","substancePk":"387061","nameOrg":"MERCK SHARP & DOHME B.V.","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"PEMBROLIZUMAB","substanceEvCode":"SUB167136"}],"atcCode":"L01FF02","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"200","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"6.9","productChangedRelationMA":true,"productChangeDescription":"Relabeled for the clinical trial and administered with ficerasup alfa","maxTreatmentPeriod":24,"timeUnitCode":"3","evCode":"PRD12081135","miaNumber":"DE_BW_01_MIA_2023_0054","devices":[],"characteristics":["4","7"],"routes":["INTRAVENOUS USE"],"allSubstancesChemicals":false,"productName":"KEYTRUDA 25 mg/mL concentrate for solution for infusion","jsonActiveSubstanceNames":"pembrolizumab","pharmaceuticalFormDisplay":"SOLUTION FOR INFUSION"},{"id":562849,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"12352440","productPharmForm":"CONCENTRATE FOR SOLUTION FOR INFUSION","euMpNumber":"PRD12081132","marketingAuthNumber":"EU/1/15/1024/003","prodAuthStatus":2,"prodName":"KEYTRUDA 25 mg/mL concentrate for solution for infusion","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"PEMBROLIZUMAB","euSubstNumber":"SUB167136","authorisationCountryCode":"EU","mrpNumber":"EMEA/H/C/003820","nameOrg":"MERCK SHARP & DOHME B.V.","productSubstances":[{"productPk":"12352440","substancePk":"387061","nameOrg":"MERCK SHARP & DOHME B.V.","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"PEMBROLIZUMAB","substanceEvCode":"SUB167136"}],"atcCode":"L01FF02","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"200","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"6.9","productChangedRelationMA":true,"productChangeDescription":"Relabeled for the clinical trial and administered with ficerasup alfa","maxTreatmentPeriod":24,"timeUnitCode":"3","evCode":"PRD12081132","miaNumber":"DE_BW_01_MIA_2023_0054","devices":[],"characteristics":["4","7"],"routes":["INTRAVENOUS USE"],"allSubstancesChemicals":false,"productName":"KEYTRUDA 25 mg/mL concentrate for solution for infusion","jsonActiveSubstanceNames":"pembrolizumab","pharmaceuticalFormDisplay":"SOLUTION FOR INFUSION"},{"id":562850,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"12352438","productPharmForm":"CONCENTRATE FOR SOLUTION FOR INFUSION","euMpNumber":"PRD4323785","marketingAuthNumber":"EU/1/15/1024/002","prodAuthStatus":2,"prodName":"KEYTRUDA 25 mg/mL concentrate for solution for infusion","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"PEMBROLIZUMAB","euSubstNumber":"SUB167136","authorisationCountryCode":"LI","mrpNumber":"EMEA/H/C/003820","nameOrg":"MERCK SHARP & DOHME B.V.","productSubstances":[{"productPk":"12352438","substancePk":"387061","nameOrg":"MERCK SHARP & DOHME B.V.","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"PEMBROLIZUMAB","substanceEvCode":"SUB167136"}],"atcCode":"L01FF02","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"200","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"6.9","productChangedRelationMA":true,"productChangeDescription":"Relabeled for the clinical trial and administered with ficerasup alfa","maxTreatmentPeriod":24,"timeUnitCode":"3","evCode":"PRD4323785","miaNumber":"DE_BW_01_MIA_2023_0054","devices":[],"characteristics":["4","7"],"routes":["INTRAVENOUS USE"],"allSubstancesChemicals":false,"productName":"KEYTRUDA 25 mg/mL concentrate for solution for infusion","jsonActiveSubstanceNames":"pembrolizumab","pharmaceuticalFormDisplay":"SOLUTION FOR INFUSION"},{"id":562851,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"12352441","productPharmForm":"CONCENTRATE FOR SOLUTION FOR INFUSION","euMpNumber":"PRD12081133","marketingAuthNumber":"EU/1/15/1024/003","prodAuthStatus":2,"prodName":"KEYTRUDA 25 mg/mL concentrate for solution for infusion","pharmForm":"SOLUTION FOR INFUSION","activeSubstanceName":"PEMBROLIZUMAB","euSubstNumber":"SUB167136","authorisationCountryCode":"IS","mrpNumber":"EMEA/H/C/003820","nameOrg":"MERCK SHARP & DOHME B.V.","productSubstances":[{"productPk":"12352441","substancePk":"387061","nameOrg":"MERCK SHARP & DOHME B.V.","substanceOrigin":"Protein - Other","actSubstOrigin":"Protein - Other","actSubstName":"PEMBROLIZUMAB","substanceEvCode":"SUB167136"}],"atcCode":"L01FF02","atcName":"-","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg milligram(s)","maxDailyDoseAmount":"200","doseUomTotal":"g gram(s)","maxTotalDoseAmount":"6.9","productChangedRelationMA":true,"productChangeDescription":"Relabeled for the clinical trial and administered with ficerasup alfa","maxTreatmentPeriod":24,"timeUnitCode":"3","evCode":"PRD12081133","miaNumber":"DE_BW_01_MIA_2023_0054","devices":[],"characteristics":["4","7"],"routes":["INTRAVENOUS USE"],"allSubstancesChemicals":false,"productName":"KEYTRUDA 25 mg/mL concentrate for solution for infusion","jsonActiveSubstanceNames":"pembrolizumab","pharmaceuticalFormDisplay":"SOLUTION FOR INFUSION"}]}],"isLowIntervention":false},"authorizedPartsII":[{"id":318808,"mscId":44336,"mscInfo":{"id":44336,"clinicalTrialId":20954,"countryOrganisationId":2008,"reportingStatusCode":"Authorised","fromDate":"2025-09-10","toDate":"2025-09-10","isProposedRms":false,"expressDecision":"unwilling","countryName":"Czechia","organisationInfo":{},"firstDecisionDate":"2025-10-08","trialStatus":"Authorised","trialPeriod":[{"id":77127,"trialStartDate":"2026-03-17","fromDate":"2026-03-17"},{"id":77126,"trialStartDate":"2026-03-17","fromDate":"2026-03-17"}],"trialRecruitmentPeriod":[{"id":122412,"recruitmentStartDate":"2026-09-08","fromDate":"2026-09-15"},{"id":122413,"recruitmentStartDate":"2026-09-08","fromDate":"2026-09-15"},{"id":122404,"recruitmentStartDate":"2026-09-08","fromDate":"2026-09-15"},{"id":122403,"recruitmentStartDate":"2026-09-08","fromDate":"2026-09-15"},{"id":122402,"recruitmentStartDate":"2026-09-08","fromDate":"2026-09-15"},{"id":122411,"recruitmentStartDate":"2026-09-08","fromDate":"2026-09-15"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":123815,"trialStartDate":"2026-03-17","fromDate":"2026-03-17"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2026-09-08"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":85659,"mscId":44336,"trialStatus":"Under evaluation","trialStatusDate":"2025-06-19T12:59:20.724"},{"id":100869,"mscId":44336,"trialStatus":"Authorised","trialStatusDate":"2025-10-08T10:48:15.243"}],"applicationTypeMsc":"1","mscName":"Czechia","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-09-01","decision":"authorized_conditions","decisionDate":"2025-10-08"},"decisionDate":"2025-10-08","recruitmentSubjectCount":6,"trialSites":[{"id":2294789,"organisationAddressInfo":{"id":1012951,"organisation":{"id":1059299,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Fakultni Nemocnice Motol A Homolka","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100012719","organisationLocationStatus":"Active"},"address":{"addressId":1142557,"oneLine":"V Uvalu 84/1, Motol","addressLine1":"V Uvalu 84/1","addressLine2":"Motol","addressLine3":"","addressLine4":"","city":"Prague","postcode":"150 00","country":2008,"countryName":"Czechia"},"phone":"+420224434764","email":"michaela.jirkovska@fnmotol.cz","isBusinessKeyValidated":true,"businessKey":"LOC-100018378"},"personInfo":{"id":2544172,"firstName":"Michaela","lastName":"Jirkovská","telephone":"+420224434764","email":"michaela.jirkovska@fnmotol.cz","title":"1"},"departmentName":"Onkologická klinika"},{"id":2230619,"organisationAddressInfo":{"id":764958,"organisation":{"id":803652,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Fakultni Nemocnice Hradec Kralove","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100022983","organisationLocationStatus":"Active"},"address":{"addressId":843317,"oneLine":"Sokolska 581, Novy Hradec Kralove","addressLine1":"Sokolska 581","addressLine2":"Novy Hradec Kralove","addressLine3":"","addressLine4":"","city":"Hradec Kralove","postcode":"500 03","country":2008,"countryName":"Czechia"},"phone":"+420495832316","email":"milan.vosmik@fnhk.cz","isBusinessKeyValidated":true,"businessKey":"ORG-100022983"},"personInfo":{"id":2473929,"firstName":"Milan","lastName":"Vošmik","telephone":"+420495832316","email":"milan.vosmik@fnhk.cz","title":"1"},"departmentName":"Klinika onkologie a radioterapie"}],"applicationStatusCode":"Authorised"},{"id":339675,"mscId":44341,"mscInfo":{"id":44341,"clinicalTrialId":20954,"countryOrganisationId":2018,"reportingStatusCode":"Authorised","fromDate":"2025-09-12","toDate":"2025-09-12","isProposedRms":false,"expressDecision":"unwilling","countryName":"Italy","organisationInfo":{},"firstDecisionDate":"2025-10-09","trialStatus":"Authorised","trialPeriod":[{"id":70091,"trialStartDate":"2025-11-27","fromDate":"2025-12-02"},{"id":70092,"trialStartDate":"2025-11-27","fromDate":"2025-12-02"}],"trialRecruitmentPeriod":[{"id":96841,"recruitmentStartDate":"2025-12-23","fromDate":"2025-12-31"},{"id":96842,"recruitmentStartDate":"2025-12-23","fromDate":"2025-12-31"},{"id":96843,"recruitmentStartDate":"2025-12-23","fromDate":"2025-12-31"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":109156,"trialStartDate":"2025-11-27","fromDate":"2025-12-02"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2025-12-23"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":85664,"mscId":44341,"trialStatus":"Under evaluation","trialStatusDate":"2025-06-19T12:59:20.824"},{"id":101833,"mscId":44341,"trialStatus":"Authorised","trialStatusDate":"2025-10-09T14:22:50.516"}],"applicationTypeMsc":"1","mscName":"Italy","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-10-02","decision":"authorized_conditions","decisionDate":"2025-10-09"},"decisionDate":"2025-10-09","recruitmentSubjectCount":53,"trialSites":[{"id":2387701,"organisationAddressInfo":{"id":774936,"organisation":{"id":813681,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Istituto Oncologico Veneto","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100007494","organisationLocationStatus":"Active"},"address":{"addressId":855173,"oneLine":"Via Gattamelata 64","addressLine1":"Via Gattamelata 64","addressLine2":"","addressLine3":"","addressLine4":"","city":"Padova","postcode":"35128","country":2018,"countryName":"Italy"},"phone":"+390498215931","email":"mariagrazia.ghi@iov.veneto.it","isBusinessKeyValidated":true,"businessKey":"ORG-100007494"},"personInfo":{"id":2646446,"firstName":"Maria Grazia","lastName":"Ghi","telephone":"+390498215931","email":"mariagrazia.ghi@iov.veneto.it","title":"1"},"departmentName":"Oncologia Medica 2"},{"id":2387693,"organisationAddressInfo":{"id":774939,"organisation":{"id":813684,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100014358","organisationLocationStatus":"Active"},"address":{"addressId":855176,"oneLine":"Largo Francesco Vito 1","addressLine1":"Largo Francesco Vito 1","addressLine2":"","addressLine3":"","addressLine4":"","city":"Rome","postcode":"00168","country":2018,"countryName":"Italy"},"phone":"+390630155202","email":"alessandra.cassano@policlinicogemelli.it","isBusinessKeyValidated":true,"businessKey":"ORG-100014358"},"personInfo":{"id":2646438,"firstName":"Alessandra","lastName":"Cassano","telephone":"+390630155202","email":"alessandra.cassano@policlinicogemelli.it","title":"1"},"departmentName":"UOC Oncologia Medica"},{"id":2387698,"organisationAddressInfo":{"id":881210,"organisation":{"id":923226,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"ARNAS G. Brotzu","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100045535","organisationLocationStatus":"Active"},"address":{"addressId":983697,"oneLine":"Piazzale Alessandro Ricchi 1","addressLine1":"Piazzale Alessandro Ricchi 1","addressLine2":"","addressLine3":"","addressLine4":"","city":"Cagliari","postcode":"09121","country":2018,"countryName":"Italy"},"phone":"+3907052965205","email":"massimo.ghiani@aob.it","isBusinessKeyValidated":true,"businessKey":"ORG-100045535"},"personInfo":{"id":2646443,"firstName":"Massimo","lastName":"Ghiani","telephone":"+3907052965205","email":"massimo.ghiani@aob.it","title":"1"},"departmentName":"S.C. Oncologia Medica,  P.O. \"A. Businco\""},{"id":2387690,"organisationAddressInfo":{"id":774917,"organisation":{"id":813662,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Fondazione IRCCS Istituto Nazionale Dei Tumori","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100008982","organisationLocationStatus":"Active"},"address":{"addressId":855154,"oneLine":"Via Giacomo Venezian 1","addressLine1":"Via Giacomo Venezian 1","addressLine2":"","addressLine3":"","addressLine4":"","city":"Milan","postcode":"20133","country":2018,"countryName":"Italy"},"phone":"+390223903352","email":"lisa.licitra@istitutotumori.mi.it","isBusinessKeyValidated":true,"businessKey":"ORG-100008982"},"personInfo":{"id":2646435,"firstName":"Lisa","lastName":"Licitra","telephone":"+390223903352","email":"lisa.licitra@istitutotumori.mi.it","title":"2"},"departmentName":"SC Oncologia Medica 3 - Tumori Testa-collo"},{"id":2387695,"organisationAddressInfo":{"id":774935,"organisation":{"id":813680,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100030362","organisationLocationStatus":"Active"},"address":{"addressId":855172,"oneLine":"Via Del Vespro 129","addressLine1":"Via Del Vespro 129","addressLine2":"","addressLine3":"","addressLine4":"","city":"Palermo","postcode":"90127","country":2018,"countryName":"Italy"},"phone":"+390916554411","email":"gaetana.rinaldi@policlinico.pa.it","isBusinessKeyValidated":true,"businessKey":"ORG-100030362"},"personInfo":{"id":2646440,"firstName":"Gaetana","lastName":"Rinaldi","telephone":"+390916554411","email":"gaetana.rinaldi@policlinico.pa.it","title":"1"},"departmentName":"U.O.C. Oncologia Medica"},{"id":2387697,"organisationAddressInfo":{"id":774928,"organisation":{"id":813673,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Azienda Ospedaliero Universitaria Pisana","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100010128","organisationLocationStatus":"Active"},"address":{"addressId":855165,"oneLine":"Via Roma 67","addressLine1":"Via Roma 67","addressLine2":"","addressLine3":"","addressLine4":"","city":"Pisa","postcode":"56126","country":2018,"countryName":"Italy"},"phone":"+39050993307","email":"lugal71@yahoo.it","isBusinessKeyValidated":true,"businessKey":"ORG-100010128"},"personInfo":{"id":2646442,"firstName":"Luca","lastName":"Galli","telephone":"+39050993307","email":"lugal71@yahoo.it","title":"1"},"departmentName":"UO Oncologia Medica 2, Ospedale Santa Chiara"},{"id":2387686,"organisationAddressInfo":{"id":774924,"organisation":{"id":813669,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Fondazione IRCCS Policlinico San Matteo","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100007361","organisationLocationStatus":"Active"},"address":{"addressId":855161,"oneLine":"Viale Camillo Golgi 19","addressLine1":"Viale Camillo Golgi 19","addressLine2":"","addressLine3":"","addressLine4":"","city":"Pavia","postcode":"27100","country":2018,"countryName":"Italy"},"phone":"+390382502094","email":"i.imarisio@smatteo.pv.it","isBusinessKeyValidated":true,"businessKey":"ORG-100007361"},"personInfo":{"id":2646431,"firstName":"Ilaria","lastName":"Imarisio","telephone":"+390382502094","email":"i.imarisio@smatteo.pv.it","title":"1"},"departmentName":"SC Oncologia"},{"id":2387699,"organisationAddressInfo":{"id":774929,"organisation":{"id":813674,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Azienda Ospedaliero Universitaria Careggi","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100010591","organisationLocationStatus":"Active"},"address":{"addressId":855166,"oneLine":"Largo Giovanni Alessandro Brambilla 3","addressLine1":"Largo Giovanni Alessandro Brambilla 3","addressLine2":"","addressLine3":"","addressLine4":"","city":"Florence","postcode":"50134","country":2018,"countryName":"Italy"},"phone":"+390557947264","email":"lorenzo.livi@unifi.it","isBusinessKeyValidated":true,"businessKey":"ORG-100010591"},"personInfo":{"id":2646444,"firstName":"Lorenzo","lastName":"Livi","telephone":"+390557947264","email":"lorenzo.livi@unifi.it","title":"2"},"departmentName":"SOD Radioterapia Oncologica"},{"id":2387688,"organisationAddressInfo":{"id":774930,"organisation":{"id":813675,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"IRCCS Istituto Nazionale Tumori Fondazione Pascale","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100010025","organisationLocationStatus":"Active"},"address":{"addressId":855167,"oneLine":"Via Mariano Semmola 52","addressLine1":"Via Mariano Semmola 52","addressLine2":"","addressLine3":"","addressLine4":"","city":"Naples","postcode":"80131","country":2018,"countryName":"Italy"},"phone":"+393489145086","email":"f.perri@istitutotumori.na.it","isBusinessKeyValidated":true,"businessKey":"ORG-100010025"},"personInfo":{"id":2646433,"firstName":"Francesco","lastName":"Perri","telephone":"+393489145086","email":"f.perri@istitutotumori.na.it","title":"1"},"departmentName":"S.C. Oncologia Clinica Sperimentale Testa-Collo e Muscolo-Scheletrica"},{"id":2387696,"organisationAddressInfo":{"id":774934,"organisation":{"id":813679,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Ospedale Isola Tiberina Gemelli Isola","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100030103","organisationLocationStatus":"Active"},"address":{"addressId":855171,"oneLine":"Via Di Ponte Quattro Capi 39","addressLine1":"Via Di Ponte Quattro Capi 39","addressLine2":"","addressLine3":"","addressLine4":"","city":"Rome","postcode":"00186","country":2018,"countryName":"Italy"},"phone":"+39066837249","email":"marco.ciaparrone@fbf-isola.it","isBusinessKeyValidated":true,"businessKey":"ORG-100030103"},"personInfo":{"id":2646441,"firstName":"Marco","lastName":"Ciaparrone","telephone":"+39066837249","email":"marco.ciaparrone@fbf-isola.it","title":"1"},"departmentName":"Unità Operativa Complessa di Oncologia"},{"id":2387685,"organisationAddressInfo":{"id":774931,"organisation":{"id":813676,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Azienda Ospedaliero-Universitaria Policlinico Umberto I","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100023585","organisationLocationStatus":"Active"},"address":{"addressId":855168,"oneLine":"Viale Del Policlinico 155","addressLine1":"Viale Del Policlinico 155","addressLine2":"","addressLine3":"","addressLine4":"","city":"Rome","postcode":"00161","country":2018,"countryName":"Italy"},"phone":"+393336433648","email":"alessio.cirillo@uniroma1.it","isBusinessKeyValidated":true,"businessKey":"ORG-100023585"},"personInfo":{"id":2646430,"firstName":"Alessio","lastName":"Cirillo","telephone":"+393336433648","email":"alessio.cirillo@uniroma1.it","title":"1"},"departmentName":"UOC Oncologia - Department of radiological, oncological and anatomopathological science"},{"id":2387687,"organisationAddressInfo":{"id":774938,"organisation":{"id":813683,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Azienda Ospedaliera Universitaria Universita' Degli Studi Della Campania Luigi Vanvitelli","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100041785","organisationLocationStatus":"Active"},"address":{"addressId":855175,"oneLine":"Via Sergio Pansini 5","addressLine1":"Via Sergio Pansini 5","addressLine2":"","addressLine3":"","addressLine4":"","city":"Naples","postcode":"80131","country":2018,"countryName":"Italy"},"phone":"+390815666729","email":"morena.fasano@unicampania.it","isBusinessKeyValidated":true,"businessKey":"ORG-100041785"},"personInfo":{"id":2646432,"firstName":"Morena","lastName":"Fasano","telephone":"+390815666729","email":"morena.fasano@unicampania.it","title":"1"},"departmentName":"UOC Oncoematologia"},{"id":2387692,"organisationAddressInfo":{"id":774933,"organisation":{"id":813678,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100010060","organisationLocationStatus":"Active"},"address":{"addressId":855170,"oneLine":"Via Pietro Albertoni 15","addressLine1":"Via Pietro Albertoni 15","addressLine2":"","addressLine3":"","addressLine4":"","city":"Bologna","postcode":"40138","country":2018,"countryName":"Italy"},"phone":"+390512142265","email":"stefania.salvagni@aosp.bo.it","isBusinessKeyValidated":true,"businessKey":"ORG-100010060"},"personInfo":{"id":2646437,"firstName":"Stefania","lastName":"Salvagni","telephone":"+390512142265","email":"stefania.salvagni@aosp.bo.it","title":"1"},"departmentName":"U.O.C. Medical Oncology"},{"id":2387691,"organisationAddressInfo":{"id":774926,"organisation":{"id":813671,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Azienda Socio Sanitaria Territoriale Santi Paolo E Carlo","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100042020","organisationLocationStatus":"Active"},"address":{"addressId":855163,"oneLine":"Via Antonio Di Rudini' 8","addressLine1":"Via Antonio Di Rudini' 8","addressLine2":"","addressLine3":"","addressLine4":"","city":"Milan","postcode":"20142","country":2018,"countryName":"Italy"},"phone":"+390281844583","email":"mauro.moroni@asst-santipaolocarlo.it","isBusinessKeyValidated":true,"businessKey":"ORG-100042020"},"personInfo":{"id":2646436,"firstName":"Mauro","lastName":"Moroni","telephone":"+390281844583","email":"mauro.moroni@asst-santipaolocarlo.it","title":"1"},"departmentName":"SC Oncologia"},{"id":2387702,"organisationAddressInfo":{"id":881213,"organisation":{"id":923229,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Humanitas Mirasole S.p.A.","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100007492","organisationLocationStatus":"Active"},"address":{"addressId":983700,"oneLine":"Via Alessandro Manzoni 56","addressLine1":"Via Alessandro Manzoni 56","addressLine2":"","addressLine3":"","addressLine4":"","city":"Rozzano","postcode":"20089","country":2018,"countryName":"Italy"},"phone":"+390282243660","email":"paolo.bossi@hunimed.eu","isBusinessKeyValidated":true,"businessKey":"ORG-100007492"},"personInfo":{"id":2646447,"firstName":"Paolo","lastName":"Bossi","telephone":"+390282243660","email":"paolo.bossi@hunimed.eu","title":"2"},"departmentName":"Dipartimento di Oncologia"},{"id":2387700,"organisationAddressInfo":{"id":774932,"organisation":{"id":813677,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Azienda Ospedaliero-Universitaria Senese","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100023562","organisationLocationStatus":"Active"},"address":{"addressId":855169,"oneLine":"Strada Delle Scotte 14","addressLine1":"Strada Delle Scotte 14","addressLine2":"","addressLine3":"","addressLine4":"","city":"Siena","postcode":"53100","country":2018,"countryName":"Italy"},"phone":"+390577586336","email":"mmaiocro@gmail.com","isBusinessKeyValidated":true,"businessKey":"ORG-100023562"},"personInfo":{"id":2646445,"firstName":"Michele","lastName":"Maio","telephone":"+390577586336","email":"mmaiocro@gmail.com","title":"2"},"departmentName":"U.O.C. Immunoterapia Oncologica"},{"id":2387689,"organisationAddressInfo":{"id":774927,"organisation":{"id":813672,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Ospedale San Raffaele S.r.l.","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100006123","organisationLocationStatus":"Active"},"address":{"addressId":855164,"oneLine":"Via Olgettina 60","addressLine1":"Via Olgettina 60","addressLine2":"","addressLine3":"","addressLine4":"","city":"Milan","postcode":"20132","country":2018,"countryName":"Italy"},"phone":"+390226433526","email":"mirabile.aurora@hsr.it","isBusinessKeyValidated":true,"businessKey":"ORG-100006123"},"personInfo":{"id":2646434,"firstName":"Aurora","lastName":"Mirabile","telephone":"+390226433526","email":"mirabile.aurora@hsr.it","title":"1"},"departmentName":"Otolaryngology department"},{"id":2387694,"organisationAddressInfo":{"id":774937,"organisation":{"id":813682,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"ASST Grande Ospedale Metropolitano Niguarda","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100006558","organisationLocationStatus":"Active"},"address":{"addressId":855174,"oneLine":"Piazza Dell'ospedale Maggiore 3","addressLine1":"Piazza Dell'ospedale Maggiore 3","addressLine2":"","addressLine3":"","addressLine4":"","city":"Milan","postcode":"20162","country":2018,"countryName":"Italy"},"phone":"+390264442291","email":"tiziana.cipani@ospedaleniguarda.it","isBusinessKeyValidated":true,"businessKey":"ORG-100006558"},"personInfo":{"id":2646439,"firstName":"Tiziana","lastName":"Cipani","telephone":"+390264442291","email":"tiziana.cipani@ospedaleniguarda.it","title":"1"},"departmentName":"Struttura Complessa Oncologia Falck"},{"id":2387684,"organisationAddressInfo":{"id":1008386,"organisation":{"id":1054723,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Ospedale Vito Fazzi Lecce","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100045616","organisationLocationStatus":"Active"},"address":{"addressId":1137036,"oneLine":"Piazza Filippo Muratore 1","addressLine1":"Piazza Filippo Muratore 1","addressLine2":"","addressLine3":"","addressLine4":"","city":"Lecce","postcode":"73100","country":2018,"countryName":"Italy"},"phone":"+390832661807","email":"graziana.ronzino@asl.lecce.it","isBusinessKeyValidated":true,"businessKey":"LOC-100075169"},"personInfo":{"id":2646429,"firstName":"Graziana","lastName":"Ronzino","telephone":"+390832661807","email":"graziana.ronzino@asl.lecce.it","title":"1"},"departmentName":"UOC Oncologia Universitaria"}],"applicationStatusCode":"Authorised"},{"id":318811,"mscId":44338,"mscInfo":{"id":44338,"clinicalTrialId":20954,"countryOrganisationId":2013,"reportingStatusCode":"Authorised","fromDate":"2025-09-19","toDate":"2025-09-19","isProposedRms":false,"expressDecision":"unwilling","countryName":"Germany","organisationInfo":{},"firstDecisionDate":"2025-10-09","trialStatus":"Authorised","trialPeriod":[{"id":73429,"trialStartDate":"2026-01-22","fromDate":"2026-01-23"},{"id":73430,"trialStartDate":"2026-01-22","fromDate":"2026-01-23"}],"trialRecruitmentPeriod":[{"id":111305,"recruitmentStartDate":"2026-05-15","fromDate":"2026-05-19"},{"id":111306,"recruitmentStartDate":"2026-05-15","fromDate":"2026-05-19"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":116105,"trialStartDate":"2026-01-22","fromDate":"2026-01-23"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2026-05-15"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":85661,"mscId":44338,"trialStatus":"Under evaluation","trialStatusDate":"2025-06-19T12:59:20.764"},{"id":101886,"mscId":44338,"trialStatus":"Authorised","trialStatusDate":"2025-10-09T15:43:48.131"}],"applicationTypeMsc":"1","mscName":"Germany","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-08-19","decision":"authorized_conditions","decisionDate":"2025-10-09"},"decisionDate":"2025-10-09","recruitmentSubjectCount":35,"trialSites":[{"id":2230651,"organisationAddressInfo":{"id":765644,"organisation":{"id":804344,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Staedtisches Klinikum Dresden","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100048550","organisationLocationStatus":"Active"},"address":{"addressId":844116,"oneLine":"Friedrichstrasse 41, Friedrichstadt","addressLine1":"Friedrichstrasse 41","addressLine2":"Friedrichstadt","addressLine3":"","addressLine4":"","city":"Dresden","postcode":"01067","country":2013,"countryName":"Germany"},"phone":"03514803740","email":"Harald.Schmalenberg@klinikum-dresden.de","isBusinessKeyValidated":true,"businessKey":"ORG-100048550"},"personInfo":{"id":2473961,"firstName":"Harald","lastName":"Schmalenberg","telephone":"03514803740","email":"Harald.Schmalenberg@klinikum-dresden.de","title":"1"},"departmentName":"4. Medizinische Klinik (Hämatologie, internistische Onkologie und Palliativmedizin)"},{"id":2230644,"organisationAddressInfo":{"id":765653,"organisation":{"id":804353,"type":"Educational Institution","typeCode":"1","name":"Technische Universitaet Dresden","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100011298","organisationLocationStatus":"Active"},"address":{"addressId":844126,"oneLine":"Fetscherstrasse 74, Johannstadt-Nord","addressLine1":"Fetscherstrasse 74","addressLine2":"Johannstadt-Nord","addressLine3":"","addressLine4":"","city":"Dresden","postcode":"01307","country":2013,"countryName":"Germany"},"phone":"03514584794","email":"gunnar.folprecht@ukdd.de","isBusinessKeyValidated":true,"businessKey":"ORG-100011298"},"personInfo":{"id":2473954,"firstName":"Gunnar","lastName":"Folprecht","telephone":"03514584794","email":"gunnar.folprecht@ukdd.de","title":"2"},"departmentName":"Medizinische Klinik und Poliklinik I"},{"id":2230658,"organisationAddressInfo":{"id":765660,"organisation":{"id":804360,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Vincentius-Diakonissen-Kliniken gAG","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100021513","organisationLocationStatus":"Active"},"address":{"addressId":844133,"oneLine":"Suedendstrasse 32, Suedweststadt","addressLine1":"Suedendstrasse 32","addressLine2":"Suedweststadt","addressLine3":"","addressLine4":"","city":"Karlsruhe","postcode":"76137","country":2013,"countryName":"Germany"},"phone":"072181083014","email":"christian.mzb@vincentius-ka.de","isBusinessKeyValidated":true,"businessKey":"ORG-100021513"},"personInfo":{"id":2473968,"firstName":"Christian","lastName":"Meyer zum Büschenfelde","telephone":"072181083014","email":"christian.mzb@vincentius-ka.de","title":"2"},"departmentName":"Medizinische Klinik 2"},{"id":2230645,"organisationAddressInfo":{"id":765659,"organisation":{"id":804359,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Universitaetsklinikum Essen AöR","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100009964","organisationLocationStatus":"Active"},"address":{"addressId":844132,"oneLine":"Hufelandstrasse 55, Holsterhausen","addressLine1":"Hufelandstrasse 55","addressLine2":"Holsterhausen","addressLine3":"","addressLine4":"","city":"Essen","postcode":"45147","country":2013,"countryName":"Germany"},"phone":"+492017232011","email":"michael.pogorzelski@uk-essen.de","isBusinessKeyValidated":true,"businessKey":"ORG-100009964"},"personInfo":{"id":2473955,"firstName":"Michael","lastName":"Pogorzelski","telephone":"+492017232011","email":"michael.pogorzelski@uk-essen.de","title":"1"},"departmentName":"Westdeutsches Tumorzentrum Innere Klinik (Tumorforschung)"},{"id":2230646,"organisationAddressInfo":{"id":765628,"organisation":{"id":804328,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Klinikum Chemnitz gGmbH","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100017820","organisationLocationStatus":"Active"},"address":{"addressId":844099,"oneLine":"Flemmingstrasse 2, Altendorf","addressLine1":"Flemmingstrasse 2","addressLine2":"Altendorf","addressLine3":"","addressLine4":"","city":"Chemnitz","postcode":"09116","country":2013,"countryName":"Germany"},"phone":"037133344560","email":"d.zolnowski@skc.de","isBusinessKeyValidated":true,"businessKey":"ORG-100017820"},"personInfo":{"id":2473956,"firstName":"Dominik","lastName":"Zolnowski","telephone":"037133344560","email":"d.zolnowski@skc.de","title":"3"},"departmentName":"Internal Medicine III"},{"id":2230657,"organisationAddressInfo":{"id":765206,"organisation":{"id":803903,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Universitaetsklinikum Ulm AöR","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100006370","organisationLocationStatus":"Active"},"address":{"addressId":843613,"oneLine":"Frauensteige 12, Mitte","addressLine1":"Frauensteige 12","addressLine2":"Mitte","addressLine3":"","addressLine4":"","city":"Ulm","postcode":"89075","country":2013,"countryName":"Germany"},"phone":"+4973150059657","email":"simon.laban@uniklinik-ulm.de","isBusinessKeyValidated":true,"businessKey":"ORG-100006370"},"personInfo":{"id":2473967,"firstName":"Simon","lastName":"Laban","telephone":"+4973150059657","email":"simon.laban@uniklinik-ulm.de","title":"2"},"departmentName":"Klinik für Hals-Nasen-Ohrenheilkunde und Kopf-Hals-Chirurgie"},{"id":2230656,"organisationAddressInfo":{"id":765505,"organisation":{"id":804202,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Klinikum Der Landeshauptstadt Stuttgart gKAöR","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100009355","organisationLocationStatus":"Active"},"address":{"addressId":843959,"oneLine":"Kriegsbergstrasse 60, Mitte","addressLine1":"Kriegsbergstrasse 60","addressLine2":"Mitte","addressLine3":"","addressLine4":"","city":"Stuttgart","postcode":"70174","country":2013,"countryName":"Germany"},"phone":"071127835623","email":"d.hahn@klinikum-stuttgart.de","isBusinessKeyValidated":true,"businessKey":"ORG-100009355"},"personInfo":{"id":2473966,"firstName":"Dennis","lastName":"Hahn","telephone":"071127835623","email":"d.hahn@klinikum-stuttgart.de","title":"1"},"departmentName":"Klinik für Hämatologie, Onkologie und Palliativmedizin Stuttgart Cancer Center"},{"id":2230653,"organisationAddressInfo":{"id":765661,"organisation":{"id":804361,"type":"Educational Institution","typeCode":"1","name":"Medizinische Hochschule Hannover","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100024473","organisationLocationStatus":"Active"},"address":{"addressId":844134,"oneLine":"Carl-Neuberg-Strasse 1, Gross Buchholz","addressLine1":"Carl-Neuberg-Strasse 1","addressLine2":"Gross Buchholz","addressLine3":"","addressLine4":"","city":"Hanover","postcode":"30625","country":2013,"countryName":"Germany"},"phone":"+495115323140","email":"ivanyi.philipp@mh-hannover.de","isBusinessKeyValidated":true,"businessKey":"ORG-100024473"},"personInfo":{"id":2473963,"firstName":"Philipp","lastName":"Ivanyi","telephone":"+495115323140","email":"ivanyi.philipp@mh-hannover.de","title":"1"},"departmentName":"Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation"},{"id":2230652,"organisationAddressInfo":{"id":765632,"organisation":{"id":804332,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Universitaetsklinikum Duesseldorf AöR","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100010552","organisationLocationStatus":"Active"},"address":{"addressId":844103,"oneLine":"Moorenstrasse 5, Bilk","addressLine1":"Moorenstrasse 5","addressLine2":"Bilk","addressLine3":"","addressLine4":"","city":"Duesseldorf","postcode":"40225","country":2013,"countryName":"Germany"},"phone":"02118117994","email":"judith.neuwahl@med.uni-duesseldorf.de","isBusinessKeyValidated":true,"businessKey":"ORG-100010552"},"personInfo":{"id":2473962,"firstName":"Judith","lastName":"Neuwahl","telephone":"02118117994","email":"judith.neuwahl@med.uni-duesseldorf.de","title":"1"},"departmentName":"Klinik für Strahlentherapie und Radioonkologie"},{"id":2230659,"organisationAddressInfo":{"id":765181,"organisation":{"id":803878,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Charite Universitaetsmedizin Berlin KöR","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100008480","organisationLocationStatus":"Active"},"address":{"addressId":843582,"oneLine":"Hindenburgdamm 30, Lichterfelde","addressLine1":"Hindenburgdamm 30","addressLine2":"Lichterfelde","addressLine3":"","addressLine4":"","city":"Berlin","postcode":"12203","country":2013,"countryName":"Germany"},"phone":"030513525","email":"konrad.klinghammer@charite.de","isBusinessKeyValidated":true,"businessKey":"ORG-100008480"},"personInfo":{"id":2473969,"firstName":"Konrad","lastName":"Klinghammer","telephone":"030513525","email":"konrad.klinghammer@charite.de","title":"2"},"departmentName":"Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie Campus Benjamin Franklin"},{"id":2230655,"organisationAddressInfo":{"id":765646,"organisation":{"id":804346,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Universitaetsmedizin Goettingen","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100022040","organisationLocationStatus":"Active"},"address":{"addressId":844118,"oneLine":"Robert-Koch-Strasse 40, Weende","addressLine1":"Robert-Koch-Strasse 40","addressLine2":"Weende","addressLine3":"","addressLine4":"","city":"Goettingen","postcode":"37075","country":2013,"countryName":"Germany"},"phone":"+495513965182","email":"judith.buentzel@med.uni-goettingen.de","isBusinessKeyValidated":true,"businessKey":"ORG-100022040"},"personInfo":{"id":2473965,"firstName":"Judith","lastName":"Büntzel","telephone":"+495513965182","email":"judith.buentzel@med.uni-goettingen.de","title":"1"},"departmentName":"Klinik für Hämatologie und Onkologie"},{"id":2230647,"organisationAddressInfo":{"id":765511,"organisation":{"id":804208,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100008474","organisationLocationStatus":"Active"},"address":{"addressId":843965,"oneLine":"Langenbeckstrasse 1, Oberstadt","addressLine1":"Langenbeckstrasse 1","addressLine2":"Oberstadt","addressLine3":"","addressLine4":"","city":"Mainz","postcode":"55131","country":2013,"countryName":"Germany"},"phone":"06131178255","email":"hildegard.nolte@unimedizin-mainz.de","isBusinessKeyValidated":true,"businessKey":"ORG-100008474"},"personInfo":{"id":2473957,"firstName":"Hildegard","lastName":"Nolte","telephone":"06131178255","email":"hildegard.nolte@unimedizin-mainz.de","title":"1"},"departmentName":"Medizinische Klinik III, Onkologie/Hämatologie"},{"id":2230654,"organisationAddressInfo":{"id":765656,"organisation":{"id":804356,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Vivantes Netzwerk fuer Gesundheit GmbH","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100023624","organisationLocationStatus":"Active"},"address":{"addressId":844129,"oneLine":"Rudower Strasse 48, Buckow","addressLine1":"Rudower Strasse 48","addressLine2":"Buckow","addressLine3":"","addressLine4":"","city":"Berlin","postcode":"12351","country":2013,"countryName":"Germany"},"phone":"030130142240","email":"maike.dewit@vivantes.de","isBusinessKeyValidated":true,"businessKey":"ORG-100023624"},"personInfo":{"id":2473964,"firstName":"Maike","lastName":"de Wit","telephone":"030130142240","email":"maike.dewit@vivantes.de","title":"2"},"departmentName":"Klinik für Innere Medizin – Hämatologie, Onkologie und Palliativmedizin"},{"id":2230648,"organisationAddressInfo":{"id":765658,"organisation":{"id":804358,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100008387","organisationLocationStatus":"Active"},"address":{"addressId":844131,"oneLine":"Ismaninger Strasse 22, Au-Haidhausen","addressLine1":"Ismaninger Strasse 22","addressLine2":"Au-Haidhausen","addressLine3":"","addressLine4":"","city":"Munich","postcode":"81675","country":2013,"countryName":"Germany"},"phone":"08941408588","email":"barbara.wollenberg@tum.de","isBusinessKeyValidated":true,"businessKey":"ORG-100008387"},"personInfo":{"id":2473958,"firstName":"Barbara","lastName":"Wollenberg","telephone":"08941408588","email":"barbara.wollenberg@tum.de","title":"2"},"departmentName":"Klinik und Poliklinik für HNO-Heilkunde"},{"id":2230650,"organisationAddressInfo":{"id":765648,"organisation":{"id":804348,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Staedtisches Klinikum Braunschweig gGmbH","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100015575","organisationLocationStatus":"Active"},"address":{"addressId":844120,"oneLine":"Celler Strasse 38","addressLine1":"Celler Strasse 38","addressLine2":"","addressLine3":"","addressLine4":"","city":"Brunswick","postcode":"38114","country":2013,"countryName":"Germany"},"phone":"05315953224","email":"H.Eggers@skbs.de","isBusinessKeyValidated":true,"businessKey":"ORG-100015575"},"personInfo":{"id":2473960,"firstName":"Hendrik","lastName":"Eggers","telephone":"05315953224","email":"H.Eggers@skbs.de","title":"1"},"departmentName":"Hämatologie und Onkologie"},{"id":2230642,"organisationAddressInfo":{"id":765651,"organisation":{"id":804351,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Universitaetsklinikum Aachen AöR","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100023618","organisationLocationStatus":"Active"},"address":{"addressId":844124,"oneLine":"Pauwelsstrasse 30","addressLine1":"Pauwelsstrasse 30","addressLine2":"","addressLine3":"","addressLine4":"","city":"Aachen","postcode":"52074","country":2013,"countryName":"Germany"},"phone":"02418080703","email":"mtometten@ukaachen.de","isBusinessKeyValidated":true,"businessKey":"ORG-100023618"},"personInfo":{"id":2473952,"firstName":"Mareike","lastName":"Tometten","telephone":"02418080703","email":"mtometten@ukaachen.de","title":"1"},"departmentName":"Klinik für Onkologie, Hämatologie und Stammzelltransplantation"}],"applicationStatusCode":"Authorised"},{"id":336652,"mscId":44342,"mscInfo":{"id":44342,"clinicalTrialId":20954,"countryOrganisationId":2024,"reportingStatusCode":"Authorised","fromDate":"2025-09-15","toDate":"2025-09-15","isProposedRms":false,"expressDecision":"unwilling","countryName":"Portugal","organisationInfo":{},"firstDecisionDate":"2025-10-06","trialStatus":"Authorised","trialPeriod":[{"id":68649,"trialStartDate":"2025-11-07","fromDate":"2025-11-12"},{"id":68650,"trialStartDate":"2025-11-07","fromDate":"2025-11-12"}],"trialRecruitmentPeriod":[{"id":93781,"recruitmentStartDate":"2025-11-20","fromDate":"2025-11-26"},{"id":93782,"recruitmentStartDate":"2025-11-20","fromDate":"2025-11-26"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":106143,"trialStartDate":"2025-11-07","fromDate":"2025-11-12"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2025-11-20"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":85665,"mscId":44342,"trialStatus":"Under evaluation","trialStatusDate":"2025-06-19T12:59:20.846"},{"id":99031,"mscId":44342,"trialStatus":"Authorised","trialStatusDate":"2025-10-06T17:43:27.72"}],"applicationTypeMsc":"1","mscName":"Portugal","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-09-18","decision":"authorized_conditions","decisionDate":"2025-10-06"},"decisionDate":"2025-10-06","recruitmentSubjectCount":21,"trialSites":[{"id":2365594,"organisationAddressInfo":{"id":776900,"organisation":{"id":815655,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Instituto Portugues De Oncologia De Lisboa Francisco Gentil E.P.E.","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100029371","organisationLocationStatus":"Active"},"address":{"addressId":857468,"oneLine":"Rua Professor Lima Basto","addressLine1":"Rua Professor Lima Basto","addressLine2":"","addressLine3":"","addressLine4":"","city":"Lisbon","postcode":"1099-023","country":2024,"countryName":"Portugal"},"phone":"+351914517388","email":"isargento@ipolisboa.min-saude.pt","isBusinessKeyValidated":true,"businessKey":"ORG-100029371"},"personInfo":{"id":2621982,"firstName":"Isabel","lastName":"Sargento","telephone":"+351914517388","email":"isargento@ipolisboa.min-saude.pt","title":"1"},"departmentName":"Oncology"},{"id":2365593,"organisationAddressInfo":{"id":776874,"organisation":{"id":815629,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Unidade Local De Saude De Gaia/Espinho E.P.E.","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100029768","organisationLocationStatus":"Active"},"address":{"addressId":857437,"oneLine":"Rua Conceicao Fernandes S/n","addressLine1":"Rua Conceicao Fernandes S/n","addressLine2":"","addressLine3":"","addressLine4":"","city":"Vila Nova De Gaia","postcode":"4434-502","country":2024,"countryName":"Portugal"},"phone":"+351227865100","email":"ricardo.teixeira.pinto@ulsge.min-saude.pt","isBusinessKeyValidated":true,"businessKey":"ORG-100029768"},"personInfo":{"id":2621981,"firstName":"Ricardo Teixeira","lastName":"Pinto","telephone":"+351227865100","email":"ricardo.teixeira.pinto@ulsge.min-saude.pt","title":"1"},"departmentName":"Oncology"},{"id":2365589,"organisationAddressInfo":{"id":776878,"organisation":{"id":815633,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Instituto Portugues De Oncologia Do Porto Francisco Gentil E.P.E.","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100033662","organisationLocationStatus":"Active"},"address":{"addressId":857441,"oneLine":"Rua Dr. Antonio Bernardino De Almeida","addressLine1":"Rua Dr. Antonio Bernardino De Almeida","addressLine2":"","addressLine3":"","addressLine4":"","city":"Porto","postcode":"4200-072","country":2024,"countryName":"Portugal"},"phone":"+351225084000","email":"claudia.vieira@ipoporto.min-saude.pt","isBusinessKeyValidated":true,"businessKey":"ORG-100033662"},"personInfo":{"id":2621977,"firstName":"Cláudia","lastName":"Vieira","telephone":"+351225084000","email":"claudia.vieira@ipoporto.min-saude.pt","title":"1"},"departmentName":"Oncology"},{"id":2365591,"organisationAddressInfo":{"id":782117,"organisation":{"id":820906,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Unidade Local De Saude De Matosinhos E.P.E.","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100044309","organisationLocationStatus":"Active"},"address":{"addressId":863614,"oneLine":"Rua Doutor Eduardo Torres","addressLine1":"Rua Doutor Eduardo Torres","addressLine2":"","addressLine3":"","addressLine4":"","city":"Senhora Da Hora","postcode":"4464-513","country":2024,"countryName":"Portugal"},"phone":"+3512293910000","email":"matilde.salgado@ulsm.min-saude.pt","isBusinessKeyValidated":true,"businessKey":"ORG-100044309"},"personInfo":{"id":2621979,"firstName":"Matilde","lastName":"Salgado","telephone":"+3512293910000","email":"matilde.salgado@ulsm.min-saude.pt"},"departmentName":"Oncology"},{"id":2365588,"organisationAddressInfo":{"id":776850,"organisation":{"id":815605,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Instituto Portugues De Oncologia De Coimbra Francisco Gentil E.P.E.","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100041326","organisationLocationStatus":"Active"},"address":{"addressId":857411,"oneLine":"Avenida Doutor Bissaya Barreto 98","addressLine1":"Avenida Doutor Bissaya Barreto 98","addressLine2":"","addressLine3":"","addressLine4":"","city":"Coimbra","postcode":"3000-075","country":2024,"countryName":"Portugal"},"phone":"+351239400200","email":"fatimamarques@ipocoimbra.min-saude.pt","isBusinessKeyValidated":true,"businessKey":"ORG-100041326"},"personInfo":{"id":2621976,"firstName":"Maria Margarida","lastName":"Teixeira","telephone":"+351239400200","email":"fatimamarques@ipocoimbra.min-saude.pt","title":"1"},"departmentName":"Oncology"},{"id":2365592,"organisationAddressInfo":{"id":776885,"organisation":{"id":815640,"type":"Pharmaceutical company","typeCode":"10","name":"CCAB Centro Clinico Academico Braga Associacao","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100041983","organisationLocationStatus":"Active"},"address":{"addressId":857450,"oneLine":"Lugar De Sete Fontes S Victor","addressLine1":"Lugar De Sete Fontes S Victor","addressLine2":"","addressLine3":"","addressLine4":"","city":"Braga","postcode":"4710-243","country":2024,"countryName":"Portugal"},"phone":"+351253027249","email":"filipa.ferreira.pereira@hb.min-saude.pt","isBusinessKeyValidated":true,"businessKey":"ORG-100041983"},"personInfo":{"id":2621980,"firstName":"Filipa","lastName":"Pereira","telephone":"+351253027249","email":"filipa.ferreira.pereira@hb.min-saude.pt","title":"1"},"departmentName":"Oncology"},{"id":2365595,"organisationAddressInfo":{"id":776894,"organisation":{"id":815649,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Unidade Local de Saude de Sao Joao E.P.E.","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100046645","organisationLocationStatus":"Active"},"address":{"addressId":857461,"oneLine":"Alameda Professor Hernani Monteiro","addressLine1":"Alameda Professor Hernani Monteiro","addressLine2":"","addressLine3":"","addressLine4":"","city":"Porto","postcode":"4200-319","country":2024,"countryName":"Portugal"},"phone":"+351225512100","email":"lucia.aguas@chsj.min-saude.pt","isBusinessKeyValidated":true,"businessKey":"ORG-100046645"},"personInfo":{"id":2621983,"firstName":"Lucia","lastName":"Águas","telephone":"+351225512100","email":"lucia.aguas@chsj.min-saude.pt","title":"1"},"departmentName":"Oncology"},{"id":2365590,"organisationAddressInfo":{"id":776864,"organisation":{"id":815619,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Unidade Local de Saude do Algarve E.P.E.","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100041767","organisationLocationStatus":"Active"},"address":{"addressId":857426,"oneLine":"Sitio Do Poco Seco","addressLine1":"Sitio Do Poco Seco","addressLine2":"","addressLine3":"","addressLine4":"","city":"Portimao","postcode":"8500-338","country":2024,"countryName":"Portugal"},"phone":"+351289891100","email":"ana.varges.gomes@chalgarve.min-saude.pt","isBusinessKeyValidated":true,"businessKey":"ORG-100041767"},"personInfo":{"id":2621978,"firstName":"Ana Varges","lastName":"Gomes","telephone":"+351289891100","email":"ana.varges.gomes@chalgarve.min-saude.pt","title":"1"},"departmentName":"Oncology"}],"applicationStatusCode":"Authorised"},{"id":318809,"mscId":44343,"mscInfo":{"id":44343,"clinicalTrialId":20954,"countryOrganisationId":2027,"reportingStatusCode":"Authorised","fromDate":"2025-07-29","toDate":"2025-07-29","isProposedRms":false,"expressDecision":"unwilling","countryName":"Spain","organisationInfo":{},"firstDecisionDate":"2025-11-03","trialStatus":"Authorised","trialPeriod":[{"id":71457,"trialStartDate":"2025-12-12","fromDate":"2025-12-19"},{"id":71458,"trialStartDate":"2025-12-12","fromDate":"2025-12-19"}],"trialRecruitmentPeriod":[{"id":97550,"recruitmentStartDate":"2025-12-30","fromDate":"2026-01-12"},{"id":97551,"recruitmentStartDate":"2025-12-30","fromDate":"2026-01-12"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":112246,"trialStartDate":"2025-12-12","fromDate":"2025-12-19"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2025-12-30"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":85666,"mscId":44343,"trialStatus":"Under evaluation","trialStatusDate":"2025-06-19T12:59:20.87"},{"id":100972,"mscId":44343,"trialStatus":"Authorised","trialStatusDate":"2025-10-08T13:14:31.924"}],"applicationTypeMsc":"1","mscName":"Spain","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-08-10","decision":"authorized","decisionDate":"2025-11-03"},"decisionDate":"2025-11-03","recruitmentSubjectCount":23,"trialSites":[{"id":2230630,"organisationAddressInfo":{"id":773492,"organisation":{"id":812228,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Hospital Universitario 12 De Octubre","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100028548","organisationLocationStatus":"Active"},"address":{"addressId":853493,"oneLine":"Avenida De Cordoba Sn","addressLine1":"Avenida De Cordoba Sn","addressLine2":"","addressLine3":"","addressLine4":"","city":"Madrid","postcode":"28041","country":2027,"countryName":"Spain"},"phone":"34913908000","email":"laraiglesias@hotmail.com","isBusinessKeyValidated":true,"businessKey":"ORG-100028548"},"personInfo":{"id":2473940,"firstName":"Lara","lastName":"Iglesias Docampo","telephone":"34913908000","email":"laraiglesias@hotmail.com","title":"1"},"departmentName":"Oncology"},{"id":2230621,"organisationAddressInfo":{"id":773493,"organisation":{"id":812229,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Hospital Clinico Universitario De Valencia","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100032606","organisationLocationStatus":"Active"},"address":{"addressId":853494,"oneLine":"Avenida Blasco Ibanez 17","addressLine1":"Avenida Blasco Ibanez 17","addressLine2":"","addressLine3":"","addressLine4":"","city":"Valencia","postcode":"46010","country":2027,"countryName":"Spain"},"phone":"34606708476","email":"gema.bruixola@gmail.com","isBusinessKeyValidated":true,"businessKey":"ORG-100032606"},"personInfo":{"id":2473931,"firstName":"Gema","lastName":"Bruixola Campos","telephone":"34606708476","email":"gema.bruixola@gmail.com","title":"1"},"departmentName":"Oncology"},{"id":2230624,"organisationAddressInfo":{"id":773518,"organisation":{"id":812254,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Hospital Clinic De Barcelona","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100009329","organisationLocationStatus":"Active"},"address":{"addressId":853524,"oneLine":"Calle Villarroel 170","addressLine1":"Calle Villarroel 170","addressLine2":"","addressLine3":"","addressLine4":"","city":"Barcelona","postcode":"08036","country":2027,"countryName":"Spain"},"phone":"34674903728","email":"mazariegos@clinic.cat","isBusinessKeyValidated":true,"businessKey":"ORG-100009329"},"personInfo":{"id":2473934,"firstName":"Manuel Alejandro","lastName":"Mazariegos Rubí","telephone":"34674903728","email":"mazariegos@clinic.cat","title":"1"},"departmentName":"Oncology"},{"id":2230623,"organisationAddressInfo":{"id":773501,"organisation":{"id":812237,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Hospital De La Santa Creu I Sant Pau","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100028622","organisationLocationStatus":"Active"},"address":{"addressId":853502,"oneLine":"Carrer De San Quinti 89","addressLine1":"Carrer De San Quinti 89","addressLine2":"","addressLine3":"","addressLine4":"","city":"Barcelona","postcode":"08041","country":2027,"countryName":"Spain"},"phone":"34935565945","email":"maguados@santpau.cat","isBusinessKeyValidated":true,"businessKey":"ORG-100028622"},"personInfo":{"id":2473933,"firstName":"María","lastName":"Aguado Sorolla","telephone":"34935565945","email":"maguados@santpau.cat","title":"1"},"departmentName":"Oncology"},{"id":2230626,"organisationAddressInfo":{"id":773450,"organisation":{"id":812186,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Clinica Universidad De Navarra","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100007650","organisationLocationStatus":"Active"},"address":{"addressId":853448,"oneLine":"Calle Marquesado De Santa Marta 1","addressLine1":"Calle Marquesado De Santa Marta 1","addressLine2":"","addressLine3":"","addressLine4":"","city":"Madrid","postcode":"28027","country":2027,"countryName":"Spain"},"phone":"34948226696","email":"jlpicazo@unav.es","isBusinessKeyValidated":true,"businessKey":"ORG-100007650"},"personInfo":{"id":2473936,"firstName":"José María","lastName":"López Picazo","telephone":"34948226696","email":"jlpicazo@unav.es","title":"1"},"departmentName":"Oncology"},{"id":2230622,"organisationAddressInfo":{"id":773461,"organisation":{"id":812197,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Clinica Universidad De Navarra","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100007650","organisationLocationStatus":"Active"},"address":{"addressId":853459,"oneLine":"Pio XII Etorbidea 36","addressLine1":"Pio XII Etorbidea 36","addressLine2":"","addressLine3":"","addressLine4":"","city":"Pamplona","postcode":"31008","country":2027,"countryName":"Spain"},"phone":"34948226696","email":"jlpicazo@unav.es","isBusinessKeyValidated":true,"businessKey":"ORG-100007650"},"personInfo":{"id":2473932,"firstName":"José María","lastName":"López Picazo","telephone":"34948226696","email":"jlpicazo@unav.es","title":"1"},"departmentName":"Oncology"},{"id":2230628,"organisationAddressInfo":{"id":773469,"organisation":{"id":812205,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Institut Catala D'oncologia","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100030394","organisationLocationStatus":"Active"},"address":{"addressId":853468,"oneLine":"Avinguda De La Gran Via De L'hospitalet 199-203","addressLine1":"Avinguda De La Gran Via De L'hospitalet 199-203","addressLine2":"","addressLine3":"","addressLine4":"","city":"L'hospitalet De Llobregat","postcode":"08908","country":2027,"countryName":"Spain"},"phone":"34932607470","email":"mplana@iconcologia.net","isBusinessKeyValidated":true,"businessKey":"ORG-100030394"},"personInfo":{"id":2473938,"firstName":"María","lastName":"Plana Serrahima","telephone":"34932607470","email":"mplana@iconcologia.net","title":"1"},"departmentName":"Oncology"},{"id":2230627,"organisationAddressInfo":{"id":773528,"organisation":{"id":812264,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Consorcio Hospital General Universitario De Valencia","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100023081","organisationLocationStatus":"Active"},"address":{"addressId":853536,"oneLine":"Avenida Tres Cruces 2","addressLine1":"Avenida Tres Cruces 2","addressLine2":"","addressLine3":"","addressLine4":"","city":"Valencia","postcode":"46014","country":2027,"countryName":"Spain"},"phone":"34963131800","email":"berrocal.alf@gmail.com","isBusinessKeyValidated":true,"businessKey":"ORG-100023081"},"personInfo":{"id":2473937,"firstName":"Alfonso","lastName":"Berrocal Jaime","telephone":"34963131800","email":"berrocal.alf@gmail.com","title":"1"},"departmentName":"Oncology"},{"id":2230625,"organisationAddressInfo":{"id":773634,"organisation":{"id":812371,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Hospital Universitario Marques De Valdecilla","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100028562","organisationLocationStatus":"Active"},"address":{"addressId":853654,"oneLine":"Avenida Valdecilla Sn","addressLine1":"Avenida Valdecilla Sn","addressLine2":"","addressLine3":"","addressLine4":"","city":"Santander","postcode":"39008","country":2027,"countryName":"Spain"},"phone":"34942202515","email":"marta.sotelo@scsalud.es","isBusinessKeyValidated":true,"businessKey":"ORG-100028562"},"personInfo":{"id":2473935,"firstName":"Marta","lastName":"Sotelo García","telephone":"34942202515","email":"marta.sotelo@scsalud.es","title":"1"},"departmentName":"Oncology"},{"id":2230620,"organisationAddressInfo":{"id":949418,"organisation":{"id":992765,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Hospital Germans Trias I Pujol","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100028928","organisationLocationStatus":"Active"},"address":{"addressId":1066654,"oneLine":"Carretera Canyet 1a Planta","addressLine1":"Carretera Canyet 1a Planta","addressLine2":"","addressLine3":"","addressLine4":"","city":"Badalona","postcode":"08916","country":2027,"countryName":"Spain"},"phone":"+34934978925","email":"aferrandod@iconcologia.net","isBusinessKeyValidated":true,"businessKey":"ORG-100028928"},"personInfo":{"id":2473930,"firstName":"Angelica","lastName":"Ferrando Díez","telephone":"+34934978925","email":"aferrandod@iconcologia.net","title":"1"},"departmentName":"Oncology"},{"id":2230629,"organisationAddressInfo":{"id":773471,"organisation":{"id":812207,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Hospital Universitari Vall D Hebron","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100030781","organisationLocationStatus":"Active"},"address":{"addressId":853470,"oneLine":"Passeig De La Vall D'Hebron 119-129","addressLine1":"Passeig De La Vall D'Hebron 119-129","addressLine2":"","addressLine3":"","addressLine4":"","city":"Barcelona","postcode":"08035","country":2027,"countryName":"Spain"},"phone":"34932543452","email":"ibrana@vhio.net","isBusinessKeyValidated":true,"businessKey":"ORG-100030781"},"personInfo":{"id":2473939,"firstName":"Irene","lastName":"Braña García","telephone":"34932543452","email":"ibrana@vhio.net","title":"1"},"departmentName":"Oncology"}],"applicationStatusCode":"Authorised"},{"id":318804,"mscId":44340,"mscInfo":{"id":44340,"clinicalTrialId":20954,"countryOrganisationId":2017,"reportingStatusCode":"Authorised","fromDate":"2025-09-18","toDate":"2025-09-18","isProposedRms":false,"expressDecision":"unwilling","countryName":"Ireland","organisationInfo":{},"firstDecisionDate":"2025-10-10","trialStatus":"Authorised","trialPeriod":[{"id":71562,"trialStartDate":"2025-12-19","fromDate":"2025-12-22"},{"id":71563,"trialStartDate":"2025-12-19","fromDate":"2025-12-22"},{"id":71564,"trialStartDate":"2025-12-19","fromDate":"2025-12-22"}],"trialRecruitmentPeriod":[{"id":102038,"recruitmentStartDate":"2026-02-23","fromDate":"2026-02-25"},{"id":102039,"recruitmentStartDate":"2026-02-23","fromDate":"2026-02-25"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":112574,"trialStartDate":"2025-12-19","fromDate":"2025-12-22"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2026-02-23"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":85663,"mscId":44340,"trialStatus":"Under evaluation","trialStatusDate":"2025-06-19T12:59:20.804"},{"id":102001,"mscId":44340,"trialStatus":"Authorised","trialStatusDate":"2025-10-10T11:13:12.957"}],"applicationTypeMsc":"1","mscName":"Ireland","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-09-07","decision":"authorized_conditions","decisionDate":"2025-10-10"},"decisionDate":"2025-10-10","recruitmentSubjectCount":10,"trialSites":[{"id":2230585,"organisationAddressInfo":{"id":776237,"organisation":{"id":814991,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Cork University Hospital","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100028972","organisationLocationStatus":"Active"},"address":{"addressId":856700,"oneLine":"Wilton","addressLine1":"Wilton","addressLine2":"","addressLine3":"","addressLine4":"","city":"Cork","postcode":"T12 DC4A","country":2017,"countryName":"Ireland"},"phone":"+353214922000","email":"Seamus.OReilly@hse.ie","isBusinessKeyValidated":true,"businessKey":"ORG-100028972"},"personInfo":{"id":2473895,"firstName":"Seamus","lastName":"O'Reilly","telephone":"+353214922000","email":"Seamus.OReilly@hse.ie","title":"2"},"departmentName":"Oncology"},{"id":2230584,"organisationAddressInfo":{"id":776236,"organisation":{"id":814990,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Beaumont Hospital","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100041548","organisationLocationStatus":"Active"},"address":{"addressId":856699,"oneLine":"Beaumont Road, Beaumont","addressLine1":"Beaumont Road","addressLine2":"Beaumont","addressLine3":"","addressLine4":"","city":"Dublin 9","postcode":"D09 V2N0","country":2017,"countryName":"Ireland"},"phone":"+35318093000","email":"patrickmorris@beaumont.ie","isBusinessKeyValidated":true,"businessKey":"ORG-100041548"},"personInfo":{"id":2473894,"firstName":"Patrick","lastName":"Morris","telephone":"+35318093000","email":"patrickmorris@beaumont.ie","title":"1"},"departmentName":"Oncology"},{"id":2230583,"organisationAddressInfo":{"id":776234,"organisation":{"id":814988,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"St James's Hospital","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100009794","organisationLocationStatus":"Active"},"address":{"addressId":856696,"oneLine":"James's Street","addressLine1":"James's Street","addressLine2":"","addressLine3":"","addressLine4":"","city":"Dublin 8","postcode":"D08 NHY1","country":2017,"countryName":"Ireland"},"phone":"014103000","email":"CGrant@STJAMES.IE","isBusinessKeyValidated":true,"businessKey":"ORG-100009794"},"personInfo":{"id":2473893,"firstName":"Cliona","lastName":"Grant","telephone":"014103000","email":"CGrant@STJAMES.IE","title":"1"},"departmentName":"Oncology"}],"applicationStatusCode":"Authorised"},{"id":318813,"mscId":44344,"mscInfo":{"id":44344,"clinicalTrialId":20954,"countryOrganisationId":2031,"reportingStatusCode":"Authorised","fromDate":"2025-09-11","toDate":"2025-09-11","isProposedRms":false,"expressDecision":"unwilling","countryName":"Poland","organisationInfo":{},"firstDecisionDate":"2025-10-10","trialStatus":"Authorised","trialPeriod":[{"id":68635,"trialStartDate":"2025-11-11","fromDate":"2025-11-12"},{"id":68636,"trialStartDate":"2025-11-11","fromDate":"2025-11-12"}],"trialRecruitmentPeriod":[{"id":101120,"recruitmentStartDate":"2026-02-13","fromDate":"2026-02-16"},{"id":101121,"recruitmentStartDate":"2026-02-13","fromDate":"2026-02-16"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":106110,"trialStartDate":"2025-11-11","fromDate":"2025-11-12"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2026-02-13"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":85667,"mscId":44344,"trialStatus":"Under evaluation","trialStatusDate":"2025-06-19T12:59:20.892"},{"id":102019,"mscId":44344,"trialStatus":"Authorised","trialStatusDate":"2025-10-10T12:47:22.167"}],"applicationTypeMsc":"1","mscName":"Poland","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-09-04","decision":"authorized_conditions","decisionDate":"2025-10-10"},"decisionDate":"2025-10-10","recruitmentSubjectCount":20,"trialSites":[{"id":2230669,"organisationAddressInfo":{"id":773224,"organisation":{"id":811960,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100009191","organisationLocationStatus":"Active"},"address":{"addressId":853168,"oneLine":"Ul. Wybrzeze Armii Krajowej 15","addressLine1":"Ul. Wybrzeze Armii Krajowej 15","addressLine2":"","addressLine3":"","addressLine4":"","city":"Gliwice","postcode":"44-102","country":2031,"countryName":"Poland"},"phone":"+48322789794","email":"cwbk@gliwice.nio.gov.pl","isBusinessKeyValidated":true,"businessKey":"ORG-100009191"},"personInfo":{"id":2473979,"firstName":"Tomasz","lastName":"Rutkowski","telephone":"+48322789794","email":"cwbk@gliwice.nio.gov.pl","title":"1"},"departmentName":"Centrum Wsparcia Badań Klinicznych"},{"id":2230667,"organisationAddressInfo":{"id":880753,"organisation":{"id":922769,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Centrum Onkologii Im. Prof. Franciszka Lukaszczyka W Bydgoszczy","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100007270","organisationLocationStatus":"Active"},"address":{"addressId":983152,"oneLine":"Ul. Izabeli Romanowskiej 2","addressLine1":"Ul. Izabeli Romanowskiej 2","addressLine2":"","addressLine3":"","addressLine4":"","city":"Bydgoszcz","postcode":"85-796","country":2031,"countryName":"Poland"},"phone":"+48523743883","email":"badania.kliniczne@co.bydgoszcz.pl","isBusinessKeyValidated":true,"businessKey":"ORG-100007270"},"personInfo":{"id":2473977,"firstName":"Bogdan","lastName":"Żurawski","telephone":"+48523743883","email":"badania.kliniczne@co.bydgoszcz.pl","title":"1"},"departmentName":"Ambulatorium Chemioterapii"},{"id":2230664,"organisationAddressInfo":{"id":773226,"organisation":{"id":811962,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100009191","organisationLocationStatus":"Active"},"address":{"addressId":853170,"oneLine":"Ul. Wilhelma Konrada Roentgena 5","addressLine1":"Ul. Wilhelma Konrada Roentgena 5","addressLine2":"","addressLine3":"","addressLine4":"","city":"Warsaw","postcode":"02-781","country":2031,"countryName":"Poland"},"phone":"+48225462376","email":"damian.kucharczyk@nio.gov.pl","isBusinessKeyValidated":true,"businessKey":"ORG-100009191"},"personInfo":{"id":2473974,"firstName":"Andrzej","lastName":"Kawecki","telephone":"+48225462376","email":"damian.kucharczyk@nio.gov.pl","title":"2"},"departmentName":"Klinika Nowotworów Głowy i Szyi"},{"id":2230668,"organisationAddressInfo":{"id":773216,"organisation":{"id":811952,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Pratia Hematologia Sp. z o.o.","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100040044","organisationLocationStatus":"Active"},"address":{"addressId":853158,"oneLine":"Ul. Tadeusza Kosciuszki 92","addressLine1":"Ul. Tadeusza Kosciuszki 92","addressLine2":"","addressLine3":"","addressLine4":"","city":"Katowice","postcode":"40-519","country":2031,"countryName":"Poland"},"phone":"+48501714019","email":"kontakt.onkologia.katowice@pratia.com","isBusinessKeyValidated":true,"businessKey":"ORG-100040044"},"personInfo":{"id":2473978,"firstName":"Agata","lastName":"Kachel-Flis","telephone":"+48501714019","email":"kontakt.onkologia.katowice@pratia.com","title":"1"},"departmentName":"Pratia Onkologia Katowice"},{"id":2230663,"organisationAddressInfo":{"id":731332,"organisation":{"id":769681,"type":"Health care","typeCode":"2","name":"Przychodnia Lekarska \"KOMED\" Roman Karaszewski","commercial":false,"isBusinessKeyValidated":false,"businessKey":"ORL-000013922","organisationLocationStatus":"Active"},"address":{"addressId":802972,"oneLine":"ul. Wojska Polskiego 6","addressLine1":"ul. Wojska Polskiego 6","addressLine2":"","addressLine3":"","addressLine4":"","city":"Konin","postcode":"62-500","country":2031,"countryName":"Poland"},"phone":"+48632406136","email":"komed.badania@gmail.com","isBusinessKeyValidated":false,"businessKey":"ORL-000013922"},"personInfo":{"id":2473973,"firstName":"Bogusława","lastName":"Karaszewska","telephone":"+48632406136","email":"komed.badania@gmail.com"},"departmentName":"N/A"},{"id":2230665,"organisationAddressInfo":{"id":773205,"organisation":{"id":811941,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Uniwersyteckie Centrum Kliniczne","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100042500","organisationLocationStatus":"Active"},"address":{"addressId":853146,"oneLine":"Ul. Mariana Smoluchowskiego 17","addressLine1":"Ul. Mariana Smoluchowskiego 17","addressLine2":"","addressLine3":"","addressLine4":"","city":"Gdansk","postcode":"80-214","country":2031,"countryName":"Poland"},"phone":"+48585844428","email":"kmatusz@gumed.edu.pl","isBusinessKeyValidated":true,"businessKey":"ORG-100042500"},"personInfo":{"id":2473975,"firstName":"Katarzyna","lastName":"Matuszewska","telephone":"+48585844428","email":"kmatusz@gumed.edu.pl","title":"1"},"departmentName":"Klinika Onkologii i Radioterapii"},{"id":2230662,"organisationAddressInfo":{"id":773212,"organisation":{"id":811948,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Mazowiecki Szpital Wojewodzki Im. Sw. Jana Pawła II W Siedlcach Sp. z o.o.","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100043855","organisationLocationStatus":"Active"},"address":{"addressId":853153,"oneLine":"Ul. Ksiecia Jozefa Poniatowskiego 26","addressLine1":"Ul. Ksiecia Jozefa Poniatowskiego 26","addressLine2":"","addressLine3":"","addressLine4":"","city":"Siedlce","postcode":"08-110","country":2031,"countryName":"Poland"},"phone":"+48256403072","email":"bbk@szpital.siedlce.pl","isBusinessKeyValidated":true,"businessKey":"ORG-100043855"},"personInfo":{"id":2473972,"firstName":"Lubomir","lastName":"Bodnar","telephone":"+48256403072","email":"bbk@szpital.siedlce.pl","title":"2"},"departmentName":"Oddział Onkologii Klinicznej i Radioterapii"},{"id":2230666,"organisationAddressInfo":{"id":773218,"organisation":{"id":811954,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Szpital Specjalistyczny Im. Ludwika Rydygiera W Krakowie Sp. z o.o.","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100043380","organisationLocationStatus":"Active"},"address":{"addressId":853161,"oneLine":"Os. Zlotej Jesieni 1","addressLine1":"Os. Zlotej Jesieni 1","addressLine2":"","addressLine3":"","addressLine4":"","city":"Cracow","postcode":"31-826","country":2031,"countryName":"Poland"},"phone":"+48126468251","email":"badaniakliniczne@rydygierkrakow.pl","isBusinessKeyValidated":true,"businessKey":"ORG-100043380"},"personInfo":{"id":2473976,"firstName":"Anna","lastName":"Kowalczyk-Tekiela","telephone":"+48126468251","email":"badaniakliniczne@rydygierkrakow.pl"},"departmentName":"Oddział Onkologii Klinicznej z pododdziałem dziennym"}],"applicationStatusCode":"Authorised"},{"id":338051,"mscId":44335,"mscInfo":{"id":44335,"clinicalTrialId":20954,"countryOrganisationId":2002,"reportingStatusCode":"Authorised","fromDate":"2025-09-16","toDate":"2025-09-16","isProposedRms":true,"expressDecision":"unwilling","countryName":"Belgium","organisationInfo":{},"firstDecisionDate":"2025-10-06","trialStatus":"Authorised","trialPeriod":[{"id":70139,"trialStartDate":"2025-12-01","fromDate":"2025-12-03"},{"id":70140,"trialStartDate":"2025-12-01","fromDate":"2025-12-03"}],"trialRecruitmentPeriod":[{"id":98632,"recruitmentStartDate":"2026-01-21","fromDate":"2026-01-21"},{"id":98633,"recruitmentStartDate":"2026-01-21","fromDate":"2026-01-21"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":109253,"trialStartDate":"2025-12-01","fromDate":"2025-12-03"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2026-01-21"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":85658,"mscId":44335,"trialStatus":"Under evaluation","trialStatusDate":"2025-06-19T12:59:20.703"},{"id":98954,"mscId":44335,"trialStatus":"Authorised","trialStatusDate":"2025-10-06T16:40:00.206"}],"applicationTypeMsc":"1","mscName":"Belgium","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-09-24","decision":"authorized_conditions","decisionDate":"2025-10-06"},"decisionDate":"2025-10-06","recruitmentSubjectCount":12,"trialSites":[{"id":2376405,"organisationAddressInfo":{"id":760860,"organisation":{"id":799533,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"CHU Helora","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100042541","organisationLocationStatus":"Active"},"address":{"addressId":838576,"oneLine":"Boulevard President Kennedy 2","addressLine1":"Boulevard President Kennedy 2","addressLine2":"","addressLine3":"","addressLine4":"","city":"Mons","postcode":"7000","country":2002,"countryName":"Belgium"},"phone":"+3265413465","email":"laure.maindiaux@helora.be","isBusinessKeyValidated":true,"businessKey":"ORG-100042541"},"personInfo":{"id":2633884,"firstName":"Laure","lastName":"Maindiaux","telephone":"+3265413465","email":"laure.maindiaux@helora.be"},"departmentName":"Oncology"},{"id":2376402,"organisationAddressInfo":{"id":760856,"organisation":{"id":799529,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Centre Hospitalier Universitaire Dinant Godinne Sainte-Elisabeth-UCL-Namur","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100040731","organisationLocationStatus":"Active"},"address":{"addressId":838572,"oneLine":"Avenue Docteur Gaston Therasse 1","addressLine1":"Avenue Docteur Gaston Therasse 1","addressLine2":"","addressLine3":"","addressLine4":"","city":"Yvoir","postcode":"5530","country":2002,"countryName":"Belgium"},"phone":"+3281423848","email":"fanny.collette@chuuclnamur.uclouvain.be","isBusinessKeyValidated":true,"businessKey":"ORG-100040731"},"personInfo":{"id":2633881,"firstName":"Fanny","lastName":"Collette","telephone":"+3281423848","email":"fanny.collette@chuuclnamur.uclouvain.be"},"departmentName":"Oncology"},{"id":2376406,"organisationAddressInfo":{"id":760853,"organisation":{"id":799526,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Centre Hospitalier Universitaire Dinant Godinne Sainte-Elisabeth-UCL-Namur","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100040731","organisationLocationStatus":"Active"},"address":{"addressId":838569,"oneLine":"Place Louise Godin 15","addressLine1":"Place Louise Godin 15","addressLine2":"","addressLine3":"","addressLine4":"","city":"Namur","postcode":"5000","country":2002,"countryName":"Belgium"},"phone":"+3281720531","email":"stephanie.henry@chuuclnamur.uclouvain.be","isBusinessKeyValidated":true,"businessKey":"ORG-100040731"},"personInfo":{"id":2633885,"firstName":"Stéphanie","lastName":"Henry","telephone":"+3281720531","email":"stephanie.henry@chuuclnamur.uclouvain.be"},"departmentName":"Oncology"},{"id":2376403,"organisationAddressInfo":{"id":760844,"organisation":{"id":799517,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Vitaz","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100041146","organisationLocationStatus":"Active"},"address":{"addressId":838560,"oneLine":"Moerlandstraat 1","addressLine1":"Moerlandstraat 1","addressLine2":"","addressLine3":"","addressLine4":"","city":"Sint-Niklaas","postcode":"9100","country":2002,"countryName":"Belgium"},"phone":"+3237602985","email":"willem.lybaert@vitaz.be","isBusinessKeyValidated":true,"businessKey":"ORG-100041146"},"personInfo":{"id":2633882,"firstName":"Willem","lastName":"Lybaert","telephone":"+3237602985","email":"willem.lybaert@vitaz.be"},"departmentName":"Oncology"},{"id":2376404,"organisationAddressInfo":{"id":760867,"organisation":{"id":799540,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Ziekenhuis Aan De Stroom","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100031111","organisationLocationStatus":"Active"},"address":{"addressId":838583,"oneLine":"Oosterveldlaan 24","addressLine1":"Oosterveldlaan 24","addressLine2":"","addressLine3":"","addressLine4":"","city":"Antwerp","postcode":"2610","country":2002,"countryName":"Belgium"},"phone":"+3234433737","email":"simon.vanwambeke@zas.be","isBusinessKeyValidated":true,"businessKey":"ORG-100031111"},"personInfo":{"id":2633883,"firstName":"Simon","lastName":"van Wambeke","telephone":"+3234433737","email":"simon.vanwambeke@zas.be"},"departmentName":"Oncology"},{"id":2376401,"organisationAddressInfo":{"id":760872,"organisation":{"id":799545,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Az St-Jan Brugge-Oostende A.V.","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100023348","organisationLocationStatus":"Active"},"address":{"addressId":838588,"oneLine":"Ruddershove 10","addressLine1":"Ruddershove 10","addressLine2":"","addressLine3":"","addressLine4":"","city":"Brugge","postcode":"8000","country":2002,"countryName":"Belgium"},"phone":"+3250452806","email":"alain.bols@azsintjan.be","isBusinessKeyValidated":true,"businessKey":"ORG-100023348"},"personInfo":{"id":2633880,"firstName":"Alain","lastName":"Bols","telephone":"+3250452806","email":"alain.bols@azsintjan.be"},"departmentName":"Oncology"}],"applicationStatusCode":"Authorised"},{"id":339762,"mscId":44334,"mscInfo":{"id":44334,"clinicalTrialId":20954,"countryOrganisationId":2000,"reportingStatusCode":"Authorised","fromDate":"2025-09-11","toDate":"2025-09-11","isProposedRms":false,"expressDecision":"unwilling","countryName":"Austria","organisationInfo":{},"firstDecisionDate":"2025-10-13","trialStatus":"Authorised","trialPeriod":[{"id":71470,"trialStartDate":"2025-12-19","fromDate":"2025-12-19"},{"id":71471,"trialStartDate":"2025-12-19","fromDate":"2025-12-19"}],"trialRecruitmentPeriod":[{"id":97911,"recruitmentStartDate":"2026-01-14","fromDate":"2026-01-14"},{"id":97912,"recruitmentStartDate":"2026-01-14","fromDate":"2026-01-14"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":112287,"trialStartDate":"2025-12-19","fromDate":"2025-12-19"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2026-01-14"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":85657,"mscId":44334,"trialStatus":"Under evaluation","trialStatusDate":"2025-06-19T12:59:20.676"},{"id":102128,"mscId":44334,"trialStatus":"Authorised","trialStatusDate":"2025-10-13T10:51:37.418"}],"applicationTypeMsc":"1","mscName":"Austria","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-09-17","decision":"authorized_conditions","decisionDate":"2025-10-13"},"decisionDate":"2025-10-13","recruitmentSubjectCount":6,"trialSites":[{"id":2388383,"organisationAddressInfo":{"id":771064,"organisation":{"id":809797,"type":"Educational Institution","typeCode":"1","name":"Medical University Of Vienna","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100006190","organisationLocationStatus":"Active"},"address":{"addressId":850637,"oneLine":"Waehringer Guertel 18-20, Alsergrund","addressLine1":"Waehringer Guertel 18-20","addressLine2":"Alsergrund","addressLine3":"","addressLine4":"","city":"Vienna","postcode":"1090","country":2000,"countryName":"Austria"},"phone":"004314040044450","email":"thorsten.fuereder@meduniwien.ac.at","isBusinessKeyValidated":true,"businessKey":"ORG-100006190"},"personInfo":{"id":2647243,"firstName":"Thorsten","lastName":"Füreder","telephone":"004314040044450","email":"thorsten.fuereder@meduniwien.ac.at","title":"2"},"departmentName":"Department of Internal Medicine I, Clinical Department of Oncology"},{"id":2388384,"organisationAddressInfo":{"id":880168,"organisation":{"id":922184,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft mbH","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100042468","organisationLocationStatus":"Active"},"address":{"addressId":982460,"oneLine":"Muellner Hauptstrasse 48","addressLine1":"Muellner Hauptstrasse 48","addressLine2":"","addressLine3":"","addressLine4":"","city":"Salzburg","postcode":"5020","country":2000,"countryName":"Austria"},"phone":"00435725525800","email":"t.melchardt@salk.at","isBusinessKeyValidated":true,"businessKey":"ORG-100042468"},"personInfo":{"id":2647244,"firstName":"Thomas","lastName":"Melchardt","telephone":"00435725525800","email":"t.melchardt@salk.at","title":"2"},"departmentName":"Department of Internal Medicine III, Oncology"}],"applicationStatusCode":"Authorised"},{"id":318812,"mscId":44339,"mscInfo":{"id":44339,"clinicalTrialId":20954,"countryOrganisationId":2014,"reportingStatusCode":"Authorised","fromDate":"2025-07-07","toDate":"2025-07-07","isProposedRms":false,"expressDecision":"unwilling","countryName":"Greece","organisationInfo":{},"firstDecisionDate":"2025-10-08","trialStatus":"Authorised","trialPeriod":[{"id":81170,"trialStartDate":"2026-04-30","fromDate":"2026-05-04"},{"id":81171,"trialStartDate":"2026-04-30","fromDate":"2026-05-04"}],"trialRecruitmentPeriod":[{"id":114893,"recruitmentStartDate":"2026-06-22","fromDate":"2026-06-23"},{"id":114894,"recruitmentStartDate":"2026-06-22","fromDate":"2026-06-23"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":131980,"trialStartDate":"2026-04-30","fromDate":"2026-05-04"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2026-06-22"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":85662,"mscId":44339,"trialStatus":"Under evaluation","trialStatusDate":"2025-06-19T12:59:20.784"},{"id":100998,"mscId":44339,"trialStatus":"Authorised","trialStatusDate":"2025-10-08T13:37:42.506"}],"applicationTypeMsc":"1","mscName":"Greece","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-09-02","decision":"authorized_conditions","decisionDate":"2025-10-08"},"decisionDate":"2025-10-08","recruitmentSubjectCount":8,"trialSites":[{"id":2230660,"organisationAddressInfo":{"id":773325,"organisation":{"id":812061,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"General University Hospital Of Larissa","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100043264","organisationLocationStatus":"Active"},"address":{"addressId":853290,"oneLine":"P. O. Box 1425","addressLine1":"P. O. Box 1425","addressLine2":"","addressLine3":"","addressLine4":"","city":"Larissa","postcode":"411 10","country":2014,"countryName":"Greece"},"phone":"+302413501000","email":"thankotsakis@hotmail.com","isBusinessKeyValidated":true,"businessKey":"ORG-100043264"},"personInfo":{"id":2473970,"firstName":"Athanasios","lastName":"Kotsakis","telephone":"+302413501000","email":"thankotsakis@hotmail.com","title":"2"},"departmentName":"Oncology Clinic"},{"id":2230661,"organisationAddressInfo":{"id":901061,"organisation":{"id":943148,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"University General Hospital Attikon General Hospital Of West Attica H Agia Varvara","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100030696","organisationLocationStatus":"Active"},"address":{"addressId":1007489,"oneLine":"Rimini 1","addressLine1":"Rimini 1","addressLine2":"","addressLine3":"","addressLine4":"","city":"Chaidari","postcode":"124 61","country":2014,"countryName":"Greece"},"phone":"+302105831664","email":"psyrri237@yahoo.com","isBusinessKeyValidated":true,"businessKey":"ORG-100030696"},"personInfo":{"id":2473971,"firstName":"Amanda","lastName":"Psyrri","telephone":"+302105831664","email":"psyrri237@yahoo.com"},"departmentName":"2nd Internal Medicine Propaedeutic Clinic"}],"applicationStatusCode":"Authorised"},{"id":318810,"mscId":44337,"mscInfo":{"id":44337,"clinicalTrialId":20954,"countryOrganisationId":2012,"reportingStatusCode":"Authorised","fromDate":"2025-09-15","toDate":"2025-09-15","isProposedRms":false,"expressDecision":"unwilling","countryName":"France","organisationInfo":{},"firstDecisionDate":"2025-10-13","trialStatus":"Authorised","trialPeriod":[{"id":71918,"trialStartDate":"2025-12-22","fromDate":"2025-12-31"},{"id":71919,"trialStartDate":"2025-12-22","fromDate":"2025-12-31"},{"id":71920,"trialStartDate":"2025-12-22","fromDate":"2025-12-31"}],"trialRecruitmentPeriod":[{"id":99879,"recruitmentStartDate":"2026-02-03","fromDate":"2026-02-03"},{"id":99880,"recruitmentStartDate":"2026-02-03","fromDate":"2026-02-03"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":113206,"trialStartDate":"2025-12-22","fromDate":"2025-12-31"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2026-02-03"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":85660,"mscId":44337,"trialStatus":"Under evaluation","trialStatusDate":"2025-06-19T12:59:20.744"},{"id":102197,"mscId":44337,"trialStatus":"Authorised","trialStatusDate":"2025-10-13T18:39:03.841"}],"applicationTypeMsc":"1","mscName":"France","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-08-20","decision":"authorized_conditions","decisionDate":"2025-10-13"},"decisionDate":"2025-10-13","recruitmentSubjectCount":22,"trialSites":[{"id":2230640,"organisationAddressInfo":{"id":761637,"organisation":{"id":800318,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Centre Hospitalier Universitaire Amiens Picardie","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100012227","organisationLocationStatus":"Active"},"address":{"addressId":839472,"oneLine":"30 Avenue De La Croix Jourdain","addressLine1":"30 Avenue De La Croix Jourdain","addressLine2":"","addressLine3":"","addressLine4":"","city":"Amiens Cedex 1","postcode":"80054","country":2012,"countryName":"France"},"phone":"0322455499","email":"Houessinon.aline@chu-amiens.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100012227"},"personInfo":{"id":2473950,"firstName":"Aline","lastName":"HOUESSINON","telephone":"0322455499","email":"Houessinon.aline@chu-amiens.fr","title":"1"},"departmentName":"MEDICAL ONCOLOGY"},{"id":2230639,"organisationAddressInfo":{"id":761567,"organisation":{"id":800248,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Institut Gustave Roussy","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100010022","organisationLocationStatus":"Active"},"address":{"addressId":839390,"oneLine":"114 Rue Edouard Vaillant","addressLine1":"114 Rue Edouard Vaillant","addressLine2":"","addressLine3":"","addressLine4":"","city":"Villejuif","postcode":"94800","country":2012,"countryName":"France"},"phone":"+33142114617","email":"Caroline.even@gustaveroussy.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100010022"},"personInfo":{"id":2473949,"firstName":"Caroline","lastName":"EVEN","telephone":"+33142114617","email":"Caroline.even@gustaveroussy.fr","title":"1"},"departmentName":"HEAD AND NECK"},{"id":2230636,"organisationAddressInfo":{"id":879985,"organisation":{"id":922000,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Centre Regional Lutte Contre Le Cancer","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100054755","organisationLocationStatus":"Active"},"address":{"addressId":982244,"oneLine":"Batiment Icans, 17 Rue Albert Calmette","addressLine1":"Batiment Icans","addressLine2":"17 Rue Albert Calmette","addressLine3":"","addressLine4":"","city":"Strasbourg","postcode":"67200","country":2012,"countryName":"France"},"phone":"+33368767390","email":"c.borelc.borel@icans.eu","isBusinessKeyValidated":true,"businessKey":"ORG-100054755"},"personInfo":{"id":2473946,"firstName":"Christian","lastName":"BOREL","telephone":"+33368767390","email":"c.borelc.borel@icans.eu"},"departmentName":"MEDICAL ONCOLOGY"},{"id":2230633,"organisationAddressInfo":{"id":761647,"organisation":{"id":800328,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Hospices Civils De Lyon","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100006597","organisationLocationStatus":"Active"},"address":{"addressId":839484,"oneLine":"103 Grande Rue De La Croix Rousse","addressLine1":"103 Grande Rue De La Croix Rousse","addressLine2":"","addressLine3":"","addressLine4":"","city":"Lyon Cedex 04","postcode":"69317","country":2012,"countryName":"France"},"phone":"+33426732770","email":"philippe.ceruse@chu-lyon.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100006597"},"personInfo":{"id":2473943,"firstName":"Philippe","lastName":"CERUSE","telephone":"+33426732770","email":"philippe.ceruse@chu-lyon.fr","title":"2"},"departmentName":"HEAD AND NECK SURGERY"},{"id":2230631,"organisationAddressInfo":{"id":761655,"organisation":{"id":800336,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Institut Curie","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100009227","organisationLocationStatus":"Active"},"address":{"addressId":839495,"oneLine":"26 Rue D Ulm","addressLine1":"26 Rue D Ulm","addressLine2":"","addressLine3":"","addressLine4":"","city":"Paris","postcode":"75005","country":2012,"countryName":"France"},"phone":"+33144324017","email":"edith.borcoman@curie.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100009227"},"personInfo":{"id":2473941,"firstName":"Edith","lastName":"BORCOMAN","telephone":"+33144324017","email":"edith.borcoman@curie.fr","title":"1"},"departmentName":"DRUG DEVELOPMENT AND INNOVATION (D3I)"},{"id":2230635,"organisationAddressInfo":{"id":761616,"organisation":{"id":800297,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Centre Hospitalier Prive Saint-Gregoire","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100043517","organisationLocationStatus":"Active"},"address":{"addressId":839451,"oneLine":"6 Boulevard De La Boutiere, Cs 56816","addressLine1":"6 Boulevard De La Boutiere","addressLine2":"Cs 56816","addressLine3":"","addressLine4":"","city":"Saint-Gregoire","postcode":"35760","country":2012,"countryName":"France"},"phone":"+33290094467","email":"aurelien.gobert@ircb.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100043517"},"personInfo":{"id":2473945,"firstName":"AURELIEN","lastName":"GOBERT","telephone":"+33290094467","email":"aurelien.gobert@ircb.fr","title":"1"},"departmentName":"MEDICAL ONCOLOGY"},{"id":2230637,"organisationAddressInfo":{"id":761606,"organisation":{"id":800287,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Institut De Cancerologie De Lorraine","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100042918","organisationLocationStatus":"Active"},"address":{"addressId":839441,"oneLine":"6 Avenue De Bourgogne, Cs 30519","addressLine1":"6 Avenue De Bourgogne","addressLine2":"Cs 30519","addressLine3":"","addressLine4":"","city":"Vandoeuvre Les Nancy Cedex","postcode":"54519","country":2012,"countryName":"France"},"phone":"+33383598564","email":"c.jaud@nancy.unicancer.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100042918"},"personInfo":{"id":2473947,"firstName":"CAMILLE","lastName":"JAUD","telephone":"+33383598564","email":"c.jaud@nancy.unicancer.fr","title":"1"},"departmentName":"MEDICAL ONCOLOGY"},{"id":2230634,"organisationAddressInfo":{"id":761572,"organisation":{"id":800253,"type":"Pharmaceutical company","typeCode":"10","name":"Centre Oscar Lambret","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100008539","organisationLocationStatus":"Active"},"address":{"addressId":839397,"oneLine":"3 Rue Frederic Combemale","addressLine1":"3 Rue Frederic Combemale","addressLine2":"","addressLine3":"","addressLine4":"","city":"Lille","postcode":"59000","country":2012,"countryName":"France"},"phone":"+33320295959","email":"c-abdeddaim@o-lambret.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100008539"},"personInfo":{"id":2473944,"firstName":"Cyril","lastName":"Abdeddaim","telephone":"+33320295959","email":"c-abdeddaim@o-lambret.fr","title":"1"},"departmentName":"MEDICAL ONCOLOGY"},{"id":2230641,"organisationAddressInfo":{"id":761642,"organisation":{"id":800323,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Oncopole Claudius Regaud","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100010774","organisationLocationStatus":"Active"},"address":{"addressId":839477,"oneLine":"1 Avenue Irene Joliot Curie","addressLine1":"1 Avenue Irene Joliot Curie","addressLine2":"","addressLine3":"","addressLine4":"","city":"Toulouse Cedex 9","postcode":"31059","country":2012,"countryName":"France"},"phone":"+33531155996","email":"sarradin.victor@iuct-oncopole.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100010774"},"personInfo":{"id":2473951,"firstName":"Victor","lastName":"SARRADIN","telephone":"+33531155996","email":"sarradin.victor@iuct-oncopole.fr","title":"1"},"departmentName":"MEDICAL ONCOLOGY"},{"id":2230632,"organisationAddressInfo":{"id":761578,"organisation":{"id":800259,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Centre De Lutte Contre Le Cancer Eugene Marquis","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100029502","organisationLocationStatus":"Active"},"address":{"addressId":839405,"oneLine":"Avenue La Bataille Flandre Dunkerque, Cs 44229","addressLine1":"Avenue La Bataille Flandre Dunkerque","addressLine2":"Cs 44229","addressLine3":"","addressLine4":"","city":"Rennes Cedex","postcode":"35042","country":2012,"countryName":"France"},"phone":"+33299253182","email":"f.estrade@rennes.unicancer.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100029502"},"personInfo":{"id":2473942,"firstName":"Florian","lastName":"ESTRADE","telephone":"+33299253182","email":"f.estrade@rennes.unicancer.fr","title":"1"},"departmentName":"MEDICAL ONCOLOGY"},{"id":2230638,"organisationAddressInfo":{"id":761652,"organisation":{"id":800333,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Centre Hospitalier Universitaire De Bordeaux","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100008602","organisationLocationStatus":"Active"},"address":{"addressId":839492,"oneLine":"1 Rue Jean Burguet, Cs 11261","addressLine1":"1 Rue Jean Burguet","addressLine2":"Cs 11261","addressLine3":"","addressLine4":"","city":"Bordeaux Cedex","postcode":"33075","country":2012,"countryName":"France"},"phone":"+33556795808","email":"amaury.daste@chu-bordeaux.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100008602"},"personInfo":{"id":2473948,"firstName":"Amaury","lastName":"DASTE","telephone":"+33556795808","email":"amaury.daste@chu-bordeaux.fr","title":"1"},"departmentName":"MEDICAL ONCOLOGY"}],"applicationStatusCode":"Authorised"}],"applicationInfo":[{"id":40850,"type":"INITIAL","status":"Authorised","ctNumber":"2024-519654-37-00","trialStatus":"Authorised","submissionDate":"2025-06-19","partI":{"assessmentOutcome":"acceptable_conditions","assessmentOutcomeDate":"2025-10-06"},"partIIInfo":[{"id":240430,"mscId":44334,"mscInfo":{"id":44334,"mscName":"Austria","countryOrganisationId":2000,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-10-06","decision":"authorized_conditions","decisionDate":"2025-10-13","reportingStatusCode":"Authorised","countryName":"Austria","trialStatus":"Authorised","firstDecisionDate":"2025-10-13"},"applicationStatusCode":"Authorised"},{"id":241495,"mscId":44335,"mscInfo":{"id":44335,"mscName":"Belgium","countryOrganisationId":2002,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-10-02","decision":"authorized_conditions","decisionDate":"2025-10-06","reportingStatusCode":"Authorised","countryName":"Belgium","trialStatus":"Authorised","firstDecisionDate":"2025-10-06"},"applicationStatusCode":"Authorised"},{"id":240060,"mscId":44336,"mscInfo":{"id":44336,"mscName":"Czechia","countryOrganisationId":2008,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-10-06","decision":"authorized_conditions","decisionDate":"2025-10-08","reportingStatusCode":"Authorised","countryName":"Czechia","trialStatus":"Authorised","firstDecisionDate":"2025-10-08"},"applicationStatusCode":"Authorised"},{"id":241122,"mscId":44337,"mscInfo":{"id":44337,"mscName":"France","countryOrganisationId":2012,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-10-01","decision":"authorized_conditions","decisionDate":"2025-10-13","reportingStatusCode":"Authorised","countryName":"France","trialStatus":"Authorised","firstDecisionDate":"2025-10-13"},"applicationStatusCode":"Authorised"},{"id":242644,"mscId":44338,"mscInfo":{"id":44338,"mscName":"Germany","countryOrganisationId":2013,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-09-23","decision":"authorized_conditions","decisionDate":"2025-10-09","reportingStatusCode":"Authorised","countryName":"Germany","trialStatus":"Authorised","firstDecisionDate":"2025-10-09"},"applicationStatusCode":"Authorised"},{"id":222956,"mscId":44339,"mscInfo":{"id":44339,"mscName":"Greece","countryOrganisationId":2014,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-07-28","decision":"authorized_conditions","decisionDate":"2025-10-08","reportingStatusCode":"Authorised","countryName":"Greece","trialStatus":"Authorised","firstDecisionDate":"2025-10-08"},"applicationStatusCode":"Authorised"},{"id":242257,"mscId":44340,"mscInfo":{"id":44340,"mscName":"Ireland","countryOrganisationId":2017,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-10-06","decision":"authorized_conditions","decisionDate":"2025-10-10","reportingStatusCode":"Authorised","countryName":"Ireland","trialStatus":"Authorised","firstDecisionDate":"2025-10-10"},"applicationStatusCode":"Authorised"},{"id":240651,"mscId":44341,"mscInfo":{"id":44341,"mscName":"Italy","countryOrganisationId":2018,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-10-06","decision":"authorized_conditions","decisionDate":"2025-10-09","reportingStatusCode":"Authorised","countryName":"Italy","trialStatus":"Authorised","firstDecisionDate":"2025-10-09"},"applicationStatusCode":"Authorised"},{"id":241103,"mscId":44342,"mscInfo":{"id":44342,"mscName":"Portugal","countryOrganisationId":2024,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-09-26","decision":"authorized_conditions","decisionDate":"2025-10-06","reportingStatusCode":"Authorised","countryName":"Portugal","trialStatus":"Authorised","firstDecisionDate":"2025-10-06"},"applicationStatusCode":"Authorised"},{"id":229331,"mscId":44343,"mscInfo":{"id":44343,"mscName":"Spain","countryOrganisationId":2027,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-09-16","decision":"authorized","decisionDate":"2025-11-03","reportingStatusCode":"Authorised","countryName":"Spain","trialStatus":"Authorised","firstDecisionDate":"2025-11-03"},"applicationStatusCode":"Authorised"},{"id":240492,"mscId":44344,"mscInfo":{"id":44344,"mscName":"Poland","countryOrganisationId":2031,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-10-06","decision":"authorized_conditions","decisionDate":"2025-10-10","reportingStatusCode":"Authorised","countryName":"Poland","trialStatus":"Authorised","firstDecisionDate":"2025-10-10"},"applicationStatusCode":"Authorised"}],"decisionDate":"2025-10-06","ctMSCsByApplication":[{"id":44334,"mscName":"Austria","reportingStatusCode":"Authorised"},{"id":44335,"mscName":"Belgium","reportingStatusCode":"Authorised"},{"id":44336,"mscName":"Czechia","reportingStatusCode":"Authorised"},{"id":44337,"mscName":"France","reportingStatusCode":"Authorised"},{"id":44338,"mscName":"Germany","reportingStatusCode":"Authorised"},{"id":44339,"mscName":"Greece","reportingStatusCode":"Authorised"},{"id":44340,"mscName":"Ireland","reportingStatusCode":"Authorised"},{"id":44341,"mscName":"Italy","reportingStatusCode":"Authorised"},{"id":44342,"mscName":"Portugal","reportingStatusCode":"Authorised"},{"id":44343,"mscName":"Spain","reportingStatusCode":"Authorised"},{"id":44344,"mscName":"Poland","reportingStatusCode":"Authorised"}],"businessKey":"IN","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":92436,"applicationId":40850,"mscId":44335,"mscName":"Belgium","decisionDate":"2025-10-06T16:40:02.969","decision":"authorized_conditions","assessmentOutcome":"acceptable","eventType":"decision","part2Id":241495,"part1Id":100839,"applicationType":"INITIAL","isRMS":true},{"id":93368,"applicationId":40850,"mscId":44334,"mscName":"Austria","decisionDate":"2025-10-13T10:51:41.31","decision":"authorized_conditions","assessmentOutcome":"acceptable","eventType":"decision","part2Id":240430,"part1Id":100839,"applicationType":"INITIAL","isRMS":false},{"id":93022,"applicationId":40850,"mscId":44341,"mscName":"Italy","decisionDate":"2025-10-09T14:22:53.209","decision":"authorized_conditions","assessmentOutcome":"acceptable","eventType":"decision","part2Id":240651,"part1Id":100839,"applicationType":"INITIAL","isRMS":false},{"id":93181,"applicationId":40850,"mscId":44344,"mscName":"Poland","decisionDate":"2025-10-10T12:47:25.464","decision":"authorized_conditions","assessmentOutcome":"acceptable","eventType":"decision","part2Id":240492,"part1Id":100839,"applicationType":"INITIAL","isRMS":false},{"id":92794,"applicationId":40850,"mscId":44343,"mscName":"Spain","decisionDate":"2025-10-08T13:14:35.794","decision":"authorized_conditions","assessmentOutcome":"acceptable","eventType":"decision","part2Id":229331,"part1Id":100839,"applicationType":"INITIAL","isRMS":false},{"id":93052,"applicationId":40850,"mscId":44338,"mscName":"Germany","decisionDate":"2025-10-09T15:43:50.96","decision":"authorized_conditions","assessmentOutcome":"acceptable","eventType":"decision","part2Id":242644,"part1Id":100839,"applicationType":"INITIAL","isRMS":false},{"id":92747,"applicationId":40850,"mscId":44336,"mscName":"Czechia","decisionDate":"2025-10-08T10:48:19.325","decision":"authorized_conditions","assessmentOutcome":"acceptable","eventType":"decision","part2Id":240060,"part1Id":100839,"applicationType":"INITIAL","isRMS":false},{"id":93132,"applicationId":40850,"mscId":44340,"mscName":"Ireland","decisionDate":"2025-10-10T11:13:17.659","decision":"authorized_conditions","assessmentOutcome":"acceptable","eventType":"decision","part2Id":242257,"part1Id":100839,"applicationType":"INITIAL","isRMS":false},{"id":92806,"applicationId":40850,"mscId":44339,"mscName":"Greece","decisionDate":"2025-10-08T13:37:46.785","decision":"authorized_conditions","assessmentOutcome":"acceptable","eventType":"decision","part2Id":222956,"part1Id":100839,"applicationType":"INITIAL","isRMS":false},{"id":93506,"applicationId":40850,"mscId":44337,"mscName":"France","decisionDate":"2025-10-13T18:39:06.422","decision":"authorized_conditions","assessmentOutcome":"acceptable","eventType":"decision","part2Id":241122,"part1Id":100839,"applicationType":"INITIAL","isRMS":false},{"id":92469,"applicationId":40850,"mscId":44342,"mscName":"Portugal","decisionDate":"2025-10-06T17:43:30.812","decision":"authorized_conditions","assessmentOutcome":"acceptable","eventType":"decision","part2Id":241103,"part1Id":100839,"applicationType":"INITIAL","isRMS":false}],"productRoleGroupDocument":[{"documentUuid":"c4259091-baa0-44f1-a425-4ddbdd23f3cc","productRoleGroupId":314092},{"documentUuid":"a22fb21c-9a7f-4d50-9a7d-b053f872d6b2","productRoleGroupId":314090}]},{"id":68432,"type":"NON SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-519654-37-00","trialStatus":"Authorised","submissionDate":"2025-11-03","partI":{"assessmentOutcome":"acceptable_conditions","assessmentOutcomeDate":"2025-10-06"},"partIIInfo":[{"id":252238,"mscId":44343,"mscInfo":{"id":44343,"mscName":"Spain","countryOrganisationId":2027,"decision":"authorized","decisionDate":"2025-11-03","reportingStatusCode":"Authorised","countryName":"Spain","trialStatus":"Authorised","firstDecisionDate":"2025-11-03"},"applicationStatusCode":"Authorised"}],"decisionDate":"2025-11-03","ctMSCsByApplication":[{"id":44343,"mscName":"Spain","reportingStatusCode":"Authorised"}],"businessKey":"NSM-1","modScope":"PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":96399,"applicationId":68432,"mscId":44343,"mscName":"Spain","decisionDate":"2025-11-03T16:54:16.783","decision":"authorized","eventType":"decision","part2Id":252238,"part1Id":105336,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false}],"productRoleGroupDocument":[{"documentUuid":"c4259091-baa0-44f1-a425-4ddbdd23f3cc","productRoleGroupId":327586},{"documentUuid":"a22fb21c-9a7f-4d50-9a7d-b053f872d6b2","productRoleGroupId":327589}]},{"id":69312,"type":"NON SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-519654-37-00","trialStatus":"Authorised","submissionDate":"2025-11-06","partI":{"assessmentOutcome":"acceptable_conditions","assessmentOutcomeDate":"2025-10-06"},"partIIInfo":[],"decisionDate":"2025-11-06","ctMSCsByApplication":[{"id":44334,"mscName":"Austria","reportingStatusCode":"Authorised"},{"id":44335,"mscName":"Belgium","reportingStatusCode":"Authorised"},{"id":44336,"mscName":"Czechia","reportingStatusCode":"Authorised"},{"id":44337,"mscName":"France","reportingStatusCode":"Authorised"},{"id":44338,"mscName":"Germany","reportingStatusCode":"Authorised"},{"id":44339,"mscName":"Greece","reportingStatusCode":"Authorised"},{"id":44340,"mscName":"Ireland","reportingStatusCode":"Authorised"},{"id":44341,"mscName":"Italy","reportingStatusCode":"Authorised"},{"id":44342,"mscName":"Portugal","reportingStatusCode":"Authorised"},{"id":44344,"mscName":"Poland","reportingStatusCode":"Authorised"},{"id":44343,"mscName":"Spain","reportingStatusCode":"Authorised"}],"businessKey":"NSM-2","modScope":"PART_I","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":96960,"applicationId":69312,"mscId":44334,"mscName":"Austria","decisionDate":"2025-11-06T16:19:12.989","decision":"authorized","eventType":"decision","part1Id":106700,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false},{"id":96960,"applicationId":69312,"mscId":44335,"mscName":"Belgium","decisionDate":"2025-11-06T16:19:12.989","decision":"authorized","eventType":"decision","part1Id":106700,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":true},{"id":96960,"applicationId":69312,"mscId":44336,"mscName":"Czechia","decisionDate":"2025-11-06T16:19:12.989","decision":"authorized","eventType":"decision","part1Id":106700,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false},{"id":96960,"applicationId":69312,"mscId":44337,"mscName":"France","decisionDate":"2025-11-06T16:19:12.989","decision":"authorized","eventType":"decision","part1Id":106700,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false},{"id":96960,"applicationId":69312,"mscId":44338,"mscName":"Germany","decisionDate":"2025-11-06T16:19:12.989","decision":"authorized","eventType":"decision","part1Id":106700,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false},{"id":96960,"applicationId":69312,"mscId":44339,"mscName":"Greece","decisionDate":"2025-11-06T16:19:12.989","decision":"authorized","eventType":"decision","part1Id":106700,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false},{"id":96960,"applicationId":69312,"mscId":44340,"mscName":"Ireland","decisionDate":"2025-11-06T16:19:12.989","decision":"authorized","eventType":"decision","part1Id":106700,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false},{"id":96960,"applicationId":69312,"mscId":44341,"mscName":"Italy","decisionDate":"2025-11-06T16:19:12.989","decision":"authorized","eventType":"decision","part1Id":106700,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false},{"id":96960,"applicationId":69312,"mscId":44342,"mscName":"Portugal","decisionDate":"2025-11-06T16:19:12.989","decision":"authorized","eventType":"decision","part1Id":106700,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false},{"id":96960,"applicationId":69312,"mscId":44344,"mscName":"Poland","decisionDate":"2025-11-06T16:19:12.989","decision":"authorized","eventType":"decision","part1Id":106700,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false},{"id":96960,"applicationId":69312,"mscId":44343,"mscName":"Spain","decisionDate":"2025-11-06T16:19:12.989","decision":"authorized","eventType":"decision","part1Id":106700,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false}],"productRoleGroupDocument":[{"documentUuid":"c4259091-baa0-44f1-a425-4ddbdd23f3cc","productRoleGroupId":331813},{"documentUuid":"a22fb21c-9a7f-4d50-9a7d-b053f872d6b2","productRoleGroupId":331815}]},{"id":69816,"type":"NON SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-519654-37-00","trialStatus":"Authorised","submissionDate":"2025-11-17","partI":{"assessmentOutcome":"acceptable_conditions","assessmentOutcomeDate":"2025-10-06"},"partIIInfo":[{"id":256921,"mscId":44334,"mscInfo":{"id":44334,"mscName":"Austria","countryOrganisationId":2000,"decision":"authorized_conditions","decisionDate":"2025-10-13","reportingStatusCode":"Authorised","countryName":"Austria","trialStatus":"Authorised","firstDecisionDate":"2025-10-13"},"applicationStatusCode":"Authorised"}],"decisionDate":"2025-11-17","ctMSCsByApplication":[{"id":44334,"mscName":"Austria","reportingStatusCode":"Authorised"}],"businessKey":"NSM-3","modScope":"PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":98281,"applicationId":69816,"mscId":44334,"mscName":"Austria","decisionDate":"2025-11-17T13:43:09.661","decision":"authorized","eventType":"decision","part2Id":256921,"part1Id":107463,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false}],"productRoleGroupDocument":[{"documentUuid":"a22fb21c-9a7f-4d50-9a7d-b053f872d6b2","productRoleGroupId":334098},{"documentUuid":"c4259091-baa0-44f1-a425-4ddbdd23f3cc","productRoleGroupId":334097}]},{"id":70418,"type":"NON SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-519654-37-00","trialStatus":"Authorised","submissionDate":"2025-11-27","partI":{"assessmentOutcome":"acceptable_conditions","assessmentOutcomeDate":"2025-10-06"},"partIIInfo":[{"id":258836,"mscId":44337,"mscInfo":{"id":44337,"mscName":"France","countryOrganisationId":2012,"decision":"authorized_conditions","decisionDate":"2025-10-13","reportingStatusCode":"Authorised","countryName":"France","trialStatus":"Authorised","firstDecisionDate":"2025-10-13"},"applicationStatusCode":"Authorised"}],"decisionDate":"2025-11-27","ctMSCsByApplication":[{"id":44337,"mscName":"France","reportingStatusCode":"Authorised"}],"businessKey":"NSM-4","modScope":"PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":99909,"applicationId":70418,"mscId":44337,"mscName":"France","decisionDate":"2025-11-27T10:42:14.513","decision":"authorized","eventType":"decision","part2Id":258836,"part1Id":108328,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false}],"productRoleGroupDocument":[{"documentUuid":"c4259091-baa0-44f1-a425-4ddbdd23f3cc","productRoleGroupId":336742},{"documentUuid":"a22fb21c-9a7f-4d50-9a7d-b053f872d6b2","productRoleGroupId":336741}]},{"id":71351,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-519654-37-00","trialStatus":"Authorised","submissionDate":"2025-12-11","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-04-02"},"partIIInfo":[{"id":271377,"mscId":44340,"mscInfo":{"id":44340,"mscName":"Ireland","countryOrganisationId":2017,"assessmentOutcome":"no_conclusion","assessmentOutcomeDate":"2026-02-26","decision":"authorized_conditions","decisionDate":"2025-10-10","reportingStatusCode":"Authorised","countryName":"Ireland","trialStatus":"Authorised","firstDecisionDate":"2025-10-10"},"applicationStatusCode":"Authorised"},{"id":286652,"mscId":44335,"mscInfo":{"id":44335,"mscName":"Belgium","countryOrganisationId":2002,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-03-26","decision":"authorized_conditions","decisionDate":"2025-10-06","reportingStatusCode":"Authorised","countryName":"Belgium","trialStatus":"Authorised","firstDecisionDate":"2025-10-06"},"applicationStatusCode":"Authorised"},{"id":271373,"mscId":44336,"mscInfo":{"id":44336,"mscName":"Czechia","countryOrganisationId":2008,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-03-27","decision":"authorized_conditions","decisionDate":"2025-10-08","reportingStatusCode":"Authorised","countryName":"Czechia","trialStatus":"Authorised","firstDecisionDate":"2025-10-08"},"applicationStatusCode":"Authorised"},{"id":276683,"mscId":44338,"mscInfo":{"id":44338,"mscName":"Germany","countryOrganisationId":2013,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-02-04","decision":"authorized_conditions","decisionDate":"2025-10-09","reportingStatusCode":"Authorised","countryName":"Germany","trialStatus":"Authorised","firstDecisionDate":"2025-10-09"},"applicationStatusCode":"Authorised"},{"id":286131,"mscId":44334,"mscInfo":{"id":44334,"mscName":"Austria","countryOrganisationId":2000,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-03-30","decision":"authorized_conditions","decisionDate":"2025-10-13","reportingStatusCode":"Authorised","countryName":"Austria","trialStatus":"Authorised","firstDecisionDate":"2025-10-13"},"applicationStatusCode":"Authorised"},{"id":271374,"mscId":44337,"mscInfo":{"id":44337,"mscName":"France","countryOrganisationId":2012,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-02-23","decision":"authorized_conditions","decisionDate":"2025-10-13","reportingStatusCode":"Authorised","countryName":"France","trialStatus":"Authorised","firstDecisionDate":"2025-10-13"},"applicationStatusCode":"Authorised"},{"id":271381,"mscId":44344,"mscInfo":{"id":44344,"mscName":"Poland","countryOrganisationId":2031,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-02-25","decision":"authorized_conditions","decisionDate":"2025-10-10","reportingStatusCode":"Authorised","countryName":"Poland","trialStatus":"Authorised","firstDecisionDate":"2025-10-10"},"applicationStatusCode":"Authorised"},{"id":271378,"mscId":44341,"mscInfo":{"id":44341,"mscName":"Italy","countryOrganisationId":2018,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-02-26","decision":"authorized_conditions","decisionDate":"2025-10-09","reportingStatusCode":"Authorised","countryName":"Italy","trialStatus":"Authorised","firstDecisionDate":"2025-10-09"},"applicationStatusCode":"Authorised"},{"id":273995,"mscId":44342,"mscInfo":{"id":44342,"mscName":"Portugal","countryOrganisationId":2024,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-02-06","decision":"authorized_conditions","decisionDate":"2025-10-06","reportingStatusCode":"Authorised","countryName":"Portugal","trialStatus":"Authorised","firstDecisionDate":"2025-10-06"},"applicationStatusCode":"Authorised"},{"id":271380,"mscId":44343,"mscInfo":{"id":44343,"mscName":"Spain","countryOrganisationId":2027,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-01-19","decision":"authorized","decisionDate":"2025-11-03","reportingStatusCode":"Authorised","countryName":"Spain","trialStatus":"Authorised","firstDecisionDate":"2025-11-03"},"applicationStatusCode":"Authorised"},{"id":273801,"mscId":44339,"mscInfo":{"id":44339,"mscName":"Greece","countryOrganisationId":2014,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-02-02","decision":"authorized_conditions","decisionDate":"2025-10-08","reportingStatusCode":"Authorised","countryName":"Greece","trialStatus":"Authorised","firstDecisionDate":"2025-10-08"},"applicationStatusCode":"Authorised"}],"decisionDate":"2026-04-02","ctMSCsByApplication":[{"id":44340,"mscName":"Ireland","reportingStatusCode":"Authorised"},{"id":44335,"mscName":"Belgium","reportingStatusCode":"Authorised"},{"id":44336,"mscName":"Czechia","reportingStatusCode":"Authorised"},{"id":44338,"mscName":"Germany","reportingStatusCode":"Authorised"},{"id":44334,"mscName":"Austria","reportingStatusCode":"Authorised"},{"id":44337,"mscName":"France","reportingStatusCode":"Authorised"},{"id":44344,"mscName":"Poland","reportingStatusCode":"Authorised"},{"id":44341,"mscName":"Italy","reportingStatusCode":"Authorised"},{"id":44342,"mscName":"Portugal","reportingStatusCode":"Authorised"},{"id":44343,"mscName":"Spain","reportingStatusCode":"Authorised"},{"id":44339,"mscName":"Greece","reportingStatusCode":"Authorised"}],"businessKey":"SM-1","modScope":"PART_I_AND_PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":117750,"applicationId":71351,"mscId":44336,"mscName":"Czechia","decisionDate":"2026-04-07T13:59:59.354","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":271373,"part1Id":114025,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":117507,"applicationId":71351,"mscId":44337,"mscName":"France","decisionDate":"2026-04-03T14:57:20.117","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":271374,"part1Id":114025,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":117623,"applicationId":71351,"mscId":44334,"mscName":"Austria","decisionDate":"2026-04-07T09:10:54.384","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":286131,"part1Id":114025,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":117696,"applicationId":71351,"mscId":44343,"mscName":"Spain","decisionDate":"2026-04-07T12:38:09.458","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":271380,"part1Id":114025,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":117656,"applicationId":71351,"mscId":44338,"mscName":"Germany","decisionDate":"2026-04-07T10:54:14.428","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":276683,"part1Id":114025,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":117356,"applicationId":71351,"mscId":44335,"mscName":"Belgium","decisionDate":"2026-04-02T13:26:53.534","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":286652,"part1Id":114025,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true},{"id":117583,"applicationId":71351,"mscId":44339,"mscName":"Greece","decisionDate":"2026-04-06T14:24:20.514","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":273801,"part1Id":114025,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":117684,"applicationId":71351,"mscId":44342,"mscName":"Portugal","decisionDate":"2026-04-07T12:11:03.991","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":273995,"part1Id":114025,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":117738,"applicationId":71351,"mscId":44344,"mscName":"Poland","decisionDate":"2026-04-07T13:51:47.388","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":271381,"part1Id":114025,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":117699,"applicationId":71351,"mscId":44341,"mscName":"Italy","decisionDate":"2026-04-07T12:43:08.32","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":271378,"part1Id":114025,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":117899,"applicationId":71351,"mscId":44340,"mscName":"Ireland","decisionDate":"2026-04-08T10:05:10.541","decision":"authorized","assessmentOutcome":"no_conclusion","eventType":"decision","part2Id":271377,"part1Id":114025,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false}],"productRoleGroupDocument":[{"documentUuid":"1d4302fe-22e0-4260-8924-6fa29108e38f","productRoleGroupId":354427},{"documentUuid":"0259d6d3-226f-4bb1-802a-6ab12f5d2a5b","productRoleGroupId":354427},{"documentUuid":"d7e70c4d-397e-4a7a-8e7e-dae538ea1a66","productRoleGroupId":354429},{"documentUuid":"f2006804-f26f-4333-adb3-8235f82e1ad8","productRoleGroupId":354429}]},{"id":81867,"type":"NON SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-519654-37-00","trialStatus":"Authorised","submissionDate":"2026-04-15","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-04-02"},"partIIInfo":[{"id":296581,"mscId":44344,"mscInfo":{"id":44344,"mscName":"Poland","countryOrganisationId":2031,"decision":"authorized_conditions","decisionDate":"2025-10-10","reportingStatusCode":"Authorised","countryName":"Poland","trialStatus":"Authorised","firstDecisionDate":"2025-10-10"},"applicationStatusCode":"Authorised"}],"decisionDate":"2026-04-15","ctMSCsByApplication":[{"id":44344,"mscName":"Poland","reportingStatusCode":"Authorised"}],"businessKey":"NSM-5","modScope":"PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":119260,"applicationId":81867,"mscId":44344,"mscName":"Poland","decisionDate":"2026-04-15T14:57:45.184","decision":"authorized","eventType":"decision","part2Id":296581,"part1Id":125420,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false}],"productRoleGroupDocument":[{"documentUuid":"d7e70c4d-397e-4a7a-8e7e-dae538ea1a66","productRoleGroupId":388504},{"documentUuid":"f2006804-f26f-4333-adb3-8235f82e1ad8","productRoleGroupId":388504},{"documentUuid":"1d4302fe-22e0-4260-8924-6fa29108e38f","productRoleGroupId":388503},{"documentUuid":"0259d6d3-226f-4bb1-802a-6ab12f5d2a5b","productRoleGroupId":388503}]},{"id":82555,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-519654-37-00","trialStatus":"Authorised","submissionDate":"2026-04-21","partI":{"assessmentOutcome":"acceptable"},"partIIInfo":[{"id":298732,"mscId":44343,"mscInfo":{"id":44343,"mscName":"Spain","countryOrganisationId":2027,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-05-06","decision":"authorized","decisionDate":"2025-11-03","reportingStatusCode":"Authorised","countryName":"Spain","trialStatus":"Authorised","firstDecisionDate":"2025-11-03"},"applicationStatusCode":"Authorised"}],"decisionDate":"2026-05-06","ctMSCsByApplication":[{"id":44343,"mscName":"Spain","reportingStatusCode":"Authorised"}],"businessKey":"SM-2","modScope":"PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":122637,"applicationId":82555,"mscId":44343,"mscName":"Spain","decisionDate":"2026-05-06T12:54:05.799","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":298732,"part1Id":126404,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false}],"productRoleGroupDocument":[{"documentUuid":"d7e70c4d-397e-4a7a-8e7e-dae538ea1a66","productRoleGroupId":391563},{"documentUuid":"f2006804-f26f-4333-adb3-8235f82e1ad8","productRoleGroupId":391563},{"documentUuid":"1d4302fe-22e0-4260-8924-6fa29108e38f","productRoleGroupId":391566},{"documentUuid":"0259d6d3-226f-4bb1-802a-6ab12f5d2a5b","productRoleGroupId":391566}]},{"id":87953,"type":"NON SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-519654-37-00","trialStatus":"Authorised","submissionDate":"2026-06-25","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-04-02"},"partIIInfo":[],"decisionDate":"2026-06-25","ctMSCsByApplication":[{"id":44340,"mscName":"Ireland","reportingStatusCode":"Authorised"},{"id":44335,"mscName":"Belgium","reportingStatusCode":"Authorised"},{"id":44336,"mscName":"Czechia","reportingStatusCode":"Authorised"},{"id":44338,"mscName":"Germany","reportingStatusCode":"Authorised"},{"id":44334,"mscName":"Austria","reportingStatusCode":"Authorised"},{"id":44337,"mscName":"France","reportingStatusCode":"Authorised"},{"id":44341,"mscName":"Italy","reportingStatusCode":"Authorised"},{"id":44342,"mscName":"Portugal","reportingStatusCode":"Authorised"},{"id":44339,"mscName":"Greece","reportingStatusCode":"Authorised"},{"id":44344,"mscName":"Poland","reportingStatusCode":"Authorised"},{"id":44343,"mscName":"Spain","reportingStatusCode":"Authorised"}],"businessKey":"NSM-6","modScope":"PART_I","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":130240,"applicationId":87953,"mscId":44340,"mscName":"Ireland","decisionDate":"2026-06-25T22:28:13.651","decision":"authorized","eventType":"decision","part1Id":134287,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false},{"id":130240,"applicationId":87953,"mscId":44335,"mscName":"Belgium","decisionDate":"2026-06-25T22:28:13.651","decision":"authorized","eventType":"decision","part1Id":134287,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":true},{"id":130240,"applicationId":87953,"mscId":44336,"mscName":"Czechia","decisionDate":"2026-06-25T22:28:13.651","decision":"authorized","eventType":"decision","part1Id":134287,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false},{"id":130240,"applicationId":87953,"mscId":44338,"mscName":"Germany","decisionDate":"2026-06-25T22:28:13.651","decision":"authorized","eventType":"decision","part1Id":134287,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false},{"id":130240,"applicationId":87953,"mscId":44334,"mscName":"Austria","decisionDate":"2026-06-25T22:28:13.651","decision":"authorized","eventType":"decision","part1Id":134287,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false},{"id":130240,"applicationId":87953,"mscId":44337,"mscName":"France","decisionDate":"2026-06-25T22:28:13.651","decision":"authorized","eventType":"decision","part1Id":134287,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false},{"id":130240,"applicationId":87953,"mscId":44341,"mscName":"Italy","decisionDate":"2026-06-25T22:28:13.651","decision":"authorized","eventType":"decision","part1Id":134287,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false},{"id":130240,"applicationId":87953,"mscId":44342,"mscName":"Portugal","decisionDate":"2026-06-25T22:28:13.651","decision":"authorized","eventType":"decision","part1Id":134287,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false},{"id":130240,"applicationId":87953,"mscId":44339,"mscName":"Greece","decisionDate":"2026-06-25T22:28:13.651","decision":"authorized","eventType":"decision","part1Id":134287,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false},{"id":130240,"applicationId":87953,"mscId":44344,"mscName":"Poland","decisionDate":"2026-06-25T22:28:13.651","decision":"authorized","eventType":"decision","part1Id":134287,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false},{"id":130240,"applicationId":87953,"mscId":44343,"mscName":"Spain","decisionDate":"2026-06-25T22:28:13.651","decision":"authorized","eventType":"decision","part1Id":134287,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":false}],"productRoleGroupDocument":[{"documentUuid":"d7e70c4d-397e-4a7a-8e7e-dae538ea1a66","productRoleGroupId":415419},{"documentUuid":"f2006804-f26f-4333-adb3-8235f82e1ad8","productRoleGroupId":415419},{"documentUuid":"1d4302fe-22e0-4260-8924-6fa29108e38f","productRoleGroupId":415418},{"documentUuid":"0259d6d3-226f-4bb1-802a-6ab12f5d2a5b","productRoleGroupId":415418}]},{"id":88720,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-519654-37-00","trialStatus":"Authorised","submissionDate":"2026-07-31","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-09-01"},"partIIInfo":[{"id":318808,"mscId":44336,"mscInfo":{"id":44336,"mscName":"Czechia","countryOrganisationId":2008,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-09-01","decision":"authorized_conditions","decisionDate":"2025-10-08","reportingStatusCode":"Authorised","countryName":"Czechia","trialStatus":"Authorised","firstDecisionDate":"2025-10-08"},"applicationStatusCode":"Authorised"},{"id":339675,"mscId":44341,"mscInfo":{"id":44341,"mscName":"Italy","countryOrganisationId":2018,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-10-02","decision":"authorized_conditions","decisionDate":"2025-10-09","reportingStatusCode":"Authorised","countryName":"Italy","trialStatus":"Authorised","firstDecisionDate":"2025-10-09"},"applicationStatusCode":"Authorised"},{"id":318811,"mscId":44338,"mscInfo":{"id":44338,"mscName":"Germany","countryOrganisationId":2013,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-08-19","decision":"authorized_conditions","decisionDate":"2025-10-09","reportingStatusCode":"Authorised","countryName":"Germany","trialStatus":"Authorised","firstDecisionDate":"2025-10-09"},"applicationStatusCode":"Authorised"},{"id":336652,"mscId":44342,"mscInfo":{"id":44342,"mscName":"Portugal","countryOrganisationId":2024,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-09-18","decision":"authorized_conditions","decisionDate":"2025-10-06","reportingStatusCode":"Authorised","countryName":"Portugal","trialStatus":"Authorised","firstDecisionDate":"2025-10-06"},"applicationStatusCode":"Authorised"},{"id":318809,"mscId":44343,"mscInfo":{"id":44343,"mscName":"Spain","countryOrganisationId":2027,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-08-10","decision":"authorized","decisionDate":"2025-11-03","reportingStatusCode":"Authorised","countryName":"Spain","trialStatus":"Authorised","firstDecisionDate":"2025-11-03"},"applicationStatusCode":"Authorised"},{"id":318804,"mscId":44340,"mscInfo":{"id":44340,"mscName":"Ireland","countryOrganisationId":2017,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-09-07","decision":"authorized_conditions","decisionDate":"2025-10-10","reportingStatusCode":"Authorised","countryName":"Ireland","trialStatus":"Authorised","firstDecisionDate":"2025-10-10"},"applicationStatusCode":"Authorised"},{"id":318813,"mscId":44344,"mscInfo":{"id":44344,"mscName":"Poland","countryOrganisationId":2031,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-09-04","decision":"authorized_conditions","decisionDate":"2025-10-10","reportingStatusCode":"Authorised","countryName":"Poland","trialStatus":"Authorised","firstDecisionDate":"2025-10-10"},"applicationStatusCode":"Authorised"},{"id":338051,"mscId":44335,"mscInfo":{"id":44335,"mscName":"Belgium","countryOrganisationId":2002,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-09-24","decision":"authorized_conditions","decisionDate":"2025-10-06","reportingStatusCode":"Authorised","countryName":"Belgium","trialStatus":"Authorised","firstDecisionDate":"2025-10-06"},"applicationStatusCode":"Authorised"},{"id":339762,"mscId":44334,"mscInfo":{"id":44334,"mscName":"Austria","countryOrganisationId":2000,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-09-17","decision":"authorized_conditions","decisionDate":"2025-10-13","reportingStatusCode":"Authorised","countryName":"Austria","trialStatus":"Authorised","firstDecisionDate":"2025-10-13"},"applicationStatusCode":"Authorised"},{"id":318812,"mscId":44339,"mscInfo":{"id":44339,"mscName":"Greece","countryOrganisationId":2014,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-09-02","decision":"authorized_conditions","decisionDate":"2025-10-08","reportingStatusCode":"Authorised","countryName":"Greece","trialStatus":"Authorised","firstDecisionDate":"2025-10-08"},"applicationStatusCode":"Authorised"},{"id":318810,"mscId":44337,"mscInfo":{"id":44337,"mscName":"France","countryOrganisationId":2012,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-08-20","decision":"authorized_conditions","decisionDate":"2025-10-13","reportingStatusCode":"Authorised","countryName":"France","trialStatus":"Authorised","firstDecisionDate":"2025-10-13"},"applicationStatusCode":"Authorised"}],"decisionDate":"2026-09-01","ctMSCsByApplication":[{"id":44336,"mscName":"Czechia","reportingStatusCode":"Authorised"},{"id":44341,"mscName":"Italy","reportingStatusCode":"Authorised"},{"id":44338,"mscName":"Germany","reportingStatusCode":"Authorised"},{"id":44342,"mscName":"Portugal","reportingStatusCode":"Authorised"},{"id":44343,"mscName":"Spain","reportingStatusCode":"Authorised"},{"id":44340,"mscName":"Ireland","reportingStatusCode":"Authorised"},{"id":44344,"mscName":"Poland","reportingStatusCode":"Authorised"},{"id":44335,"mscName":"Belgium","reportingStatusCode":"Authorised"},{"id":44334,"mscName":"Austria","reportingStatusCode":"Authorised"},{"id":44339,"mscName":"Greece","reportingStatusCode":"Authorised"},{"id":44337,"mscName":"France","reportingStatusCode":"Authorised"}],"businessKey":"SM-4","modScope":"PART_I_AND_PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":140905,"applicationId":88720,"mscId":44343,"mscName":"Spain","decisionDate":"2026-09-07T17:30:35.387","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":318809,"part1Id":135393,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":140872,"applicationId":88720,"mscId":44338,"mscName":"Germany","decisionDate":"2026-09-07T16:24:54.38","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":318811,"part1Id":135393,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":140258,"applicationId":88720,"mscId":44336,"mscName":"Czechia","decisionDate":"2026-09-02T13:21:31.35","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":318808,"part1Id":135393,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":142803,"applicationId":88720,"mscId":44334,"mscName":"Austria","decisionDate":"2026-09-21T13:17:01.624","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":339762,"part1Id":135393,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":140125,"applicationId":88720,"mscId":44337,"mscName":"France","decisionDate":"2026-09-01T17:37:31.353","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":318810,"part1Id":135393,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":140984,"applicationId":88720,"mscId":44340,"mscName":"Ireland","decisionDate":"2026-09-08T11:09:33.048","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":318804,"part1Id":135393,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":140356,"applicationId":88720,"mscId":44339,"mscName":"Greece","decisionDate":"2026-09-03T10:00:02.074","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":318812,"part1Id":135393,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":140755,"applicationId":88720,"mscId":44344,"mscName":"Poland","decisionDate":"2026-09-07T10:12:00.32","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":318813,"part1Id":135393,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":142648,"applicationId":88720,"mscId":44342,"mscName":"Portugal","decisionDate":"2026-09-18T18:42:42.273","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":336652,"part1Id":135393,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":144965,"applicationId":88720,"mscId":44341,"mscName":"Italy","decisionDate":"2026-10-05T12:37:20.605","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":339675,"part1Id":135393,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":false},{"id":143832,"applicationId":88720,"mscId":44335,"mscName":"Belgium","decisionDate":"2026-09-28T11:11:48.757","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":338051,"part1Id":135393,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true}],"productRoleGroupDocument":[{"documentUuid":"1d4302fe-22e0-4260-8924-6fa29108e38f","productRoleGroupId":418803},{"documentUuid":"0259d6d3-226f-4bb1-802a-6ab12f5d2a5b","productRoleGroupId":418803},{"documentUuid":"d7e70c4d-397e-4a7a-8e7e-dae538ea1a66","productRoleGroupId":418801},{"documentUuid":"f2006804-f26f-4333-adb3-8235f82e1ad8","productRoleGroupId":418801}]}],"trialGlobalEnd":[],"memberStatesConcerned":[{"mscName":"Belgium","mscId":44335,"firstDecisionDate":"2025-10-06T16:40:02.969","lastDecisionDate":"2026-09-28T11:11:48.757","mscPublicStatusCode":4},{"mscName":"Austria","mscId":44334,"firstDecisionDate":"2025-10-13T10:51:41.31","lastDecisionDate":"2026-09-21T13:17:01.624","mscPublicStatusCode":4},{"mscName":"Italy","mscId":44341,"firstDecisionDate":"2025-10-09T14:22:53.209","lastDecisionDate":"2026-10-05T12:37:20.605","mscPublicStatusCode":4},{"mscName":"Poland","mscId":44344,"firstDecisionDate":"2025-10-10T12:47:25.464","lastDecisionDate":"2026-09-07T10:12:00.32","mscPublicStatusCode":4},{"mscName":"Spain","mscId":44343,"firstDecisionDate":"2025-10-08T13:14:35.794","lastDecisionDate":"2026-09-07T17:30:35.387","mscPublicStatusCode":4},{"mscName":"Germany","mscId":44338,"firstDecisionDate":"2025-10-09T15:43:50.96","lastDecisionDate":"2026-09-07T16:24:54.38","mscPublicStatusCode":4},{"mscName":"Czechia","mscId":44336,"firstDecisionDate":"2025-10-08T10:48:19.325","lastDecisionDate":"2026-09-02T13:21:31.35","mscPublicStatusCode":4},{"mscName":"Ireland","mscId":44340,"firstDecisionDate":"2025-10-10T11:13:17.659","lastDecisionDate":"2026-09-08T11:09:33.048","mscPublicStatusCode":4},{"mscName":"Greece","mscId":44339,"firstDecisionDate":"2025-10-08T13:37:46.785","lastDecisionDate":"2026-09-03T10:00:02.074","mscPublicStatusCode":4},{"mscName":"France","mscId":44337,"firstDecisionDate":"2025-10-13T18:39:06.422","lastDecisionDate":"2026-09-01T17:37:31.353","mscPublicStatusCode":4},{"mscName":"Portugal","mscId":44342,"firstDecisionDate":"2025-10-06T17:43:30.812","lastDecisionDate":"2026-09-18T18:42:42.273","mscPublicStatusCode":4}],"eudraCt":{"isTransitioned":false}},"events":{"temporaryHaltList":[],"trialEvents":[{"mscId":44334,"mscName":"Austria","events":[{"notificationType":"START_OF_TRIAL","date":"2025-12-19"},{"notificationType":"START_OF_RECRUITMENT","date":"2026-01-14"}]},{"mscId":44335,"mscName":"Belgium","events":[{"notificationType":"START_OF_TRIAL","date":"2025-12-01"},{"notificationType":"START_OF_RECRUITMENT","date":"2026-01-21"}]},{"mscId":44336,"mscName":"Czechia","events":[{"notificationType":"START_OF_TRIAL","date":"2026-03-17"},{"notificationType":"START_OF_RECRUITMENT","date":"2026-09-08"}]},{"mscId":44337,"mscName":"France","events":[{"notificationType":"START_OF_TRIAL","date":"2025-12-22"},{"notificationType":"START_OF_RECRUITMENT","date":"2026-02-03"}]},{"mscId":44338,"mscName":"Germany","events":[{"notificationType":"START_OF_TRIAL","date":"2026-01-22"},{"notificationType":"START_OF_RECRUITMENT","date":"2026-05-15"}]},{"mscId":44339,"mscName":"Greece","events":[{"notificationType":"START_OF_TRIAL","date":"2026-04-30"},{"notificationType":"START_OF_RECRUITMENT","date":"2026-06-22"}]},{"mscId":44340,"mscName":"Ireland","events":[{"notificationType":"START_OF_TRIAL","date":"2025-12-19"},{"notificationType":"START_OF_RECRUITMENT","date":"2026-02-23"}]},{"mscId":44341,"mscName":"Italy","events":[{"notificationType":"START_OF_TRIAL","date":"2025-11-27"},{"notificationType":"START_OF_RECRUITMENT","date":"2025-12-23"}]},{"mscId":44342,"mscName":"Portugal","events":[{"notificationType":"START_OF_TRIAL","date":"2025-11-07"},{"notificationType":"START_OF_RECRUITMENT","date":"2025-11-20"}]},{"mscId":44343,"mscName":"Spain","events":[{"notificationType":"START_OF_TRIAL","date":"2025-12-12"},{"notificationType":"START_OF_RECRUITMENT","date":"2025-12-30"}]},{"mscId":44344,"mscName":"Poland","events":[{"notificationType":"START_OF_TRIAL","date":"2025-11-11"},{"notificationType":"START_OF_RECRUITMENT","date":"2026-02-13"}]}],"unexpectedEvents":[],"seriousBreaches":[],"urgentSafetyMeasures":[]},"results":{},"documents":[{"title":"D1_Protocol_2024-519654-37_redacted","uuid":"76110eef-781d-4fdc-a319-0fac9c90ae74","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"3.0","systemVersion":"4"},{"title":"D1_Protocol_EL_2024-519654-37_redacted","uuid":"6edb74b6-66e1-43ed-acf7-4a64497fb42f","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":32,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"3.0","systemVersion":"4"},{"title":"D1_Placebo justification_2024-519654-37_Redacted","uuid":"b0fe7db9-c03d-4a85-a408-d00a83f68413","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1.0","systemVersion":"1"},{"title":"D4_Patient facing document_EORTC_QLQ-C30_AT_Redacted","uuid":"55358804-9bab-4f01-a1c3-b3b0468322eb","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_EORTC_QLQ-C30_BEL_Du_Redacted","uuid":"2fb9ea1a-e15e-485b-947b-03434a437cbe","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_EORTC_QLQ-C30_BEL_Fr_Redacted","uuid":"08aa28c8-4023-40c5-a43e-45d5bfb49d0d","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_EORTC_QLQ-C30_CZ_Redacted","uuid":"c626e46a-7270-499d-94f5-16c23f9c350e","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_EORTC_QLQ-C30_DE_Redacted","uuid":"1121fcd5-dfad-43ab-9c48-43afd6faaddd","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_EORTC_QLQ-C30_EL_Redacted","uuid":"20710754-6c95-4dce-a3df-dc0a58f52d86","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_EORTC_QLQ-C30_ES_Redacted","uuid":"f8a3b314-2318-49b0-9e2a-f3bcef734ea0","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_EORTC_QLQ-C30_FR_Redacted","uuid":"0d5ff841-0577-488f-a8f4-17a34a2cad22","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_EORTC_QLQ-C30_IE_Redacted","uuid":"0d2abcf0-97f2-4211-822e-a8d341f278be","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_EORTC_QLQ-C30_IT_Redacted","uuid":"dcd46eba-2ee6-4166-aa86-9f6ac773afe3","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_EORTC_QLQ-C30_PL_Redacted","uuid":"4fa5afb5-76c8-4e95-a213-f969d32c6281","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_EORTC_QLQ-C30_PT_Redacted","uuid":"d86a0f92-4e34-4cbc-83f9-079716419f99","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_EORTC_QLQ-H_N35_AT_Redacted","uuid":"6e71ad09-667f-4329-8028-a7bc5f123c11","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_EORTC_QLQ-H_N35_BEL_Du_Redacted","uuid":"206538d6-12a2-4b75-8b3a-0995cbe4e68c","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_EORTC_QLQ-H_N35_BEL_Fr_Redacted","uuid":"f1660601-7bcb-4ef8-852e-b2fb298c37d0","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_EORTC_QLQ-H_N35_CZ_Redacted","uuid":"7acbcbf4-35a6-4e48-8038-259327654ac6","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_EORTC_QLQ-H_N35_DE_Redacted","uuid":"4ebd66b1-ad78-4597-baec-d67e7b671cc4","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_EORTC_QLQ-H_N35_EL_Redacted","uuid":"3623d1a8-2eb7-474f-8e1d-697881c0a743","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_EORTC_QLQ-H_N35_ES_Redacted","uuid":"d04ec622-8425-4d21-b210-2ec99fee7352","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_EORTC_QLQ-H_N35_FR_Redacted","uuid":"f25ce3e7-d0b1-45ea-9401-65d92216f3c1","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_EORTC_QLQ-H_N35_IE_Redacted","uuid":"305220a2-da60-4246-a72e-357ed42bcc11","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_EORTC_QLQ-H_N35_IT_Redacted","uuid":"db31ab1b-96ae-4928-bd8c-01eaa909a212","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_EORTC_QLQ-H_N35_PL_Redacted","uuid":"16bac6a2-1deb-493d-b2ab-001203be943e","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_EORTC_QLQ-H_N35_PT_Redacted","uuid":"c2db198f-357c-4f4c-8405-6cbceb15aa7f","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_EQ-5D-5L_AT_Redacted","uuid":"c0ae6164-cb33-40d1-afc5-4a23687d67e8","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_EQ-5D-5L_BEL_Du_Redacted","uuid":"31f4976e-bf13-48b9-b05f-4380ce7a0d24","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_EQ-5D-5L_BEL_Fr_Redacted","uuid":"d38ef766-aadf-4c82-b714-df059322b858","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_EQ-5D-5L_CZ_Redacted","uuid":"36c6e5e0-9f53-4e7d-99af-f31dca88dba1","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_EQ-5D-5L_DE_Redacted","uuid":"88b7fadf-4d7a-4ed4-be07-a31c76e5a281","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_EQ-5D-5L_EL_Redacted","uuid":"0ee22513-e391-4bf6-85e9-cf091f59e93b","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_EQ-5D-5L_ES_Redacted","uuid":"03f9a2bb-5b94-46c2-ac4c-28a596ed9143","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_EQ-5D-5L_FR_Redacted","uuid":"a3836499-7b1c-41b0-b2cf-73ab0b472cc0","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_EQ-5D-5L_IE_Redacted","uuid":"c63583cc-a3f5-47fe-9696-292563862daa","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_EQ-5D-5L_IT_Redacted","uuid":"c88b52d8-16dc-4af5-bd59-3bc5fe95de9d","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_EQ-5D-5L_PL_Redacted","uuid":"873b0e8f-cb94-49b6-b8c3-76a766fed5d1","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_EQ-5D-5L_PT_Redacted","uuid":"11c98450-0c2c-4172-862d-fb34ea236a37","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_Main Menu Screenshots_AT_Redacted","uuid":"1da47285-baef-4afd-ae4b-c49fe48d89ea","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1.0","systemVersion":"1"},{"title":"D4_Patient facing document_Main Menu Screenshots_BEL_Du_Redacted","uuid":"4ce2fc41-5f7f-4f85-a64b-658c69344e58","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1.0","systemVersion":"1"},{"title":"D4_Patient facing document_Main Menu Screenshots_BEL_Fr_Redacted","uuid":"950deb14-8996-444f-af8d-5672cd5f776e","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1.0","systemVersion":"1"},{"title":"D4_Patient facing document_Main Menu Screenshots_CZ_Redacted","uuid":"744800fd-f5f6-41b5-b4e2-6127d6ed98c8","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1.0","systemVersion":"1"},{"title":"D4_Patient facing document_Main Menu Screenshots_DE_Redacted","uuid":"6e4fd25d-db7c-4268-9ac2-0ad53317efaa","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1.0","systemVersion":"1"},{"title":"D4_Patient facing document_Main Menu Screenshots_EL_Redacted","uuid":"24f206dc-9930-4d57-a933-22df0d3eb8fe","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1.0","systemVersion":"1"},{"title":"D4_Patient facing document_Main Menu Screenshots_ES_Redacted","uuid":"1df8bf98-8a0c-4a12-8dd9-c42c6e582689","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1.0","systemVersion":"1"},{"title":"D4_Patient facing document_Main Menu Screenshots_FR_Redacted","uuid":"29bf856e-bb8f-4381-bc8b-f33a3ee2aac3","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1.0","systemVersion":"1"},{"title":"D4_Patient facing document_Main Menu Screenshots_IE_Redacted","uuid":"60aa83d0-a18b-43fe-a869-b3bce3f7f52a","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1.0","systemVersion":"1"},{"title":"D4_Patient facing document_Main Menu Screenshots_IT_Redacted","uuid":"42cb1c4c-5dc1-4a36-9715-540e99b19068","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1.0","systemVersion":"1"},{"title":"D4_Patient facing document_Main Menu Screenshots_PL_Redacted","uuid":"8e5aaab0-efbc-4a4a-a044-023096a8eb6b","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1.0","systemVersion":"1"},{"title":"D4_Patient facing document_Main Menu Screenshots_PT_Redacted","uuid":"37a957f5-0bf9-4443-aec9-f02f9f715177","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1.0","systemVersion":"1"},{"title":"D4_Patient facing document_Training_AT_Redacted","uuid":"4df36506-5306-40e3-a497-39cba07d5549","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_Training_BEL_Du_Redacted","uuid":"6438f622-97ab-45f4-9dbb-fc3c3434b9aa","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_Training_BEL_Fr_Redacted","uuid":"3b95a3e2-2b79-463b-b3f2-8b5ac6871fc4","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_Training_CZ_Redacted","uuid":"6b493189-68a2-4d15-b8dd-49bec192632f","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_Training_DE_Redacted","uuid":"e56753ac-695a-481f-98e3-a6034d24c578","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_Training_EL_Redacted","uuid":"60b8f588-1a75-403d-b796-99cc203243f3","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_Training_ES_Redacted","uuid":"108bc404-8bad-4c80-9258-7e0c618d03db","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_Training_FR_Redacted","uuid":"f6f3eda0-a15b-4675-9ff7-0ff8d9605caf","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_Training_IE_Redacted","uuid":"b7c43955-bbc0-446f-83d0-d5ce91be47a3","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_Training_IT_Redacted","uuid":"5a610b2d-57e4-4ed7-8ac5-dfbbe4d165ed","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_Training_PL_Redacted","uuid":"d5cdad5d-ce18-4e36-ab0e-8de7d3281b39","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing document_Training_PT_Redacted","uuid":"4e5fd43c-ee6d-4e9a-8c83-c50695012aa9","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D1_Protocol_2024-519654-37_Addendum 1_Redacted","uuid":"9113fd7f-d9d8-48c3-9648-c52e51c2d891","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D1_ Protocol Addendum 1_EL_2024-519654-37_Redacted","uuid":"f1a8cb69-0a1c-4965-8dee-68d7c03aff75","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":32,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D1_Protocol Clarification Letter 1_2024-519654-37_redacted","uuid":"6b7d17e0-fcbb-47b2-b1df-ddaeb4ff29ab","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D1_Protocol Clarification Letter 1_EL_2024-519654-37_redacted","uuid":"68449031-8bde-4608-bd31-ff350cc2e54b","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":32,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1","systemVersion":"1"},{"title":"D1_NTF 88_Protocol_2024-519654-37_PDL1 testing_Incl Crit_Redacted","uuid":"18afa076-83b3-43f5-b8bc-a39b12f83174","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"NA","systemVersion":"0.01"},{"title":"D1_NTF 88_Protocol_EL_2024-519654-37_PDL1 testing_Incl Crit_Redacted","uuid":"98e6fe5e-a5ab-4e25-ad46-ef00a063d59f","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":32,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"NA","systemVersion":"0.01"},{"title":"D1_Protocol Lay Synopsis_AT_2024-519654-37_redacted","uuid":"ff5b1f97-a4a4-4581-a103-1f8a8bb443f3","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":27,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1.5","systemVersion":"2"},{"title":"D1_Protocol Lay Synopsis_BEL_2024-519654-37_De_redacted","uuid":"3a8e2a8e-c960-4eff-a922-aa2e700c4848","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":28,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1.5","systemVersion":"2"},{"title":"D1_Protocol Lay Synopsis_BEL_2024-519654-37_Du_redacted","uuid":"6b7ef7dd-59af-4fc8-9996-e44d73af2854","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":36,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1.5","systemVersion":"2"},{"title":"D1_Protocol Lay Synopsis_BEL_2024-519654-37_Fr_redacted","uuid":"1c7e6363-a6d1-4e2a-aca8-ccc51b4d05bf","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":33,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1.5","systemVersion":"2"},{"title":"D1_Protocol Lay Synopsis_CZ_2024-519654-37_redacted","uuid":"13c787a0-9a8f-4fdf-8e0c-16cfdc4c005c","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":2,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1.5","systemVersion":"2"},{"title":"D1_Protocol Lay Synopsis_EL_2024-519654-37_redacted","uuid":"5a8a19e1-f8f9-4027-a10d-8e5deaa1ca5d","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":32,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1.5","systemVersion":"2"},{"title":"D1_Protocol Lay Synopsis_ENG_2024-519654-37_Redacted","uuid":"67a26382-d5cd-4f26-9728-8982907c3e69","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1.5","systemVersion":"2"},{"title":"D1_Protocol Lay Synopsis_ES_2024-519654-37_redacted","uuid":"7d97730f-4e0e-47d6-9438-7e093faf3d75","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1.5","systemVersion":"2"},{"title":"D1_Protocol Lay Synopsis_FR_2024-519654-37_redacted","uuid":"78d3969e-fcc8-41dd-b2c0-dbc846ddbcac","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":34,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1.5","systemVersion":"2"},{"title":"D1_Protocol Lay Synopsis_IT_2024-519654-37_Redacted","uuid":"15b94e69-5f3d-4abc-9fb2-f4bf825b1b88","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1.5","systemVersion":"2"},{"title":"D1_Protocol Lay Synopsis_PL_2024-519654-37_redacted","uuid":"019c0925-722f-431d-b97a-1480eec6a46b","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1.5","systemVersion":"2"},{"title":"D1_Protocol Lay Synopsis_PT_2024-519654-37_Redacted","uuid":"2cd91486-56fb-4627-95e5-1a0348c9caf4","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":20,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"1.5","systemVersion":"2"},{"title":"D1_Protocol Technical Synopsis_CZ_2024-519654-37_Redacted","uuid":"81641421-16a8-453e-9f83-44655a1fc7ca","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":2,"fileType":"PDF","associatedEntityId":135393,"manualVersion":"2.0","systemVersion":"3"},{"title":"E2_Keytruda EU SmPC","uuid":"1d4302fe-22e0-4260-8924-6fa29108e38f","documentType":"19","documentTypeLabel":"Summary of Product Characteristics (SmPC) (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":418803,"manualVersion":"NA","systemVersion":"3"},{"title":"E2_EU SmPC_Keytruda_TC","uuid":"0259d6d3-226f-4bb1-802a-6ab12f5d2a5b","documentType":"19","documentTypeLabel":"Summary of Product Characteristics (SmPC) (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":418803,"manualVersion":"NA","systemVersion":"1"},{"title":"E2_Keytruda EU SmPC","uuid":"d7e70c4d-397e-4a7a-8e7e-dae538ea1a66","documentType":"19","documentTypeLabel":"Summary of Product Characteristics (SmPC) (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":418801,"manualVersion":"NA","systemVersion":"2"},{"title":"E2_EU SmPC_Keytruda_TC","uuid":"f2006804-f26f-4333-adb3-8235f82e1ad8","documentType":"19","documentTypeLabel":"Summary of Product Characteristics (SmPC) (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":418801,"manualVersion":"NA","systemVersion":"1"},{"title":"K1_Recruitment arrangements_Public","uuid":"9ff05181-6ccf-490e-83fb-fad37b9d48ad","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":318808,"manualVersion":"2.0","systemVersion":"2"},{"title":"K2_Recruitment material_Patient Brochure_Redacted","uuid":"1ccd2f9e-3eab-464c-b952-c6857be33732","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":2,"fileType":"PDF","associatedEntityId":318808,"manualVersion":"V02 CZEcs","systemVersion":"2"},{"title":"K2_Recruitment material_Video_QR Code Access_Public","uuid":"60b51ddd-4b7d-4f68-8a64-1f3b7b283f10","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":318808,"manualVersion":"1.0","systemVersion":"1"},{"title":"K2_Recruitment material_Video_Transcript_Public","uuid":"36a1072b-7a6c-4b11-91f7-6dcd4b0ae399","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":2,"fileType":"PDF","associatedEntityId":318808,"manualVersion":"1","systemVersion":"1"},{"title":"L1_SIS and ICF_DPCF_Redacted","uuid":"934518a5-daf8-4814-aff1-09e423afdda7","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":2,"fileType":"PDF","associatedEntityId":318808,"manualVersion":"5.1.0","systemVersion":"1"},{"title":"L1_SIS and ICF_Future Research_Redacted","uuid":"22aaeca0-b8d5-4339-99f4-f58ca86bf58f","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":2,"fileType":"PDF","associatedEntityId":318808,"manualVersion":"5.1.0","systemVersion":"1"},{"title":"L1_SIS and ICF_Main_Redacted","uuid":"1c4785d3-8489-4527-a485-d2c1e74a8e90","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":2,"fileType":"PDF","associatedEntityId":318808,"manualVersion":"9.6.0","systemVersion":"4"},{"title":"L1_SIS and ICF_Optional Biopsy_Redacted","uuid":"aceec7f5-0fc7-4501-a088-2c1781d0cfbe","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":2,"fileType":"PDF","associatedEntityId":318808,"manualVersion":"2.1.0","systemVersion":"1"},{"title":"L1_SIS and ICF_Pregnancy FU_Redacted","uuid":"fdf299b4-8651-4fc2-ac34-b4b0530b7b3c","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":2,"fileType":"PDF","associatedEntityId":318808,"manualVersion":"4.2.0","systemVersion":"2"},{"title":"L1_SIS and ICF_Pre-Screening_Redacted","uuid":"138c62b3-ed88-42c8-a801-2dce4b5802bc","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":2,"fileType":"PDF","associatedEntityId":318808,"manualVersion":"5.3.0","systemVersion":"3"},{"title":"L1_SIS and ICF_Withdrawal of Participation_Redacted","uuid":"11a4a5b9-a535-4221-969d-26f29a71d761","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":2,"fileType":"PDF","associatedEntityId":318808,"manualVersion":"1.1.0","systemVersion":"1"},{"title":"L1_SIS and ICF_Main_Highlighted_Redacted","uuid":"789ecdf5-7e9a-4d2e-bf8e-915dbe90fd73","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":2,"fileType":"PDF","associatedEntityId":318808,"manualVersion":"9.6.0","systemVersion":"2"},{"title":"L1_SIS and ICF_Pregnancy FU_Highlighted_Redacted","uuid":"3c71316c-49e7-48fb-a9d5-71b6e52be863","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":2,"fileType":"PDF","associatedEntityId":318808,"manualVersion":"4.2.0","systemVersion":"1"},{"title":"L1_SIS and ICF_Pre-Screening_Highlighted_Redacted","uuid":"da19352c-1a7d-4494-b440-0db46db1432d","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":2,"fileType":"PDF","associatedEntityId":318808,"manualVersion":"5.3.0","systemVersion":"2"},{"title":"K1_Recruitment arrangements_public","uuid":"0ea4bada-4cec-402a-b295-2098f52dc6b5","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":339675,"manualVersion":"2.0","systemVersion":"2"},{"title":"K2_Recruitment material_Patient Brochure_redacted","uuid":"f1af6aed-744d-4d76-841d-29f19af8b1b3","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":339675,"manualVersion":"02","systemVersion":"2"},{"title":"K2_Recruitment Material_Video_QR Code Access_Public","uuid":"3e266b97-2317-4682-a0ea-0bbed9e6abf9","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":339675,"manualVersion":"1.0","systemVersion":"1"},{"title":"K2_Recruitment Material_Video_Transcript_Public","uuid":"1276154d-e173-4190-8c65-aaec93ffe503","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":339675,"manualVersion":"1.0","systemVersion":"1"},{"title":"L1_SIS and ICF_Main_redacted","uuid":"b084b279-19b3-4187-9d92-04a41dd4f726","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":339675,"manualVersion":"9.7.0","systemVersion":"5"},{"title":"L1_SIS and ICF_Optional Future Research_redacted","uuid":"2828f445-4a39-42b8-8e2b-7910b1f68ed9","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":339675,"manualVersion":"2.2.0","systemVersion":"2"},{"title":"L1_SIS and ICF_Optional Biopsy_redacted","uuid":"78623dec-7c1c-473e-8373-81d1a46ccbb1","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":339675,"manualVersion":"2.2.0","systemVersion":"2"},{"title":"L1_SIS and ICF_Pre-Screening_redacted","uuid":"fed3eac7-5ba8-4e48-8fbb-fc9a534dec52","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":339675,"manualVersion":"5.4.0","systemVersion":"4"},{"title":"L1_SIS and ICF_Privacy_redacted","uuid":"b9c0116e-3195-4464-bbea-c98e9861ec4c","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":339675,"manualVersion":"9.3.0","systemVersion":"3"},{"title":"L1_SIS and ICF_PGx_redacted","uuid":"003c90f4-b94a-45e3-b383-dc8259be470f","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":339675,"manualVersion":"3.2.0","systemVersion":"2"},{"title":"L2_Other subject information material_GP Letter_redacted","uuid":"9a83c4fa-9243-4f6f-861b-f742097ac2ae","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":339675,"manualVersion":"3.0","systemVersion":"3"},{"title":"L1_SIS and ICF_Withdrawal of Samples_redacted","uuid":"700113fd-4721-4a45-b2e5-b1bd489c33ae","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":339675,"manualVersion":"1.2.0","systemVersion":"2"},{"title":"L1_SIS and ICF_Pregnant Partner_redacted","uuid":"b175b646-d158-413b-b0ee-65ace4087ed9","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":339675,"manualVersion":"4.3.0","systemVersion":"3"},{"title":"L1_SIS and ICF_Withdrawal of Participation_public","uuid":"59652216-05f5-4f12-8534-cecc5498220d","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":14,"fileType":"PDF","associatedEntityId":339675,"manualVersion":"1.2.0","systemVersion":"2"},{"title":"K1_Recruitment Arrangements_public","uuid":"9db38067-84df-4650-ad56-cec9c64d21e2","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":318811,"manualVersion":"2.0","systemVersion":"2"},{"title":"K2_Recruitment Material_Patient Brochure_redacted","uuid":"bc8d40a5-a752-4fb4-84e1-660ed1d8aae1","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":4,"fileType":"PDF","associatedEntityId":318811,"manualVersion":"02","systemVersion":"2"},{"title":"K2_Recruitment Material_Video_Transcript_public","uuid":"7a109896-107c-4df0-97c0-36063d921f7d","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":4,"fileType":"PDF","associatedEntityId":318811,"manualVersion":"2.0","systemVersion":"1"},{"title":"K2_Recruitment Material_Video_QR Access Code_public","uuid":"e589fd40-7695-4995-ba11-a7831ed52ddd","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":318811,"manualVersion":"1.0","systemVersion":"1"},{"title":"L1_SIS and ICF_Main_redacted","uuid":"6ebeb238-18df-44d3-8d6b-fec30d0dd12e","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":4,"fileType":"PDF","associatedEntityId":318811,"manualVersion":"9.7.0","systemVersion":"6"},{"title":"L1_SIS and ICF_Opt Biopsy_redacted","uuid":"d7f0bb0b-d25e-4189-a97a-b246dba19f43","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":4,"fileType":"PDF","associatedEntityId":318811,"manualVersion":"2.2.0","systemVersion":"2"},{"title":"L1_SIS and ICF_PGx_redacted","uuid":"76125543-e235-49e4-9224-a76b449c5d6d","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":4,"fileType":"PDF","associatedEntityId":318811,"manualVersion":"3.3.0","systemVersion":"3"},{"title":"L1_SIS and ICF_Opt Future Research_redacted","uuid":"ae6f0d6b-5317-4c3b-9316-0735de92114d","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":4,"fileType":"PDF","associatedEntityId":318811,"manualVersion":"1.2.0","systemVersion":"2"},{"title":"L1_SIS and ICF_PP_redacted","uuid":"5ad07541-c323-4550-aa32-39d70ee13ad7","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":4,"fileType":"PDF","associatedEntityId":318811,"manualVersion":"4.4.0","systemVersion":"4"},{"title":"L1_SIS and ICF_Patient Reimbursement_redacted","uuid":"37c57c41-aba2-4b00-81ca-576c87063442","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":4,"fileType":"PDF","associatedEntityId":318811,"manualVersion":"1.3.0","systemVersion":"3"},{"title":"L1_SIS and ICF_Prescreen_redacted","uuid":"f349f44e-7593-488a-9f92-4de59d00acc1","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":4,"fileType":"PDF","associatedEntityId":318811,"manualVersion":"5.7.0","systemVersion":"6"},{"title":"K1_Recruitment arrangements_Public","uuid":"0cca5f5d-a6b5-4976-b328-1ee892200bfe","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":336652,"manualVersion":"2.0","systemVersion":"2"},{"title":"K2_Recruitment material_Patient Brochure_redacted","uuid":"de6102ac-7650-4cb4-b439-44160afbc44d","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":336652,"manualVersion":"02","systemVersion":"2"},{"title":"K2_Recruitment material_Patient Brochure_redacted","uuid":"ab7e24b4-c368-4250-8c53-2f264501e7c5","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":20,"fileType":"PDF","associatedEntityId":336652,"manualVersion":"02","systemVersion":"2"},{"title":"K2_Recruitment material_Video_QR Codes Access_Public","uuid":"e8f9ba36-208a-4c55-93b0-5982c23ccc64","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":336652,"manualVersion":"1.0","systemVersion":"1"},{"title":"K2_Recruitment material_Video_Transcript_Public","uuid":"4d39bc75-fbf3-47fc-adf2-ef34ac40dec6","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":20,"fileType":"PDF","associatedEntityId":336652,"manualVersion":"3.0","systemVersion":"3"},{"title":"L1_SIS and ICF_Main_redacted","uuid":"8367b6f6-185c-41d1-a40c-fb506ee10122","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":336652,"manualVersion":"9.6.0","systemVersion":"6"},{"title":"L1_SIS and ICF_Main_redacted","uuid":"ab97e424-0ba8-4454-863e-e8e58a0d0234","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":20,"fileType":"PDF","associatedEntityId":336652,"manualVersion":"9.6.0","systemVersion":"5"},{"title":"L1_SIS and ICF_Optional Biopsy_redacted","uuid":"02ba9816-1587-4352-b6ad-ad4f9b44c71f","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":336652,"manualVersion":"2.1.0","systemVersion":"1"},{"title":"L1_SIS and ICF_Optional Biopsy_redacted","uuid":"9aa209e5-bf4c-4aa6-a5eb-a516cb51dbee","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":20,"fileType":"PDF","associatedEntityId":336652,"manualVersion":"2.1.0","systemVersion":"1"},{"title":"L1_SIS and ICF_PGx_redacted","uuid":"c3c4ee20-f0a0-480c-bf84-648a3a565977","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":336652,"manualVersion":"3.1.0","systemVersion":"1"},{"title":"L1_SIS and ICF_PGx_redacted","uuid":"0baed6cd-8d41-4aff-9b31-3693bda31ac2","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":20,"fileType":"PDF","associatedEntityId":336652,"manualVersion":"3.1.0","systemVersion":"1"},{"title":"L1_SIS and ICF_PP_redacted","uuid":"4edaddb4-1416-462d-8150-5ef89300e686","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":336652,"manualVersion":"4.2.0","systemVersion":"2"},{"title":"L1_SIS and ICF_PP_redacted","uuid":"dcf3b918-a910-45da-b87a-6e6942d012bf","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":20,"fileType":"PDF","associatedEntityId":336652,"manualVersion":"4.2.0","systemVersion":"2"},{"title":"L1_SIS and ICF_Pre-screening_redacted","uuid":"05df5ee1-a306-4fc9-8529-686abb4b5204","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":336652,"manualVersion":"5.4.0","systemVersion":"4"},{"title":"L1_SIS and ICF_Pre-screening_redacted","uuid":"21b184bd-2916-487a-8f63-a86a5b321acb","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":20,"fileType":"PDF","associatedEntityId":336652,"manualVersion":"5.4.0","systemVersion":"4"},{"title":"L1_SIS and ICF_Withdrawal of Participation_public","uuid":"b833bd0d-80e2-4a2a-a23f-3686aa920a53","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":336652,"manualVersion":"1.1.0","systemVersion":"1"},{"title":"L1_SIS and ICF_Withdrawal of Participation_public","uuid":"d9bc5517-ff53-45a0-a3f7-60ac21b6c989","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":20,"fileType":"PDF","associatedEntityId":336652,"manualVersion":"1.1.0","systemVersion":"1"},{"title":"L1_SIS and ICF_Withdrawal of Samples_redacted","uuid":"b5bbf6b1-65d4-42fc-a374-954475a71f76","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":336652,"manualVersion":"1.1.0","systemVersion":"1"},{"title":"L1_SIS and ICF_Withdrawal of Samples_redacted","uuid":"62fa47d7-7065-48c6-b260-a5ff0837e397","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":20,"fileType":"PDF","associatedEntityId":336652,"manualVersion":"1.1.0","systemVersion":"1"},{"title":"L2_Other subject information material_GP Letter_redacted","uuid":"8e64ccb5-43c9-4a75-9464-9b7f4167d6c3","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":20,"fileType":"PDF","associatedEntityId":336652,"manualVersion":"3.0","systemVersion":"3"},{"title":"L2_Other subject information material_Subject ID Card_public","uuid":"53e8aeca-b347-43c5-9acf-82f155bc0683","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":336652,"manualVersion":"1.0","systemVersion":"1"},{"title":"L2_Other subject information material_Subject ID Card_public","uuid":"d5ccb5e0-da27-44d6-b90a-0d473f54db2d","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":20,"fileType":"PDF","associatedEntityId":336652,"manualVersion":"1.0","systemVersion":"1"},{"title":"K1_Recruitment arragements_Public","uuid":"e636be0b-81fd-4b24-8519-20e005326dab","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":318809,"manualVersion":"02","systemVersion":"2"},{"title":"K2_Recruitment material_Patient Brochure_Redacted","uuid":"cb995e33-691b-43a5-8719-7dd9bc47e60f","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":318809,"manualVersion":"02","systemVersion":"2"},{"title":"K2_Recruitment material QR Codes and Link","uuid":"e56d445c-8b9a-45f9-8c33-541be5cb53c1","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":318809,"manualVersion":"1_0","systemVersion":"1"},{"title":"K2_Recruitment material Video transcript","uuid":"a8787167-6928-4283-a93c-350257b4aa09","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":318809,"manualVersion":"1_0","systemVersion":"1"},{"title":"L1_SIS and ICF_Main_Clean_Redacted","uuid":"3ebe083e-0c99-4761-b048-5284f7cbd37e","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":318809,"manualVersion":"9.6.0","systemVersion":"5"},{"title":"L1_SIS and ICF_Prescreening_Clean_Redacted","uuid":"57c4ddb1-d543-41d1-8257-272b7eea877b","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":318809,"manualVersion":"5.4.0","systemVersion":"5"},{"title":"L1_SIS and ICF_Pharmacogenetic_Clean_Redacted","uuid":"a9dd0d9f-1851-4ca4-8305-0cc9ee8493bc","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":318809,"manualVersion":"3.1.0","systemVersion":"1"},{"title":"L1_SIS and ICF_Pregnant Partner_Clean_Redacted","uuid":"41282d87-9c2b-43b8-9c59-1d0830d2ff06","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":318809,"manualVersion":"4.2.0","systemVersion":"2"},{"title":"L1_SIS and ICF_Reimbursement Participant_Clean_Redacted","uuid":"6d970e3b-8cb2-4f59-bc28-b6d5a28eeafb","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":318809,"manualVersion":"1.0","systemVersion":"1"},{"title":"L1_SIS and ICF_Reimbursement Caregiver_Clean_Redacted","uuid":"aac2ba77-688b-4aeb-a9c0-444a8674ce26","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":7,"fileType":"PDF","associatedEntityId":318809,"manualVersion":"1.0","systemVersion":"1"},{"title":"K1_Recruitment arrangements_Public","uuid":"2f35f165-643f-4a57-a7e5-07abc7edf3fa","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":318804,"manualVersion":"2","systemVersion":"2"},{"title":"K2_Recruitment material Patient Brochure_Redacted","uuid":"caa079d1-4eb0-4536-953d-63d5159534c8","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":318804,"manualVersion":"V02","systemVersion":"2"},{"title":"K2_Recruitment Material_Video_QR Code Access_Public","uuid":"a94e7157-128c-4f89-9ce5-cb8c9b870afd","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":318804,"manualVersion":"1-0","systemVersion":"1"},{"title":"K2_Recruitment Material_Video_Transcript_Public","uuid":"67904a22-d0c6-47b5-8cd9-28c900d8f8fc","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":318804,"manualVersion":"1-0","systemVersion":"1"},{"title":"L1_SIS and ICF_Withdrawal of Participation_public","uuid":"93208781-6847-46b4-b905-1c9d0628a880","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":318804,"manualVersion":"1-2-0","systemVersion":"2"},{"title":"L1_SIS and ICF_Withdrawal of Samples_Redacted","uuid":"9bae4a0c-30a8-49bf-bea1-cd9bfdc98962","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":318804,"manualVersion":"1-2-0","systemVersion":"2"},{"title":"L1_SIS and ICF_PGx_Redacted","uuid":"883896d8-363d-4ca4-8267-af595d846dd9","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":318804,"manualVersion":"3-3-0","systemVersion":"3"},{"title":"L1_SIS and ICF_Pregnant Partner_Redacted","uuid":"9634bb51-b9c5-41d2-bf02-b451fc5b79bb","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":318804,"manualVersion":"4-4-0","systemVersion":"5"},{"title":"L1_SIS and ICF_Pre-Screen_Redacted","uuid":"664d9852-f350-497f-816e-e5f2de02dc05","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":318804,"manualVersion":"5-5-0","systemVersion":"5"},{"title":"L1_SIS and ICF_Main_Redacted","uuid":"00a4e3b9-997a-4ff0-856d-afd8fc5fdf50","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":318804,"manualVersion":"9-6-0","systemVersion":"6"},{"title":"L1_SIS and ICF_Future Research_redacted","uuid":"69f45d93-5a0b-40f4-9033-e8a6611cbd37","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":318804,"manualVersion":"5-1-0","systemVersion":"1"},{"title":"L1_SIS and ICF_Greenphire_redacted","uuid":"f7c3893a-6e0a-44d9-a812-965aaccf1401","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":318804,"manualVersion":"1-1-0","systemVersion":"1"},{"title":"L1_SIS and ICF_Pregnant Participant_redacted","uuid":"06f2de17-07aa-4ab1-96c2-905360601e82","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":318804,"manualVersion":"3-1-0","systemVersion":"1"},{"title":"K1_Recruitment Arrangements_Public","uuid":"af65516a-ae4e-40c3-aa89-30ae81182029","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":318813,"manualVersion":"2.0","systemVersion":"2"},{"title":"K2_Recruitment material_Patient Brochure_redacted","uuid":"d9493055-411e-4822-ba2c-cab609002bdb","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":318813,"manualVersion":"V02","systemVersion":"2"},{"title":"K2_Recruitment material_QR_Code_and_Link_public","uuid":"45a633ad-62c6-4d64-94bb-1ffdfbf58e45","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":318813,"manualVersion":"1.0","systemVersion":"1"},{"title":"K2_Recruitment material_Study_Script_public","uuid":"212e0a65-dcb5-47d2-acb1-127c6405d15f","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":318813,"manualVersion":"01","systemVersion":"1"},{"title":"L1_SIS and ICF_Main_redacted","uuid":"7a6bc209-8bcd-4643-a0b5-49b3a82ac35b","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":318813,"manualVersion":"9.7.0","systemVersion":"4"},{"title":"L1_SIS and ICF_Optional Biopsy_redacted","uuid":"2bb34350-e3af-4fa3-a7a2-5eb69cb86aac","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":318813,"manualVersion":"3.2.0","systemVersion":"2"},{"title":"L1_SIS and ICF_Pharmacogenetics_redacted","uuid":"264b9171-dd13-472f-9a0b-410dd2b1f3f7","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":318813,"manualVersion":"3.1.0","systemVersion":"1"},{"title":"L1_SIS and ICF_Pregnancy and Pregnant Partner_redacted","uuid":"83dcd80f-bc76-4b90-afb2-3c6f985473af","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":318813,"manualVersion":"4.3.0","systemVersion":"3"},{"title":"L1_SIS and ICF_Prescreening_redacted","uuid":"ea8c8698-9757-40a9-b6be-7782d661bfd2","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":318813,"manualVersion":"5.5.0","systemVersion":"4"},{"title":"L1_SIS and ICF_Withdrawal of Participation_redacted","uuid":"b5e38635-7c3a-4864-8650-9f556e791657","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":318813,"manualVersion":"1.1.0","systemVersion":"1"},{"title":"L1_SIS and ICF_Withdrawal of Samples_redacted","uuid":"3d5f2211-c712-43ed-b95c-7a7a6bf2ca35","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":19,"fileType":"PDF","associatedEntityId":318813,"manualVersion":"1.1.0","systemVersion":"1"},{"title":"K1_Recruitment Arrangements_Public","uuid":"730e5038-2b14-4243-97b9-77d51a6fcee6","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":338051,"manualVersion":"2.0","systemVersion":"2"},{"title":"K2_Recruitment Material_Patient Brochure_FR_Redacted","uuid":"8b2bfa68-600b-425f-af01-a2f722d40ab4","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":33,"fileType":"PDF","associatedEntityId":338051,"manualVersion":"02","systemVersion":"2"},{"title":"K2_Recruitment Material_Patient Brochure_DU_Redacted","uuid":"7a3a8540-0b15-4cb6-87f6-947dc77f4ff1","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":36,"fileType":"PDF","associatedEntityId":338051,"manualVersion":"02","systemVersion":"2"},{"title":"K2_Recruitment Material_Patient Brochure_EN_Redacted","uuid":"2e4fc429-7b7c-46f8-87db-cf7e155bccc8","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":338051,"manualVersion":"02","systemVersion":"2"},{"title":"K2_Recruitment Material_Video_Transcript_EN_Public","uuid":"7ed64181-f3ac-4603-bed9-37e7221053b3","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":338051,"manualVersion":"1.0","systemVersion":"1"},{"title":"K2_Recruitment Material_Video_Transcript_FR_Public","uuid":"bdb4d2f0-8e89-498c-bb65-ab69af9cd22c","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":33,"fileType":"PDF","associatedEntityId":338051,"manualVersion":"1.0","systemVersion":"1"},{"title":"K2_Recruitment Material_Video_Transcript_DU_Public","uuid":"9087b3a5-556c-404a-acea-8b1eb958df8b","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":36,"fileType":"PDF","associatedEntityId":338051,"manualVersion":"1.0","systemVersion":"1"},{"title":"K2_Recruitment Material_Video_QR Code Access_Public","uuid":"65d7d573-56c6-4b0b-ae70-47bb8cbeed6e","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":338051,"manualVersion":"1.0","systemVersion":"1"},{"title":"L1_SIS and ICF_Main_EN_Redacted","uuid":"6788904c-9b5a-4311-94c9-e5ea98f337e6","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":338051,"manualVersion":"9.6.0","systemVersion":"5"},{"title":"L1_SIS and ICF_Main_DU_Redacted","uuid":"5b0ee6dd-6911-4c5e-94ca-f1c5046693e1","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":36,"fileType":"PDF","associatedEntityId":338051,"manualVersion":"9.6.0","systemVersion":"5"},{"title":"L1_SIS and ICF_Main_FR_Redacted","uuid":"11317e6f-76b1-4a2e-aa8d-27c1bf4faa46","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":33,"fileType":"PDF","associatedEntityId":338051,"manualVersion":"9.6.0","systemVersion":"5"},{"title":"L1_SIS and ICF_Pregnancy FU_DU_Redacted","uuid":"b83405e4-b760-4ec7-91d1-7897bc314b3b","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":36,"fileType":"PDF","associatedEntityId":338051,"manualVersion":"4.4.0","systemVersion":"4"},{"title":"L1_SIS and ICF_Pregnancy FU_FR_Redacted","uuid":"6dfb9b61-7c8b-4f53-8500-b150eb569815","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":33,"fileType":"PDF","associatedEntityId":338051,"manualVersion":"4.4.0","systemVersion":"4"},{"title":"L1_SIS and ICF_Pregnancy FU_EN_Redacted","uuid":"4f367a34-adb1-4dec-91be-7c8e2aebe226","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":338051,"manualVersion":"4.4.0","systemVersion":"4"},{"title":"L1_SIS and ICF_Pre-Screening_EN_Redacted","uuid":"279d9c69-8164-4491-b43c-11e499e7487e","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":338051,"manualVersion":"5.5.0","systemVersion":"4"},{"title":"L1_SIS and ICF_Pre-Screening_DU_Redacted","uuid":"d36df899-d7aa-4170-8b61-8ac6a926a517","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":36,"fileType":"PDF","associatedEntityId":338051,"manualVersion":"5.5.0","systemVersion":"4"},{"title":"L1_SIS and ICF_Pre-Screening_FR_Redacted","uuid":"5cce53f6-ee02-45a1-ac80-3491519124d2","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":33,"fileType":"PDF","associatedEntityId":338051,"manualVersion":"5.5.0","systemVersion":"4"},{"title":"L1_SIS and ICF_Sponsor Statement_Redacted","uuid":"5a67d528-860c-487b-9abe-a31b66368825","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":338051,"manualVersion":"1.0","systemVersion":"1"},{"title":"K2_Recruitment material Patient Brochure_redacted","uuid":"5c22f349-8aa1-4dd3-a541-c412fcb3e715","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":27,"fileType":"PDF","associatedEntityId":339762,"manualVersion":"02","systemVersion":"2"},{"title":"K1_Recruitment arrangements and consent_Public","uuid":"e3b74708-bbe6-4b0f-8c25-260c2d41bbef","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":339762,"manualVersion":"2.0","systemVersion":"2"},{"title":"K2_Recruitment Material_Video_QR Code Link_public","uuid":"28cfb83e-49c2-4d0e-aa4c-f9c80ee0fb49","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":339762,"manualVersion":"1.0","systemVersion":"1"},{"title":"K2_Recruitment Material_Video_Transcript_public","uuid":"e4916ce1-a74c-4d6f-9e26-2e3da0c56f6f","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":27,"fileType":"PDF","associatedEntityId":339762,"manualVersion":"2.0","systemVersion":"1"},{"title":"L1_SIS and ICF_Future Research ICF_Redacted","uuid":"15119898-01af-4327-a82a-b33c7adcae35","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":27,"fileType":"PDF","associatedEntityId":339762,"manualVersion":"5.3.0","systemVersion":"3"},{"title":"L1_SIS and ICF_PGx ICF_Redacted","uuid":"12c20917-fba2-497b-b108-d15336093ea2","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":27,"fileType":"PDF","associatedEntityId":339762,"manualVersion":"3.3.0","systemVersion":"3"},{"title":"L1_SIS and ICF_Withdrawal Participation_Redacted","uuid":"00000a6c-69d5-4b86-a596-0276247d26fd","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":27,"fileType":"PDF","associatedEntityId":339762,"manualVersion":"1.4.0","systemVersion":"4"},{"title":"L1_SIS and ICF_Withdrawal Samples_Redacted","uuid":"76b6388c-5200-4cc5-89f3-f58c4ad82030","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":27,"fileType":"PDF","associatedEntityId":339762,"manualVersion":"1.4.0","systemVersion":"4"},{"title":"L1_SIS and ICF_Site Information ICF_Investigator Fureder_MedUniWien_Redacted","uuid":"6c8e04d4-4154-40d8-859b-fd9d03dc275c","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":27,"fileType":"PDF","associatedEntityId":339762,"manualVersion":"1.0","systemVersion":"1"},{"title":"L1_SIS and ICF_Site Information ICF_Investigator Melchardt_Salzburg_Redacted","uuid":"fd12bdb9-655b-42b4-abb1-288ca3bf7865","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":27,"fileType":"PDF","associatedEntityId":339762,"manualVersion":"2.0","systemVersion":"2"},{"title":"L1_SIS and ICF_Main ICF_Redacted","uuid":"67d39b25-d3d6-4c11-b4c1-0489b98fa160","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":27,"fileType":"PDF","associatedEntityId":339762,"manualVersion":"9.9.0","systemVersion":"7"},{"title":"L1_SIS and ICF_PreScreen ICF_Redacted","uuid":"6ce2052a-75a5-454e-a301-fab14342ea63","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":27,"fileType":"PDF","associatedEntityId":339762,"manualVersion":"5.6.0","systemVersion":"5"},{"title":"L1_SIS and ICF_PP ICF_Redacted","uuid":"6f562507-7197-47aa-9a4e-944809b41905","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":27,"fileType":"PDF","associatedEntityId":339762,"manualVersion":"4.4.0","systemVersion":"4"},{"title":"L1_SIS and ICF_Optional Biopsy ICF_Redacted","uuid":"35887c9e-65a6-4308-88d9-5a8e0c32b580","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":27,"fileType":"PDF","associatedEntityId":339762,"manualVersion":"2.3.0","systemVersion":"4"},{"title":"L1_SIS and ICF_Patient Reimbursement_Redacted","uuid":"41a99fdb-96c5-480a-848f-21d13785f7de","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":27,"fileType":"PDF","associatedEntityId":339762,"manualVersion":"1.3.0","systemVersion":"3"},{"title":"K1_Recruitment Arrangements_Public","uuid":"8a6920e3-c3ab-4c27-8045-64a659745159","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":318812,"manualVersion":"2.0","systemVersion":"2"},{"title":"K2_Recruitment Material_Patient Brochure_Redacted","uuid":"b813ea92-cd85-4f90-b38b-b0ccb13dd101","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":5,"fileType":"PDF","associatedEntityId":318812,"manualVersion":"2.0","systemVersion":"2"},{"title":"K2_ Recruitment material_Physician Referral Letter_Redacted","uuid":"62b52efb-5f2e-4c1c-8dae-a9c3cd815973","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":318812,"manualVersion":"02","systemVersion":"1"},{"title":"K2_Recruitment Material_Study Talking Points Guide_Redacted","uuid":"a84b3d90-57a6-4789-bfc5-5b5e3342a853","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":318812,"manualVersion":"3.0","systemVersion":"1"},{"title":"K2_Recruitment_Material_Study Fact Sheet_Redacted","uuid":"777fdfab-70b2-4fe9-8b22-506fbb068a2b","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":318812,"manualVersion":"3.0","systemVersion":"1"},{"title":"K2_Recruitment Material_Video_QR Code Link_Public","uuid":"98abd891-9c4b-41ef-b99c-6d8cd5973974","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":318812,"manualVersion":"1.0","systemVersion":"1"},{"title":"K2_Recruitment Material_Video_Transcript_Public","uuid":"070af10f-5cdd-477f-bb95-21c12bae3702","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":32,"fileType":"PDF","associatedEntityId":318812,"manualVersion":"2.0","systemVersion":"1"},{"title":"L1_SIS and ICF_Optional Biopsy_redacted","uuid":"97ee0edf-270a-4e36-86a2-644fe61fc001","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":5,"fileType":"PDF","associatedEntityId":318812,"manualVersion":"3.3.0","systemVersion":"3"},{"title":"L1_SIS and ICF_PGx_redacted","uuid":"d439ef1e-0ff3-425c-bdcd-0e452e80534a","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":5,"fileType":"PDF","associatedEntityId":318812,"manualVersion":"3.2.0","systemVersion":"2"},{"title":"L1_SIS and ICF_PP_redacted","uuid":"17e21dc6-e261-40ce-9e8d-102847e805a4","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":5,"fileType":"PDF","associatedEntityId":318812,"manualVersion":"4.3.0","systemVersion":"3"},{"title":"L1_SIS and ICF_Withdrawal Participation_redacted","uuid":"1e1d62f7-7535-4944-b137-b33a0f796433","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":5,"fileType":"PDF","associatedEntityId":318812,"manualVersion":"1.3.0","systemVersion":"2"},{"title":"L1_SIS and ICF_Withdrawal Samples_redacted","uuid":"9423a24c-35b8-4228-bb56-daec0c8da7fb","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":5,"fileType":"PDF","associatedEntityId":318812,"manualVersion":"1.2.0","systemVersion":"2"},{"title":"L1_SIS and ICF_Main_redacted","uuid":"c914036e-d6e5-4f6d-852f-3f2fe0cf9fde","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":5,"fileType":"PDF","associatedEntityId":318812,"manualVersion":"9.4.0","systemVersion":"3"},{"title":"L1_SIS and ICF_Opt Future Research_redacted","uuid":"4cbd2d64-f196-48b5-89ae-6966c184db9b","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":5,"fileType":"PDF","associatedEntityId":318812,"manualVersion":"7.3.0","systemVersion":"3"},{"title":"L1_SIS and ICF_Prescreening_redacted","uuid":"9d53f0c5-c473-47bd-8cd3-69ee97e62a47","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":5,"fileType":"PDF","associatedEntityId":318812,"manualVersion":"5.4.0","systemVersion":"3"},{"title":"K2_Recruitment Material_Patient Brochure_Redacted","uuid":"a4c4d9c7-2cea-4951-b2d1-e9d3e3e8f191","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":34,"fileType":"PDF","associatedEntityId":318810,"manualVersion":"02","systemVersion":"2"},{"title":"K1_Recruitment Arrangements_Public","uuid":"19658b96-7649-4938-9799-f43b04ce13fa","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":34,"fileType":"PDF","associatedEntityId":318810,"manualVersion":"2-0","systemVersion":"3"},{"title":"K2_Recruitment Material_Video_QR Code Access","uuid":"3a7a62ac-2d80-4fcd-acf5-bb2b70e61382","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":318810,"manualVersion":"1-0","systemVersion":"1"},{"title":"K2_Recruitment Material_Video_Transcript","uuid":"4e5e1121-277d-4828-b196-76a80522a234","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":34,"fileType":"PDF","associatedEntityId":318810,"manualVersion":"1-0","systemVersion":"1"},{"title":"L1_SIS and ICF_Main_Redacted","uuid":"361bc660-346f-488d-8468-52d7d38672a7","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":34,"fileType":"PDF","associatedEntityId":318810,"manualVersion":"9-6-0","systemVersion":"5"},{"title":"L1_SIS and ICF_PGx_Redacted","uuid":"77cb054e-e2d3-4efa-a8cb-5735049c5c2e","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":34,"fileType":"PDF","associatedEntityId":318810,"manualVersion":"3-3-0","systemVersion":"3"},{"title":"L1_SIS and ICF_Pregnancy FU_Redacted","uuid":"14863466-1975-4432-8590-a8daba3e47bb","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":34,"fileType":"PDF","associatedEntityId":318810,"manualVersion":"4-4-0","systemVersion":"4"},{"title":"L1_SIS and ICF_Pre-Screening_Redacted","uuid":"9c6709a1-9309-40af-bb8e-39024ce1560a","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":34,"fileType":"PDF","associatedEntityId":318810,"manualVersion":"5-5-0","systemVersion":"4"},{"title":"L1_SIS and ICF_Withdrawal of Biomedical Research _Redacted","uuid":"9368a1af-4bdc-4a36-b3e4-db5daa8c73ea","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":34,"fileType":"PDF","associatedEntityId":318810,"manualVersion":"1-3-0","systemVersion":"3"},{"title":"L1_SIS and ICF_Withdrawal of Participation_Redacted","uuid":"ae34beb2-03f4-43fb-bc93-a46a823c5519","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":34,"fileType":"PDF","associatedEntityId":318810,"manualVersion":"1-3-0","systemVersion":"3"},{"title":"L1_SIS and ICF_Addendum","uuid":"23c7a78a-ca3f-42f9-9dbf-8d7601f0e433","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":34,"fileType":"PDF","associatedEntityId":318810,"manualVersion":"1-2-0","systemVersion":"1"}],"trialRegion":"Both","trialRegionCode":3,"correctiveMeasures":[]}